WO2022187289A1 - Methods and compositions for the delivery of retroviral particles - Google Patents
Methods and compositions for the delivery of retroviral particles Download PDFInfo
- Publication number
- WO2022187289A1 WO2022187289A1 PCT/US2022/018404 US2022018404W WO2022187289A1 WO 2022187289 A1 WO2022187289 A1 WO 2022187289A1 US 2022018404 W US2022018404 W US 2022018404W WO 2022187289 A1 WO2022187289 A1 WO 2022187289A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- rips
- formulation
- rip
- cell
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 431
- 239000002245 particle Substances 0.000 title claims abstract description 192
- 230000001177 retroviral effect Effects 0.000 title claims abstract description 187
- 238000000034 method Methods 0.000 title abstract description 206
- 238000009472 formulation Methods 0.000 claims abstract description 337
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 180
- 210000000822 natural killer cell Anatomy 0.000 claims abstract description 156
- 230000010076 replication Effects 0.000 claims abstract description 81
- 238000001727 in vivo Methods 0.000 claims abstract description 30
- 102000019034 Chemokines Human genes 0.000 claims abstract description 21
- 108010012236 Chemokines Proteins 0.000 claims abstract description 21
- 210000004027 cell Anatomy 0.000 claims description 550
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 166
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 162
- 229920001184 polypeptide Polymers 0.000 claims description 159
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 125
- 108090000623 proteins and genes Proteins 0.000 claims description 124
- 102000040430 polynucleotide Human genes 0.000 claims description 107
- 108091033319 polynucleotide Proteins 0.000 claims description 107
- 239000002157 polynucleotide Substances 0.000 claims description 107
- 102000004169 proteins and genes Human genes 0.000 claims description 87
- 238000007920 subcutaneous administration Methods 0.000 claims description 71
- 230000027455 binding Effects 0.000 claims description 69
- 206010028980 Neoplasm Diseases 0.000 claims description 61
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 59
- -1 CCL22 Proteins 0.000 claims description 53
- 230000002103 transcriptional effect Effects 0.000 claims description 49
- 210000004369 blood Anatomy 0.000 claims description 48
- 239000008280 blood Substances 0.000 claims description 48
- 239000012634 fragment Substances 0.000 claims description 47
- 102100037904 CD9 antigen Human genes 0.000 claims description 45
- 102000004127 Cytokines Human genes 0.000 claims description 44
- 108090000695 Cytokines Proteins 0.000 claims description 44
- 101710147327 Calcineurin B homologous protein 1 Proteins 0.000 claims description 42
- 101710205625 Capsid protein p24 Proteins 0.000 claims description 42
- 101710177166 Phosphoprotein Proteins 0.000 claims description 42
- 101710149279 Small delta antigen Proteins 0.000 claims description 42
- 230000004913 activation Effects 0.000 claims description 41
- 230000002401 inhibitory effect Effects 0.000 claims description 37
- 230000001589 lymphoproliferative effect Effects 0.000 claims description 37
- 239000012528 membrane Substances 0.000 claims description 37
- 241001430294 unidentified retrovirus Species 0.000 claims description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 33
- 238000007918 intramuscular administration Methods 0.000 claims description 27
- 241000700605 Viruses Species 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 24
- 230000000799 fusogenic effect Effects 0.000 claims description 24
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 23
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 23
- 102100036842 C-C motif chemokine 19 Human genes 0.000 claims description 21
- 102100036846 C-C motif chemokine 21 Human genes 0.000 claims description 21
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims description 21
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 claims description 21
- 102100034871 C-C motif chemokine 8 Human genes 0.000 claims description 20
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 18
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 16
- 230000003302 anti-idiotype Effects 0.000 claims description 16
- 241000282414 Homo sapiens Species 0.000 claims description 14
- 102100025250 C-X-C motif chemokine 14 Human genes 0.000 claims description 12
- 101000858068 Homo sapiens C-X-C motif chemokine 14 Proteins 0.000 claims description 12
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims description 12
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 12
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 12
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 12
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 11
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims description 11
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 11
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims description 11
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 11
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 11
- 102000005962 receptors Human genes 0.000 claims description 11
- 108020003175 receptors Proteins 0.000 claims description 11
- 102100036848 C-C motif chemokine 20 Human genes 0.000 claims description 10
- 102100021942 C-C motif chemokine 28 Human genes 0.000 claims description 10
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 10
- 102100032366 C-C motif chemokine 7 Human genes 0.000 claims description 10
- 101710155833 C-C motif chemokine 8 Proteins 0.000 claims description 10
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 claims description 10
- 101000897477 Homo sapiens C-C motif chemokine 28 Proteins 0.000 claims description 10
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims description 10
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 claims description 10
- 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 claims description 10
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 8
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- 102000000588 Interleukin-2 Human genes 0.000 claims description 8
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 8
- 239000006285 cell suspension Substances 0.000 claims description 8
- 239000003792 electrolyte Substances 0.000 claims description 8
- 102000009027 Albumins Human genes 0.000 claims description 7
- 108010088751 Albumins Proteins 0.000 claims description 7
- 241000283690 Bos taurus Species 0.000 claims description 7
- 102000003812 Interleukin-15 Human genes 0.000 claims description 7
- 108090000172 Interleukin-15 Proteins 0.000 claims description 7
- 239000000084 colloidal system Substances 0.000 claims description 7
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 6
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims description 6
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims description 6
- 102100020997 Fractalkine Human genes 0.000 claims description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 6
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 6
- 102100034221 Growth-regulated alpha protein Human genes 0.000 claims description 6
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims description 6
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 claims description 6
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims description 6
- 101000854520 Homo sapiens Fractalkine Proteins 0.000 claims description 6
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 claims description 6
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims description 6
- 108010002352 Interleukin-1 Proteins 0.000 claims description 6
- 102000000589 Interleukin-1 Human genes 0.000 claims description 6
- 102000003810 Interleukin-18 Human genes 0.000 claims description 6
- 108090000171 Interleukin-18 Proteins 0.000 claims description 6
- 102100021592 Interleukin-7 Human genes 0.000 claims description 6
- 108010002586 Interleukin-7 Proteins 0.000 claims description 6
- 241000714177 Murine leukemia virus Species 0.000 claims description 6
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 6
- 239000008121 dextrose Substances 0.000 claims description 6
- 230000004068 intracellular signaling Effects 0.000 claims description 6
- 108010065805 Interleukin-12 Proteins 0.000 claims description 5
- 102000013462 Interleukin-12 Human genes 0.000 claims description 5
- 102100030704 Interleukin-21 Human genes 0.000 claims description 5
- 108700012920 TNF Proteins 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 108010074108 interleukin-21 Proteins 0.000 claims description 5
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 4
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 4
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 4
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 4
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 4
- 238000007912 intraperitoneal administration Methods 0.000 claims description 4
- 241000712079 Measles morbillivirus Species 0.000 claims description 3
- 241000710960 Sindbis virus Species 0.000 claims description 3
- 108010067390 Viral Proteins Proteins 0.000 claims description 3
- 229960000548 alemtuzumab Drugs 0.000 claims description 3
- 229940127554 medical product Drugs 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 101800001467 Envelope glycoprotein E2 Proteins 0.000 claims 7
- 101800001271 Surface protein Proteins 0.000 claims 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 4
- 229940008421 amivantamab Drugs 0.000 claims 4
- 229950002817 burosumab Drugs 0.000 claims 4
- 108010023376 caplacizumab Proteins 0.000 claims 4
- 229950004930 enfortumab vedotin Drugs 0.000 claims 4
- 229950010245 ibalizumab Drugs 0.000 claims 4
- 229950000720 moxetumomab pasudotox Drugs 0.000 claims 4
- 229950007943 risankizumab Drugs 0.000 claims 4
- 229950000143 sacituzumab govitecan Drugs 0.000 claims 4
- ULRUOUDIQPERIJ-PQURJYPBSA-N sacituzumab govitecan Chemical compound N([C@@H](CCCCN)C(=O)NC1=CC=C(C=C1)COC(=O)O[C@]1(CC)C(=O)OCC2=C1C=C1N(C2=O)CC2=C(C3=CC(O)=CC=C3N=C21)CC)C(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN(N=N1)C=C1CNC(=O)C(CC1)CCC1CN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O ULRUOUDIQPERIJ-PQURJYPBSA-N 0.000 claims 4
- 239000011734 sodium Substances 0.000 claims 4
- 229910052708 sodium Inorganic materials 0.000 claims 4
- 229950005515 tildrakizumab Drugs 0.000 claims 4
- 229940049679 trastuzumab deruxtecan Drugs 0.000 claims 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 3
- 239000011777 magnesium Substances 0.000 claims 3
- 229910052749 magnesium Inorganic materials 0.000 claims 3
- 239000011591 potassium Substances 0.000 claims 3
- 229910052700 potassium Inorganic materials 0.000 claims 3
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims 2
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims 2
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 claims 2
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 claims 2
- 102100027207 CD27 antigen Human genes 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 241001502567 Chikungunya virus Species 0.000 claims 2
- 102100039061 Cytokine receptor common subunit beta Human genes 0.000 claims 2
- 102100026234 Cytokine receptor common subunit gamma Human genes 0.000 claims 2
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 claims 2
- 102100030751 Eomesodermin homolog Human genes 0.000 claims 2
- 241000712469 Fowl plague virus Species 0.000 claims 2
- 241000713813 Gibbon ape leukemia virus Species 0.000 claims 2
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 claims 2
- 102100028113 Granulocyte-macrophage colony-stimulating factor receptor subunit alpha Human genes 0.000 claims 2
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 claims 2
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 claims 2
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 claims 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 2
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 claims 2
- 101001055227 Homo sapiens Cytokine receptor common subunit gamma Proteins 0.000 claims 2
- 101000956427 Homo sapiens Cytokine receptor-like factor 2 Proteins 0.000 claims 2
- 101001064167 Homo sapiens Eomesodermin homolog Proteins 0.000 claims 2
- 101000746364 Homo sapiens Granulocyte colony-stimulating factor receptor Proteins 0.000 claims 2
- 101000916625 Homo sapiens Granulocyte-macrophage colony-stimulating factor receptor subunit alpha Proteins 0.000 claims 2
- 101000824104 Homo sapiens High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 claims 2
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 claims 2
- 101000852865 Homo sapiens Interferon alpha/beta receptor 2 Proteins 0.000 claims 2
- 101001001420 Homo sapiens Interferon gamma receptor 1 Proteins 0.000 claims 2
- 101000599613 Homo sapiens Interferon lambda receptor 1 Proteins 0.000 claims 2
- 101000960952 Homo sapiens Interleukin-1 receptor accessory protein Proteins 0.000 claims 2
- 101001076418 Homo sapiens Interleukin-1 receptor type 1 Proteins 0.000 claims 2
- 101000852965 Homo sapiens Interleukin-1 receptor-like 2 Proteins 0.000 claims 2
- 101001083151 Homo sapiens Interleukin-10 receptor subunit alpha Proteins 0.000 claims 2
- 101001003149 Homo sapiens Interleukin-10 receptor subunit beta Proteins 0.000 claims 2
- 101001003147 Homo sapiens Interleukin-11 receptor subunit alpha Proteins 0.000 claims 2
- 101001003142 Homo sapiens Interleukin-12 receptor subunit beta-1 Proteins 0.000 claims 2
- 101001003138 Homo sapiens Interleukin-12 receptor subunit beta-2 Proteins 0.000 claims 2
- 101001003135 Homo sapiens Interleukin-13 receptor subunit alpha-1 Proteins 0.000 claims 2
- 101001003132 Homo sapiens Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims 2
- 101001003140 Homo sapiens Interleukin-15 receptor subunit alpha Proteins 0.000 claims 2
- 101001019598 Homo sapiens Interleukin-17 receptor A Proteins 0.000 claims 2
- 101001019600 Homo sapiens Interleukin-17 receptor B Proteins 0.000 claims 2
- 101001019602 Homo sapiens Interleukin-17 receptor C Proteins 0.000 claims 2
- 101001019588 Homo sapiens Interleukin-17 receptor D Proteins 0.000 claims 2
- 101001019590 Homo sapiens Interleukin-17 receptor E Proteins 0.000 claims 2
- 101000961065 Homo sapiens Interleukin-18 receptor 1 Proteins 0.000 claims 2
- 101001019615 Homo sapiens Interleukin-18 receptor accessory protein Proteins 0.000 claims 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 2
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 claims 2
- 101001044893 Homo sapiens Interleukin-20 receptor subunit alpha Proteins 0.000 claims 2
- 101001044895 Homo sapiens Interleukin-20 receptor subunit beta Proteins 0.000 claims 2
- 101001044883 Homo sapiens Interleukin-22 receptor subunit alpha-1 Proteins 0.000 claims 2
- 101000853012 Homo sapiens Interleukin-23 receptor Proteins 0.000 claims 2
- 101001037246 Homo sapiens Interleukin-27 receptor subunit alpha Proteins 0.000 claims 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 2
- 101001043817 Homo sapiens Interleukin-31 receptor subunit alpha Proteins 0.000 claims 2
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 claims 2
- 101000960936 Homo sapiens Interleukin-5 receptor subunit alpha Proteins 0.000 claims 2
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims 2
- 101000599056 Homo sapiens Interleukin-6 receptor subunit beta Proteins 0.000 claims 2
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims 2
- 101001055219 Homo sapiens Interleukin-9 receptor Proteins 0.000 claims 2
- 101001042362 Homo sapiens Leukemia inhibitory factor receptor Proteins 0.000 claims 2
- 101000917821 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-c Proteins 0.000 claims 2
- 101000586302 Homo sapiens Oncostatin-M-specific receptor subunit beta Proteins 0.000 claims 2
- 101001123448 Homo sapiens Prolactin receptor Proteins 0.000 claims 2
- 101000946863 Homo sapiens T-cell surface glycoprotein CD3 delta chain Proteins 0.000 claims 2
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 2
- 101000738413 Homo sapiens T-cell surface glycoprotein CD3 gamma chain Proteins 0.000 claims 2
- 101000946833 Homo sapiens T-cell surface glycoprotein CD8 beta chain Proteins 0.000 claims 2
- 101000799466 Homo sapiens Thrombopoietin receptor Proteins 0.000 claims 2
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 2
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 2
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 2
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 claims 2
- 102100036718 Interferon alpha/beta receptor 2 Human genes 0.000 claims 2
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 claims 2
- 102100036157 Interferon gamma receptor 2 Human genes 0.000 claims 2
- 102100037971 Interferon lambda receptor 1 Human genes 0.000 claims 2
- 108700003107 Interleukin-1 Receptor-Like 1 Proteins 0.000 claims 2
- 102100039880 Interleukin-1 receptor accessory protein Human genes 0.000 claims 2
- 102100026016 Interleukin-1 receptor type 1 Human genes 0.000 claims 2
- 102100036706 Interleukin-1 receptor-like 1 Human genes 0.000 claims 2
- 102100036697 Interleukin-1 receptor-like 2 Human genes 0.000 claims 2
- 102100030236 Interleukin-10 receptor subunit alpha Human genes 0.000 claims 2
- 102100020788 Interleukin-10 receptor subunit beta Human genes 0.000 claims 2
- 102100020787 Interleukin-11 receptor subunit alpha Human genes 0.000 claims 2
- 102100020790 Interleukin-12 receptor subunit beta-1 Human genes 0.000 claims 2
- 102100020792 Interleukin-12 receptor subunit beta-2 Human genes 0.000 claims 2
- 102100020791 Interleukin-13 receptor subunit alpha-1 Human genes 0.000 claims 2
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims 2
- 102100020789 Interleukin-15 receptor subunit alpha Human genes 0.000 claims 2
- 102100035018 Interleukin-17 receptor A Human genes 0.000 claims 2
- 102100035014 Interleukin-17 receptor B Human genes 0.000 claims 2
- 102100035012 Interleukin-17 receptor C Human genes 0.000 claims 2
- 102100035015 Interleukin-17 receptor D Human genes 0.000 claims 2
- 102100035016 Interleukin-17 receptor E Human genes 0.000 claims 2
- 102100039340 Interleukin-18 receptor 1 Human genes 0.000 claims 2
- 102100035010 Interleukin-18 receptor accessory protein Human genes 0.000 claims 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 2
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 claims 2
- 102100022706 Interleukin-20 receptor subunit alpha Human genes 0.000 claims 2
- 102100022705 Interleukin-20 receptor subunit beta Human genes 0.000 claims 2
- 108010017411 Interleukin-21 Receptors Proteins 0.000 claims 2
- 102100030699 Interleukin-21 receptor Human genes 0.000 claims 2
- 102100022723 Interleukin-22 receptor subunit alpha-1 Human genes 0.000 claims 2
- 102100036672 Interleukin-23 receptor Human genes 0.000 claims 2
- 102100040066 Interleukin-27 receptor subunit alpha Human genes 0.000 claims 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 2
- 102100021594 Interleukin-31 receptor subunit alpha Human genes 0.000 claims 2
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 claims 2
- 102100039881 Interleukin-5 receptor subunit alpha Human genes 0.000 claims 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 2
- 102100037795 Interleukin-6 receptor subunit beta Human genes 0.000 claims 2
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims 2
- 102100026244 Interleukin-9 receptor Human genes 0.000 claims 2
- 101150113776 LMP1 gene Proteins 0.000 claims 2
- 102100031775 Leptin receptor Human genes 0.000 claims 2
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 claims 2
- 102100029206 Low affinity immunoglobulin gamma Fc region receptor II-c Human genes 0.000 claims 2
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 claims 2
- 101150053046 MYD88 gene Proteins 0.000 claims 2
- 241000725171 Mokola lyssavirus Species 0.000 claims 2
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 claims 2
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 claims 2
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 claims 2
- 241000526636 Nipah henipavirus Species 0.000 claims 2
- 102100030098 Oncostatin-M-specific receptor subunit beta Human genes 0.000 claims 2
- 102100029000 Prolactin receptor Human genes 0.000 claims 2
- 241000711798 Rabies lyssavirus Species 0.000 claims 2
- 241000710961 Semliki Forest virus Species 0.000 claims 2
- 102100035891 T-cell surface glycoprotein CD3 delta chain Human genes 0.000 claims 2
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 2
- 102100037911 T-cell surface glycoprotein CD3 gamma chain Human genes 0.000 claims 2
- 102100034928 T-cell surface glycoprotein CD8 beta chain Human genes 0.000 claims 2
- 102000043977 Tetraspanins Human genes 0.000 claims 2
- 108700031126 Tetraspanins Proteins 0.000 claims 2
- 102100034196 Thrombopoietin receptor Human genes 0.000 claims 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 2
- 241000710951 Western equine encephalitis virus Species 0.000 claims 2
- 229960000446 abciximab Drugs 0.000 claims 2
- 229960002964 adalimumab Drugs 0.000 claims 2
- 229950008995 aducanumab Drugs 0.000 claims 2
- 229940125490 aducanumab-avwa Drugs 0.000 claims 2
- 229960004539 alirocumab Drugs 0.000 claims 2
- 229950010117 anifrolumab Drugs 0.000 claims 2
- 229940125488 anifrolumab fnia Drugs 0.000 claims 2
- 229960003852 atezolizumab Drugs 0.000 claims 2
- 229940121526 atoltivimab Drugs 0.000 claims 2
- 229950002916 avelumab Drugs 0.000 claims 2
- 229940121530 balstilimab Drugs 0.000 claims 2
- 229960004669 basiliximab Drugs 0.000 claims 2
- 229940018964 belantamab mafodotin Drugs 0.000 claims 2
- 229940126166 belantamab mafodotin-blmf Drugs 0.000 claims 2
- 229960003270 belimumab Drugs 0.000 claims 2
- 229950000321 benralizumab Drugs 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- 229950008086 bezlotoxumab Drugs 0.000 claims 2
- 229950002853 bimekizumab Drugs 0.000 claims 2
- 229960003008 blinatumomab Drugs 0.000 claims 2
- 229960000455 brentuximab vedotin Drugs 0.000 claims 2
- 229960003735 brodalumab Drugs 0.000 claims 2
- 229950000025 brolucizumab Drugs 0.000 claims 2
- 229960001838 canakinumab Drugs 0.000 claims 2
- 229950002176 caplacizumab Drugs 0.000 claims 2
- 229960000419 catumaxomab Drugs 0.000 claims 2
- 229940121420 cemiplimab Drugs 0.000 claims 2
- 229960003115 certolizumab pegol Drugs 0.000 claims 2
- 229960005395 cetuximab Drugs 0.000 claims 2
- 229950004730 crizanlizumab Drugs 0.000 claims 2
- 229960002806 daclizumab Drugs 0.000 claims 2
- 229960002204 daratumumab Drugs 0.000 claims 2
- 229960001251 denosumab Drugs 0.000 claims 2
- 229960004497 dinutuximab Drugs 0.000 claims 2
- 229940121432 dostarlimab Drugs 0.000 claims 2
- 229940125494 dostarlimab-gxly Drugs 0.000 claims 2
- 229950003468 dupilumab Drugs 0.000 claims 2
- 229950009791 durvalumab Drugs 0.000 claims 2
- 229960002224 eculizumab Drugs 0.000 claims 2
- 229960001776 edrecolomab Drugs 0.000 claims 2
- 229960000284 efalizumab Drugs 0.000 claims 2
- 229960004137 elotuzumab Drugs 0.000 claims 2
- 229950004645 emapalumab Drugs 0.000 claims 2
- 229950006925 emicizumab Drugs 0.000 claims 2
- 229950006063 eptinezumab Drugs 0.000 claims 2
- 229950001616 erenumab Drugs 0.000 claims 2
- 229950004341 evinacumab Drugs 0.000 claims 2
- 229960002027 evolocumab Drugs 0.000 claims 2
- 238000000249 far-infrared magnetic resonance spectroscopy Methods 0.000 claims 2
- 229940116862 faricimab Drugs 0.000 claims 2
- 229950011509 fremanezumab Drugs 0.000 claims 2
- 229950000118 galcanezumab Drugs 0.000 claims 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 claims 2
- 229960001743 golimumab Drugs 0.000 claims 2
- 229950010864 guselkumab Drugs 0.000 claims 2
- 229960001001 ibritumomab tiuxetan Drugs 0.000 claims 2
- 229960002308 idarucizumab Drugs 0.000 claims 2
- 229950005015 inebilizumab Drugs 0.000 claims 2
- 229940050282 inebilizumab-cdon Drugs 0.000 claims 2
- 229960000598 infliximab Drugs 0.000 claims 2
- 229950004101 inotuzumab ozogamicin Drugs 0.000 claims 2
- 108010085650 interferon gamma receptor Proteins 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 229950007752 isatuximab Drugs 0.000 claims 2
- 229960005435 ixekizumab Drugs 0.000 claims 2
- 229950005287 lanadelumab Drugs 0.000 claims 2
- 108010019813 leptin receptors Proteins 0.000 claims 2
- 229950009758 loncastuximab tesirine Drugs 0.000 claims 2
- 229940121580 maftivimab Drugs 0.000 claims 2
- 229950003135 margetuximab Drugs 0.000 claims 2
- 229960005108 mepolizumab Drugs 0.000 claims 2
- 230000002297 mitogenic effect Effects 0.000 claims 2
- 229950007699 mogamulizumab Drugs 0.000 claims 2
- 229960003816 muromonab-cd3 Drugs 0.000 claims 2
- 229940015638 narsoplimab Drugs 0.000 claims 2
- 229960005027 natalizumab Drugs 0.000 claims 2
- 229960002915 nebacumab Drugs 0.000 claims 2
- 229960000513 necitumumab Drugs 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 229960003419 obiltoxaximab Drugs 0.000 claims 2
- 229960003347 obinutuzumab Drugs 0.000 claims 2
- 229950005751 ocrelizumab Drugs 0.000 claims 2
- 229960002450 ofatumumab Drugs 0.000 claims 2
- 229950008516 olaratumab Drugs 0.000 claims 2
- 229960000470 omalizumab Drugs 0.000 claims 2
- 229940121476 omburtamab Drugs 0.000 claims 2
- 229950009057 oportuzumab monatox Drugs 0.000 claims 2
- 229960000402 palivizumab Drugs 0.000 claims 2
- 229960001972 panitumumab Drugs 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 229940063500 penpulimab Drugs 0.000 claims 2
- 229960002087 pertuzumab Drugs 0.000 claims 2
- 229950009416 polatuzumab vedotin Drugs 0.000 claims 2
- 229940126167 polatuzumab vedotin-piiq Drugs 0.000 claims 2
- 229960002633 ramucirumab Drugs 0.000 claims 2
- 229960003876 ranibizumab Drugs 0.000 claims 2
- 229950007085 ravulizumab Drugs 0.000 claims 2
- 229960004910 raxibacumab Drugs 0.000 claims 2
- 229960003254 reslizumab Drugs 0.000 claims 2
- 229940018007 retifanlimab Drugs 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 229950010968 romosozumab Drugs 0.000 claims 2
- 229950006348 sarilumab Drugs 0.000 claims 2
- 229940060041 satralizumab Drugs 0.000 claims 2
- 229960004540 secukinumab Drugs 0.000 claims 2
- 229960003323 siltuximab Drugs 0.000 claims 2
- 229940121497 sintilimab Drugs 0.000 claims 2
- 229940121331 sutimlimab Drugs 0.000 claims 2
- 229940121503 tafasitamab Drugs 0.000 claims 2
- 229950008160 tanezumab Drugs 0.000 claims 2
- 229950010127 teplizumab Drugs 0.000 claims 2
- 229950010259 teprotumumab Drugs 0.000 claims 2
- 229950008998 tezepelumab Drugs 0.000 claims 2
- 229950004269 tisotumab vedotin Drugs 0.000 claims 2
- 229960003989 tocilizumab Drugs 0.000 claims 2
- 229940121514 toripalimab Drugs 0.000 claims 2
- 229950000835 tralokinumab Drugs 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- 229960001612 trastuzumab emtansine Drugs 0.000 claims 2
- 229950004593 ublituximab Drugs 0.000 claims 2
- 229960003824 ustekinumab Drugs 0.000 claims 2
- 229960004914 vedolizumab Drugs 0.000 claims 2
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 claims 1
- 102100022594 ATP-binding cassette sub-family G member 1 Human genes 0.000 claims 1
- 102100026882 Alpha-synuclein Human genes 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 claims 1
- 102000003952 Caspase 3 Human genes 0.000 claims 1
- 108090000397 Caspase 3 Proteins 0.000 claims 1
- 241000711969 Chandipura virus Species 0.000 claims 1
- 101100126877 Dictyostelium discoideum ccbl gene Proteins 0.000 claims 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims 1
- 206010066919 Epidemic polyarthritis Diseases 0.000 claims 1
- 208000000832 Equine Encephalomyelitis Diseases 0.000 claims 1
- 101150089023 FASLG gene Proteins 0.000 claims 1
- 241000714165 Feline leukemia virus Species 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101000840551 Homo sapiens Hexokinase-2 Proteins 0.000 claims 1
- 101001050577 Homo sapiens Kinesin-like protein KIF2A Proteins 0.000 claims 1
- 101001006892 Homo sapiens Krueppel-like factor 10 Proteins 0.000 claims 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 1
- 101001026214 Homo sapiens Potassium voltage-gated channel subfamily A member 5 Proteins 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 101001048456 Homo sapiens Protein Hook homolog 2 Proteins 0.000 claims 1
- 101000761581 Homo sapiens Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B delta isoform Proteins 0.000 claims 1
- 101001068027 Homo sapiens Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Proteins 0.000 claims 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims 1
- 101000687808 Homo sapiens Suppressor of cytokine signaling 2 Proteins 0.000 claims 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 1
- 101000638161 Homo sapiens Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 claims 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims 1
- 101001001300 Human cytomegalovirus (strain Towne) 65 kDa phosphoprotein Proteins 0.000 claims 1
- 101150026829 JUNB gene Proteins 0.000 claims 1
- 102100023426 Kinesin-like protein KIF2A Human genes 0.000 claims 1
- 102100027798 Krueppel-like factor 10 Human genes 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 108010090314 Member 1 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 claims 1
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 claims 1
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 claims 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 claims 1
- 241001504519 Papio ursinus Species 0.000 claims 1
- 241000711965 Piry virus Species 0.000 claims 1
- 241000710942 Ross River virus Species 0.000 claims 1
- 102100024927 Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B delta isoform Human genes 0.000 claims 1
- 102100034464 Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Human genes 0.000 claims 1
- 101150045565 Socs1 gene Proteins 0.000 claims 1
- 108700027336 Suppressor of Cytokine Signaling 1 Proteins 0.000 claims 1
- 102100024779 Suppressor of cytokine signaling 1 Human genes 0.000 claims 1
- 102100024784 Suppressor of cytokine signaling 2 Human genes 0.000 claims 1
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 claims 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 1
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 claims 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 208000037797 influenza A Diseases 0.000 claims 1
- 208000037798 influenza B Diseases 0.000 claims 1
- 208000037799 influenza C Diseases 0.000 claims 1
- 208000037800 influenza D Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 229950009756 loncastuximab Drugs 0.000 claims 1
- 229940125493 loncastuximab tesirine-lpyl Drugs 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 241000701447 unidentified baculovirus Species 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 abstract description 130
- 239000000243 solution Substances 0.000 description 136
- 150000007523 nucleic acids Chemical class 0.000 description 86
- 239000013598 vector Substances 0.000 description 86
- 235000018102 proteins Nutrition 0.000 description 84
- 239000000427 antigen Substances 0.000 description 75
- 108091007433 antigens Proteins 0.000 description 75
- 102000036639 antigens Human genes 0.000 description 75
- 102000039446 nucleic acids Human genes 0.000 description 60
- 108020004707 nucleic acids Proteins 0.000 description 60
- 230000014509 gene expression Effects 0.000 description 47
- 108091008874 T cell receptors Proteins 0.000 description 45
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 45
- 230000003612 virological effect Effects 0.000 description 36
- 230000002463 transducing effect Effects 0.000 description 27
- 210000003719 b-lymphocyte Anatomy 0.000 description 25
- 239000011541 reaction mixture Substances 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 230000000670 limiting effect Effects 0.000 description 23
- 239000002679 microRNA Substances 0.000 description 23
- 230000001939 inductive effect Effects 0.000 description 22
- 238000004806 packaging method and process Methods 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 18
- 238000010361 transduction Methods 0.000 description 17
- 230000026683 transduction Effects 0.000 description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 description 16
- 230000006044 T cell activation Effects 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 16
- 210000004379 membrane Anatomy 0.000 description 16
- 230000011664 signaling Effects 0.000 description 16
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 15
- 239000000306 component Substances 0.000 description 14
- 230000004927 fusion Effects 0.000 description 14
- 108700011259 MicroRNAs Proteins 0.000 description 13
- 230000002458 infectious effect Effects 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 210000000440 neutrophil Anatomy 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 102100034349 Integrase Human genes 0.000 description 12
- 238000011194 good manufacturing practice Methods 0.000 description 12
- 239000000017 hydrogel Substances 0.000 description 12
- 230000001976 improved effect Effects 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 229920002674 hyaluronan Polymers 0.000 description 11
- 210000001165 lymph node Anatomy 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 241000713666 Lentivirus Species 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 9
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 229960003160 hyaluronic acid Drugs 0.000 description 9
- 108091070501 miRNA Proteins 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 8
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 210000000170 cell membrane Anatomy 0.000 description 8
- 238000002659 cell therapy Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 7
- 208000033878 Tertiary Lymphoid Structures Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 108700019146 Transgenes Proteins 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 210000001616 monocyte Anatomy 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000003908 quality control method Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000000284 resting effect Effects 0.000 description 6
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 5
- 101000798762 Anguilla anguilla Troponin C, skeletal muscle Proteins 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 5
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 5
- 101000666340 Homo sapiens Tenascin Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 102100038126 Tenascin Human genes 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 230000000120 cytopathologic effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000012239 gene modification Methods 0.000 description 5
- 230000005017 genetic modification Effects 0.000 description 5
- 235000013617 genetically modified food Nutrition 0.000 description 5
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 5
- 210000005260 human cell Anatomy 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 101710091045 Envelope protein Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 241000204031 Mycoplasma Species 0.000 description 4
- 101710188315 Protein X Proteins 0.000 description 4
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- 108020004422 Riboswitch Proteins 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000007910 cell fusion Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000000447 dimerizing effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 230000009368 gene silencing by RNA Effects 0.000 description 4
- 201000005787 hematologic cancer Diseases 0.000 description 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 3
- 102100025618 C-X-C chemokine receptor type 6 Human genes 0.000 description 3
- 241001663880 Gammaretrovirus Species 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 3
- 101000856683 Homo sapiens C-X-C chemokine receptor type 6 Proteins 0.000 description 3
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
- 108010061833 Integrases Proteins 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 108091027967 Small hairpin RNA Proteins 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 3
- 238000011467 adoptive cell therapy Methods 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 210000003651 basophil Anatomy 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000409 cytokine receptor agonist Substances 0.000 description 3
- 102000003675 cytokine receptors Human genes 0.000 description 3
- 108010057085 cytokine receptors Proteins 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000002716 delivery method Methods 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 238000011577 humanized mouse model Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000004324 lymphatic system Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- HWXBTNAVRSUOJR-GSVOUGTGSA-N (R)-2-hydroxyglutaric acid Chemical compound OC(=O)[C@H](O)CCC(O)=O HWXBTNAVRSUOJR-GSVOUGTGSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241000714175 Abelson murine leukemia virus Species 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 2
- 241000713840 Avian erythroblastosis virus Species 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 description 2
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 2
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 2
- 102100025222 CD63 antigen Human genes 0.000 description 2
- 102100027221 CD81 antigen Human genes 0.000 description 2
- 102100027217 CD82 antigen Human genes 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 241000714475 Fujinami sarcoma virus Species 0.000 description 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 2
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 2
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 2
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 description 2
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 description 2
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 2
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 2
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 2
- 101000914469 Homo sapiens CD82 antigen Proteins 0.000 description 2
- 101000980823 Homo sapiens Leukocyte surface antigen CD53 Proteins 0.000 description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 description 2
- 102000001974 Hyaluronidases Human genes 0.000 description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 102100024221 Leukocyte surface antigen CD53 Human genes 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010025327 Lymphopenia Diseases 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 102000003735 Mesothelin Human genes 0.000 description 2
- 108090000015 Mesothelin Proteins 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 241000713862 Moloney murine sarcoma virus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 208000007587 Transfusion-Related Acute Lung Injury Diseases 0.000 description 2
- 102000008579 Transposases Human genes 0.000 description 2
- 108010020764 Transposases Proteins 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 201000005969 Uveal melanoma Diseases 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000008151 electrolyte solution Substances 0.000 description 2
- 229940021013 electrolyte solution Drugs 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 229940027278 hetastarch Drugs 0.000 description 2
- 229940099552 hyaluronan Drugs 0.000 description 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
- 229960002773 hyaluronidase Drugs 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 239000012212 insulator Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229940001447 lactate Drugs 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000000581 natural killer T-cell Anatomy 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000004976 peripheral blood cell Anatomy 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 108091007428 primary miRNA Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229920002725 thermoplastic elastomer Polymers 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000005758 transcription activity Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- RJBDSRWGVYNDHL-XNJNKMBASA-N (2S,4R,5S,6S)-2-[(2S,3R,4R,5S,6R)-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(E,2R,3S)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-5-amino-6-[(1S,2R)-2-[(2S,4R,5S,6S)-5-amino-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-4-hydroxyoxane-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3NC(C)=O)[C@H](O[C@@]3(C[C@@H](O)[C@H](N)[C@H](O3)[C@H](O)[C@@H](CO)O[C@@]3(C[C@@H](O)[C@H](N)[C@H](O3)[C@H](O)[C@H](O)CO)C(O)=O)C(O)=O)[C@H]2O)[C@H](O)[C@H]1O)[C@@H](O)\C=C\CCCCCCCCCCCCC RJBDSRWGVYNDHL-XNJNKMBASA-N 0.000 description 1
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 108010087905 Adenovirus E1B Proteins Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
- 241001664176 Alpharetrovirus Species 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
- 101100208110 Arabidopsis thaliana TRX4 gene Proteins 0.000 description 1
- 102000016904 Armadillo Domain Proteins Human genes 0.000 description 1
- 108010014223 Armadillo Domain Proteins Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 241000713826 Avian leukosis virus Species 0.000 description 1
- 241000713834 Avian myelocytomatosis virus 29 Species 0.000 description 1
- 241000700663 Avipoxvirus Species 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 241001231757 Betaretrovirus Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000711443 Bovine coronavirus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 108700012439 CA9 Proteins 0.000 description 1
- 108010058905 CD44v6 antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101100372806 Caenorhabditis elegans vit-3 gene Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 241000712083 Canine morbillivirus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 241001492329 Cercopithecine alphaherpesvirus 9 Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 description 1
- 208000037845 Cutaneous squamous cell carcinoma Diseases 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108010025905 Cystine-Knot Miniproteins Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241000289632 Dasypodidae Species 0.000 description 1
- 241001663879 Deltaretrovirus Species 0.000 description 1
- 102100034289 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 Human genes 0.000 description 1
- 101100425276 Dictyostelium discoideum trxD gene Proteins 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 101150084967 EPCAM gene Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 108010055196 EphA2 Receptor Proteins 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- 201000005231 Epithelioid sarcoma Diseases 0.000 description 1
- 241001663878 Epsilonretrovirus Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000713859 FBR murine osteosarcoma virus Species 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 108010069446 Fertilins Proteins 0.000 description 1
- 102000001133 Fertilins Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000714188 Friend murine leukemia virus Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 208000007990 Giant Cell Tumor of Tendon Sheath Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 101710114810 Glycoprotein Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102100032530 Glypican-3 Human genes 0.000 description 1
- 102100022662 Guanylyl cyclase C Human genes 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101710121925 Hemagglutinin glycoprotein Proteins 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
- 101100334515 Homo sapiens FCGR3A gene Proteins 0.000 description 1
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 description 1
- 101000899808 Homo sapiens Guanylyl cyclase C Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 1
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 1
- 101000633445 Homo sapiens Structural maintenance of chromosomes protein 2 Proteins 0.000 description 1
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000711920 Human orthopneumovirus Species 0.000 description 1
- 241000712003 Human respirovirus 3 Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- 101150074862 KLRC3 gene Proteins 0.000 description 1
- 101150018199 KLRC4 gene Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 241000713821 Mason-Pfizer monkey virus Species 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091033773 MiR-155 Proteins 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 102100023123 Mucin-16 Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101900288004 Mumps virus Hemagglutinin-neuraminidase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000711466 Murine hepatitis virus Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101100154863 Mus musculus Txndc2 gene Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 241000713883 Myeloproliferative sarcoma virus Species 0.000 description 1
- 206010073137 Myxoid liposarcoma Diseases 0.000 description 1
- 208000020258 Myxoid/round cell liposarcoma Diseases 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 1
- 102100022701 NKG2-E type II integral membrane protein Human genes 0.000 description 1
- 102100022700 NKG2-F type II integral membrane protein Human genes 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010079855 Peptide Aptamers Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101900025731 Porcine respiratory coronavirus Spike glycoprotein Proteins 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102100040120 Prominin-1 Human genes 0.000 description 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 1
- 101710120463 Prostate stem cell antigen Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 238000003326 Quality management system Methods 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 229920001954 Restylane Polymers 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108700019718 SAM Domain and HD Domain-Containing Protein 1 Proteins 0.000 description 1
- 101150114242 SAMHD1 gene Proteins 0.000 description 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241001559173 Simian rubulavirus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 101710167605 Spike glycoprotein Proteins 0.000 description 1
- 241000713896 Spleen necrosis virus Species 0.000 description 1
- 241000713675 Spumavirus Species 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 101000677856 Stenotrophomonas maltophilia (strain K279a) Actin-binding protein Smlt3054 Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 101000936720 Streptococcus gordonii Accessory secretory protein Asp5 Proteins 0.000 description 1
- 102100029540 Structural maintenance of chromosomes protein 2 Human genes 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 201000008754 Tenosynovial giant cell tumor Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 208000026487 Triploidy Diseases 0.000 description 1
- 108010028230 Trp-Ser- His-Pro-Gln-Phe-Glu-Lys Proteins 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 1
- 229940127174 UCHT1 Drugs 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 description 1
- 101100207515 Xenopus laevis trim33 gene Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 108091008108 affimer Proteins 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229920003232 aliphatic polyester Polymers 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 101150058049 car gene Proteins 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000003693 cell processing method Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000011118 depth filtration Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000009454 functional inhibition Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000006972 gastroesophageal adenocarcinoma Diseases 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 101150118163 h gene Proteins 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 229940089982 healon Drugs 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000001894 hemadsorption Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000003426 interchromosomal effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000004901 leucine-rich repeat Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011469 lymphodepleting chemotherapy Methods 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 101710130522 mRNA export factor Proteins 0.000 description 1
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000005741 malignant process Effects 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 208000021937 marginal zone lymphoma Diseases 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 108091007426 microRNA precursor Proteins 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000013009 nonpyrogenic isotonic solution Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 208000007312 paraganglioma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920001562 poly(N-(2-hydroxypropyl)methacrylamide) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 201000006366 primary open angle glaucoma Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000012429 release testing Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 102200006539 rs121913529 Human genes 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 102000023888 sequence-specific DNA binding proteins Human genes 0.000 description 1
- 108091008420 sequence-specific DNA binding proteins Proteins 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- 201000011138 superficial basal cell carcinoma Diseases 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 208000005925 vesicular stomatitis Diseases 0.000 description 1
- 229940042596 viscoat Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
- C07K2319/912—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation containing a GPI (phosphatidyl-inositol glycane) anchor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- PCT/US2020/048843 filed August 31, 2020 is a continuation-in-part of International Application No. PCT/US2019/049259, filed September 2, 2019; and claims the benefit of U.S. Provisional Application No. 62/894,849, filed September 1, 2019; U.S. Provisional Application No. 62/894,852, filed September 1, 2019; U.S. Provisional Application No. 62/894,853, filed September 1, 2019; U.S. Provisional Application No. 62/894,926, filed September 2, 2019; U.S. Provisional Application No. 62/943,207, filed December 3, 2019; and U.S. Provisional Application No. 62/985,741, filed March 5, 2020; International Application No.
- PCT/US2019/049259 is a continuation-in-part of International Application No. PCT/US2018/051392 filed September 17, 2018; and claims the benefit of U.S. Provisional Application No. 62/726,293, filed September 2, 2018; U.S. Provisional Application No. 62/726,294, filed September 2, 2018; U.S. Provisional Application No. 62/728,056 filed September 6, 2018; U.S. Provisional Application No. 62/732,528, filed September 17, 2018; U.S. Provisional Application No. 62/821,434, filed March 20, 2019; and U.S. Provisional Application No.
- PCT/US2017/023112 claims the benefit of U.S. Provisional Application No. 62/390,093, filed March 19, 2016; U.S. Provisional Application No. 62/360,041, filed July 8, 2016; and U.S. Provisional Application No. 62/467,039, filed March 3, 2017; International Application No. PCT/US2017/041277 claims the benefit of International Application No. PCT/US2017/023112, filed March 19, 2017; U.S. Patent Application No. 15/462,855, filed March 19, 2017; U.S. Provisional Application No. 62/360,041, filed July 8, 2016; and U.S. Provisional Application No. 62/467,039, filed March 3, 2017; U.S. Application No.
- This disclosure relates to the fields of immunology and immunotherapy, and more specifically, to methods and retroviruses for the genetic modification of lymphocytes, and methods for using the same.
- Lymphocytes isolated from a subject can be activated in vitro and genetically modified to express synthetic proteins that enable redirected engagement with other cells and environments based upon the genetic programs incorporated.
- synthetic proteins include engineered T cell receptors (TCRs) and chimeric antigen receptors (CARs).
- TCRs engineered T cell receptors
- CARs chimeric antigen receptors
- One CAR that is currently used is a fusion of an extracellular recognition domain (e.g., an antigen-binding domain), a transmembrane domain, and one or more intracellular signaling domains encoded by a replication incompetent recombinant retrovirus.
- CAR therapies not only bring many difficult to tolerate adverse events to patients, but further cannot be controlled for propagation rate in vivo once introduced into the body, nor safely directed towards targets that are also expressed outside the tumor.
- CAR therapies today are typically infused from cells expanded ex vivo from 12 to 28 days using doses from 1 x 10 s to 1 x 10 s cells/kg and are directed towards targets, for example tumor targets, for which off tumor on target toxicity is generally acceptable.
- Such cell lines and methods would be useful in analyzing different components of recombinant viruses, such as recombinant retroviral particles, and for methods that use packaging cells lines for the production of recombinant retroviral particles.
- recombinant viruses such as recombinant retroviral particles
- packaging cells lines for the production of recombinant retroviral particles.
- cytokines bind to and stimulate T cells and NK cells nonspecifically, thus reducing the amount of cytokines available to stimulate the CAR T cells or NK cells.
- the cytokines also can diffuse away further reducing the cytokines available to stimulate the CAR T cells or NK cells.
- kits that simplify and speed up the process of genetically modifying lymphocytes, in illustrative embodiments T cells and/or NK cells.
- Some aspects and embodiments provided herein are well-suited for point-of-care cell processing and do not require transport of cells to specialized processing facilities.
- methods, uses, compositions, and kits provided herein help overcome issues related to the effectiveness and safety of methods for transducing and/or modifying and in illustrative embodiments genetically modifying lymphocytes such as T cells and/or NK cells. Certain embodiments of such methods are useful for performing adoptive cell therapy with these cells.
- kits for modifying lymphocytes, especially T cell and/or NK cells, and/or for regulating the activity of transduced, genetically modified, and/or modified T cells and/or NK cells are provided herein.
- Such methods, compositions, and kits provide improved efficacy and safety over current technologies, especially with respect to T cells and/or NK cells that express engineered T cell receptors (TCRs), chimeric antigen receptors (CARs), and in illustrative embodiments microenvironment restricted biologic (“MRB”) CARs.
- TCRs engineered T cell receptors
- CARs chimeric antigen receptors
- MRB microenvironment restricted biologic
- Transduced and/or modified and in illustrative embodiments genetically modified T cells and/or NK cells that are produced by and/or used in methods provided herein include functionality and combinations of functionality, in illustrative embodiments delivered either ex vivo, or in certain illustrative aspects in vivo, from retroviral (e.g., lentiviral) genomes via retroviral (e.g., lentiviral) particles, that provide improved features for such cells and for methods that utilize such cells, such as research methods, commercial production methods, and adoptive cellular therapy.
- retroviral e.g., lentiviral
- retroviral particles e.g., lentiviral particles
- such cells can be produced in vivo, or in less time ex vivo, and that have improved growth properties that can be better regulated.
- such methods, uses, compositions, and kits include, or are adapted for intramuscular or in further illustrative embodiments, subcutaneous delivery to a subject.
- methods are provided for transducing and/or modifying and in illustrative embodiments genetically modifying lymphocytes such as T cells and/or NK cells, and in illustrative embodiments, in vivo or ex vivo methods for transducing, genetically modifying, and/or modified resting or dividing T cells and/or NK cells.
- Some of these aspects involve less or no ex-vivo cell processing and in illustrative embodiments can be performed much more quickly than previous methods, which can facilitate more efficient research, more effective commercial production, safer methods for modifying a subject’s lymphocytes, and improved methods of patient care.
- compositions, and kits provided herein can be used as research tools, in commercial production, and in adoptive cellular therapy using replication incompetent retroviral particles (RIPs) and using transduced and/or modified and in illustrative embodiments genetically modified T cells and/or NK cells expressing a TCR or a CAR.
- RIPs replication incompetent retroviral particles
- transduction reactions can be ex vivo transduction reactions that include enriched PBMCs, TNCs, or blood cells without prior cellular enrichment, such as in whole blood that are simplified, and quicker methods for performing ex-vivo cell processing, for example for CAR-T therapy. Such methods require less specialized instrumentation and training.
- RNAs capable of engrafting in a lymphoreplete environment.
- patients or subjects are not lymphodepleted prior to reinfusion with modified and/or genetically modified T cells and or NK cells.
- genetic constructs that are especially well- suited to provide genetically modified T cells and/or NK cells the ability to survive and proliferate in a more controllable manner.
- constitutive promoters operably linked to lymphoproliferative elements or inducible promoters operably linked to secreted cytokines such aspects and embodiments provide inducible promoters operably linked to membrane-bound lymphoproliferative elements, that when induced by CAR-binding to its target, can induce proliferation of T cells and/or NK cells, such as, for example, those present in the tumor microenvironment.
- RIPs replication incompetent recombinant retroviral particles
- methods for delivering, administering, and/or injecting replication incompetent recombinant retroviral particles (RIPs) to a subject that include administering a RIP formulation comprising the RIPs to the subject.
- the RIPs can be any of the RIPs disclosed herein.
- FIG. 1 shows a FACS plot of peripheral blood from an NSG-SGM3 CD34-humanized mouse 19 days after it was injected IP with GCAR-19GU RIPs.
- FIG. 2 shows a graph of the number of B cells per pi blood in NSG-SGM3 CD34-humanized mice at various days after they were mock injected IP with PBS or injected IP with GCAR-19GU RIPs. The graph represents the average of 5 mice from each group.
- FIG. 3 shows a FACS plot of peripheral blood from an NSG-MHC1/2-DKO PBMC-humanized mouse 19 days after it was injected IP with GCAR-19GU RIPs.
- chimeric antigen receptor or “CAR” or “CARs” refers to engineered receptors, which graft an antigen specificity onto cells, for example T cells, NK cells, macrophages, and stem cells.
- the CARs of the invention include at least one antigen-specific targeting region (ASTR), a transmembrane domain (TM), and an intracellular activating domain (I AD) and can include a stalk, and one or more co-stimulatory domains (CSDs).
- ASTR antigen-specific targeting region
- TM transmembrane domain
- I AD intracellular activating domain
- the CAR is a bispecific CAR, which is specific to two different antigens or epitopes. After the ASTR binds specifically to a target antigen, the IAD activates intracellular signaling.
- the IAD can redirect T cell specificity and reactivity toward a selected target in a non-MHC-restricted manner, exploiting the antigen-binding properties of antibodies.
- the non-MHC-restricted antigen recognition gives T cells expressing the CAR the ability to recognize an antigen independent of antigen processing, thus bypassing a major mechanism of tumor escape.
- CARs advantageously do not dimerize with endogenous T cell receptor (TCR) alpha and beta chains.
- cell “aggregate” means a cluster of cells that adhere to each other.
- the term “constitutive T cell or NK cell promoter” refers to a promoter which, when operably linked with a polynucleotide that encodes or specifies a gene product, causes the gene product to be produced in a cell under most or all physiological conditions of the cell.
- inducible promoter or “activatable promoter” refer to promoters that when operably linked with a polynucleotide that encodes or specifies a gene product, cause the gene product to be produced in a cell substantially only when a promoter-specific inducer is present in the cell. Inducible promoters have no, or a low level, of basal transcription activity but the transcription activity increases, sometimes greatly, in the presence of an inducing signal.
- insulator refers to a cis-regulatory element that mediates intra- and inter-chromosomal interactions and can block interactions between enhancers and promoters. Typically, insulators are between 200 and 2000 base pairs in length and contain clustered binding sites for sequence specific DNA-binding proteins.
- the term "microenvironment” means any portion or region of a tissue or body that has constant or temporal, physical, or chemical differences from other regions of the tissue or regions of the body.
- a tumor microenvironment refers to the environment in which a tumor exists, which is the non-cellular area within the tumor and the area directly outside the tumorous tissue but does not pertain to the intracellular compartment of the cancer cell itself.
- the tumor microenvironment can refer to any and all conditions of the tumor milieu including conditions that create a structural and or functional environment for the malignant process to survive and/or expand and/or spread.
- the tumor microenvironment can include alterations in conditions such as, but not limited to, pressure, temperature, pH, ionic strength, osmotic pressure, osmolality, oxidative stress, concentration of one or more solutes, concentration of electrolytes, concentration of glucose, concentration of hyaluronan, concentration of lactic acid or lactate, concentration of albumin, levels of adenosine, levels of R-2-hydroxyglutarate, concentration of pyruvate, concentration of oxygen, and/or presence of oxidants, reductants, or co-factors, as well as other conditions a skilled artisan will understand.
- conditions such as, but not limited to, pressure, temperature, pH, ionic strength, osmotic pressure, osmolality, oxidative stress, concentration of one or more solutes, concentration of electrolytes, concentration of glucose, concentration of hyaluronan, concentration of lactic acid or lactate, concentration of albumin, levels of adenosine, levels of R-2-hydroxyglutar
- polynucleotide and “nucleic acid” refer to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides.
- this term includes, but is not limited to, single-, double-, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or a polymer comprising purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural, or derivatized nucleotide bases.
- an “approved biologic” is a macromolecule that meets the requirements of a biologic provided by a government regulatory agency such as, but not limited to, the Food And Drug Administration of the U.S. (USFDA), European Medicines Agency (EMA), National Medical Products Administration of China (NMPA) (Chinese FDA), or the Pharmaceutical and Food Safety Bureau (PFSB) of Japan and has been approved by such regulatory agency either as a stand-alone biologic, or as part of a combination product or method.
- USFDA Food And Drug Administration of the U.S.
- EMA European Medicines Agency
- NMPA National Medical Products Administration of China
- PFSB Pharmaceutical and Food Safety Bureau
- antibody includes polyclonal and monoclonal antibodies, including intact antibodies and fragments of antibodies which retain specific binding to antigen.
- the antibody fragments can be, but are not limited to, fragment antigen binding (Fab) fragments, Fab' fragments,
- the term includes genetically engineered and/or otherwise modified forms of immunoglobulins, such as intrabodies, peptibodies, chimeric antibodies, single-chain antibodies, fully human antibodies, humanized antibodies, fusion proteins including an antigen-specific targeting region of an antibody and a non-antibody protein, heteroconjugate antibodies, multispecific, e.g., bispecific, antibodies, diabodies, triabodies, and tetrabodies, tandem di-scFv's, and tandem tri-scFv's.
- antibody should be understood to include functional antibody fragments thereof.
- the term also includes intact or full-length antibodies, including antibodies of any class or subclass, including IgG and sub-classes thereof, IgM, IgE, IgA, and IgD.
- antibody fragment includes a portion of an intact antibody, for example, the antigen binding or variable region of an intact antibody.
- antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies (Zapata et af, Protein Eng.
- the terms "single-chain Fv,” “scFv,” or “sFv” antibody fragments include the VH and VL domains of antibody, wherein these domains are present in a single polypeptide chain.
- the Fv polypeptide further includes a polypeptide linker or spacer between the VH and VL domains, which enables the sFv to form the desired structure for antigen binding.
- VF1 and VL domains refer to VH and VL domains that have been isolated from a host without further molecular evolution to change their affinities when generated in an scFv format under specific conditions such as those disclosed in US patent 8709755 B2 and application WO/2017/033331A1.
- antibody mimetic refers to an organic compound that specifically binds a target sequence and has a structure distinct from a naturally-occurring antibody.
- Antibody mimetics may comprise a protein, a nucleic acid, or a small molecule, and a skilled artisan can understand when each type is relevant.
- the target sequence to which an antibody mimetic of the disclosure specifically binds may be an antigen.
- Antibody mimetics may provide superior properties over antibodies including, but not limited to, superior solubility, tissue penetration, stability towards heat and enzymes (e.g., resistance to enzymatic degradation), and lower production costs.
- Antibody mimetics include, but are not limited to, an affibody, an afflilin, an affimer, an affitin, an alphabody, an alphamab, an anticalin, a peptide aptamer, an armadillo repeat protein, an atrimer, an avimer (also known as avidity multimer), a C-type lectin domain, a cysteine-knot miniprotein, a cyclic peptide, a cytotoxic T -lymphocyte associated protein-4, a DARPin (Designed Ankyrin Repeat Protein), a fibrinogen domain, a fibronectin binding domain (FN3 domain) (e.g., adnectin or monobody), a fynomer, a knottin, a Kunitz domain peptide, a nanofitin, a leucine-rich repeat domain, a lipocalm domain, a mAb 2 or FcabTM, a nanobody, a nanoCL
- CDR complementarity-determining region
- the sequences of the framework regions of different light or heavy chains are relatively conserved within a species.
- the framework region of an antibody that is the combined framework regions of the constituent light and heavy chains, serves to position and align the CDRs in three dimensional space.
- the amino acid sequences of the CDRs and framework regions can be determined using various well-known definitions in the art, e.g., Rabat, Chothia, international ImMunoGeneTics database (IMGT), and AbM (see, e.g., Johnson and Wu, Nucleic Acids Res. 2000 Jan 1; 28(1): 214-218 and Johnson et al., Nucleic Acids Res., 29:205-206 (2001); Chothia & Lesk, (1987) J. Mol. Biol.
- CDRs herein are determined using “Fab Analysis” on the World Wide Web at vbase2.org (Retter et al.,
- idiotype refers to the segment of an antibody or an antibody mimetic that determines its specificity for antigen, for example, a structure of a variable region of an antibody, a T cell receptor, or an antibody mimetic that is a shared characteristic between a group of antibodies, T-cell receptors, or antibody mimetics based upon the antigen binding specificity and therefore structure of their variable regions.
- the idiotype of an antibody typically includes the variable region, e.g., the CDRs and framework regions. For antibodies, the idiotype is located in the Fab region.
- expression of the idiotype usually requires participation of the variable regions of both heavy and light chains that form the antigen-combining site.
- expression of the idiotype usually requires participation of the variable regions of one polypeptide that forms the antigen-combining site.
- the idiotype varies depending on the type of antibody mimetic, but includes the region necessary for binding the cognate antigen.
- a “therapeutic antibody” or “therapeutic antibody mimetic” is an antibody or an antibody mimetic that has been demonstrated using an in vivo assay, for example, in humans, to have therapeutic activity.
- the term “recognize” refers to the ability of one molecule to bind to another molecule, for example, the ability of a receptor to bind its ligand or the ability of an antibody to bind its target.
- affinity refers to the equilibrium constant for the reversible binding of two agents and is expressed as a dissociation constant (Kd).
- Kd dissociation constant
- Affinity can be at least 1-fold greater, at least 2-fold greater, at least 3-fold greater, at least 4-fold greater, at least 5-fold greater, at least 6-fold greater, at least 7-fold greater, at least 8-fold greater, at least 9-fold greater, at least 10-fold greater, at least 20- fold greater, at least 30-fold greater, at least 40-fold greater, at least 50-fold greater, at least 60-fold greater, at least 70-fold greater, at least 80-fold greater, at least 90-fold greater, at least 100-fold greater, or at least 1000-fold greater, or more, than the affinity of an antibody for unrelated amino acid sequences.
- Affinity of an antibody to a target protein can be, for example, from about 100 nanomolar (nM) to about 0.1 nM, from about 100 nM to about 1 picomolar (pM), or from about 100 nM to about 1 femtomolar (fM) or more.
- nM nanomolar
- pM picomolar
- fM femtomolar
- the term “avidity” refers to the resistance of a complex of two or more agents to dissociation after dilution.
- the terms “immunoreactive” and “preferentially binds” are used interchangeably herein with respect to antibodies and/or antigen-binding fragments.
- binding refers to a direct association between two molecules, due to, for example, covalent, electrostatic, hydrophobic, and ionic and/or hydrogen-bond interactions, including interactions such as salt bridges and water bridges.
- Non-specific binding would refer to binding with an affinity of less than about 10 7 M, e.g., binding with an affinity of 10 6 M, 10 5 M, 10 4 M, etc.
- cell surface expression system or “cell surface display system” refers to the display or expression of a protein or portion thereof on the surface of a cell.
- a cell is generated that expresses proteins of interest fused to a cell-surface protein.
- a protein is expressed as a fusion protein with a transmembrane domain.
- the term “element” includes polypeptides, including fusions of polypeptides, regions of polypeptides, and functional mutants or fragments thereof and polynucleotides, including microRNAs and shRNAs, and functional mutants or fragments thereof.
- region is any segment of a polypeptide or polynucleotide.
- a "domain” is a region of a polypeptide or polynucleotide with a functional and/or structural property.
- the terms "stalk” or “stalk domain” refer to a flexible polypeptide connector region providing structural flexibility and spacing to flanking polypeptide regions and can consist of natural or synthetic polypeptides.
- a stalk can be derived from a hinge or hinge region of an immunoglobulin (e.g., IgGl) that is generally defined as stretching from Glu216 to Pro230 of human IgGl (Burton (1985) Molec. Immunol., 22: 161-206). Hinge regions of other IgG isotypes may be aligned with the IgGl sequence by placing the first and last cysteine residues forming inter-heavy chain disulfide (S-S) bonds in the same positions.
- IgGl immunoglobulin
- S-S inter-heavy chain disulfide
- the stalk may be of natural occurrence or non-natural occurrence, including but not limited to an altered hinge region, as disclosed in U.S. Pat. No. 5,677,425.
- the stalk can include a complete hinge region derived from an antibody of any class or subclass.
- the stalk can also include regions derived from CD 8, CD28, or other receptors that provide a similar function in providing flexibility and spacing to flanking regions.
- isolated means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring).
- a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated.
- Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.
- polypeptide is a single chain of amino acid residues linked by peptide bonds. A polypeptide does not fold into a fixed structure nor does it have any posttranslational modification. A “protein” is a polypeptide that folds into a fixed structure. “Polypeptides” and “proteins” are used interchangeably herein.
- a polypeptide may be “purified” to remove contaminant components of a polypeptide’s natural environment, e.g., materials that would interfere with diagnostic or therapeutic uses for the polypeptide such as, for example, enzymes, hormones, and other proteinaceous or nonproteinaceous solutes.
- a polypeptide can be purified (1) to greater than 90%, greater than 95%, or greater than 98%, by weight of antibody as determined by the Lowry method, for example, more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-PAGE) under reducing or nonreducing conditions using Coomassie blue or silver stain.
- SDS-PAGE sodium dodecyl sulfate- polyacrylamide gel electrophoresis
- immune cells generally includes white blood cells (leukocytes) which are derived from hematopoietic stem cells (HSC) produced in the bone marrow.
- HSC hematopoietic stem cells
- Immune cells includes, e.g., lymphocytes (T cells, B cells, natural killer (NK) cells) and myeloid-derived cells (neutrophil, eosinophil, basophil, monocyte, macrophage, dendritic cells).
- T cell includes all types of immune cells expressing CD3 including T-helper cells (CD4 + cells), cytotoxic T cells (CD8 + cells), T-reguIatory cells (Treg) and gamma-delta T cells.
- NKT cells which are CD3+, CD56+, and either CD4+ or CD8+, are considered a type of T cells herein.
- Surface expression of CD3 can be transiently decreased or eliminated in T cells, as has been observed with some of the methods for modifying T cells disclosed herein.
- Such modified CD4+ or CD8+ lymphocytes that have transiently decreased/absent CD3 surface expression are still considered T cells in this disclosure.
- Reference to a “CD” or cluster of differentiation marker, such as CD3+, CD4+, CD8+, CD56+ herein, relates to surface expression of such polypeptide.
- surface expression is a continuum between positive and negative, and can be assessed by FACS analysis, where cells are determined to be positive or negative based on user cutoffs known in the art.
- NK cell includes lymphocytes that express CD56 on their surface (CD56+ lymphocytes). NKT cells, which are CD3+, CD56+, and either CD4+ or CD8+, are considered a type of NK cells herein.
- a "cytotoxic cell” includes CD8 + T cells, natural -killer (NK) cells, NK-T cells, gd T cells, a subpopulation of CD4 + cells, and neutrophils, which are cells capable of mediating cytotoxicity responses.
- stem cell generally includes pluripotent or multipotent stem cells.
- stem cells includes, e.g., embryonic stem cells (ES); mesenchymal stem cells (MSC); induced- pluripotent stem cells (iPS); and committed progenitor cells (hematopoietic stem cells (FISC); bone marrow derived cells, etc.).
- treatment refers to obtaining a desired pharmacologic and/or physiologic effect.
- the effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disease and/or adverse effect attributable to the disease.
- Treatment covers any treatment of a disease in a mammal, e.g., in a human, and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; and (c) relieving the disease, i.e., causing regression of the disease.
- the terms “individual”, “subject”, “host”, and “patient” refer to a mammal, including, but not limited to, humans, murines (e.g., rats, mice), lagomorphs (e.g., rabbits), nonhuman primates, humans, canines, felines, ungulates (e.g., equines, bovines, ovines, porcines, caprines), etc.
- murines e.g., rats, mice
- lagomorphs e.g., rabbits
- nonhuman primates humans
- canines felines
- ungulates e.g., equines, bovines, ovines, porcines, caprines
- the terms “therapeutically effective amount” or “efficacious amount” refers to the amount of an agent, or combined amounts of two agents, that, when administered to a mammal or other subject for treating a disease, is sufficient to affect such treatment for the disease.
- the “therapeutically effective amount” will vary depending on the agent(s), the disease and its severity and the age, weight, etc., of the subject to be treated.
- the term “evolution” or “evolving” refers to using one or more methods of mutagenesis to generate a different polynucleotide encoding a different polypeptide, which is itself an improved biological molecule and/or contributes to the generation of another improved biological molecule.
- Physiological or "normal” or “normal physiological” conditions are conditions such as, but not limited to, pressure, temperature, pH, ionic strength, osmotic pressure, osmolality, oxidative stress, concentration of one or more solutes, concentration of electrolytes, concentration of glucose, concentration of hyaluronan, concentration of lactic acid or lactate, concentration of albumin, levels of adenosine, levels of R-2-hydroxyglutarate, concentration of pyruvate, concentration of oxygen, and/or presence of oxidants, reductants, or co-factors, as well as other conditions, that would be considered within a normal range at the site of administration, or at the tissue or organ at the site of action, to a subject.
- a “transduced cell” or a “stably transfected cell” is a cell that contains an exogenous nucleic acid(s) that is integrated into the genome of the cell.
- a “genetically modified cell” is a cell that contains an exogenous nucleic acid(s) regardless of whether the exogenous nucleic acid(s) is integrated into the genome of the cell, and regardless of the method used to introduce the exogenous nucleic acid(s) into the cell.
- Exogenous nucleic acid(s) inside a cell that are not integrated into the genome of the cell can be referred to as “extrachromosomal” herein.
- a “modified cell” is a cell that is associated with a recombinant nucleic acid vector (also called a “polynucleotide vector” or a “gene vector” herein), which in illustrative embodiments is a replication incompetent recombinant retroviral particle (also called a “RIR retroviral particle” or a “RIP” herein), that contains an exogenous nucleic acid, or a cell that has been genetically modified by an exogenous nucleic acid.
- a recombinant nucleic acid vector also called a “polynucleotide vector” or a “gene vector” herein
- a replication incompetent recombinant retroviral particle also called a “RIR retroviral particle” or a “RIP” herein
- a modified cell associates with a replication incompetent recombinant retroviral particle through interactions between proteins on the surface of the cell and proteins on the surface of the replication incompetent recombinant retroviral particle, including pseudotyping elements and/or T cell activation elements.
- a lipid-based reagent such as a liposomal reagent
- the lipid-based reagent containing nucleic acid associates with the lipid bilayer of the modified cell before fusing or being internalized by the modified cell.
- nucleic acid such as polyethylenimine (PEI) or calcium phosphate-based transfection
- PKI polyethylenimine
- the nucleic acid is typically associated with a positively charged transfection reagent to form the recombinant nucleic acid vector that associates with the negatively charged membrane of the modified cell before the complex is internalized by the modified cell.
- Other means or methods of stably transfecting or genetically modifying cells include electroporation, ballistic delivery, and microinjection.
- a “polypeptide” as used herein can include part of or an entire protein molecule as well as any posttranslational or other modifications.
- a pseudotyping element as used herein can include a “binding polypeptide” that includes one or more polypeptides, typically glycoproteins, that identify and bind the target host cell, and one or more “fusogenic polypeptides” that mediate fusion of the retroviral and target host cell membranes, thereby allowing a retroviral genome to enter the target host cell.
- the “binding polypeptide” as used herein can also be referred to as a “T cell and/or NK cell binding polypeptide” or a “target engagement element,” and the “fusogenic polypeptide” can also be referred to as a “fusogenic element”.
- a “resting” lymphocyte such as for example, a resting T cell, is a lymphocyte in the GO stage of the cell cycle that does not express activation markers such as Ki-67. Resting lymphocytes can include naive T cells that have never encountered specific antigen and memory T cells that have been altered by a previous encounter with an antigen. A “resting” lymphocyte can also be referred to as a “quiescent” lymphocyte.
- lymphodepletion involves methods that reduce the number of lymphocytes in a subject, for example by administration of a lymphodepletion agent. Lymphodepletion can also be attained by partial body or whole body fractioned radiation therapy.
- a lymphodepletion agent can be a chemical compound or composition capable of decreasing the number of functional lymphocytes in a mammal when administered to the mammal.
- One example of such an agent is one or more chemotherapeutic agents.
- Such agents and dosages are known, and can be selected by a treating physician depending on the subject to be treated.
- lymphodepletion agents include, but are not limited to, fludarabine, cyclophosphamide, cladribine, denileukin diftitox, alemtuzumab or combinations thereof.
- RNA interference is a biological process in which RNA molecules inhibit gene expression or translation by neutralizing targeted RNA molecules.
- the RNA target may be mRNA, or it may be any other RNA susceptible to functional inhibition by RNAi.
- an “inhibitory RNA molecule” refers to an RNA molecule whose presence within a cell results in RNAi and leads to reduced expression of a transcript to which the inhibitory RNA molecule is targeted.
- An inhibitory RNA molecule as used herein has a 5’ stem and a 3’ stem that is capable of forming an RNA duplex.
- the inhibitory RNA molecule can be, for example, a miRNA (either endogenous or artificial) or a shRNA, a precursor of a miRNA (i.e., a Pri-miRNA or Pre-miRNA) or shRNA, or a dsRNA that is either transcribed or introduced directly as an isolated nucleic acid, to a cell or subject.
- a miRNA either endogenous or artificial
- a shRNA a precursor of a miRNA (i.e., a Pri-miRNA or Pre-miRNA) or shRNA
- a dsRNA that is either transcribed or introduced directly as an isolated nucleic acid, to a cell or subject.
- double stranded RNA or “dsRNA” or “RNA duplex” refers to RNA molecules that are comprised of two strands. Double-stranded molecules include those comprised of two RNA strands that hybridize to form the duplex RNA structure or a single RNA strand that doubles back on itself to form a duplex structure. Most, but not necessarily all of the bases in the duplex regions are base- paired. The duplex region comprises a sequence complementary to a target RNA.
- the sequence complementary to a target RNA is an antisense sequence, and is frequently from 18 to 29, from 19 to 29, from 19 to 21, or from 25 to 28 nucleotides long, or in some embodiments between 18, 19, 20, 21, 22, 23, 24, 25 on the low end and 21, 22, 23, 24, 25, 26, 27, 2829, or 30 on the high end, where a given range always has a low end lower than a high end.
- Such structures typically include a 5’ stem, a loop, and a 3’ stem connected by a loop which is contiguous with each stem and which is not part of the duplex.
- the loop comprises, in certain embodiments, at least 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides.
- the loop comprises from 2 to 40, from 3 to 40, from 3 to 21, or from 19 to 21 nucleotides, or in some embodiments between 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 on the low end and 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, or 40 on the high end, where a given range always has a low end lower than a high end.
- microRNA flanking sequence refers to nucleotide sequences including microRNA processing elements.
- MicroRNA processing elements are the minimal nucleic acid sequences which contribute to the production of mature microRNA from precursor microRNA. Often these elements are located within a 40 nucleotide sequence that flanks a microRNA stem-loop structure. In some instances, the microRNA processing elements are found within a stretch of nucleotide sequences of between 5 and 4,000 nucleotides in length that flank a microRNA stem-loop structure.
- linker when used in reference to a multiplex inhibitory RNA molecule refers to a connecting means that joins two inhibitory RNA molecules.
- a “recombinant retrovirus” refers to a non-replicable, or “replication incompetent”, retrovirus unless it is explicitly noted as a replicable retrovirus.
- the terms “recombinant retrovirus” and “recombinant retroviral particle” are used interchangeably herein.
- retrovirus/retroviral particle can be any type of retroviral particle including, for example, gamma retrovirus, and in illustrative embodiments, lentivirus.
- retroviral particles typically are formed in packaging cells by transfecting the packing cells with plasmids that include packaging components such as Gag, Pol and Rev, an envelope or pseudotyping plasmid that encodes a pseudotyping element, and a transfer, genomic, or retroviral (e.g., lentiviral) expression vector, which is typically a plasmid on which a gene(s) or other coding sequence of interest is encoded.
- packaging components such as Gag, Pol and Rev
- an envelope or pseudotyping plasmid that encodes a pseudotyping element
- a transfer, genomic, or retroviral (e.g., lentiviral) expression vector which is typically a plasmid on which a gene(s) or other coding sequence of interest is encoded.
- a retroviral (e.g., lentiviral) expression vector includes sequences (e.g., a 5’ LTR and a 3’ LTR flanking e.g., a psi packaging element and a target heterologous coding sequence) that promote expression and packaging after transfection into a cell.
- sequences e.g., a 5’ LTR and a 3’ LTR flanking e.g., a psi packaging element and a target heterologous coding sequence
- lentivirus and “lentiviral particle” are used interchangeably herein.
- a “framework” of a miRNA consists of “5’ microRNA flanking sequence” and/or “3’ microRNA flanking sequence” surrounding a miRNA and, in some cases, a loop sequence that separates the stems of a stem-loop structure in a miRNA.
- the “framework” is derived from naturally occurring miRNAs, such as, for example, miR-155.
- the terms “5’ microRNA flanking sequence” and “5’ arm” are used interchangeably herein.
- the terms “3’ microRNA flanking sequence” and “3’ arm” are used interchangeably herein.
- miRNA precursor refers to an RNA molecule of any length which can be enzymatically processed into an miRNA, such as a primary RNA transcript, a pri-miRNA, or a pre- rniRNA.
- construct refers to an isolated polypeptide or an isolated polynucleotide encoding a polypeptide.
- a polynucleotide construct can encode a polypeptide, for example, a lymphoproliferative element.
- a skilled artisan will understand whether a construct refers to an isolated polynucleotide or an isolated polypeptide depending on the context.
- MOI Multiplicity of Infection ratio where the MOI is equal to the ratio of the number of virus particles used for infection per number of cells. Functional titering of the number of virus particles can be performed using FACS and reporter expression, as non-limiting examples.
- PBMCs peripheral blood mononuclear cells
- lymphocytes e.g., T cells, NK cells, and B cells
- monocytes e.g., red blood cells, platelets and granulocytes (i.e., neutrophils, eosinophils, and basophils).
- syncytium-inducing polypeptide refers to a membrane polypeptide or a portion thereof that causes cell fusion, with such cell fusion leading to the formation of syncytia.
- Syncytium- inducing polypeptides are a type of fusogenic envelope protein as disclosed herein.
- Syncytium-inducing polypeptides as used herein encompass those proteins naturally produced by viruses, particularly the so- called fusogenic membrane proteins (FMPs) and fusogenic membrane glycoproteins (FMGs), that mediate virus-cell fusion, as well as cell-cell fusion of infected cells.
- FMPs fusogenic membrane proteins
- FMGs fusogenic membrane glycoproteins
- Syncytium- inducing polypeptides as used herein further encompass non-viral polypeptides known to mediate cell-cell fusion events in vivo.
- a "viral fusogenic membrane glycoprotein” is a virally-derived fusogenic membrane protein that, in nature, mediates membrane fusion of a virus to its host target cell.
- a syncytium-inducing polypeptide (or portion thereof) or fusogenic membrane glycoprotein (or portion thereof), as used herein, has the ability, when in isolation from a virus, to mediate or induce fusion between a cell expressing the fusogenic membrane glycoprotein and a cell expressing a receptor for the fusogenic membrane glycoprotein. Examples of fusogenic membrane proteins include, but are not limited to fertilin b.
- the viral fusogenic membrane glycoprotein subset of the fusogenic membrane proteins includes, but is not limited to: type G glycoproteins in Rabies, Mokola, vesicular stomatitis and Toga viruses; murine hepatitis virus JFiM surface projection protein; porcine respiratory coronavirus spike- and membrane glycoproteins; avian infectious bronchitis spike glycoprotein and its precursor; bovine enteric coronavirus spike protein; the F and H, HN or G genes of Measles virus, canine distemper virus, Newcastle disease virus, human parainfluenza virus 3, simian virus 41, Sendai virus and human respiratory syncytial virus; gH of human herpes virus 1 and simian varicella virus, with the chaperone protein gL; human, bovine and cercopithicine herpesvirus gB; envelope glycoproteins of Friend murine leukemia virus and Mason Pfizer monkey virus; influenza haemagglutinin; G protein of Vesicular Sto
- syncytium-inducing polypeptides function alone, while others require more than one different polypeptide to have fusion-promoting activity.
- syncytium-inducing polypeptide is meant to encompass single fusion-promoting polypeptides as well as each of the polypeptides required for promoting fusion when there is a requirement for more than one.
- the term “about” refers to a value 10% less or 10% more than the disclosed value.
- “about 1% sucrose” would include 0.9% to 1.1% sucrose.
- transducing units refers to the number of viral particles in a solution that are capable of transducing a target cell, and can be calculated by transducing any target cell, for example, Jurkat cells, and measuring the expression of a transgene in the target cells, as determined, for example, by serial dilution and analysis of transgene expression by qPCR for the lentiviral genome using the Lenti-XTM qRT-PCR Titration Kit (Takara, #631235).”
- the term “or” is understood to be inclusive.
- the term “and/or” as used in a phrase such as “A and/or B” herein includes each of the following: A and B; A or B; A (alone); and B (alone).
- the term “and/or” as used in a phrase such as “A, B, and/or C” includes each of the following: A, B, and C; A, B, or C; A or B; A or C;
- the present disclosure overcomes prior art challenges by providing improved methods and compositions for modifying and in illustrative embodiments genetically modifying lymphocytes, for example NK cells and in illustrative embodiments, T cells.
- Some of the methods and compositions herein provide simplified and more rapid processes for transducing or transfecting lymphocytes that avoid some steps that require specialized devices.
- the methods provide an important step toward democratization of cell therapy methods.
- Illustrative methods and compositions for modifying lymphocytes, for example NK cells and in illustrative embodiments, T cells are performed ex vivo or in vivo by direct administration of replication incompetent recombinant retroviral particles (RIPs) to a subject.
- RIPs replication incompetent recombinant retroviral particles
- compositions for modifying T cells and/or NK cells are performed in less time than prior methods, and in fact in some embodiments, provide rapid point of care methods.
- compositions that have many uses, including their use in these improved methods are provided, including RIP and/or cell formulation and/or compositions that are adapted for perilymphatic, intranodal or subcutaneous administration.
- Some of these compositions include modified and in illustrative embodiments genetically modified lymphocytes that have improved proliferative and survival qualities, including in in vivo growth and engraftment and/or in ex vivo and/or in vitro culturing, for example in the absence of growth factors.
- Such RIP formulations and modified and in illustrative embodiments genetically modified lymphocytes will have utility, for example, as research tools to more easily transduce T cells and NK cells in vivo, ex vivo, or in vitro to understand factors that influence T cell proliferation and survival, and for commercial production, for example for the production of certain factors, such as growth factors and immunomodulatory agents, that can be harvested and tested or used in commercial products.
- Such RIP formulations and modified and genetically modified lymphocytes having have utility in the treatment of many disorders, such as in immune cell or gene therapy, in illustrative embodiments, for the treatment of hyperproliferative cell disorders such as cancer.
- Illustrative methods and compositions for immune cell therapy herein include, are compatible with, are effective for, and/or are adapted for perilymphatic, subcutaneous, intraperitoneal, or intramuscular delivery and cell and/or RIP formulations for such delivery.
- Some of these delivery methods and cell formulations i.e., delivery compositions
- promote cell aggregation promotes cell proliferation and survival that in some embodiments is further enhanced by the addition of antigen, growth factors and immunomodulatory agents to the cell formulation or to the site of administration of the cell formulation.
- target antigen availability e.g., epitope or antigen masking
- aspects and embodiments provided herein include direct injection of RIPs into a subject, wherein T cells and/or NK cells are modified in vivo.
- methods provided herein include directly administering (e.g., delivering, introducing, or injecting) viral particles to a subject.
- methods for administering viral particles into a subject to modify, and in illustrative embodiments, genetically modify and/or transduce T cells and/or NK cells in vivo, i.e., in the subject.
- the viral particles are retroviral particles.
- the retroviral particles are replication incompetent recombinant retroviral particles (RIPs). Many of the aspects and embodiments herein refer to RIPs, and a skilled artisan can understand how other viral and/or retroviral particles can be used.
- RIP formulations modifying compositions comprising RIPs, delivery solutions comprising RIPs, RIPs for use in a method, methods of making RIP formulations, in vivo compositions comprising RIPs, and in vivo reaction mixtures comprising RIPs are provided herein.
- the RIPs include one or more polynucleotides that encode an engineered signaling polypeptide, e.g., a CAR, engineered TCR, and/or a lymphoproliferative element (LE).
- the LE is a constitutively active LE.
- the RIP formulation includes activation elements, either in solution or present on the surface of the RIPs, to facilitate genetic modification of T cells and/or NK cells in vivo.
- the RIPs include a binding element and a fusogenic element on the surface of the RIP.
- one or both of the binding element and fusogenic element can be a pseudotyping element.
- the activation element is a binding element and the fusogenic element is a pseudotyping element.
- a method for administering replication incompetent recombinant retroviral particles (RIPs) to a subject comprising: administering a formulation comprising the RIPs to the subject, wherein the RIPs comprise: a) an activation element on the surface of the RIPs; and b) a polynucleotide comprising one or more transcriptional units, wherein each of the one or more transcriptional units encode one or more engineered signaling polypeptides.
- the engineered signaling polypeptide can be any of the engineered signaling polypeptides disclosed elsewhere herein, for example, a CAR, an engineered TCR, and/or a lymphoproliferative element.
- a method for administering replication incompetent recombinant retroviral particles (RIPs) to a subject comprising: administering a formulation comprising the RIPs to the subject, wherein the RIPS comprise: a) an activation element on the surface of the RIPs; and b) a polynucleotide encoding a lymphoproliferative element (LE) and encoding a chimeric antigen receptor (CAR), wherein the LE is constitutively active.
- the RIPS comprise: a) an activation element on the surface of the RIPs; and b) a polynucleotide encoding a lymphoproliferative element (LE) and encoding a chimeric antigen receptor (CAR), wherein the LE is constitutively active.
- the activation element can be any of the activation elements disclosed elsewhere herein.
- the RIPs further comprise a binding element and/or a fusogenic element on the surface of the RIPs. Any of the binding or fusogenic elements disclosed elsewhere herein can be used.
- the administering can include administering the RIPs intravenously or perivascularly.
- the RIPs can be administered perivascularly.
- Perivascular administration includes intratumoral, intranodal, and perilymphatic administration.
- the RIPs can be administered intratumorally, intranodally, or, in illustrative embodiments, perilymphaticly.
- Perilymphatic administration includes subcutaneous, interstitial, intraperitoneal, intramuscular, and intradermal administration, and in some embodiments, the RIPs can be administered subcutaneously, interstitially, intraperitoneally, intramuscularly, or intradermally. In some embodiments, the RIPs can be delivered intranodally or subcutaneously. Any formulation herein, including those that comprise RIPs, can also be referred to as a composition, such as a modifying composition if it includes for example, RIPs, or a delivery solution. [0089] Introduction or administration of RIPs into a subject can be by direct delivery into lymph nodes.
- the RIPs can be injected into or administered to the inguinal, axillary, and/or cervical lymph nodes.
- the lymph nodes into which the RIPs are delivered are lymph node metastases.
- the lymph nodes are tumor-draining lymph nodes.
- the lymph nodes are not tumor-draining lymph nodes.
- the lymph nodes comprise TILs.
- RIP formulations herein can include components, and thus can have properties, to improve their effectiveness, for example when introduced to a subject, which in non-limiting examples can be by subcutaneous delivery.
- the RIPs are formulated to comprise a means for retaining the RIPs at or near the site of delivery or to be effective for, configured to, and/or adapted for retention near the site of delivery.
- the RIPs are formulated such that they are effective for, adapted to and/or configured to retain the RIPs at or near the site of delivery, or have a means to retain the RIPs at or near the site of delivery.
- the RIPs delivered subcutaneously comprise a membrane-bound cytokine.
- the RIPs delivered subcutaneously comprise a membrane-bound chemokine.
- the RIPs are delivered in a depot formulation.
- the RIPs are delivered in a hydrogel. Depot formulations and hydrogels are discussed in more detail herein.
- RIPs are formulated to comprise a means for inhibiting localized absorption into the blood.
- RIPs are formulated such that they are effective for, adapted to and/or configured to inhibit localized absorption into the blood.
- RIPs are formulated to comprise a means for entry into the lymphatics.
- the RIPs are delivered in a soluble formulation.
- the RIPs are formulated with an effective amount of one or more excipients that promote lymphatic absorption (a “lymphagogue”).
- the lymphagogue is selected from human serum albumin, hyaluronidase, colloids including non-sulfated dextrans, dextrans wherein the molecular weight is greater than 10K, 40K, 100K, 200K, 500K, 1000K, or 2000K kDa, and other agents that decrease the local residence time of the RIPs at the site of delivery (e.g., subcutaneous).
- the RIPs are formulated for delivery in a buffer that includes salts, typically in an effective amount for in vivo delivery.
- the formulation comprises phosphate-buffered saline (PBS).
- the formulation further comprises lactose such as from 0.25% lactose to 10% lactose, for example 0.5% to 10%, 0.5% to 8%, 1% to 8%, 1% to 10%, 2% to 8%, 2% to 6%, 3% to 6%, 3% to 5%, 3.5% to 4.5%, 3.6% to 4.4%, 3.7% to 4.3%, 3.8% to 4.2%, 3.9% to 4.1% about 4% lactose or 4% lactose.
- the formulation has a volume of, and/or the RIP formulation and/or cell formulation delivered to a subject has a volume of, between 0.5 and 25 ml, 0.5 and 20 ml, 0.5 and 10 ml, 0.5 and 7.5 ml, 0.5 and 6 ml, 1.0 and 25 ml, 1.0 and 20 ml, 1.0 and 7.5 ml, 1.0 and 5.0 ml, 1 and 5 ml, 2.5 and 25 ml, 2.5 and 20 ml, 2.5 and 7.5 ml, or 2.5 and 5.0 ml.
- a cell formulation can be combined with a RIP formulation immediately before, or within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or 30 minutes of injection and thus some, most, or all cells are not modified, genetically modified or transduced.
- a method for administering RIPs to a subject comprising administering a RIP formulation further comprises administering (sometimes referred to herein as coadministering) a cell formulation (also referred to herein as a cell suspension or cell mixture) to the subject.
- the cell formulation comprises whole blood collected from the subject.
- the cell formulation comprises neutrophils from the subject.
- the cell formulation comprises dendritic cells from the subject.
- the cell formulation comprises macrophages from the subject.
- the whole blood has been subjected to a PBMC and TNC enrichment procedure and the cell formulation comprises enriched cells.
- the cell formulation comprises PBMCs.
- the cell formulation administered to the subject comprises T cells and/or NK cells.
- the cells for example PBMCs, in illustrative embodiments are not/have not been exposed to a vector such as a RIP ex vivo, but are or have been exposed to an activation element (e.g. anti-CD3 and/or anti-CD28) before being coadministered, such that they are in activated state when they are coadministered and/or their signaling pathways have been engaged ex vivo such that they will become activated after coadministration to the subject with or without further exposure to an activation element.
- an activation element e.g. anti-CD3 and/or anti-CD28
- RIPs that are co-administered with such coadministered cells can have an activation element on their surface and/or can encode an LE.
- RIPs that are coadministered with such activated cells which in illustrative embodiments have not been exposed to a vector (e.g. RIP) ex vivo, do comprise either or both an activation element on their surface and/or a polynucleotide encoding an LE.
- the cells are modified, i.e, have been contacted with a RIP before administration to the subject.
- the cells are unmodified, i.e., have not been contacted with a RIP before administration to the subject.
- the RIP formulation and cell formulation can be administered, delivered, introduced, or injected within 0.5, 1, 2, 3, 4, or 5 cm of each other at a target delivery site of the subject, for example on the surface of the skin of the subject.
- the administering the cell formulation to the subject occurs simultaneously or within 1, 2, 3, 4, 5, 10, 15, 30, 45, or 60 minutes or 1, 2, 3, 4, 5, 6, 7, or 8 hours of the administering the RIP formulation to the subject.
- a method for administering RIPs and/or cells to a subject comprises administering at least 0.1 ml, 0.5 ml, 1 ml, 1.5 ml, 2 ml, 2.5 ml, 3 ml, 4 ml, or 5 ml, 10 ml, 15 ml, 20 ml, or 25 ml of any of the formulations disclosed herein that comprise RIPs to the subject.
- a method for administering RIPs and/or cells to a subject comprises administering 0.1 to 20 ml of a RIP formulation to the subject.
- the method for administering RIPs and/or cells to the subject comprises administering 1 to 10 ml or 1 to 20 ml or 1 to 25 ml of a RIP formulation to the subject. In illustrative embodiments, the method for administering RIPs and/or cells to the subject comprises administering 2 to 3 ml of a RIP formulation. In some embodiments, the method for administering RIPs and/or cells to a subject can include any route of administration as disclosed herein. In illustrative embodiments, the method for administering RIPs and/or cells to a subject can include administering the RIPs and/or cells perilymphatically.
- the method for administering RIPs and/or cells to a subject can include either a single dosage or multiple dosages. In some embodiments, the method for administering RIPs and/or cells to a subject can include more than 1, 2, 3, 4, 5, or a greater number of dosages.
- a method for administering RIPs to a subject comprises administering at least 1, 10, 100, 1000, 10 4 , 10 s , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10", 10 12 , 10 13 , or 10 14 total transducing units (TUs) to the subject.
- the method for administering RIPs to a subject comprises administering 1 x 10 5 to 4 x 10 9 total TUs to the subject.
- the method for administering RIPs to a subject comprises administering 1 x 10 6 to 5 x 10 9 total TUs to the subject.
- the TUs administered can be measured in terms of the weight in kg of the subject, i.e., TUs/kg.
- a method for administering RIPs to a subject comprises administering at least 1, 10, 100, 1000, 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , or 10 14 TU/kg to the subject.
- the method for administering RIPs to a subject comprises administering 1 to 10 14 TU/kg, 10 3 to 10 14 TU/kg, or 10 6 to 10 14 TU/kg, or 10 3 to 10 8 TU/kg, or 10 4 to 10 7 TU/kg to the subject, wherein kg refers to the weight of the subject.
- the TUs administered can be measured in terms of the number of target cells found in 1 ml of blood of the subject, i.e., TUs/target cell/ml blood of the subject.
- a method for administering RIPs to a subject comprises administering 1 ng/kg/day to 500 mg/kg/day to the subject. In some embodiments, a method for administering RIPs to a subject comprises administering 1 ng/kg/day to 100 mg/kg/day for a period of 1, 2, 3, 4, 5, 6, or 7 days or consecutive days, or days in a 1, 2, 3, 4, 5, or 6-month period, such as 1 day per month over a 1, 2, 3, 4, 5, or 6 month period.
- a method for administering RIPs to a subject comprises administering at least 1.0 x 10 4 , 1.0 x 10 5 , 1.0 x 10 6 , or 1.0 x 10 7 genome copies (GC) to the subject.
- a method for administering RIPs to a subject comprises administering 1.0 x 10 4 to 1.0 x 10 15 GC to the subject.
- the method for administering RIPs to a subject comprises administering 1.0 x 10 9 to 1.0 x 10 15 GC to the subject.
- the dosage administered can be in terms of GC/kg of the subject.
- the method of administering RIPs to a subject comprises administering 1.0 x 10 9 to 1.0 x 10 15 GC/kg to the subject.
- a method for administering RIPs to a subject comprises administering at least 1.0 x 10 4 , 1.0 x 10 5 , 1.0 x 10 6 , or 1.0 x 10 7 infectious units to the subject.
- a method for administering RIPs to a subject comprises administering 1.0 x 10 4 to 1.0 x 10 15 infectious units to the subject.
- the method of administering RIPs to a subject comprises administering 1.0 X 10 9 to 1.0 X 10 15 infectious units/kg to the subject as per the body weight. Infectious unit can be quantified by techniques available in the art and include viral particle number determination, fluorescence microscopy, and titer by plaque assay.
- the number of adenovirus particles can be determined by measuring the absorbance at A260.
- infectious units can also be determined by quantitative immunofluorescence of vector specific proteins using monoclonal antibodies or by plaque assay.
- methods that calculate the infectious units include the plaque assay, in which titrations of the virus are grown on cell monolayers and the number of plaques is counted after several days to several weeks.
- the infectious titer is determined, such as by plaque assay, for example an assay to assess cytopathic effects (CPE).
- CPE assay is performed by serially diluting virus on monolayers of cells, such as F1FF cells, that are overlaid with agarose.
- infectious units can be determined using an endpoint dilution (TCID50) method, which determines the dilution of virus at which 50% of the cell cultures are infected and hence, generally, can determine the titer within a certain range, such as one log.
- TCID50 endpoint dilution
- a method for administering RIPs to a subject comprises administering at least 1.0 x 10 4 , 1.0 x 10 s , 1.0 x 10 6 , or 1.0 x 10 7 plaque forming units (PFU) to the subject.
- a method for administering RIPs to a subject comprises administering 1.0 x 10 4 to 1.0 x 10 15 PFU to the subject.
- the method for administering RIPs to a subject comprises administering 1.0 x 10 9 to 1.0 x 10 15 PFU to the subject.
- the method of administering RIPs to a subject comprises administering 1.0 x 10 9 to 1.0 x 10 15 PFU/kg to the subject as per the body weight.
- a method for administering RIPs to a subject comprises administering at least 1.0 x 10 3 , 1.0 x 10 4 , 1.0 x 10 s , 1.0 x 10 6 , or 1.0 x 10 7 dimming units (DU), as disclosed elsewhere herein, to the subject.
- a method for administering RIPs to a subject comprises administering 1.0 x 10 3 to 1.0 x 10 15 DU to the subject.
- a method for administering RIPs to a subject comprises administering 1.0 x 10 3 to 1.0 x 10 6 DU to the subject.
- the method of administering RIPs to a subject comprises administering 10 to 1.0 x 10 13 DU/kg to the subject as per the body weight.
- the amount of RIPs administered to the subject can be such that it prevents producing too many integrations (also referred to as integrants) in an individual cell.
- integrants also referred to as integrants
- on average 5 or 3 or fewer integrants measured as lentigenome copies per cellular genome are generated.
- on average 3 or fewer integrants are generated.
- on average 2 or fewer integrants are generated.
- the present disclosure provides various treatment methods that include administering, delivering, and/or injecting replication incompetent recombinant retroviral particles (RIPs) directly to a subject.
- RIPs have an activation element associated with the surface of the RIPs and include a polynucleotide that encodes one or more of a lymphoproliferative element (LE), an engineered T cell receptor (“engineered TCR”), and a chimeric antigen receptor (CAR).
- the LE is a constitutively active LE.
- the RIPs encode both an LE and a CAR.
- Such RIPs are capable of, adapted for, and/or effective for transducing T cells and/or NK cells in vivo, such that the in vivo transduced T cells and NK cells express the LE, engineered TCR, and/or CAR.
- An engineered TCR or a CAR of the present disclosure when expressed by and present in a T lymphocyte or an NK cell, can mediate cytotoxicity toward a target cell.
- Such methods herein typically involve administration of substantially purified or purified RIPs to a subject as provided herein.
- An engineered TCR or CAR of the present disclosure binds to an antigen present on a target cell, thereby mediating killing of a target cell by a T lymphocyte or an NK cell genetically modified to produce the engineered T cell receptor or CAR.
- an engineered T cell receptor or an ASTR of the CAR binds to an antigen present on the surface of a target cell.
- the present disclosure in some aspects provides methods of killing, or inhibiting the growth of, a target cell, that involve contacting a cytotoxic immune effector cell (e.g., a cytotoxic T cell, or an NK cell) that is genetically modified to produce a subject engineered T cell receptor or CAR with a target cell, such that the T lymphocyte or NK cell recognizes an antigen present on the surface of the target cell, and mediates killing of the target cell.
- a cytotoxic immune effector cell e.g., a cytotoxic T cell, or an NK cell
- the present disclosure provides a method of treating a disease or disorder in an individual having the disease or disorder, the method including: a. introducing an expression vector including a polynucleotide sequence encoding a CAR and/or an LE (e.g. a constitutively active LE) into a subject to produce a genetically engineered cell, for example, a genetically engineered cytotoxic cell, T cell, and/or NK cell.
- the method of treating includes administering both an expression vector (e.g, a RIP formulation) and a genetically engineered cytotoxic cell (e.g., a cell formulation comprising modified, genetically modified, or transduced T cells and/or NK cells).
- the method of treating includes administering an expression vector (e.g., a RIP formulation) and unmodified cells (e.g., a cell formulation comprising unmodified cells (e.g.
- the unmodified cells can be from the subject.
- the unmodified cells from the cell formulation and the cells present in the subject before administration can be modified by the RIPs in the RIP formulation.
- the RIP formulation modifies cells in the subject and produces a persistent population of cells in the subject, as disclosed elsewhere herein.
- the cells modified by the RIP formulation include the cells from a separately administered cell formulation.
- the RIPs and/or cells administered to a subject for a method of treating can include administration of cytokines, as disclosed elsewhere herein.
- the cytokines are part, of or co-administered with, a formulation.
- the cytokines can be membrane-bound cytokines on the surface of the RIPs or cells, and in illustrative embodiments, chemokines membrane-bound.
- Cells administered to a subject including a membrane-bound cytokine would typically come from the recent fusion of the cell with a RIP expressing said membrane-bound cytokine, and not from expression of the membrane-bound cytokine in the cell.
- the cytokine or membrane-bound cytokine can include one or more of IL-1, IL-2, IL-7, IL- 12, IL-15, IL-18, IL-21, TNFa, IRNg, GM-CSF, CCL1, CCL2 (MCP-1), CCL3, CCL5, CCL7 (MCP-3), CCL8 (MCP-2), CCL19, CCL20, CCL21, CCL22, CCL28, CXCL1, CXCL9, CXCL10, CXCL11, CXCL12, CXCL14 (BRAK), or CX3CL1, or a variant of any of the preceding, or an active fragment of any of the preceding.
- the cytokine or membrane-bound cytokine and in illustrative embodiments, the chemokine or membrane-bound chemokine can be CCL1, CCL2 (MCP-1), CCL3, CCL5, CCL7 (MCP-3), CCL8 (MCP-2), CCL19, CCL20, CCL21, CCL22, or CCL28, or a variant of any of the preceding, or an active fragment of any of the preceding.
- Methods provided herein such as adoptive cell therapies, methods for producing persistent populations of cells, methods for delivering a formulation (e.g., a modified cell T cell and/or NK cell formulation, a RIP formulation, and/or an unmodified T cell and/or NK cell formulation), etc. as non limiting examples, are especially adopted for treating cancer.
- a formulation e.g., a modified cell T cell and/or NK cell formulation, a RIP formulation, and/or an unmodified T cell and/or NK cell formulation
- Such cancer can be any type of cancer.
- such methods can be used for treating a subject who has, or a tumor associated with ovarian cancer, soft tissue sarcoma, peripheral T cell cancer, colorectal cancer, intrahepatic cholangiocarcinoma, glioblastoma, esophageal cancer, cutaneous T cell lymphoma, non-hodgkin lymphoma, urothelial cancer, basal cell carcinoma, epithelioid sarcoma, pancreatic cancer, non-small cell lung carcinoma, hodgkin lymphoma, renal cell carcinoma, mesothelioma, metastatic uveal melanoma, kidney cancer, blood cancer, F1ER2 -expressing cancers, non-melanoma skin cancer, liposarcoma, hepatocellular carcinoma, small lymphocytic lymphoma, prostate cancer, breast cancer, anal cancer, marginal zone lymphoma, cutaneous squamous cell carcinoma, thyroid cancer, medullary thyroid cancer, triple-
- methods herein can be used to treat tumors that express any one or more of the tumor-associated antigens and/or tumor-specific antigens provided herein, and engineered T cell receptors and CARs can be designed to recognize such targets, for example, any of the tumor-associated antigens and/or tumor-specific antigens disclosed elsewhere herein.
- tumor associated or tumor specific antigens include blood tumor antigens provided herein elsewhere in this specification, and in some non-limiting embodiments includes the following antigens, most or all of which are believed to be associated with solid tumors: AXL, CD44v6, CAIX, CEA, CD133, c-Met, EGFR, EGFRvIII, Epcam, EphA2, GD2, GPC3, GUCY2C, HER1, HER2, ICAM-1, IL13Ra2, ILllRa, Kras, Kras G12D, LI CAM, MAGE, MET, Mesothelin, MUC1, MUC16 ecto, NKG2D, NY-ESO-1, PSCA, ROR-2, WT-1.
- any of the methods provided herein that involve an administering step can be combined with administration of another cancer therapy, which in certain embodiments, can be a cancer vaccine, for example delivered subcutaneously.
- another cancer therapy which in certain embodiments, can be a cancer vaccine, for example delivered subcutaneously.
- such methods provided herein that include administering genetically modified T cells and/or NK cells into a subject, especially where the subject has, is afflicted with, or is suspected of having cancer can further include delivering an effective dose of an immune checkpoint inhibitor to the subject.
- This checkpoint inhibitor delivery can occur before, after, or at the same time as administering the genetically modified T cells and/or NK cells.
- Immune checkpoint inhibitors are known and various compounds are approved and in clinical development. Check point molecules, many of which are the target of checkpoint inhibitor compounds, include, but not limited to an anti-PDl antibody.
- the administering is for treating cancer in the subject, and wherein a tumor in the subject regresses within 60 days, 45 days, 30 days, or 14 days after said administering.
- the tumor is a blood cancer, for example DLBCL, that in illustrative examples expresses any of the blood cancer antigens provided herein.
- the tumor is a solid tumor that expresses a solid tumor antigen, which in certain illustrative embodiments is a HER2 positive solid tumor, such as, but not limited to, breast cancer.
- the administering is for treating cancer in the subject, and wherein the subject experiences stable disease, at least a partial response, or a complete response, in illustrative embodiments by RECIST1.1 criteria, within 90 days, 75 days, 60 days, 45 days, 30 days, or 14 days after said administering.
- the tumor shrinks by at least 10%, 20%, 25%, 30%, 50% or more.
- a partial response occurs when the sum of tumor lesions reduces by 30% or more and is confirmed at least 4 weeks after the prior scan without the appearance of new lesions and/or any pathological lymph nodes have a reduction in short axis to less than 10 mm.
- a complete response occurs when all target and non-target lesions disappear.
- the administering is for treating cancer in the subject, and wherein the subject experiences at least a partial response or experiences a complete response within 60 days, 45 days, 30 days, or 14 days after said administering.
- the subject is a human afflicted with cancer.
- the cell formulation is administered 2, 3, 4, 5, 6, or more times, or in illustrative embodiments only once to the subject before stable disease, or in illustrative embodiments a partial response or a complete response is achieved.
- a second formulation is administered to the subject at a second, third, fourth, etc. timepoint between 1 day and 1 month, 2 months, 3 months, 6 months, or 12 months after the administering a first cell formulation, wherein the second formulation can be identical to the first formulation, or can comprises any of the formulations provided herein.
- RIPs and/or modified and/or or unmodified lymphocytes e.g., modified T cells and/or NK cells
- the administration of the modified T cells and/or NK cells, or RIPs is performed in a method that does not require lymphodepletion of the subject for successful engraftment in the subject and/or for successful reduction of tumor volume in the subject, or that is performed on a mammalian (e.g., human) subject that has not been subjected to lymphodepletion in the prior days, weeks, or months or ever before such administration (e.g., subcutaneous administration).
- the administration is performed on a mammalian (e.g., human) subject that is not suffering from a low white blood cell count, lymphopenia or lymphocytopenia.
- the subcutaneous administration is performed on a subject having a lymphocyte count in the normal range (i.e., 1,000 and 4,800 lymphocytes in 1 microliter (pL) of blood). In certain embodiments, the subcutaneous administration is performed on a subject having between 1,000 and 5,000, over 300, over 500, over 1,000, over 1,500, or over 2,000 lymphocytes per pL of blood).
- the administration for example subcutaneous administration, is performed on a mammalian (e.g., human) subject that is lymphoreplete, that has an effective number of lymphocytes, that has at least 50%, 60%, 75%, 80%, or 90% of the normal number of lymphocytes in a healthy human, and/or having more than 10, 20, 30, 40, 50, 60, 70, 75, 80, 85, 90, or 95% of their lymphocytes before such administration.
- a mammalian e.g., human subject that is lymphoreplete
- an effective number of lymphocytes that has at least 50%, 60%, 75%, 80%, or 90% of the normal number of lymphocytes in a healthy human, and/or having more than 10, 20, 30, 40, 50, 60, 70, 75, 80, 85, 90, or 95% of their lymphocytes before such administration.
- Recombinant viral particle formulations are disclosed in methods and compositions provided herein, for example, to modify cells, as non-limiting examples human cells, primary cells, T cells and/or NK cells to make genetically modified and/or transduced cells, human cells, primary cells, T cells and/or NK cells.
- the recombinant viral particles, and formulations thereof, are themselves aspects of the present disclosure.
- the recombinant viral particles included in aspects provided herein are recombinant retroviral particles, and are further replication incompetent, meaning that a recombinant retroviral particle cannot replicate once it leaves the packaging cell, and thus cannot replicate in a subject, for example when administered to the subject.
- retroviral particles are replication incompetent, and if such retroviral particles include nucleic acids in their genome that are not native to the retrovirus, they are “recombinant retroviral particles.”
- the recombinant retroviral particles are lend viral particles.
- RIPs Replication incompetent recombinant retroviral particles are referred to herein as RIPs and formulations that include RIPs can be referred to as RIP formulations.
- RIP formulations A skilled artisan can understand how the various aspects and embodiments disclosed herein could be modified for other viral and retroviral particles, or for non- viral recombinant vectors.
- Cell formulations are provided herein that include for example T cells and/or NK cells. Such formulations, in illustrative embodiments are provided by methods provided herein. Any of the cell formulations provided herein can include, in non-limiting examples, self-driving CAR-T cells. In one aspect, provided herein is a cell formulation comprising a population of self-driving CAR-T cells, such as modified, genetically modified, transcribed, transfected, and/or stably integrated self-driving CAR-T cells in a delivery solution.
- the delivery solution, RIP formulation, or cell formulation is compatible with, effective for or even adapted for perilymphatic, subcutaneous, or intramuscular delivery to keep cells aggregated locally to enable a controlled release of cells into the circulation.
- concentration of unmodified or modified cells in a delivery solution or formulation for perilymphatic, subcutaneous, or intramuscular delivery in some embodiments is higher than that typically delivered intravenously.
- concentration of white blood cells in the delivery solution or formulation for perilymphatic, subcutaneous, or intramuscular delivery is greater than about 1.5 x 10 s cells/ml, about 5 x 10 s cells/ml, about 1 x 10 9 cells/ml to 1.2 x 10 9 cells/ml.
- cells for example mixtures of modified and unmodified lymphocytes or unmodified cells alone as discussed herein, or, in other embodiments, viral particles (e.g., RIPs) are formulated in a delivery solution or cell formulation such that they are capable of, effective for, and adapted for perilymphatic, intranodal, subcutaneous, or intramuscular administration.
- viral particles e.g., RIPs
- certain embodiments of commercial container and kit aspects provided herein are or include a container of sterile perilymphatic, intranodal, subcutaneous, and/or intramuscular delivery solution, which in some embodiments is stored refrigerated.
- Such delivery solutions are capable of, and in illustrative embodiments effective for, and in further illustrative embodiments adapted for, perilymphatic, subcutaneous, intranodal, or intramuscular administration, and in illustrative embodiments subcutaneous administration.
- such delivery solutions and/or formulations typically have a pH and ionic composition that provides an environment in which RIPs to be administered retain their transducing ability (i.e. are effective for, compatible with, or even adapted for transducing cells in vivo, in illustrative embodiments NK cells and/or T cells) and/or cells (e.g. NK cells and/or T cells) to be administered can survive until they are administered, for example for at least 1 hour, and typically can survive for at least 4 hours.
- a pH and ionic composition that provides an environment in which RIPs to be administered retain their transducing ability (i.e. are effective for, compatible with, or even adapted for transducing cells in vivo, in illustrative embodiments NK cells and/or T cells) and/or cells (e.g. NK cells and/or T cells) to be administered can survive until they are administered, for example for at least 1 hour, and typically can survive for at least 4 hours.
- a delivery solution and/or a formulation can include one or more of any of the buffers or salts, including concentrations, disclosed in the Exemplary Embodiments section, for example, PBS, HBSS, saline, Ringer's lactate solution, Plasma-Lyte, and others.
- a delivery solution and/or a formulation can include one or more, for example two or more, three or more, four or more, or five or more, of any other components, including concentrations, disclosed in the Exemplary Embodiments section, for example, DMSO, human serum albumin (HSA), colloids (e.g., dextran (40 kDa to 2 MDa), hetastarch, albumin, PEG (5 kDa - 100 kDa)), sugars (e.g., dextrose, lactose, sucrose, or trehalose), and others.
- HSA human serum albumin
- colloids e.g., dextran (40 kDa to 2 MDa), hetastarch, albumin, PEG (5 kDa - 100 kDa)
- sugars e.g., dextrose, lactose, sucrose, or trehalose
- a delivery solution and/or a formulation is or includes a multiple electrolyte solution.
- a delivery solution can be or include a sterile, nonpyrogenic isotonic solution in a container, such as a single dose container.
- Such solution in certain embodiments is suitable or adapted for intravenous administration or intraperitoneal administration as well as perilymphatic, subcutaneous, and/or intramuscular administration.
- a delivery solution and/or a formulation can include any of the multiple electrolyte solutions, including concentrations, disclosed in the Exemplary Embodiments section, for example, the multiple electrolyte injection solution can be Plasma-Lyte A Injection pH 7.4 available from various commercial suppliers, and others.
- a delivery solution and/or a formulation is frozen before being thawed and administered to a subject.
- the delivery solution and/or the formulation can be stored at less than 0, -15, or -70 °C for a certain number of days.
- the delivery solution and/or the formulation can include any of the freezing storage temperatures and times disclosed in the Exemplary Embodiments section.
- the delivery solution and/or formulation can be frozen for 1, 2, 3, 4, 5, or 6 days, or 1, 2, 3, or 4 weeks, or 1, 2, 3, 4, 5, 6, 9, or 12 months, or indefinitely, before they are administered to, or in illustrative embodiments of cell formulations and delivery solutions comprising cells, readministered back to the subject.
- the RIPs and/or cells can be tested for various quality control attributes disclosed elsewhere herein, for example, viral concentration, purity, and/or potency, and/or one or more cell and/or gene therapy quality control tests.
- a delivery solution and/or a formulation is never frozen before being administered to a subject.
- the delivery solution and/or the formulation can be stored at 2 to 8 °C for a certain number of days.
- the delivery solution and/or the formulation can include any of the non-freezing storage temperatures and times disclosed in the Exemplary Embodiments section.
- a delivery solution and/or a formulation includes DMSO.
- the delivery solution and/or the formulation can include about 6% DMSO (v/v).
- the delivery solution and/or the formulation contains no DMSO.
- the delivery solution and/or the formulation can include any of the DMSO concentrations disclosed in the Exemplary Embodiments section.
- a delivery solution and/or a formulation includes a colloid.
- the delivery solution and/or the formulation can include one or more of dextran (40 kDa to 2,000 kDa, or 40 kDa to 2 x 10 6 kDa), hetastarch, albumin, PEG (5 kDa - 100 kDa).
- a delivery solution and/or a formulation includes human serum albumin (HSA).
- HSA human serum albumin
- the delivery solution and/or the formulation can include 2.5% to 7.5% HSA (w/v) (e.g., 25 to 75 mg/ml).
- the delivery solution or the formulation includes no HSA.
- the delivery solution and/or the formulation can include any of the colloids and respective concentrations disclosed in the Exemplary Embodiments section.
- a delivery solution and/or a formulation includes 1% to 10% DMSO and 0.20% to 5% HSA.
- the delivery solution and/or the formulation includes 2% to 8%, 3% to 7%, or 4.5% to 8% DMSO and 0.25% to 7.5%, 0.25% to 6%, or 0.25% to 5% HSA.
- the delivery solution and/or the formulation includes 5% to 7.5% DMSO and 4% to 6% HSA.
- a delivery solution and/or a formulation includes a sugar.
- the delivery solution and/or the formulation can include one or more of dextrose, lactose, trehalose, and/or sucrose.
- the delivery solution and/or the formulation can include 3 to 7% dextrose (w/v) (e.g., 30 to 70 mg/ml).
- the delivery solution and/or the formulation can include 2 to 8% lactose.
- the delivery solution and/or the formulation can include 2 to 8% sucrose.
- the delivery solution and/or the formulation can include 2 to 8% trehalose.
- the delivery solution and/or the formulation can include any of the sugars and respective concentrations disclosed in the Exemplary Embodiments section.
- a delivery solution and/or formulation are disclosed in more detail herein and in the Exemplary Embodiments, and can be delivered either in the same delivery solution and/or formulation or in different delivery solutions and/or formulations, e.g., a delivery solution and a RIP formulation, or a first and second delivery solution.
- these other components can be delivered along with the delivery solution and/or formulation, or can be delivered days (e.g., 1, 2, 3, 4, 5, 6, or 7 days), weeks (e.g., 1, 2, 4, or 4 weeks), or even months (e.g., 1, 2, 3, 6, 12, or 24 months) before or after the first delivery solution and/or formulation.
- the persistence of genetically modified CAR-T cells near the site of subcutaneous administration further demonstrates an advantage of certain embodiments provided herein wherein the subcutaneous administration is performed near (e.g., within 1,
- a site of neoplastic (e.g., cancerous) cells such as a tumor, or an organ comprising a tumor, including for example, the spleen or lymph nodes in the case of blood cancers.
- neoplastic e.g., cancerous
- the delivery solution and/or formulation can be substantially free of bovine protein as disclosed in the Exemplary Embodiments herein. In some embodiments of any of the delivery solutions and/or formulations provided herein, the delivery solution and/or formulation can be substantially free of nonhuman and non-viral protein as disclosed in the Exemplary Embodiments herein.
- the purity of RIPs in a delivery solution or RIP formulation can be determined using the ratio of the amount of protein from the host cells used to generate the RIPs to the transducing units (amount host cell protein/TU).
- the ratio of host cell protein to TUs can be 10, 5, 3, 2, or 1 ng or less host cell protein/TU or 750, 500, 400, 300, 200, 100, 50, 40, 30, 20, or 10 pg or less host cell protein/TU.
- the host cells used to generate the RIPs can be human cells.
- the host cell can be primary cells.
- the host cell can be immortalized cells.
- the host cells can be HEK, HEK-293, HEK-293T, HEK-293E, HEK-293 FT, HEK-293S, HEK-293SG, HEK-293 FTM, HEK- 293SGGD, HEK-293A, 293RTV, GP2-293, MDCK, C127, COS-7, A549, HeLa, CHO, mouse myeloma, PerC6, 91-1, or Vero cells.
- the host cells are HEK, HEK293, HEK293T, HEK293A, PerC6 or 91-1.
- the potency of RIPs present in a delivery solution or RIP formulation can be determined using the ratio of the TUs to the ng of p24 protein.
- the ratio of the TUs to the ng of p24 protein can be 100, 200, 300, 400, 500, 1,000, 4,000, 10,000, 12,500, or 15,000 or more TUs/ng of p24 protein.
- the concentration of RIPs present in a delivery solution and/or RIP formulation can be at least 1 x 10 6 , 5 x 10 6 , 1 x 10 7 , 5 x 10 7 , 1 x 10 8 , 2 x 10 8 , 5 x 10 8 , or 1 x 10 9 TU/ml.
- the concentration of RIPs present in a delivery solution and/or RIP formulation can be any of the concentrations disclosed in the Exemplary Embodiments section herein.
- the volume of the cell formulation including the modified and/or unmodified lymphocytes is less than traditional CAR-T methods, which typically are infusion-delivery methods, and can be less than, or less than about 1 ml, about 2 ml, about 3 ml, about 4 ml, about 5 ml, about 10 ml, about 15 ml, about 20 ml, or about 25 ml.
- the advantageously short time between drawing (collecting) blood and reintroducing the unmodified or modified lymphocytes into the subject means that in some embodiments, some lymphocytes are associated with the recombinant nucleic acid vectors, and in illustrative embodiments the replication incompetent recombinant retroviral particles, are not yet genetically modified. In some embodiments, at least 5% of the modified lymphocytes are not genetically modified. In some embodiments, the modified lymphocytes are genetically modified and contain the polynucleotide, either extrachromosomal or integrated into the genome. In some embodiments, the polynucleotide can be extrachromosomal in at least 5% of the modified lymphocytes.
- the modified lymphocytes are not transduced.
- the lymphocytes include co-administration with a RIP formulation or RIPs in a delivery solution, the lymphocytes have not been contacted with a RIP disclosed herein, and thus none of the lymphocytes are modified, genetically modified, or transduced with such a RIP.
- the short contacting time in certain embodiments also results in many of the modified lymphocytes in cell formulations herein, having on their surfaces, binding polypeptides, fusogenic polypeptides, and in some embodiments T cell activation elements that originated on the surface of retroviral particles, either through association with the recombinant retroviral particles or by fusion of the retroviral envelopes with the plasma membranes, including at the time of the optional delivery step.
- the modified lymphocytes in the cell formulation include a pseudotyping element and/or a T cell activation element, e.g., a T cell activating antibody.
- the pseudotyping element and/or T cell activation element can be bound to the surface of the modified lymphocytes through, for example, a T cell receptor, CD28, 0X40, 4-1BB, ICOS, CD9, CD53, CD63, CD81, CD82, and/or the pseudotyping element and/or T cell activation element can be present in the plasma membrane of the modified lymphocytes.
- the lymphocytes have not been contacted with a RIP disclosed herein, and thus none of the lymphocytes include a pseudotyping element or a T cell activation element bound to the surface of the lymphocytes and thus none of the lymphocytes are modified, genetically modified, or transduced lymphocytes.
- cell formulations are provided herein that include for example T cells and/or NK cells. Such formulations, in illustrative embodiments are provided by methods provided herein. Any of the cell formulations provided herein can include selfdriving CAR-T cells.
- a cell formulation comprising a population of unmodified, modified, genetically modified, transcribed, transfected, and/or stably integrated T cells and/or NK cells, including in non-limiting examples, self-driving CAR-T cells and/or NK cells in a delivery solution.
- lymphocytes are contacted with recombinant nucleic acid vectors and modified lymphocytes are ex vivo after such contacting in some illustrative embodiments provided herein, in these embodiments some or all of the T and NK cells do not yet express the recombinant nucleic acid or have not yet integrated the recombinant nucleic acid into the genome of the cell, and some of the retroviral particles in embodiments including these, may be associated with, but may have not fused with the target cell membrane, before being used or included in any of the methods or compositions provided herein, including, but not limited to, being introduced or reintroduced back into a subject, or before being used to prepare a cell formulation.
- cell formulation aspects and embodiments are provided herein that can be produced, for example, from these illustrative methods provided herein, such as for example, rapid point of care methods that in illustrative embodiments involve subcutaneous administration.
- Such cell formulations including but not limited to those set out immediately below and in the Exemplary Embodiments section herein, can exist at the time of collection of cells after they are contacted with a recombinant retroviral vector and optionally rinsed, and can exist up to and including at the time of administration to a subject, in illustrative embodiments subcutaneously.
- cell formulations comprising T cells and/or NK cells, wherein less than 90%, 80%, 75%, 70%, 60%, 50%, 40%, 30%, 25%, 20%, 10%, or 5% of the cells in the cell formulation are T cells and/or NK cells.
- none of the cells have been contacted with a RIP disclosed herein and thus none of the cells are modified, genetically modified, or transduced.
- cell formulations comprising lymphocytes, NK cells, and/or T cells, are provided wherein at least 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%,
- T cells in the cell formulation are modified cells, for example, modified with polynucleotides comprising nucleic acids that encode anti-idiotype polypeptides provided herein.
- polynucleotides can optionally encode a CAR, TCR, inhibitory RNA, or LE, as provided herein.
- lymphocytes between 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, and 70% of the lymphocytes are modified on the low end of the range and 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, and 95% of the lymphocytes are modified cells on the high end of the range, for example between 5% and 95%, 10% and 90%, 25% and 75%, and 25% and 95%.
- At least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or all of the modified lymphocytes within the cell formulation are not genetically modified, transduced, or stably transfected.
- the modified lymphocytes are not genetically modified, transduced, or stably transfected on the low end of the range and 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, and 99% or all of the modified lymphocytes are not genetically modified, transduced, or stably transfected on the high end of the range, for example between 5% and 95%, 10% and 90%, 25% and 75%, and 25% and 95%.
- the polynucleotide of genetically modified lymphocytes can be either extrachromosomal or integrated into the genome in these cell formulations that are formed after contacting and incubation, and at the time of optional administration. In some embodiments of these cell formulations, at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or all of the genetically modified lymphocytes have an extrachromosomal polynucleotide.
- between 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, and 70% of the modified or genetically modified lymphocytes have an extrachromosomal polynucleotide on the low end of the range and 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, and 99% or all of the modified or genetically modified lymphocytes have an extrachromosomal polynucleotide on the high end of the range, for example between 5% and 95%, 10% and 90%, 25% and 75%, and 25% and 95%.
- At least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or all of the modified or genetically modified lymphocytes are not transduced or stably transfected in these cell formulations, for example as a result of methods for genetically modifying T cells and/or NK cells provided herein.
- the modified or genetically modified lymphocytes are not transduced on the low end of the range and 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, and 99% or all of the modified or genetically modified lymphocytes are not transduced or stably transfected on the high end of the range, for example between 5% and 95%, 10% and 90%, 25% and 75%, and 25% and 95%.
- fewer of the modified or genetically modified lymphocytes can engraft if delivered intravenously compared to when delivered subcutaneously. In some embodiments, at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% fewer lymphocytes engraft when delivered intravenously compared to when delivered subcutaneously.
- cell formulations including such formulations in existence at the time of collection of cells after they are contacted with a recombinant retroviral vector and optionally rinsed, and existing up to and including the time of administration to a subject, comprise at least two of unmodified lymphocytes, modified lymphocytes, and genetically modified lymphocytes. In some embodiments, such cell formulations comprise more unmodified lymphocytes than modified lymphocytes. In some embodiments of such cell formulations that are produced by methods provided herein, the percent of T cells and NK cells that are modified, genetically modified, transduced, and/or stably transfected is at least 5%, at least 10%, at least 15%, or at least 20%.
- lymphocytes in whole blood, between 1% and 20%, or between 5% and 20%, or between 1% and 15%, or between 5% and 15%, or between 7% and 12% or about 10% of lymphocytes, and in some embodiments of T cells and/or NK cells in the whole blood that is added to a reaction mixture or that is used to create a reaction mixture, are genetically modified and/or transduced and present in resultant cell formulations.
- the lymphocytes are not contacted with a recombinant nucleic acid vector, such as a replication incompetent recombinant retroviral particle, and are not modified.
- the lymphocytes are tumor infiltrating lymphocytes. In some embodiments, the lymphocytes are tumor infiltrating lymphocytes before or after the tumor infiltrating lymphocytes are in contact a recombinant nucleic acid vector. In some embodiments, the lymphocytes comprise both tumor infiltrating lymphocytes and T cells and/or NK cells before or after the T cells and/or NK cells contact a recombinant nucleic acid vector.
- cell formulations wherein at least 25%, 30%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or all of the modified T and/or NK cells in the cell formulation do not express a CAR, or a transposase in certain embodiments, and/or do not have a CAR associated with their cell membrane.
- cell formulations wherein at least 25%, 30%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or all of the modified T and/or NK cells in a cell formulation contain recombinant viral reverse transcriptase or integrase.
- T cells and/or NK cells are contacted with retroviral particles to modify the T cells and/or NK cells within hours of delivery, some or most of the reverse transcriptase and integrase present within the retroviral particles that moves into a T cell and/or NK cell after it fuses with a retroviral particle, would still be present in the modified T cells and/or NK cells at the time of delivery.
- cell formulations wherein at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or all of the modified T and NK cells in a cell formulation do not express the recombinant mRNA (e.g., encoding a CAR and/or a recombinant transposase).
- recombinant mRNA e.g., encoding a CAR and/or a recombinant transposase
- cell formulations wherein at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or all of the modified T and NK cells in such cell formulation do not have the recombinant nucleic acid stably integrated into their genomes. In some embodiments, greater than 50%, 60%, 70%, 75%, 80% or 90% of the cells, NK cells, and/or T cells in a cell formulation are viable.
- cell formulations comprising modified lymphocytes that can be introduced or reintroduced in methods herein, include monocytes and/or B cells.
- some of the B cells are modified during a contacting step when they are contacted by recombinant nucleic acid vectors, for example, naked DNA vectors, or in illustrative embodiments replication incompetent recombinant retroviral particles.
- At least some but not more than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the B cells are modified in cell formulations, which can optionally be administered or readministered. In illustrative embodiments, some of the B cells are not modified in such formulations and methods. In further illustrative embodiments, at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of the B cells are not modified in such formulations and methods.
- modified lymphocytes are present in cell formulations along with unmodified lymphocytes, which optionally are delivered to a subject intramuscularly or subcutaneously.
- the modified lymphocytes in the cell formulations and optionally introduced into the subject can be allogeneic lymphocytes.
- the lymphocytes are from a different person, and the lymphocytes from the subject are not modified.
- no blood is collected from the subject to harvest lymphocytes.
- Neutrophils in illustrative embodiments, are present in the cell formulation, as a nonlimiting example a cell formulation for delivering modified T cells and/or NK cells subcutaneously, at a concentration too high for intravenous delivery when considering the safety of a subject into which the cell formulation is administered.
- the injection or delivery of neutrophils intravenously can lead to pulmonary compromise, for example, as a result of transfusion-related acute lung injury (TRALI) and/or acute respiratory distress syndrome (ARDS).
- TRALI transfusion-related acute lung injury
- ARDS acute respiratory distress syndrome
- this situation can arise when the method for producing the modified lymphocytes does not involve a PBMC enrichment step before the cell formulation comprising the modified lymphocytes is prepared, and before the solution is optionally delivered subcutaneously to a subject.
- neutrophils are present in the cell formulation, for example at the time of the optional delivery step. More specifically, in some embodiments, at least 5%, at least 10%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, or at least 75% of the neutrophils present in a blood sample that is subjected to a method for modifying herein, are present in the cell formulation, including at the time of the optional delivery step. In some embodiments, at least 5%, at least 10%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, or at least 75% of the cells present in the cell formulation are neutrophils, including at the time of the optional delivery step.
- between 5%, 10%, 15%, 20%, 25%, 30%, or 40% of the cells present in the cell formulation are neutrophils at the low end of the range and 30%, 40%, 50%, 60%, 70%, or 75% of the cells present in the cell formulation are neutrophils at the high end of the range, including at the time of the optional delivery step, for example between 5% and 50%, 20% and 50%, 30% and 75%, or 50% and 75% of the cells present in the cell formulation are neutrophils, including at the time of the optional delivery step.
- At least 5%, at least 10%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, or at least 75% of the monocytes present in a blood sample that is subjected to a method for modifying herein are present in a cell formulation, including at the time of the optional delivery step.
- at least 5%, at least 10%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, or at least 75% of the B cells present in a blood sample that is subjected to a method for modifying herein are present in the resulting cell formulation, including at the time of the optional delivery step.
- the cell formulation can include a PBMC fraction, which includes the modified T and NK cells.
- a PBMC fraction which includes the modified T and NK cells.
- at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 50%, 75%, 80%, 85%, 90%, or 95%, or between 1% and 95%, 5% and 95%, 5% and 50%, or 10% and 50% of the modified T and NK cells in a cell formulation are genetically modified.
- the volume of delivery solution, RIP formulation, or cell formulation or other solution administered varies depending on the route of administration, as provided elsewhere herein. Delivery solutions, RIP formulations, or cell formulations injected perilymphatically, subcutaneously, or intramuscularly typically have smaller volumes than those delivered via infusion. In some embodiments, the volume of the delivery solution, RIP formulation, or cell formulation is not more than 1 ml, 2 ml, 3 ml, 4 ml, 5 ml, 10 ml, 15 ml, 20 ml, 25 ml, 30 ml, 35 ml, 40 ml, 45 ml, or 50 ml.
- the volume of the delivery solution, RIP formulation, or cell formulation can be between 0.20 ml, 0.25 ml, 0.5 ml, 1 ml, 2 ml, 3 ml, 4 ml, 5 ml, 10 ml, 15 ml, 20 ml, or 25 ml on the low end of the range and 0.5 ml, 1 ml, 2 ml, 3 ml, 4 ml, 5 ml, 10 ml, 15 ml, 20 ml, 25 ml, 30 ml, 35 ml, 40 ml, 45 ml, 50 ml, 75 ml,
- the volume can be between 0.2 ml and 10 ml, 0.5 ml and 10 ml, 0.5 and 2 ml, 1 ml and 250 ml, 1 ml and 100 ml, 10 ml and 100 ml, or 1 ml and 10 ml.
- a delivery solution, RIP formulation, or cell formulation can be less than 10 ml, between 1 ml and 25 ml, and in illustrative embodiments between 1 ml and 3 ml, between 1 ml and 5 ml, or between 1 ml and 10 ml.
- the volume of the delivery solution, RIP formulation, or cell formulation can be between 0.20 ml, 0.25 ml, 0.5 ml, 1 ml, 2 ml, 3 ml, 4 ml, and 5 ml on the low end of the range and 0.5 ml, 1 ml, 2 ml, 3 ml, 4 ml, 5 ml, 10 ml, 15 ml, 20 ml, 25 ml, 30 ml, 35 ml, 40 ml, 45 ml, and 50 ml on the high end of the range.
- a 70 kg subject is dosed at 1.0 x 10 6 T cells/kg by administering 1 ml of a delivery formulation of T cells at 7.0 x 10 7 cells/ml subcutaneously.
- a delivery solution, RIP formulation, or cell formulation can include hyaluronidase when the volume of the solution is at least 2 ml, 3 ml, 4 ml, 5 ml, 10 ml, 15 ml, 20 ml, or 25 ml.
- the delivery solution can be used to resuspend and/or elute cells from the filter in volumes that can be those provided above.
- a delivery solution provided herein is an elution solution.
- unmodified, modified and in illustrative embodiments genetically modified lymphocytes are introduced or reintroduced into the subject by intradermal, intratumoral or intramuscular administration and in illustrative embodiments, perilymphatic or subcutaneous administration using a cell formulation present in a subcutaneous delivery device, such as a sterile syringe that is adapted to deliver a solution subcutaneously.
- a subcutaneous delivery device such as a sterile syringe that is adapted to deliver a solution subcutaneously.
- a subcutaneous delivery device that holds a solution (e.g., a delivery solution, RIP formulation, or cell formulation herein) and has an open or openable end, which in illustrative embodiments is the open end of a needle, for administering the solution (e.g., delivery solution, RIP formulation, or cell formulation) subcutaneously from the liquid holding portion of the device.
- a subcutaneous delivery device is effective for, and in illustrative embodiments adapted for subcutaneous delivery, or effective to inject subcutaneously or adapted to inject subcutaneously.
- Non-limiting examples of subcutaneous delivery devices that are adapted to deliver a solution subcutaneously include subcutaneous catheters, such as indwelling subcutaneous catheters, such as for example, the Insuflon ® (Becton Dickinson) and needless closed indwelling subcutaneous catheter systems, for example with wings, such as for example, the Saf-T- Intima ® (Becton Dickinson).
- the delivery device can include a pump, for example an infusion pump or a peristaltic pump.
- the delivery solution, RIP formulation, or cell formulation is fluidly connected to any of the needles disclosed herein, for example a needle compatible with, effective for, adapted for, or adapted to deliver subcutaneously or effective to deliver subcutaneously.
- the needle can have a gauge between 26 and 30.
- the subcutaneous delivery device is a subcutaneous delivery pen.
- Such a pen can include a syringe effective to deliver subcutaneously or adapted to deliver subcutaneously enclosed within a housing and can include a needle guard. Examples of such pens include pens used to deliver sumatriptan.
- said delivery solution, RIP formulation, or cell formulation is present in a subcutaneous delivery device, for example a syringe, with a needle that has penetrated the skin of a subject where RIPs and/or unmodified and modified T cells and/or NK cells are present in the syringe (i.e., the subject receiving the subcutaneous injection is the source of the RIPs or autologous cells being injected), and in some embodiments is located with its open end in the subcutaneous tissue of the subject.
- the subcutaneous delivery device e.g., syringe
- a delivery device such as a syringe that is compatible with intramuscular and, in illustrative embodiments, subcutaneous delivery, is any delivery device (e.g., syringe) that can be successfully used for intramuscular or subcutaneous delivery, and includes those delivery devices (e.g., syringes) that are effective for and adapted for intramuscular or subcutaneous delivery, plus general purpose syringes and syringes that are specifically designed for other purposes and that can be successfully employed for intramuscular or subcutaneous delivery in at least some embodiments.
- syringe any delivery device (e.g., syringe) that can be successfully used for intramuscular or subcutaneous delivery, and includes those delivery devices (e.g., syringes) that are effective for and adapted for intramuscular or subcutaneous delivery, plus general purpose syringes and syringes that are specifically designed for other purposes and that can be successfully employed for intramuscular or subcutaneous delivery in at least some embodiment
- a needle is inserted through the skin at a 45° to 90° angle.
- some embodiments include injecting a delivery solution, RIP formulation, or cell formulation subcutaneously at an angle of 45° to 90° with respect to the skin, as well as a delivery solution, RIP formulation, or cell formulation contained within a syringe or other subcutaneous delivery device, having a needle at a 45° to 90° angle to the skin of a subject.
- a syringe that is effective for intramuscular and, in illustrative embodiments, subcutaneous delivery, or effective to inject intramuscularly or subcutaneously is a syringe with parameters that are typically effective for intramuscular or subcutaneous delivery, for example, a needle with a gauge between 20 and 22 and a length between 1 inch and 1.5 inches is typically effective for intramuscular delivery and a needle with a gauge between 26 and 30 and a length between 0.5 inches and 0.625 inches is typically effective for subcutaneous delivery.
- a syringe that is adapted for subcutaneous delivery, or adapted to inject subcutaneously is any syringe that is specifically made for subcutaneous delivery.
- One such syringe adapted for subcutaneous delivery uses a core annular flow that allows subcutaneous delivery of highly concentrated biological drug formulations not normally deliverable subcutaneously (Jayaprakash V et al. Adv Healthc Mater. 2020 Aug 24; e2001022).
- Another syringe adapted for subcutaneous delivery uses a shorter needle than generally used (Pager A, Expert Opin Drug Deliv. 2020 Aug 9; 1 - 14).
- Another syringe adapted for subcutaneous delivery uses a 29G/5-bevel needle with a Thermo Plastic Elastomer (TPE) needle shield (Jaber A et al. BMC Neurol. 2008 Oct 10; 8:38).
- TPE Thermo Plastic Elastomer
- the outer diameter of the needle is less than 0.026”. In some embodiments, the outer diameter of the needle is at most 0.01625”, 0.01865”, 0.01825”, 0.02025”, 0.02255”, or 0.02525”. In some embodiments, the needle is a 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 26s, 27, 28, 29, or 30 gauge needle. In some embodiments, the length of the needle is not more than 1 inch or 0.5 inches. In illustrative embodiments, the needle is 26, 26s, 27, 28, 29, or 30 gauge needle and the length of the needle is between 0.5 inches and 0.625 inches. In some embodiments, the needle can be a winged infusion set, also known as a butterfly or scalp vein needle. In some embodiments, the introduction or reintroduction can be performed using a subcutaneous catheter.
- subcutaneous and intramuscular delivery methods permit the components of the delivery solution, RIP formulation, or cell formulation to remain in close proximity within a subject, for example in illustrative embodiments for up to several days, several weeks, or even several months as a controlled release while creating a local environment for T cell and/or NK cell activation and expansion while maintaining properties similar to what T and NK cells encounter in the lymphoid organs such as the spleen or lymph node.
- RIPs from a RIP formulation injected at a local injection site using perilymphatic, subcutaneous, or intramuscular methods provided herein can transduce T and NK cells present in the subject, or when co-administered with PBMCs, for example, T and/or NK cells, isolated from the subject, can transduce the co-administered T and/or NK cells.
- the local injection controlled release of modified, genetically modified, and/or transduced cells will result in genetically modified cells expanding at the site of subcutaneous administration for days (e.g., for up to 5, 7, 14, 17, 21, or 28 days) or months (e.g., for up to 1, 2, 3, 6, 12, or 24 months) with genetically modified CAR-T cells or CAR-NK cells migrating away from the site of subcutaneous administration to other sites of the body, for example to tumors.
- genetically modified CAR-T cells can appear in lymphatics or circulation migrating away from a subcutaneous administration site after days (e.g., 1, 2, 3, 4, 5, 6, or 7 days), weeks (e.g., 1, 2, 4, or 4 weeks), and even months (e.g., 1, 2, 3, 6, 12, or 24 months) after modified T cells and/or NK cells are injected subcutaneously into a subject.
- days e.g., 1, 2, 3, 4, 5, 6, or 7 days
- weeks e.g., 1, 2, 4, or 4 weeks
- months e.g., 1, 2, 3, 6, 12, or 24 months
- This persistence of genetically modified T cells and/or NK cells, such as CAR-T cells, subcutaneously provides an advantageous local environment where other components native or non native to the subject, such as molecules (ions), macromolecules (e.g., DNA, RNA, peptides, and polypeptides) and/or other cells that can affect the modified CAR-T cells, can be recruited or delivered subcutaneously at or near the site of delivery of the modified CAR-T cells.
- molecules ions
- macromolecules e.g., DNA, RNA, peptides, and polypeptides
- tertiary lymphoid structures comprising lymphatic vasculature have been observed after delivery of modified T cells and/or NK cells.
- lymphatic vasculature provides a venue for modified T cells and/or NK cells administered subcutaneously to access the local lymphatic circulation, after which they can gain access to the systemic circulation and, for example, access the blood.
- modified T cells and/or NK cells administered subcutaneously to access the local lymphatic circulation, after which they can gain access to the systemic circulation and, for example, access the blood.
- tertiary lymphoid structures have been observed to comprise activated lymphoid cells.
- lymphoid structures comprising aggregates of actively dividing genetically modified T cells and/or NK cells and lymphatic vasculature in proximity to such aggregates.
- tertiary lymphoid structures and/or the genetically modified CAR-T cells can persist near a site of subcutaneous administration for at least 1, 2, 3, 4, 5, 6, or 7 days, 1, 2, 3, 4, 5, 6, 7, or 8 weeks, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 24 months.
- tertiary lymphoid structures and/or the genetically modified CAR-T cells persist near the site of subcutaneous administration for at least 1, 2, 3, 4, 5, 6, or 7 days, 1, 2, 3, or 4 weeks, or 1, 2, or 3 months.
- tertiary lymphoid structures and/or the genetically modified CAR-T cells can persist near a site of subcutaneous administration for between 1 day and 24 months, 7 days and 12 months, 2 weeks and 6 months, 3 weeks and 8 weeks, or 4 weeks and 6 weeks.
- tertiary lymphoid structures and/or the genetically modified CAR-T cells can persist near a site of subcutaneous administration for between 1 week and 3, 4, 5, 6, 7, 8, 9, or 10 weeks, for example between 1 week and 8 weeks, 1 week and 7 weeks, or 1 week and 6 weeks.
- At least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% of the cells in tertiary lymphoid structures and/or of the genetically modified cells can remain localized within 1, 2, 3, 4, or 5 cm of site of administration.
- the cell formulation for subcutaneous or intramuscular delivery is a depot formulation or emulsion of cells that promotes cell aggregation, and a delivery solution herein used to prepare such a depot cell formulation, includes the accessory components that provide depot properties.
- the cells may be aggregated in the formulation, for example before it is administered to a subject, or for example within 1 hour, 45 minutes, 30 minutes, 15 minutes, 10 minutes, 5 minutes, or 1 minute of cells, for example modified lymphocytes as provided herein, being formulated in a delivery solution, for example comprising an aggregating agent to produce the formulation.
- At least 10%, 20%, 25%, 50%, 75%, 90%, 95%, or 99% of the cells in a cell formulation provided herein are aggregated. Such aggregation can be determined, for example, using microscopic counting of individual cells versus cells that are associated with at least one other cell, or by counting the number of cells on average, a cell within a formulation is associated with.
- the cell formulation is designed for controlled or delayed release with tissue expansion to accommodate cell expansion.
- a delivery solution provided herein, for subcutaneous or intramuscular delivery is a depot formulation.
- a depot (i.e., sustained release) formulation is typically an aqueous or oleaginous suspension or solution.
- the delivery solution or cell formulation includes components that form an artificial extracellular matrix such as a hydrogel.
- a depot delivery solution comprises an effective amount of alginate, collagen, and/or dextran to form a depot formulation.
- PEG polyethylene glycol
- One class of polymers that can be used to make gel-fonning biomaterials, and can be included in delivery solutions and cell formulations provided herein, is composed of polyethylene glycol) (PEG) and its copolymers with aliphatic polyesters, such as poly(lactic acid) (PLA), poly(D,L-lactic-co- glycolic acid) (PLGA), poly (e-capro lactone) (PCL) and polyphosphazenes.
- thermosensitive triblock copolymers based on poly(N-(2-hydroxypropyl methacrylamide lactate) and poly(ethyleneglycol) (p(HPMAm-lac)-PEG), capable of spontaneous self-assembling in physiological environments (Vermonden et. al 2006, Langmuir 22: 10180-10184).
- the hydrogel used in a delivery solution or cell formulation herein contains hyaluronic acid (HA).
- HA can have carboxylic acid groups that can be modified with 1- ethyl-3 -(3 -dimethyl aminopropyl)-l-carbodiimide hydrochloride to react with amine groups on proteins, peptides, polymers, and linkers, such as those found on modified lymphocytes provided herein, preferentially in the presence of N-hydroxysuccinimide.
- Antibodies, cytokines and peptides can be chemically conjugated to HA using such methods to produce a hydrogel for co-injection as a cell emulsion in some cell formulation embodiments provided herein. Additionally, in some embodiments,
- HA in delivery solutions and cell formulations is a polymer (e g., Healon) and/or are crosslinked (e g., restylane (Abbive/Allergan)), for example lightly crosslinked, through its -OH groups with agents such as glutaraldehyde to reduce the local catabolism of the material following subcutaneous injection.
- the HA used in delivery' solutions and cell formulations herein can be of variable length and viscosity.
- the HA used in delivery' solutions and cell formulations herein can further be crosslinked with other glycosaminoglycans such as chondroitin sulfate (e.g., Viscoat) or polymers or surfactants.
- a matrix such as a hydrogel matrix
- a cell formulation herein when used in a cell formulation herein, can be configured for, or adapted to permit migration of cells through the matrix.
- the degree of substitution of the hydrogel and concentration at the time of crosslinking will influence porosity swelling ratio and Youngs Modulus (or stiffness). Initial 1% substitution of HA with tyramine for example at 1 mg/ml when subsequently crosslinked in the presence of peroxide will result in a hydrogel with higher porosity and lower stiffness than 3% substitution and 5 mg/ml solution.
- the shear modulus is or is about 2.5 kPa, about 3 kPa, about 3.5 kPa, or about 4 kPa.
- the delivery solution, a composition in the kit, or the cell formulation includes one or more cytokines such as IL-2, IL-7, IL-15, IL-21, or variants thereof, or an active fragment of any of the preceding and/or cytokine receptor agonists, such as an IL-15 agonist.
- cytokines such as IL-2, IL-7, IL-15, IL-21, or variants thereof, or an active fragment of any of the preceding and/or cytokine receptor agonists, such as an IL-15 agonist.
- the delivery solution, a composition in the kit, and/or the cell formulation includes one or more of IL-1, IL-2, IL-7, IL-12, IL-15, IL-18, IL-21, TNFa, IFNy, GM-CSF, CCL1, CCL2 (MCP-1), CCL3, CCL5, CCL7 (MCP-3), CCL8 (MCP-2), CCL19, CCL20, CCL21, CCL22, CCL28, CXCL1, CXCL9, CXCL10, CXCL11, CXCL12, CXCL14 (BRAK), CX3CL1, and variants thereof, and an active fragment of any of the preceding.
- the delivery solution, a composition in the kit, and/or the cell formulation does not include IL-2, IL-7, IL-15, or IL-21.
- the delivery solution, a composition in the kit, and/or the cell formulation includes one or more of IL-1, IL-12, IL-18, TNFa, IFNy, GM-CSF, and variants thereof, and an active fragment of any of the preceding.
- the delivery solution, a composition in the kit, and/or the cell formulation includes one or more of CCL1, CCL2 (MCP-1), CCL3, CCL5, CCL7 (MCP-3), CCL8 (MCP-2), CCL19, CCL20,
- the delivery solution, a composition in the kit, and/or the cell formulation includes one or more of CCL19, CCL21, and variants thereof, and an active fragment of any of the preceding capable of binding to CCR7 and/or CXCR3.
- the delivery solution, a composition in the kit, or the cell formulation includes one or more of CXCL1, CXCL9, CXCL10, CXCL11, CXCL12, CXCL14 (BRAK), and variants thereof, and an active fragment of any of the preceding.
- the delivery solution, a composition in the kit, and/or the cell formulation includes one or more of CX3CL1, and variants thereof, and an active fragment of any of the preceding.
- the delivery solution, a composition in the kit, and/or the cell formulation includes one or more polypeptides capable of binding to CCR2, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CXCR3, CXCR4, CXCR5, CXCR6, and/or Cx3crl .
- the delivery solution, a composition in the kit, and/or the cell formulation includes one or more polypeptides capable of binding to CCR7, CXCR3, CXCR4, and/or CXCR6.
- the delivery solution, a composition in the kit, and/or the cell formulation includes one or more polypeptides capable of binding to CCR1, CC42, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CXCR3, CXCR4, CXCR5, and/or CXCR6.
- the cytokine does not bind to a cytokine receptor included in the delivery solution, kit, or cell formulation, and/or does not bind to a cytokine receptor that is encoded by a polynucleotide in the delivery solution, cell formulation, or kit.
- the cytokines can be modified cytokines that, not to be limited by theory, selectively activate complexes that drive proliferation.
- the modified cytokine is a modified IL-2, for example, a fusion protein with a circularly-permuted IL-2 with the extracellular domain of IL-2R ⁇ (see, e.g., Lopes et al, J Tmmunother Cancer 2020 Apr; 8(1): e000673).
- the cytokines, modified cytokines, or cytokine receptor agonists can also be administered in one or administrations separate from the cell formulation, before, contemporaneous to, or after the administration including the delivery solution or cell formulation.
- two or more separate administrations can be in escalating doses.
- two or more administrations can be at the same dose.
- two or more administrations can include the same or different cytokines, modified cytokines, and or cytokine receptor agonists.
- the separate administrations can be a series of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 administrations. In some embodiments, the separate administrations occur on consecutive days.
- the cell formulation includes antibodies or polypeptides that are capable of binding CD2, CD3, CD28, 0X40, 4-1BB, ICOS, CD9, CD53, CD63, CD81, and/or CD82.
- the EDC- NHS reaction may be used for linking such proteins to HA or through other intermediates described above.
- these cytokines, antibodies, or polypeptides are crosslinked to components of a hydrogel.
- the hydrogel may be mixed with the cell suspension using a syringe connector and two syringes prior to injection.
- these cytokines, antibodies, or polypeptides are in solution.
- the delivery solution or the cell formulation includes RNA that encodes for these cytokines, antibodies, or polypeptides.
- the antigen can be added to or co-administered with modified and/or genetically modified T cells and/or NK cells.
- the antigen is a protein, a glycoprotein, a carbohydrate or fragment thereof such as a peptide, glycopeptide, or functional group.
- the antigen can be soluble.
- the antigen is from a non-human source.
- the antigen can be immobilized on a surface of the artificial matrix, such as a hydrogel.
- the antigen is a nucleic acid such as DNA or RNA.
- the nucleic acid encodes a protein or peptide antigen that is an antigen recognized by the CAR.
- the antigen can be expressed on the surface of a cell comprising the nucleic acid encoding the protein or peptide antigen, such that the cell is a target cell, referred to as feeder cells herein.
- target cells are present in large numbers in whole blood and are naturally present in the cell formulation without having to be added.
- B cells are present in whole blood, isolated TNCs, and isolated PBMCs and would naturally be present in the cell formulation and could serve as target cells for T cells and/or NK cells expressing a CAR directed to CD19 or CD22, as non-limiting examples which are both expressed on B cells.
- target cells are not present in whole blood or are not present in large numbers in whole blood and thus are added exogenously, for example, feeder cells.
- target cells can be isolated or enriched from the subject, such as from a tumor sample, using methods known in the art.
- cells from the subject or from a source other than the subject, including cell lines are modified to express the appropriate antigen.
- the targets cells are treated to reduce their proliferative capacity by for example, radiation or chemotherapeutic agents before they are administered to a subject.
- the antigen expressed on the target cell can include all or a portion of the protein that contains the antigen. In further illustrative embodiments, the antigen expressed on the target cell can include all or a portion of the extracellular domain of the protein that includes the antigen. In some embodiments, the antigen is an antibody that recognizes the ASTR of the CAR, such as an anti idiotype antibody directed to the scFv domain of the CAR. In some embodiments, the antigen expressed on the target cell can be a fusion with a transmembrane domain that anchors it to the cell surface. Any of the transmembrane domains disclosed elsewhere herein can be used.
- the antigen expressed on the target cell can be a fusion with a stalk domain. Any of the stalk domains disclosed elsewhere herein can be used.
- the antigen can be a fusion with a CD8 stalk and transmembrane domain (SEQ ID NO:24).
- cells in a first cell mixture are modified with a recombinant nucleic acid vector encoding a target antigen, which can be referred to herein as “artificial antigen presenting cells” or “aAPCs”, and cells in a separate second cell mixture from the same subject are modified to express the CAR that binds the antigen.
- aAPC artificial antigen presenting cells
- T-APC T cell
- modified T-APCs can include, as non-limiting examples, B cells, dendritic cells, and macrophages, and in illustrative embodiments dendritic cells and macrophages such as where a corresponding CAR-T target is a B cell cancer target, and can be generated using methods provided herein where reaction mixtures for modification (e.g., transduction) include a T cell binding polypeptide, such as a polypeptide directed to CD3.
- the cell mixture is whole blood, isolated TNCs, isolated PBMCs.
- the first cell mixture can be modified with a recombinant nucleic acid vector encoding a fusion protein of the extracellular domain of Her2 and the transmembrane domain of PDGF and the second cell mixture can be modified with a recombinant nucleic acid vector encoding a CAR directed to FIER2.
- the cells can then be formulated into the delivery solution or otherwise administered to the subject at varying CAR effector cell-to-target-cell ratios.
- the effector-to-target ratio at the time of formulation or administration is, or is about 10:1, about 9:1, about 8:1, about 7:1, about 6:1, about 5:1, about 4:1, about 3:1, about 2; 1 , about 1:1, about 1:2, about 1:3, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, or about 1:10.
- target cells are co-administered with the modified T and/or NK cells subcutaneously or intramuscularly.
- the proliferation and survival of genetically modified T cells and/or NK cells expressing a CAR can also be promoted by CAR signaling initiated by cross-linking the CARs by interactions other than through the CAR’s ASTRs binding to their cognate antigens.
- a small molecule or protein can cross-link and activate CARs on the surface of a cell.
- an antibody can cross-link and activate CARs on the surface of a cell.
- the antibody recognizes an epitope in the extracellular domain of the CAR, such as in the stalk or spacer domain.
- the epitope can be an epitope tag such as His5 (HHHHH; SEQ ID NO:76), HisX6 (HHHHHH ; SEQ ID NO:77), c-myc (EQKLISEEDL; SEQ ID NO:75), Flag (DYKDDDDK; SEQ ID NO:74), Strep Tag (WSHPQFEK; SEQ ID NO:78), HA Tag (YPYDVPDYA; SEQ ID NO:73), RYIRS (SEQ ID NO:79), Phe-His-His-Thr (SEQ ID NO:80), or WEAAAREACCRECCARA (SEQ ID NO:81).
- epitope tag such as His5 (HHHHH; SEQ ID NO:76), HisX6 (HHHHHH ; SEQ ID NO:77), c-myc (EQKLISEEDL; SEQ ID NO:75), Flag (DYKDDDDK; SEQ ID NO:74), Strep Tag (WSHPQFEK; SEQ ID NO:78), HA Tag (Y
- the epitope is common to an intracellular antigen that is not reactive to an extracellular receptor.
- the epitope tag is the HisX6 tag (SEQ ID NO:77).
- the CARs can be cross-linked and activated by adding soluble antibodies that bind the epitope tag.
- the CARs can be cross- linked and activated by adding cells, also referred to herein as universal feeder cells, expressing antibodies, or antibody mimetics, that bind the epitope tag.
- the antibody or antibody mimetic associates with the cell membrane through a GPI anchor.
- the antibody or antibody mimetic associates with the cell membrane through a transmembrane domain.
- a stalk or spacer separates the antibody or antibody mimetic, from the transmembrane domain.
- the same universal feeder cells for example, universal feeder cells expressing an anti-HisX6 scFv attached to a CD8a stalk and transmembrane domain, can be used with cells that express CARs with ASTRs that bind to different antigens but that include the HisX6 epitope tag in their stalk. These universal feeder cells can be used with cells expressing different CARs containing a common epitope tag.
- the anti-HisX6 universal feeder cells can be used with cells expressing a CAR that binds to Her2 and includes the HisX6 epitope tag and could also be used with cells expressing a CAR that binds to Axl and includes the HisX6 epitope tag.
- the combination of the universal feeder cell and the CAR can enable CAR-T propagation before the cells engage their cognate antigen.
- the ASTR of the CAR is microenvironment restricted, the use of the universal feeder cell binding to antigen may enable expansion outside that restrictive environment.
- Recombinant retroviral particles are disclosed in methods and compositions provided herein, for example, to modify cells, as non-limiting examples human cells, primary cells, T cells and/or NK cells to make genetically modified and/or transduced cells, human cells, primary cells, T cells and/or NK cells. Such modifying can occur in vivo, ex vivo, or in vitro.
- the recombinant retroviral particles are themselves aspects of the present disclosure.
- the recombinant retroviral particles included in aspects provided herein are replication incompetent, meaning that a recombinant retroviral particle cannot replicate once it leaves the packaging cell.
- retroviral particles are replication incompetent, and if such retroviral particles include nucleic acids in their genome that are not native to the retrovirus, they are “recombinant retroviral particles.” In illustrative embodiments, the recombinant retroviral particles are lenti viral particles.
- replication incompetent recombinant retroviral particles for use in transducing cells, typically lymphocytes and illustrative embodiments T cells and/or NK cells.
- the replication incompetent recombinant retroviral particles can include an envelope protein.
- the envelope protein can be a pseudotyping element.
- the envelope protein can be an activation element.
- the replication incompetent recombinant retroviral particles include both a pseudotyping element and an activation element.
- the replication incompetent recombinant retroviral particles can include any of the pseudotyping elements discussed elsewhere herein.
- the replication incompetent recombinant retroviral particles can include any of the activation elements discussed elsewhere herein.
- a replication incompetent recombinant retroviral particle that includes a polynucleotide with nucleic acids that encode at least one of a CAR, a TCR, an LE, an anti-idiotype polypeptide, and a cytokine, and an inhibitory RNA provided in any of the aspects and embodiments herein.
- Such polypeptide typically includes nucleic acids that further encode at least one of a CAR, a TCR, an LE, a cytokine, and an inhibitory RNA.
- the RIP includes a polynucleotide including: A) one or more transcriptional units operatively linked to a promoter active in T cells and/or NK cells, wherein the one or more transcriptional units encode at least one or anti-idiotype polypeptide, an engineered T cell receptor, or a chimeric antigen receptor (CAR); and B) a pseudotyping element and a T cell activation element on its surface, wherein the T cell activation element is not encoded by a polynucleotide in the replication incompetent recombinant retroviral particle.
- the T cell activation element can be any of the activation elements discussed elsewhere herein.
- the T cell activation element can be anti-CD3 scFvFc.
- the pseudotyping element may not be present.
- a replication incompetent recombinant retroviral particle including a polynucleotide including one or more transcriptional units operatively linked to a promoter active in T cells and/or NK cells, wherein the one or more transcriptional units encode a first polypeptide including an engineered T cell receptor or a chimeric antigen receptor (CAR) and a second polypeptide including a lymphoproliferative element.
- CAR chimeric antigen receptor
- the lymphoproliferative element can be a chimeric lymphoproliferative element.
- the lymphoproliferative element does not comprise IF-7 tethered to the IF-7 receptor alpha chain or a fragment thereof.
- the lymphoproliferative element does not comprise IF- 15 tethered to the IF-2/IF-15 receptor beta chain.
- the engineered T cell receptor, CAR, or other transgene is expressed, displayed, and/or otherwise incorporated in the surface of the replication incompetent retroviral particle at a reduced level that is less than 70%, 60%, 50%, 40%, 30%, 20%, 10%, or 5% of the surface expression compared to when the transgene is expressed from an EFl-a or PGK promoter, and in illustrative embodiments, when the transgene is expressed from an EFl-a or PGK promoter in the absence of additional elements (such as degrons or inhibitory RNAs) to reduce such surface expression.
- additional elements such as degrons or inhibitory RNAs
- the gene vector is substantially free of the protein transcript encoded by nucleic acid of the gene vector, and/or the RIPs do not express or comprise a detectable amount of the engineered T cell receptor or CAR on their surface, or express or comprise a reduced amount of the engineered T cell receptor or CAR on their surface.
- a replication incompetent recombinant retroviral particle comprising a polynucleotide comprising one or more transcriptional units operatively linked to a promoter active in T cells and/or NK cells, wherein the one or more transcriptional units encode a first polypeptide comprising a chimeric antigen receptor (CAR) and a second polypeptide comprising a lymphoproliferative element (LE), in illustrative embodiments a chimeric lymphoproliferative element (CLE), for example a constitutively active CLE.
- CAR chimeric antigen receptor
- LE lymphoproliferative element
- CLE chimeric lymphoproliferative element
- the chimeric lymphoproliferative element does not comprise a cytokine tethered to its cognate receptor or tethered to a fragment of its cognate receptor.
- the LE such as the CLE, comprises a first lymphoproliferative element polypeptide (“LE polypeptide”) and a second LE polypeptide, wherein the first LE polypeptide has a different amino acid sequence from the second LE polypeptide and the first LE polypeptide and the second LE polypeptide are capable of, adapted to, and/or are configured to dimerize with each other.
- L polypeptide first lymphoproliferative element polypeptide
- second LE polypeptide comprises a first lymphoproliferative element polypeptide (“LE polypeptide”) and a second LE polypeptide, wherein the first LE polypeptide has a different amino acid sequence from the second LE polypeptide and the first LE polypeptide and the second LE polypeptide are capable of, adapted to, and/or are configured to dimerize with each other.
- such an LE is a heterodimeric LE where the first LE polypeptide and the second LE polypeptide comprise a first extracellular dimerizing motif and a second extracellular dimerizing motif, respectively, that are capable of, adapted to, and/or configured to dimerize with each other.
- such an LE is a heterodimeric LE where the first LE polypeptide and the second LE polypeptide comprise a first intracellular dimerizing motif and a second intracellular dimerizing motif, respectively, that are capable of, adapted to, and/or configured to dimerize with each other.
- a recombinant retroviral particle that includes (i) a pseudotyping element capable of binding to a T cell and/or NK cell and facilitating membrane fusion of the recombinant retroviral particle thereto; (ii) a polynucleotide having one or more transcriptional units operatively linked to a promoter active in T cells and/or NK cells, wherein the one or more transcriptional units encode a first engineered signaling polypeptide having a chimeric antigen receptor that includes an antigen-specific targeting region, a transmembrane domain, and an intracellular activating domain, and a second engineered signaling polypeptide that includes at least one lymphoproliferative element; wherein expression of the first engineered signaling polypeptide and/or the second engineered signaling polypeptide are regulated by an in vivo control element; and (iii) an activation element on its surface, wherein the activation element is capable of binding to a T cell
- the promoter active in T cells and/or NK cells is not active in the packaging cell line or is only active in the packaging cell line in an inducible manner.
- either of the first and second engineered signaling polypeptides can have a chimeric antigen receptor and the other engineered signaling polypeptide can have at least one lymphoproliferative element.
- replication incompetent recombinant retroviral particles that include a polynucleotide encoding a self-driving CAR. Details regarding such replication incompetent recombinant retroviral particles, and composition and method aspects including a self-driving CAR, are disclosed in more detail herein, for example in the Self-Driving CAR Methods and Compositions section and in the Exemplary Embodiments section.
- RNA sequences that are included in replication incompetent, recombinant retroviral particles are provided throughout this disclosure, such as, for example, pseudotyping elements, activation elements, and membrane bound cytokines, as well as nucleic acid sequences that are included in a genome of a replication incompetent, recombinant retroviral particle such as, but not limited to, nucleic acid sequences encoding an anti-idiotype polypeptide, nucleic acid sequences encoding a CAR; nucleic acid sequences encoding a lymphoproliferative element; nucleic acids encoding a cytokine; nucleic acid sequences encoding a control element, such as a riboswitch; a promoter, especially a promoter that is constitutively active or inducible in a T cell; and nucleic acid sequences encoding an inhibitory RNA molecule.
- various aspects provided herein such as methods of making recombinant retroviral particles, methods for performing adoptive cell therapy, and methods for transducing T cells, produce and/or include replication incompetent, recombinant retroviral particles.
- Replication incompetent recombinant retroviruses that are produced and/or included in such methods themselves form separate aspects of the present disclosure as replication incompetent, recombinant retroviral particle compositions, which can be in an isolated form.
- Such compositions can be in dried down (e.g., lyophilized) form or can be in a suitable solution or medium known in the art for storage and use of retroviral particles.
- a replication incompetent recombinant retroviral particle having in its genome a polynucleotide having one or more nucleic acid sequences operatively linked to a promoter active in T cells and/or NK cells that in some instances, includes a first nucleic acid sequence that encodes one or more (e.g., two or more) inhibitory RNA molecules directed against one or more RNA targets and a second nucleic acid sequence that encodes a chimeric antigen receptor, or CAR, as described herein.
- a first nucleic acid sequence that encodes one or more (e.g., two or more) inhibitory RNA molecules directed against one or more RNA targets and a second nucleic acid sequence that encodes a chimeric antigen receptor, or CAR, as described herein.
- a third nucleic acid sequence is present that encodes at least one (e.g., 1, 2, 3, or 4) lymphoproliferative element described previously herein that is not an inhibitory RNA molecule.
- the polynucleotide incudes one or more riboswitches as presented herein, operably linked to the first nucleic acid sequence, the second nucleic acid sequence, and/or the third nucleic acid sequence, if present. In such a construct, expression of one or more inhibitory RNAs, the CAR, and/or one or more lymphoproliferative elements that are not inhibitory RNAs is controlled by the riboswitch.
- two to 10 inhibitory RNA molecules are encoded by the first nucleic acid sequence.
- two to six inhibitory RNA molecules are encoded by the first nucleic acid sequence.
- 4 inhibitory RNA molecules are encoded by the first nucleic acid sequence.
- the first nucleic acid sequence encodes one or more inhibitory RNA molecules and is located within an intron.
- the intron includes ah or a portion of a promoter.
- the promoter can be a Pol I, Pol II, or Pol III promoter.
- the promoter is a Pol II promoter.
- the intron is adjacent to and downstream of the promoter active in a T cell and/or NK cell.
- the intron is EFl- ⁇ intron A.
- Recombinant retroviral particle embodiments herein include those wherein the retroviral particle comprises a genome that includes one or more nucleic acids encoding one or more inhibitory RNA molecules.
- the retroviral particle comprises a genome that includes one or more nucleic acids encoding one or more inhibitory RNA molecules.
- nucleic acids that encode inhibitory RNA molecules that can be included in a genome of a retroviral particle including combinations of such nucleic acids with other nucleic acids that encode a CAR or a lymphoproliferative element other than an inhibitory RNA molecule, are included for example, in the inhibitory RNA section provided herein, as well as in various other paragraphs that combine these embodiments.
- various alternatives of such replication incompetent recombinant retroviruses can be identified by exemplary nucleic acids that are disclosed within packaging cell line aspects disclosed herein.
- disclosure in this section of a recombinant retroviral particle that includes a genome that encodes one or more (e.g., two or more) inhibitory RNA molecules can be combined with various alternatives for such nucleic acids encoding inhibitory RNA molecules provided in other sections herein.
- nucleic acids encoding one or more inhibitory RNA molecules can be combined with various other functional nucleic acid elements provided herein, as for example, disclosed in the section herein that focuses on inhibitory RNA molecules and nucleic acid encoding these molecules.
- the various embodiments of specific inhibitory RNA molecules provided herein in other sections can be used in recombinant retroviral particle aspects of the present disclosure.
- recombinant retroviral vectors such as lentiviral vectors
- These elements are included in the packaging cell line section and in details for making replication incompetent, recombinant retroviral particles provided in the Examples section and as illustrated in WO2019/055946.
- lentiviral particles typically include packaging elements REV, GAG and POL, which can be delivered to packaging cell lines via one or more packaging plasmids, a pseudotyping element, various examples which are provided herein, which can be delivered to a packaging cell line via a pseudotyping plasmid, and a genome, which is produced by a polynucleotide that is delivered to a host cell via a transfer plasmid.
- This polynucleotide typically includes the viral LTRs and a psi packaging signal.
- the 5’ LTR can be a chimeric 5’ LTR fused to a heterologous promoter, which includes 5’ LTRs that are not dependent on Tat transactivation.
- Vpu such as a polypeptide comprising Vpu (sometimes called a “Vpu polypeptide” herein) including but not limited to, Src-FLAG-Vpu
- Vpu polypeptide including but not limited to, Src-FLAG-Vpu
- Vpx such as Src-FLAG-Vpx, is packaged within the retroviral particle.
- Vpu and Vpx is packaged within the retroviral particle for any composition or method aspect and embodiment that includes a retroviral particle provided herein.
- Retroviral particles included in various aspects of the present disclosure are in illustrative embodiments, replication incompetent, especially for safety reasons for embodiments that include introducing cells transduced with such retroviral particles into a subject.
- retroviral particles are not produced from the transduced cell. Modifications to the retroviral genome are known in the art to assure that retroviral particles that include the genome are replication incompetent.
- replication competent recombinant retroviral particles can be used.
- the retroviral particles lack a functional integrase.
- the retroviral RNA is reverse transcribed, but does not integrate into the host cell genome.
- a skilled artisan will recognize that the functional elements discussed herein can be delivered to packaging cells and/or to T cells using different types of vectors, such as expression vectors.
- vectors such as expression vectors.
- Illustrative aspects of the present disclosure utilize retroviral vectors, and in some particularly illustrative embodiments lentiviral vectors.
- Other suitable expression vectors can be used to achieve certain embodiments herein.
- Such expression vectors include, but are not limited to, viral vectors (e.g., viral vectors based on vaccinia virus; poliovirus; adenovirus (see, e.g., Li et al., Invest Opthalmol Vis Sci 35:2543 2549, 1994; Borras et al., Gene Ther 6:515 524, 1999; Li and Davidson, PNAS 92:77007704, 1995; Sakamoto etal, H Gene Ther 5:1088 1097, 1999; WO 94/12649, WO 93/03769; WO 93/19191; WO 94/28938; WO 95/11984 and WO 95/00655); adeno-associated virus (see, e.g., Ali et al., Hum Gene Ther 9:81 86, 1998, Flannery et al, PNAS 94:69166921, 1997; Bennett et al., Invest Opthalmol Vis Sci 38:285728
- a retroviral vector e.g., Murine Leukemia Virus, spleen necrosis virus, and vectors derived from retroviruses such as Rous Sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, human immunodeficiency virus, myeloproliferative sarcoma virus, and mammary tumor virus, for example a gamma retrovirus; or human immunodeficiency virus (see, e.g., Miyoshi et al, PNAS 94:1031923, 1997; Takahashi et al, J Virol 73:78127816, 1999); and the like.
- retroviral vector e.g., Murine Leukemia Virus, spleen necrosis virus, and vectors derived from retroviruses such as Rous Sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, human immunodeficiency virus, myeloproliferative sarcoma virus,
- replication incompetent recombinant retroviral particles are a common tool for gene delivery (Miller, Nature (1992) 357:455-460).
- the ability of replication incompetent recombinant retroviral particles to deliver an unrearranged nucleic acid sequence into a broad range of rodent, primate and human somatic cells makes replication incompetent recombinant retroviral particles well suited for transferring genes to a cell.
- the replication incompetent recombinant retroviral particles can be derived from the Alpharetrovirus genus, the Betaretrovirus genus, the Gammaretrovirus genus, the Deltaretrovirus genus, the Epsilonretrovirus genus, the Lentivirus genus, or the Spumavirus genus.
- retroviruses suitable for use in the methods disclosed herein.
- murine leukemia virus MMV
- human immunodeficiency virus HIV
- equine infectious anaemia virus EIAV
- mouse mammary tumor virus MMTV
- Rous sarcoma virus RSV
- Fujinami sarcoma virus FuSV
- Moloney murine leukemia virus Mo-MLV
- FBR MSV FBR murine osteosarcoma virus
- Mo-MSV Abelson murine leukemia virus
- A-MLV Avian myelocytomatosis virus-29
- AEV Avian erythroblastosis virus
- retroviruses A detailed list of retroviruses may be found in Coffin et al (“Retroviruses” 1997 Cold Spring Harbor Laboratory Press Eds: J M Coffin, S M Hughes, H E Varmus pp 758-763). Details on the genomic structure of some retroviruses may be found in the art. By way of example, details on HIV may be found from the NCBI Genbank (i.e., Genome Accession No. AF033819).
- the replication incompetent recombinant retroviral particles can be derived from the Lentivirus genus. In some embodiments, the replication incompetent recombinant retroviral particles can be derived from HIV, SIV, or FIV. In further illustrative embodiments, the replication incompetent recombinant retroviral particles can be derived from the human immunodeficiency virus (HIV) in the Lentivirus genus. Lentiviruses are complex retroviruses which, in addition to the common retroviral genes gag, pol and env, contain other genes with regulatory or structural function.
- HIV human immunodeficiency virus
- a typical lentivirus is the human immunodeficiency virus (HIV), the etiologic agent of AIDS in vivo, HIV can infect terminally differentiated cells that rarely divide, such as lymphocytes and macrophages.
- HIV human immunodeficiency virus
- replication incompetent recombinant retroviral particles provided herein contain Vpx polypeptide.
- replication incompetent recombinant retroviral particles provided herein comprise and/or contain Vpu polypeptide.
- a retroviral particle is a lentiviral particle.
- Such retroviral particle typically includes a retroviral genome within a capsid which is located within a viral envelope.
- DNA-containing viral particles are utilized instead of recombinant retroviral particles.
- viral particles can be adenoviruses, adeno-associated viruses, herpesviruses, cytomegaloviruses, poxviruses, avipox viruses, influenza viruses, vesicular stomatitis virus (VSV), or Sindbis virus.
- VSV vesicular stomatitis virus
- a skilled artisan will appreciate how to modify the methods disclosed herein for use with different viruses and retroviruses, or retroviral particles.
- functional units can be included in such genomes to induce integration of all or a portion of the DNA genome of the viral particle into the genome of a T cell transduced with such virus.
- the HIV RREs and the polynucleotide region encoding HIV Rev can be replaced with N-terminal RGG box RNA binding motifs and a polynucleotide region encoding ICP27.
- the polynucleotide region encoding HIV Rev can be replaced with one or more polynucleotide regions encoding adenovirus E1B 55-kDa and E4 Orf6.
- replication incompetent recombinant retroviral particles can include nucleic acids encoding a self-driving CAR, as disclosed elsewhere herein.
- retroviral particles whose genome comprises one or more first transcriptional units operably linked to an inducible promoter inducible in at least one of a T cell or an NK cell, and one or more second transcriptional units operably linked to a constitutive T cell or NK cell promoter, wherein the number of nucleotides between the 5’ end of the one or more first transcriptional units and the 5’ end of the one or more second transcriptional units is less than the number of nucleotides between the 3’ end of the one or more first transcriptional units and the 3’ end of the one or more second transcriptional units, a) wherein at least one of the one or more first transcriptional units encodes a lymphoproliferative element, b) and wherein at least one of the one or more second transcriptional units encodes
- the nucleic acids within the first transcriptional unit or the second transcriptional unit can further encode an anti-idiotype polypeptide according to an of the embodiments provided herein.
- the replication incompetent recombinant retroviral particles can further display a T cell activation element.
- T cells contacted and transduced with these replication incompetent recombinant retroviral particles that include nucleic acids encoding a self-driving CAR can receive an initial boost of transcription from the CAR-stimulated inducible promoters as the T cell activation element can stimulate the inducing signal of the CAR-stimulated inducible promoters.
- the binding of the T cell activation element can induce the calcium ion influx that results in dephosphorylation of NFAT and its subsequent nuclear translocation and binding to NFAT-responsive promoters.
- the lymphoproliferative elements transcribed and translated from these CAR- stimulated inducible promoters can give an initial increase in proliferation to these cells.
- the T cell activation element can be a membrane-bound anti-CD3 antibody, and can be GPI-linked or otherwise displayed on virus.
- the membrane-bound anti-CD3 antibody can be fused to a viral envelope protein, such as MuLV, VSV-G, a Henipavirus-G such as NiV-G, or variants and fragments thereof.
- the isolated replication incompetent retroviral particles are a large-scale batch contained in a large-scale container.
- Such large-scale batch can have titers, for example of 10 6 - 10 s TU/ml and a total batch size of between lxlO 10 TU and lxlO 13 TU, lxlO 11 TU and lxlO 13 TU, lxlO 12 TU and lxlO 13 TU, lxlO 10 TU and 5xl0 12 TU, or lxlO 11 TU and 5xl0 12 TU.
- retroviral particles for any aspect or embodiment provided herein are substantially pure, as discussed in more detail herein.
- lentiviral genomes have a limitation to the number of polynucleotides that can be packaged into the viral particle.
- the polypeptides encoded by the polynucleotide encoding region can be truncations or other deletions that retain a functional activity such that the polynucleotide encoding region is encoded by less nucleotides than the polynucleotide encoding region for the wild-type polypeptide.
- the polypeptides encoded by the polynucleotide encoding region can be fusion polypeptides that can be expressed from one promoter.
- the fusion polypeptide can have a cleavage signal to generate two or more functional polypeptides from one fusion polypeptide and one promoter.
- some functions that are not required after initial ex vivo transduction are not included in the retroviral genome, but rather are present on the surface of the replication incompetent recombinant retroviral particles via the packaging cell membrane. These various strategies are used herein to maximize the functional elements that are packaged within the replication incompetent recombinant retroviral particles.
- the recombinant retroviral genome to be packaged can be between 1,000, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, and 8,000 nucleotides on the low end of the range and 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, and 11,000 nucleotides on the high end of the range.
- the retroviral genome to be packaged includes one or more polynucleotide regions encoding a first and second engineering signaling polypeptide as disclosed in detail herein.
- the recombinant retroviral genome to be packaged can be less than 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, or 11,000 nucleotides.
- Functions discussed elsewhere herein that can be packaged include required retroviral sequences for retroviral assembly and packaging, such as a retroviral rev, gag, and pol coding regions, as well as a 5' LTR and a 3' LTR, or an active truncated fragment thereof, a nucleic acid sequence encoding a retroviral cis-acting RNA packaging element, and a cPPT/CTS element.
- required retroviral sequences for retroviral assembly and packaging such as a retroviral rev, gag, and pol coding regions, as well as a 5' LTR and a 3' LTR, or an active truncated fragment thereof, a nucleic acid sequence encoding a retroviral cis-acting RNA packaging element, and a cPPT/CTS element.
- a replication incompetent recombinant retroviral particle herein can include any one or more or all of the following, in some embodiments in reverse orientation with respect to a 5’ to 3’ orientation established by the retroviral 5’ LTR and 3’ LTR (as illustrated in WO20 19/055946 as a non-limiting example): one or more polynucleotide regions encoding a first and second engineering signaling polypeptide, at least one of which includes at least one lymphoproliferative element (e.g., that each comprises 1 or 2 lymphoproliferative element polypeptides); a second engineered signaling polypeptide that can include a chimeric antigen receptor; an miRNA, a control element, such as a riboswitch, which typically regulates expression of the first and/or the second engineering signaling polypeptide; a safety switch polypeptide, an intron, a promoter that is active in a target cell, such as a T cell,
- a delivery composition or suspension for example for treating or preventing a disease, for example cancer or tumor growth, comprising polynucleotides, such as polynucleotide vectors, in illustrative replication incompetent recombinant retroviral particle (RIPs), or modified cells, such as modified lymphocytes, modified TILs, modified lymphocytes other than B cells, or modified T cells and/or modified NK cells as an active ingredient.
- polynucleotides such as polynucleotide vectors, in illustrative replication incompetent recombinant retroviral particle (RIPs), or modified cells, such as modified lymphocytes, modified TILs, modified lymphocytes other than B cells, or modified T cells and/or modified NK cells as an active ingredient.
- RIPs replication incompetent recombinant retroviral particle
- an infusion composition or other RIP or cell formulation for treating or preventing cancer or tumor growth comprising polynucleotides such as polynucleotide vectors, in illustrative embodiments RIPs, or modified cells, such as modified lymphocytes, modified TILs, modified lymphocytes other than B cells, or modified T cells and/or modified NK cells.
- polynucleotides such as polynucleotide vectors, in illustrative embodiments RIPs, or modified cells, such as modified lymphocytes, modified TILs, modified lymphocytes other than B cells, or modified T cells and/or modified NK cells.
- polynucleotides such as polynucleotide vectors, in illustrative embodiments RIPs, or modified cells, such as modified lymphocytes, modified TILs, modified lymphocytes other than B cells, or modified T cells and/or modified NK cells of the delivery composition or infusion composition can include any of the aspects, embodiments, or subembodiments discussed above or elsewhere herein, for example that include nucleic acids that encode anti-idiotype polypeptides, a CAR, an LE, a cytokine and/or a TCR.
- a container such as a commercial container or package, or a kit comprising the same, comprising polynucleotides, such as polynucleotide vectors, for example RIPs, or modified cells, such as modified lymphocytes, modified TILs, modified lymphocytes other than B cells, or modified T cells and/or modified NK cells according to any of the aspects and embodiments provided herein.
- polynucleotides such as polynucleotide vectors, for example RIPs
- modified cells such as modified lymphocytes, modified TILs, modified lymphocytes other than B cells, or modified T cells and/or modified NK cells according to any of the aspects and embodiments provided herein.
- the polynucleotides such as polynucleotide vectors, for example RIPs, or modified cells, such as modified lymphocytes, modified TILs, modified lymphocytes other than B cells, or modified T cells and/or modified NK cells can comprise in their genome a polynucleotide comprising one or more nucleic acid sequences operatively linked to a promoter active in T cells and/or NK cells.
- a nucleic acid sequence of the one or more nucleic acid sequences can encode an anti-idiotype polypeptide, an inhibitory RNA, a cytokine, a lymphoproliferative element, a TCR, and/or a chimeric antigen receptor (CAR) comprising an antigen-specific targeting region (ASTR), a transmembrane domain, and an intracellular activating domain.
- a nucleic acid sequence of the one or more nucleic acid sequences can encode one, two or more inhibitory RNA molecules directed against one or more RNA targets.
- the container that contains the polynucleotides can be an infusion bag, tube, vial, well of a plate, or other vessel for storage of polynucleotides, such as polynucleotide vectors, for example RIPs, or modified cells, such as modified lymphocytes, modified TILs, modified lymphocytes other than B cells, or modified T cells and/or modified NK cells.
- polynucleotides such as polynucleotide vectors, for example RIPs
- modified cells such as modified lymphocytes, modified TILs, modified lymphocytes other than B cells, or modified T cells and/or modified NK cells.
- some aspects provided herein comprise a container comprising polynucleotides, such as polynucleotide vectors, for example RIPs, or modified cells, such as modified lymphocytes, modified TILs, modified lymphocytes other than B cells, or modified T cells and/or modified NK cells, wherein such biologic includes any nucleic acid(s) or other component(s) disclosed herein.
- polynucleotides such as polynucleotide vectors, for example RIPs
- modified cells such as modified lymphocytes, modified TILs, modified lymphocytes other than B cells, or modified T cells and/or modified NK cells, wherein such biologic includes any nucleic acid(s) or other component(s) disclosed herein.
- Such container in illustrative embodiments includes substantially pure polynucleotides, such as polynucleotide vectors, for example RIPs, or modified cells, such as modified lymphocytes, modified TILs, modified lymphocytes other than B cells, or modified T cells and/or modified NK cells, sometimes referred to herein for shorthand, as a substantially biologic.
- substantially pure polynucleotides such as polynucleotide vectors, for example RIPs
- modified cells such as modified lymphocytes, modified TILs, modified lymphocytes other than B cells, or modified T cells and/or modified NK cells, sometimes referred to herein for shorthand, as a substantially biologic.
- a preparation and/or container of substantially pure retroviral particles is sterile, and negative for mycoplasma, replication competent retroviruses of the same type, and adventitious viruses according to standard protocols (see e.g., “Viral Vector Characterization: A Look at Analytical Tools”; October 10, 2018 (available at https://cellculturedish.com/viral-vector-characterization-analytical-tools/)).
- Exemplary methods for generating substantially pure biologies and cells for cell therapy are known. For example, for such methods with respect to RIPs, viral supernatants can be purified by a combination of depth filtration, TFF, benzonase treatment, diafiltration, and formulation.
- a substantially pure biologic meets all of the following characteristics based on quality control testing results: a) negative for mycoplasma; b) endotoxin at less than 25 EU/ml, and in certain further illustrative embodiments, less than 10 EU/ml; c) absence of replication competent retroviruses detected of the same type as purposefully in the container (e.g., lentiviruses) detected; and d) absence of adventitious viruses detected.
- the biologic is a viral particle, such as a retroviral particle
- it meets the following quality control testing results: a) less than 1 pg host cell DNA/transducing unit (TU), and in certain further illustrative embodiments, less than 0.3 pg/TU; b) less than 100 residual plasmid copies/TU, and in certain further illustrative embodiments, less than 10 copies/TU of any plasmid used to make the recombinant retroviral particles; c) less than 1 ng host cell protein/TU, and in certain further illustrative embodiments, less than 50 pg host cell protein/TU; and/or d) greater than 100 TU/ng p24 protein, and in certain further illustrative embodiments, greater than 10,000 TU/ng p24 protein.
- TU host cell DNA/transducing unit
- Retroviral particles are ty pically tested against release specifications that include some or all of those provided above, before they are released to a customer.
- Mycoplasma testing can be performed in accordance with The United States Pharmacopeia’s (USP) chapter ⁇ 63> or by a rapid method such as RT- PCR of samples for the absence mycoplasma.
- Endotoxin testing can be performed in accordance with USP chapter ⁇ 85> or a rapid method such as Endosafe® nexgen-PTSTM from Charles River.
- Replication competent retrovirus can be tested by assaying for reverse transcriptase activity by qPCR-based Product Enhanced Reverse Transcriptase (PERT) assay or a rapid RCL assay.
- PERT Product Enhanced Reverse Transcriptase
- Potency of each particle may be defined on the basis of p24 viral capsid protein or viral RNA genome copies and can be converted to infectious titer by measuring functional gene transfer Transducing Units (TUs) in a bioassay.
- TUs functional gene transfer Transducing Units
- Determination of infectious titer of purified bulk retrovirus material and finished product by bioassay and qPCR is an exemplary 7 analytical test method for the determination of infectious titer of retroviruses.
- An indicator cell bank such as Jurkat or FlXT(a HEK293T cell variant)
- An indicator cell bank may be seeded at 150,000 cells per well, followed by exposure to serial dilutions of the retrovirus product. Dilutions of purified retrovirus particles are made on indicator cells, for example from 1 :200 to 1 : 1,600.
- a reference standard virus may be added for system suitability. Following 4 days (or 2 to 4 days) of incubation with retrovirus, the cells are harvested, DNA extracted and purified.
- a standard curve for example from 100- 10,000,000 copies/ well, of human genome and unique retroviral genome sequence plasmid pDNA amplicons are used followed by addition of genomic DNA of the cell samples exposed to retrovirus particles.
- the Cq values of both the retrovirus amplicon and the endogenous control such as human RNAseP are extrapolated back to copies per reaction. From these values the integrated genome copy number is calculated.
- indicator cells such as F1EK 293T have been characterized as being triploid, hence 3 copies of a single copy gene per cell should be utilized in the calculation.
- a Transducing Unit (TU) per ml retrovirus particles may be determined.
- 1 TU is the amount of functional viral particles in a solution that generates 1 transgene integration when the viral solution is added to 100 permissive cells.
- Potency testing can include potency testing against release specifications with purity and specific activity.
- potency release testing of final product can include measurement of the number of Transducing Units (TU) compared to viral particle quantity (e.g., by performing an ELISA against a viral protein, for example, for lentivirus by performing a p24 capsid protein ELISA with a cutoff of at least 100, 1,000, 2,000 or 2,500 TU/ng p24), and CAR functionality, for example by measuring interferon gamma release by a reporter cell line exposed to gene modified cells.
- RIP formulations herein can have potency or potency range equal to any of the potency testing cutoffs and ranges herein.
- the purity of replication incompetent recombinant retroviral particles can be determined using the ratio of the amount of protein from the host cells used to generate the of RIPs to the transducing units (amount host cell protein/TU).
- the ratio of host cell protein to TUs can be 10, 5, 3, 2, or 1 ng or less host cell protein/TU or 750, 500, 400, 300, 200, 100, 50, 40, 30, 20, or 10 pg or less host cell protein/TU.
- the ratio of host cell protein to TUs can be 1 ng or less host cell protein/TU.
- the ratio of host cell protein to TUs can be 50 pg or less host cell protein/TU.
- the host cell is a F1EK cell line or variant thereof.
- the ratio of F1EK protein to TUs can be 10, 5, 3, 2, or 1 ng or less F1EK protein/TU or 750, 500, 400, 300, 200, 100, 50, 40, 30, 20, or 10 pg or less F1EK protein/TU.
- the ratio of F1EK protein to Tus can be 1 ng or less protein/TU.
- the ratio of F1EK protein to Tus can be 50 pg or less F1EK protein/TU.
- the potency of RIPs present in a delivery solution or RIP formulation can be determined using the ratio of the TUs to the ng of p24 protein.
- the ratio of the TUs to the ng of p24 protein can be 100, 200, 300, 400, 500, 1,000, 4,000, 10,000, 12,500, or 15,000 or more TUs/ng of p24 protein.
- the purity and potency of RIPs in a substantially pure biologic can be any of the combinations provided in the Exemplary Embodiments section herein.
- the quality control testing can include the ratios of host cell protein/TU and the TU/ng p24 protein being, respectively: 1 ng host cell protein/TU or less and 100 TU/ng p24 protein or more; 1 ng host cell protein/TU or less and 500 TU/ng p24 protein or more; 1 ng host cell protein/TU or less and 1,000 TU/ng p24 protein or more; 1 ng host cell protein/TU or less and 5,000 TU/ng p24 protein or more; 1 ng host cell protein/TU or less and 10,000 TU/ng p24 protein or more; 1 ng host cell protein/TU or less and 12,500 TU/ng p24 protein or more; 1 ng host cell protein/TU or less and 15,000 TU/ng p24 protein or more; 50 pg host cell protein/TU or less and 100 TU/ng p24 protein or more; 50 pg host cell protein/TU or less and 500 TU/ng p24 protein or more; 50 pg host
- the host cell can be a HEK 293 cell line or variant thereof including a HEK 293T cell line.
- the quality control testing can include the ratios of HEK protein/TU and TU/ng p24 protein being, respectively: 1 ng HEK protein/TU or less and 100 TU/ng p24 protein or more; 1 ng HEK protein/TU or less and 500 TU/ng p24 protein or more; 1 ng HEK protein/TU or less and 1,000 TU/ng p24 protein or more; 1 ng HEK protein/TU or less and 5,000 TU/ng p24 protein or more; 1 ng HEK protein/TU or less and 10,000 TU/ng p24 protein or more; 1 ng HEK protein/TU or less and 12,500 TU/ng p24 protein or more; 1 ng HEK protein/TU or less and 15,000 TU/ng p24 protein or more; 50 pg HEK protein/TU or less
- kits or isolated replication incompetent recombinant retroviral particle aspects herein that include a container of such retroviral particles, sufficient recombinant retroviral particles are present in the container to achieve an MOI (the number of Transducing Units, or TUs applied per cell) in a reaction mixture made using the retroviral particles, of between 0.1 and 50, 0.5 and 50, 0.5 and 20, 0.5 and 10, 1 and 25, 1 and 15, 1 and 10, 1 and 5, 2 and 15, 2 and 10, 2 and 7, 2 and 3, 3 and 10, 3 and 15, or 5 and 15 or at least 0.1, 0.5, 1, 2, 2.5, 3, 5, 10 or 15, or to achieve an MOI of at least 0.1, 0.5, 1, 2, 2.5, 3, 5, 10 or 15.
- MOI the number of Transducing Units, or TUs applied per cell
- the Transducing Units of virus particles provided in the kit should enable the use an MOI that prevents producing too many integrants in an individual cell, on average less than 5, 4, or 3 lentigenome copies per cellular genome and more preferably 1 copy per cell.
- MOI can be based on 1, 2.5, 5, 10, 20, 25, 50, 100, 250, 500, or 1,000 ml of reaction mixture assuming lxlO 6 target cells/ml, for example in the case of whole blood, assuming 1 x 10 6 PBMCs/ml of blood.
- a container of retroviral particles can include between 1 x 10 5 and 1 x 10 9 , 1 x 10 5 and 1 x 10 8, 1 x 10 5 and 5 x 10 7 , 1 x 10 5 and 1 x 10 7 , 1 x 10 5 and 1 x 10 6 ; 5 x 10 5 and 1 x 10 9 ; 5 x 10 5 and 1 x 10 8 , 5 x 10 5 and 5 x 10 7 , 5 x 10 5 and 1 x 10 7 , 5 x 10 5 and 1 x 10 7 , 5 x 10 5 and 1 x 10 6 , or 1 x 10 7 and 1 x 10 9 , 1 x 10 7 and 5 x 10 7 , 1 x 10 6 and 1 x 10 7 , and 1 x 10 6 and 5 x 10 6 TUs.
- the container can contain between 1 x 10 7 and 1 x 10 9 , 5 x 10 6 and 1 x 10 8 , 1 x 10 6 and 5 x 10 7 , 1 x 10 6 and 5 x 10 6 or between 5 xlO 7 and 1 xlO 8 retroviral Transducing Units.
- such numbers of particles would support between 1 and 100 ml of blood at an MOI of between 1 and 10.
- as little as 10 ml, 5 ml, 3 ml, or even 2.5 ml of blood can be processed for T cell and/or NK cell modification and optionally subcutaneous and/or intramuscular administration methods provided herein.
- an advantage of the present methods is that in some illustrative embodiments, they require far fewer retroviral particle Transducing Units than prior methods that involve nucleic acids encoding a CAR, such as CAR-T methods.
- Each container that contains retroviral particles can have, for example, a volume of between 0.05 ml and 5 ml, 0.05 ml and 1 ml, 0.05 ml and 0.5 ml, 0.1 ml and 5 ml, 0.1 ml and 1 ml, 0.1 ml and 0.5 ml, 0.1 and 10 ml, 0.5 and 10 ml, 0.5 ml and 5 ml, 0.5 ml and 1 ml, 1.0 ml and 10.0 ml, 1.0 ml and 5.0 ml, 10 ml and 100 ml, 1 ml and 20 ml, 1 ml and 10 ml, 1 ml and 5 ml, 1 ml and 2 ml, 2 ml and 20 ml, 2 ml and 10 ml, 2 ml and 5 ml, 0.25 ml to 10 ml, 0.25 to 5 ml, or 0.
- retroviral particles in the container are GMP-grade, or cGMP-grade retroviral particles (i.e., produced under GMP or current GMP requirements according to a regulatory agency), or the product of a retroviral manufacturing process performed using GMP systems.
- retroviral particles are typically made using a USA FDA (i.e., U.S. GMP or U.S. cGMP), EMA (i.e.,
- EMA GMP or EMA cGMP National Medical Products Administration (NMPA) of China (i.e., Chinese FDA) (i.e., NMPA GMP or NMPA cGMP) good manufacturing practice (GMP), for example using GMP quality systems and GMP procedural controls.
- NMPA GMP or NMPA cGMP National Medical Products Administration
- GMP-grade retroviral particles are typically sterile. This can be accomplished for example, by filtering retroviral particles, for example substantially pure retroviral particles, with a 0.45 pm or a 0.22 pm filter.
- GMP-grade retroviral particles are typically substantially pure, and prepared with control manufacturing test specifications for potency, quality and safety.
- the solution comprising retroviral particles in the container is free of detectable bovine proteins, which can be referred to as “bovine-free”.
- bovine-free such solution of retroviral particles can be bovine free because bovine proteins, such as bovine serum proteins, are not used in culturing the packaging cells during retrovirus production.
- the solution of retroviral particles is GMP-grade and bovine-free.
- Substantially pure nucleic acid solutions are typically bovine-free and manufactured in bovine-free broth.
- lentiviral particles in certain exemplary reaction mixtures provided herein, between 0.1 and 50, 0.5 and 50, 0.5 and 20, 0.5 and 10, 1 and 25, 1 and 15, 1 and 10, 1 and 5, 2 and 15, 2 and 10, 2 and 7, 2 and 3, 3 and 10, 3 and 15, or 5 and 15, multiplicity of infection (MOI); or at least 1 and less than 6, 11, or 51 MOI; or in some embodiments, between 5 and 10 MOI units of replication incompetent recombinant retroviral particles are present.
- the MOI can be at least 0.1, 0.5, 1, 2, 2.5, 3, 5, 10 or 15.
- compositions and methods for transducing lymphocytes in blood in certain embodiments higher MOI can be used than in methods wherein PBMCs are isolated and used in the reaction mixtures.
- illustrative embodiments of compositions and methods for transducing lymphocytes in whole blood assuming lxlO 6 PBMCs/ml of blood, can use retroviral particles with an MOI of between 1 and 50, 2 and 25, 2.5 and 20, 2.5 and 10, 4 and 6, or about 5, and in some embodiments between 5 and 20, 5 and 15, 10 and 20, or 10 and 15.
- TCR complex including TCRoc, TP3 ⁇ 4b, and CD3, on CD4 positive (CD4+) cells and CD8 positive (CD8+) cells is reduced or “dimmed” when such cells are contacted with polynucleotide vectors (e.g., replication incompetent recombinant (RIR) retroviral particles) displaying a binding polypeptide that binds the TCR complex, e.g., a T cell activation element, as is the case in certain illustrative embodiments herein. This dimming is largely the result of internalization of the TCR complex upon activation.
- polynucleotide vectors e.g., replication incompetent recombinant (RIR) retroviral particles
- RIR replication incompetent recombinant
- the extent of this dimming increases as the concentration of a given gene vector is increased in the reaction mixture and correlates with the ability of the gene vector to activate and enter cells.
- internalization of other surface polypeptides after binding to polypeptides on the surface of a gene vector results in dimming of the surface polypeptide on the cell being contacted with the gene vector and may be common during transduction using other binding polypeptides.
- a percent reduction in surface polypeptide expression on cells contacted with a gene vector comprising a binding polypeptide compared to surface polypeptide expression on cells not contacted with the gene vector comprising a binding polypeptide is used to quantitate the potency of a gene vector and determine the appropriate dose of gene vector used to modify a population of cells.
- a percent reduction in surface TCR complex expression on cells contacted with a gene vector compared to surface TCR complex expression on cells not contacted with the gene vector is used to quantitate the potency of a gene vector and determine the appropriate dose of gene vector used to modify a population of cells.
- a “Dimming Unit” is the amount of gene vector (e.g., RIR retroviral particles) that reduces the surface expression of a surface polypeptide in 1 ml of a cell mixture after contacting with the gene vector for 4 hours at 37 °C and 5% CO2 by 50% compared to the surface expression of the surface polypeptide in the cell mixture under similar conditions but not contacted with the gene vector.
- the surface polypeptide is typically a binding partner of a binding polypeptide present on the surface of the gene vector.
- the surface polypeptide is a TCR complex polypeptide.
- the TCR complex polypeptide is CD3D, CD3E,
- CD3G, CD3Z, TCRa, or TCR CD3G, CD3Z, TCRa, or TCR .
- the binding partner is CD3 and the binding polypeptide is anti-CD3.
- the ability of a polynucleotide vector to reduce surface expression of a surface polypeptide should be determined for each preparation of a polynucleotide vector. In some embodiments, the ability of a polynucleotide vector to reduce surface expression of a surface polypeptide is determined based on target cell number. In some embodiments, the ability of a polynucleotide vector to reduce surface expression of a surface polypeptide is based on the volume the cells.
- the reduction of surface expression of a surface polypeptide can be referred to as dimming the surface polypeptide.
- CD3 is dimmed on that cell and the cell can be called CD3-, even though the cell may still contain CD3 not expressed on its surface.
- T cells that temporarily internalize and dim CD3 are T cells and will eventually re-express CD3 on their cell surfaces such that they are again CD3+.
- a method for determining an amount of a polynucleotide vector preparation to dim surface expression of a surface polypeptide by a dimming percentage on cells in a dimming volume comprising: a) forming a plurality of reaction mixtures comprising a plurality of volumes of the polynucleotide vector preparation and a plurality of volumes of a cell mixture, wherein at least two of the reaction mixtures in the plurality of reaction mixtures comprise different volumes of the polynucleotide vector preparation and/or the cell mixture, wherein the cell mixture comprises a plurality of cells comprising the surface polypeptide on their surfaces, and wherein the polynucleotide vector preparation comprises a plurality of polynucleotide vectors comprising a binding polypeptide on their surfaces capable of binding the surface polypeptide; b) incubating the reaction mixtures; c) measuring the surface expression of the surface polypeptide in the reaction mixtures and in an uncontacted
- the amount of the cell mixture in the reaction mixtures is based on volume. In some embodiments, the amount of the cell mixture in the reaction mixtures is based on numbers of target cells.
- the polynucleotide vector preparation is a viral preparation. In illustrative embodiments, the viral preparation is a replication incompetent recombinant retroviral particle preparation.
- the dimming percentage (percentage of cells dimmed) is 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, or 97%. In illustrative embodiments, the dimming percentage is at least or about 80%, 85%, 90%, or 95%.
- the dimming volume is 0.25 ml, 0.5 ml, 0.75 ml, 1 ml, 2 ml, 3 ml, 4 ml, 5 ml, 10 ml, 15 ml, 20 ml, or 25 ml.
- the surface polypeptide can be CD3D, CD3E, CD3G, CD3Z, TCRa, TCR]3, CD16A, NKp46, 2B4, CD2, DNAM, or NKG2C, NKG2D, NKG2E, NKG2F, and/or NKG2H.
- the surface polypeptide is a TCR complex polypeptide.
- the TCR complex polypeptide is CD3D, CD3E, CD3G, CD3Z, TCRa, or TCR .
- the surface polypeptide is CD3E.
- the binding polypeptide can be any of the activation elements disclosed in the Activation Elements section herein. In such embodiments, the surface polypeptide can be the binding partner of the activation element.
- the cell mixture is whole blood.
- the cell mixture has been subjected to a red blood cell depletion procedure.
- the whole blood is collected from a healthy subject, e.g., a subject that does not have or is not known or suspected to have a disease, disorder, or condition associated with an elevated expression of an antigen.
- the whole blood is collected from a subject with a disease, disorder, or condition associated with an elevated expression of an antigen, wherein the polynucleotide vector will be administered to the subject or other subjects with the disease disorder, or condition.
- the whole blood is collected from each subject and the Dimming Units are calculated for each subject individually.
- the reaction mixtures can be incubated for less than or about 24, 12, 10, 8, 6, 4, or 2 hours or 60, 45, 30, 15, 10, or 5 minutes, or for just an initial contacting. In some embodiments, the reaction mixtures can be incubated for between 10 minutes and 24 hours, or between 10 minutes and 8 hours, or for between 1 hour and 8 hours, or for between 1 hour and 6 hours, or in illustrative embodiments, for between 3.5 and 4.5 hours or for 4 hours. In some embodiments, the reaction mixtures can be incubated at about 10 °C, 15 °C, 20 °C, 25 °C, 30 °C, 37 °C, or 42 °C. In some embodiments, the reaction mixtures are incubated without CO2. In illustrative embodiments, the reaction mixtures are incubated with 5% CO2.
- the surface expression of the surface polypeptide is measured by a fluorescence-activated cell sorting (FACS) method.
- FACS fluorescence-activated cell sorting
- the antibody used in a FACS method is GMP.
- a CD3 antibody is used to determine surface expression of the surface polypeptide.
- the CD3 antibody is UCHT1, OKT-3, HIT3A, TRX4, X35-3, VIT3, BMA030 (BW264/56), CLB-T3/3, CRIS7, YTH12.5, FI 11409, CLB-T3.4.2, TR-66, TR66.opt, HuM291, WT31, WT32, SPv-T3b, 11D8, XIII-141, XIII46, XIII-87, 12F6, T3/RW2-8C8, T3/RW24B6, OKT3D, M-T301, SMC2, F101.01, and/or SK7.
- the CD3 antibody is PerCP Mouse Anti-Human CD3 - Clone SK7 (BD, 347344).
- cells present in the cell mixture are separated from unbound polynucleotide vector in the incubated reaction mixture.
- the polynucleotide vector preparation is a RIP preparation
- the dimming percentage is 50%
- the dimming volume is 1 ml
- the surface polypeptide is CD3
- the cell mixture is whole blood collected from a healthy subject
- the reaction mixture is incubated for 4 hours at 37 °C and 5% CO2 and the method is used to calculate Dimming Units.
- Such methods can be used to determine the amount of retroviral particles in a polynucleotide vector preparation that reduces surface polypeptide expression on cells by a specific percentage. This amount can then be used to determine an amount of the preparation of retroviral particles to use for subsequent transductions of whole blood, isolated PBMCs, or isolated TNCs.
- the amount of a preparation of the polynucleotide vector, for example replication incompetent recombinant retroviral particles, to add to the lymphocytes can be determined using the method above.
- Dimming Units can be used in any of the aspects or embodiments herein that include a contacting step to determine the amount of the polynucleotide vector to add. As 1 DU of the polynucleotide vector reduces the surface expression of the surface polypeptide by 50% in a 1 ml volume of cells, 10 DUs of the polynucleotide vector reduces the surface expression of the surface polypeptide by 50% in 10 ml of a cell mixture.
- sufficient DUs are added to a volume of cells to reduce surface expression of the surface polypeptide, for example CD3, by greater than 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, or 97% after contacting with the polynucleotide vector compared to the surface expression of the surface polypeptide in the cell mixture under similar conditions but not contacted with the polynucleotide vector.
- sufficient DUs are added to a volume of cells to reduce surface expression of the surface polypeptide by greater than 80%, 85%, 90%, or 95% after contacting with the polynucleotide vector compared to the surface expression of the surface polypeptide in the cell mixture under similar conditions but not contacted with the polynucleotide vector.
- at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12, 13, 14, 15, 16, 17, 18, 19 or 20 DU are added per ml of cell mixture.
- between 5 and 20 DU, 5 and 15 DU, 10 and 20 DU, or 13 and 18 DU are added per ml of cell mixture.
- the target cells are lymphocytes, for example T cells or NK cells.
- the cells are in whole blood, isolated PBMCs, or isolated TNCs.
- the cells are the remaining fraction of whole blood after lysing red blood cells.
- sufficient DUs are added to dim a population of cells a specific percentage, for example, to dim CD3 on a population of T cells by greater than 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, or 97%.
- sufficient dimming units of a polynucleotide vector, and in illustrative embodiments RIP are present to increase the percentage of surface dimmed surface polypeptide, and in illustrative embodiments dimmed surface CD3-, in a population of cells, and in illustrative embodiments T cells, to at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, or 97%.
- the composition including cells can include at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12, 13, 14, 15, 16, 17, 18, 19 or 20 DU per ml of the cells, for example at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12, 13, 14, 15, 16, 17, 18, 19 or 20 DU per ml of blood, cell formulation, or population of cells.
- kits for modifying NK cells and/or, in illustrative embodiments, T cells includes one or a plurality of containers containing polynucleotides, typically substantially pure polynucleotides comprising one or more first transcriptional units operatively linked to a promoter active in T cells and/or NK cells, wherein the one or more first transcriptional units encode a first polypeptide comprising a first chimeric antigen receptor (CAR), sometimes referred to as a first CAR, and one or more containers of accessory component(s), also called accessory kit components herein.
- the polynucleotides e.g., retroviral particles
- the container such as the cryopreservation infusion bag
- the container can hold 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, or 500 ml or less of blood.
- the container for example the cryopreservation infusion bag, can hold at least 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, or 500 ml of blood.
- the container for example the cryopreservation infusion bag
- the container can hold between 1, 2, 3, 4, 5, 10, 15, 20, 25, and 50 ml of blood on the low end of the range and 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, and 500 ml of blood on the high end of the range.
- the container for example the cryopreservation infusion bag
- the container for example the cryopreservation infusion bag
- the container can hold between 1 and 10 ml, 5 and 25 ml, 10 and 50 ml, 25 and 100 ml, 50 and 200 ml, or 100 and 500 ml of blood.
- the container for example the cryopreservation infusion bag
- the container for example the cryopreservation infusion bag, does not include heparin.
- the number of cells delivered can be sufficient to provide between 1 x 10 s cells and 1 x 10 9 , between 1 x 10 6 cells and 1 x 10 9 , or between 1 x 10 6 cells and 5 x 10 s , for example CAR-positive viable T cells and/or NK cells per kg of body weight of the subject to which the cells are to be delivered.
- the commercial container can include the aforementioned ranges x 50-150 kg, or 50- 100kg.
- the commercial container includes between 1 x 10 7 and 1 x 10 n cells, between 1 x 10 s and 1 x 10 n cells, or between 1 x 10 s and 5 x 10 10 cells, for example CAR-positive viable T cells and/or NK cells, or in an illustrative embodiment, cells that are positive for an anti-idiotype extracellular recognition domain.
- the polynucleotides encoding any of the various polypeptides disclosed herein, e.g., a CAR are located in the genome of retroviral particles, typically substantially pure retroviral particles, according to any of the replication incompetent recombinant retroviral particle aspects and embodiments provided herein.
- the replication incompetent recombinant retroviral particles in the kit comprise a polynucleotide comprising one or more transcriptional units operatively linked to a promoter active in T cells and/or NK cells, wherein the one or more first transcriptional units encode a first polypeptide comprising an anti-idiotype polypeptide, a CAR, a TCR, and/or an LE and optionally encode a second polypeptide comprising an anti-idiotype polypeptide, a CAR, a TCR, and/or an LE, according to any of the embodiments provided herein.
- a kit provided herein can include a container containing the polynucleotides, such as polynucleotide vectors, for example RIPs, or modified cells, such as, modified lymphocytes, modified TILs, modified lymphocytes other than B cells, for example modified T cells and/or NK cells, and an accessory kit.
- the accessory kit components can include one or more of the following: a. one or more containers containing a delivery solution compatible with, in illustrative embodiments effective for, and in further illustrative embodiments adapted for subcutaneous and/or intramuscular administration as provided herein; b. one or more containers of hyaluronidase as provided herein; c.
- one or more blood bags such as a blood collection bag, in illustrative embodiments comprising an anticoagulant in the bag, or in a separate container, a blood processing buffer bag, a blood processing waste collection bag, and a blood processing cell sample collection bag; d. one or more sterile syringes compatible with, in illustrative embodiments effective for, and in further illustrative embodiments adapted for, subcutaneous or intramuscular delivery of T cells and/or NK cells; e.
- a T cell activation element as disclosed in detail herein for example anti-CD3 provided in solution in the container containing the reto viral particle, or in a separate container, or in illustrative embodiments, is associated with a surface of the replication incompetent retroviral particle; f. one or a plurality of leukoreduction filtration assemblies; g. one or more containers containing a solution or media compatible with, in illustrative embodiments effective for, and in further illustrative embodiments adapted for transduction of T cells and/or NK cells; h.
- one or more containers containing polynucleotides typically substantially pure polynucleotides (e.g., found within recombinant retroviral particles according to any embodiment herein), comprising one or more second transcriptional units operatively linked to a promoter active in T cells and/or NK cells, wherein the one or more second transcriptional units encode a polypeptide comprising a second CAR directed against a different target epitope, and in certain embodiments a different antigen, in illustrative embodiments found on a same target cancer cell (e.g., B cell); k.
- polynucleotides typically substantially pure polynucleotides (e.g., found within recombinant retroviral particles according to any embodiment herein)
- the one or more second transcriptional units encode a polypeptide comprising a second CAR directed against a different target epitope, and in certain embodiments a different antigen, in illustrative embodiments found on a same target cancer cell (e.
- the blood bags can hold 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, or 500 ml or less of blood.
- the blood bags can hold at least 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, or 500 ml of blood. In some embodiments, the blood bags can hold between 1, 2, 3, 4, 5, 10, 15, 20, 25, and 50 ml of blood on the low end of the range and 10, 15, 20, 25,
- the blood bag can hold between 1, 2, 3, 4, 5, 10, 15, 20, 25, and 50 ml of blood on the low end of the range and 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, and 500 ml of blood on the high end of the range.
- the blood bag can hold between 1 and 10 ml, 5 and 25 ml, 10 and 50 ml,
- the blood bags can include heparin. In other embodiments, the blood bags do not include heparin.
- kits that include an antigen or a cognate antigen, less than 50%, 40%, 30%, 20%, 10%, 5%, or 1% of the polypeptides in the kit are non-human, i.e., produced from non-human sources.
- the kit may be a single-pack/use kit, but in other embodiments the kit is a multi-pack or multi-use kit for the processing of more than one blood sample from contacting with nucleic acids encoding a CAR optionally thru subcutaneous administration.
- a container of nucleic acids encoding a CAR (and optionally a paired container of nucleic acids encoding a second CAR in certain embodiments) in the kit is used for one performance of a method for modifying T cells and/or NK cells and optionally subcutaneous administration.
- the container(s) containing nucleic acids encoding a CAR and optionally a second CAR is typically stored and shipped frozen.
- a kit can include sufficient containers (e.g., vials) of nucleic acids encoding a CAR (and optionally paired containers encoding a second CAR in certain embodiments) for 1, 2, 3, 4, 5, 6, 10, 12, 20, 24, 50 and 100 performances of a method for modifying a T cell and/or NK cell provided herein, and thus can include 1 , 2, 3, 4, 5, 6, 10, 12, 20, 24, 50 and 100 containers (e.g., vials) of nucleic acids encoding the CAR (e.g., retroviral particles), and similarly is considered a 1, 2, 3, 4, 5, 6, 10, 12, 20, 24, 50 and 100 pack, performance, administration or X kit, respectively.
- accessory components in the kit would be provided for similar numbers of performances of a method for modifying T cells and/or NK cells and optionally subcutaneous administration, using the kit.
- the one or more leukoreduction filtration assemblies typically include(s) one or a plurality of leukoreduction filters or leukoreduction filter sets, each typically within a filter enclosure, as well as a plurality of connected sterile tubes connected or adapted to be connected thereto, and a plurality of valves connected or adapted to be connected thereto, that are adapted for use in a single use closed blood processing system.
- leukoreduction filtration assembly for each container of nucleic acid encoding a CAR in a kit.
- a 20-pack kit in illustrative embodiments, includes 20 vials of nucleic acids encoding a CAR and 20 leukoreduction filtration assemblies.
- a kit herein comprises one or a plurality of containers containing nucleic acids and one or more leukoreduction filtration assemblies.
- Such a kit can optionally be intended to be used for administration to a subject via any route including for example, infusion or in illustrative embodiments intramuscular and/or in further illustrative embodiments, subcutaneous delivery.
- such a kit optionally includes other accessory components that are intended to be used with such route of administration.
- the one or more containers of subcutaneous or intramuscular delivery solution is typically sterile and can include a total combined volume, or individually per container, of 100 ml to 5 L, 1 ml to 1 L, 1 ml to 500 ml, 1 ml to 250 ml, 1 ml to 200 ml, 1 ml to 100 ml, 1 ml to 10 ml, or 1 ml to 5 ml; 5 ml to 1 L, 5 ml to 500 ml, 5 ml to 250 ml, 5 ml to 100 ml,
- the kit comprises a plurality of containers of subcutaneous delivery solution, with each container having a volume of between 10 ml and 200 ml, 10 ml and 100 ml, 1 ml and 20 ml, 1 ml and 10 ml, 1 ml and 5 ml, 1 ml and 2 ml, 2 ml and 20 ml, 2 ml and 10 ml, 2 ml and 5 ml, 0.25 ml to 10 ml, 0.25 to 5 ml, or 0.25 to 2 ml.
- a 20-pack kit in illustrative embodiments, includes 20 vials of nucleic acids encoding a CAR and 20 containers of sterile delivery solution.
- accessory components of the kit can further include one or more of the following: a. one or more containers containing a delivery solution adapted for, compatible with, and/or effective for, intravenous or intraperitoneal administration as provided herein; and b. Instructions, either physically or digitally associated with other kit components, for the use thereof, for example for delivering modified T cells and/or NK cells to a subject intravenously or intraperitoneally.
- kits for modifying a T cell or NK cell wherein the use of the kit includes: contacting the T cell or NK cell ex vivo with the replication incompetent recombinant retroviral particle, wherein the replication incompetent recombinant retroviral particle includes a pseudotyping element on a surface and a T cell activation element on the surface, wherein said contacting facilitates transduction of the T cell or NK cell by the replication incompetent recombinant retroviral particle, thereby producing a modified and in illustrative embodiments genetically modified T cell or NK cell.
- aspects that include the use of a replication incompetent recombinant retroviral particle in the manufacture of a kit for modifying a T cell or NK cell. Details regarding polynucleotides, and replication incompetent recombinant retroviral particles that contain such polynucleotides are disclosed in more detail herein, and in the Exemplary Embodiments section.
- the T cell or NK cell can be from a subject.
- the T cell activation element can be membrane-bound.
- the contacting can be performed for between 1, 2, 3, 4, 5, 6, 7, or 8 hours on the low end of the range and 4, 5, 6, 7, 8, 10, 12, 15, 18, 21, and 24 hours on the high end of the range, for example, between 1 and 12 hours.
- the replication incompetent recombinant retroviral particle for use in the manufacture of a kit can include any of the aspects, embodiments, or sub embodiments discussed elsewhere herein.
- kits such as a commercial container or package, or a kit comprising the same, comprising isolated packaging cells, in illustrative embodiments isolated packaging cells from a packaging cell line, according to any of the packaging cell and/or packaging cell line aspects provided herein.
- the kit includes additional containers that include additional reagents such as buffers or reagents used in methods provided herein.
- additional reagents such as buffers or reagents used in methods provided herein.
- any replication incompetent recombinant retroviral particle provided herein in any aspect, in the manufacture of a kit for modifying and in illustrative embodiments genetically modifying a T cell or NK cell according to any aspect provided herein.
- any packaging cell or packaging cell line provided herein in any aspect, in the manufacture of a kit for producing the replication incompetent recombinant retroviral particles according to any aspect provided herein.
- a pharmaceutical composition for treating or preventing cancer or tumor growth comprising a replication incompetent recombinant retroviral particle as an active ingredient.
- an infusion composition or other cell formulation for treating or preventing cancer or tumor growth comprising a replication incompetent recombinant retroviral particle.
- the replication incompetent recombinant retroviral particle of the pharmaceutical composition or infusion composition can include any of the aspects, embodiments, or subembodiments discussed above or elsewhere herein.
- any methods used in any aspects provided herein can include a step for modifying and in illustrative embodiments genetically modifying lymphocytes, PBMCs, and in illustrative embodiments NK cells and/or in further illustrative embodiments, T cells, ex vivo or in vivo through direct administration of RIPs, can include a step of collecting blood from a subject.
- the blood includes blood components including blood cells such as lymphocytes (e.g., T cells and NK cells) that can be used in methods and compositions provided herein.
- the subject is a human subject afflicted with cancer (i.e., a human cancer subject).
- blood can be collected or obtained from a subject by any suitable method known in the art as discussed in more detail herein, and as such the collected blood or blood-derived component can be referred to as a “blood-derived product” and typically is a “peripheral blood-derived product,” since typically it is isolated from peripheral blood.
- the blood-derived product can be collected by venipuncture or any other blood collection method known in the art, by which a sample of unfractionated whole blood is collected in a vessel, for example a blood bag, or by which leukocytes and lymphocytes are isolated from blood, such as by apheresis (e.g., leukapheresis or lymphoplasmapheresis).
- apheresis e.g., leukapheresis or lymphoplasmapheresis.
- the volume of blood (e.g., unfractionated whole blood) collected is between 1 and 5 ml, 5 and 10 ml, 10 and 15 ml, 15 and 20 ml, 20 and 25 ml, 5 and 25 ml, 25 ml and 250 ml, 25 ml and 125 ml, 50 ml and 100 ml, or 50 ml and 250 ml, 75 ml and 125 ml, 90 ml and 120 ml, or between 95 and 110 ml.
- the volume of blood collected can be between 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 175, 200, 225, 250, 275, 300, 350,
- lymphocytes e.g., T cells and/or NK cells
- T cells and/or NK cells can be obtained by apheresis.
- the volume of blood taken and processed during apheresis is between 0.5, 0.6, 0.7, 0.75, 0.8, 0.9, 1, 1.25, or 1.5 total blood volumes of a subject on the low end of the range and 0.6, 0.7, 0.75, 0.8, 0.9, 1, 1.25, 1.5 1.75, 2, 2.25, or 2.5 total blood volumes of a subject on the high end of the range, for example between 0.5 and 2.5, 0.5 and 2, 0.5 and 1.5, or between 1 and 2 total blood volumes.
- the total blood volume of a human typically ranges from 4.5 to 6 L and thus much more blood is typically taken and processed during apheresis than if unfractionated whole blood is collected.
- target blood cells e.g., T cells
- target blood cells e.g., T cells
- target blood cells therein would be processed according to a method provided herein, which in certain illustrative embodiments results in the target blood cells becoming modified, genetically modified, and/or transduced.
- apheresis e.g., leukapheresis or lymphoplasmapheresis
- a cell fraction comprising T cells and/or NK cells (e.g., to provide a leukopak or a lymphoplasmapak)
- NK cells e.g., to provide a leukopak or a lymphoplasmapak
- Such reaction mixture can be used in any method herein.
- apheresis e.g., leukapheresis or lymphoplasmapheresis
- blood cells e.g., White blood cells or lymphocytes
- T cells and /or NK cells in the subject are contacted by the RIPs, and modified, and illustrative embodiments genetically modified and transduced. Further details regarding such in vivo reaction mixtures can be found in other sections of this specification, for example in the Exemplary Embodiments section herein
- lymphocytes in reaction mixtures that relate to composition and method aspects for modifying lymphocytes in whole blood provided herein, and in aspects and embodiments herein that include coadministering lymphocytes, such as unmodified T cells and/or NK cells, lymphocytes, including NK cells and T cells, can be present at a lower percent of blood cells, and at a lower percentage of white blood cells, in the coadministered lymphocytes or in the reaction mixture, than methods that involve a PBMC enrichment procedure before coadministering or forming the reaction mixture. For example, in some embodiments of these aspects, more granulocytes or neutrophils are present in cell populations that are coadministered or in the reaction mixture than NK cells or even T cells.
- T cells can be for example, between 10, 20, 30, or 40% of the lymphocytes of the population of coadministered cells or the reaction mixture on the low end of the range, and between 40, 50, 60, 70, 80, or 90% of the lymphocytes of the population of coadministered cells or the reaction mixture on the high end of the range.
- T cells comprise between 10 and 90%, between 20 and 90%, between 30 and 90%, between 40 and 90%, between 40 and 80%, or between 45% to 75% of the lymphocytes. In such embodiments, for example,
- NK cells can be present at between 1, 2, 3, 4, or 5% of the lymphocytes of the reaction mixture on the low end of the range, and between 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14% of the lymphocytes of the reaction mixture on the high end of the range.
- T cells comprise between 1 and 14%, between 2 and 14%, between 3 and 14%, between 4 and 14%, between 5 and 14%, between 5 to 13%, between 5 to 12%, between 5 to 11% or between 5 to 10% of the lymphocytes of the reaction mixture.
- T cells can be at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%,
- composition and method aspects for transducing lymphocytes in whole blood typically do not involve any blood fractionation such as a PBMC enrichment step of a blood sample, before lymphocytes from the blood sample are contacted with recombinant nucleic acid vectors, for example retroviral particles, in the reaction mixtures disclosed herein for those aspects.
- recombinant nucleic acid vectors for example retroviral particles
- lymphocytes in unfractionated whole blood are contacted with recombinant retroviral particles.
- neutrophils/granulocytes are separated away from other blood cells before the cells are coadministered to a subject, or contacted with RIPs in an ex vivo reaction mixture.
- peripheral blood mononuclear cells including peripheral blood lymphocytes (PBLs) such as T cell and/or NK cells
- PBLs peripheral blood lymphocytes
- T cell and/or NK cells are isolated away from other components of a blood sample using for example, a PBMC enrichment procedure, before they are typically formulated into a cell formulation and coadministered to a subject, or before they are combined into an ex vivo reaction mixture with retroviral particles.
- PBLs peripheral blood lymphocytes
- a PBMC enrichment procedure is a procedure in which PBMCs are enriched at least 25-fold, and typically at least 50-fold from other blood cell types. For example, it is believed that PBMCs make up less than 1% of blood cells in whole blood. After a PBMC enrichment procedure, at least 30%, and in some examples as many as 70% of cells isolated in the PBMC fraction are PBMCs. It is possible that even higher enrichment of PBMCs is achieved using some PBMC enrichment procedures. Various different PBMC enrichment procedures are known in the art.
- a PBMC enrichment procedure is a ficoll density gradient centrifugation process that separates the main cell populations, such as lymphocytes, monocytes, granulocytes, and red blood cells, throughout a density gradient medium.
- the aqueous medium includes ficoll, a hydrophilic polysaccharide that forms the high density solution. Layering of whole blood over or under a density medium without mixing of the two layers followed by centrifugation will disperse the cells according to their densities with the PBMC fraction forming a thin white layer at the interface between the plasma and the density gradient medium (see e.g., Panda and Ravindran (2013) Isolation of Human PBMCs. BioProtoc. Vol. 3(3)).
- centripetal forces can be used to separate PBMCs from other blood components, in ficoll using the spinning force of a Sepax cell processing system.
- apheresis for example leukapheresis
- PBMCs can be used to isolate cells, such as PBMCs.
- AMICUS RBCX Frsenius-Kabi
- Trima Accel Tuumo BCT
- Cells isolated by apheresis typically contain T cells, B cells, NK cells, monocytes, granulocytes, other nucleated white blood cells, red blood cells, and/or platelets.
- the cells collected by apheresis can be washed to remove the plasma fraction and to place the cells in an appropriate buffer or media, such as phosphate buffered saline (PBS) or wash solution lacks calcium and may lack magnesium or may lack many if not all divalent cations, for subsequent processing steps.
- PBS phosphate buffered saline
- the cells collected by apheresis can be genetically modified by any of the methods provided herein.
- the cells collected by apheresis can be used to prepare any of the cell formulations provided herein.
- the cells collected by apheresis can be resuspended in a variety of biocompatible buffers, such as, for example, Ca-free, Mg -free PBS.
- leukapheresis can be used to isolate cells, such as lymphocytes.
- a leukopak can be used in any embodiment that includes TNCs.
- a buffy coat can be used in another PBMC enrichment method.
- an automated leukapheresis collection system such as SPECTRA OPTIA® APHERESIS SYSTEM from Terumo BCT, Inc.
- Lakewood, CO 80215, USA is used to separate the inflow of whole blood from the target PBMC fraction using high-speed centrifugation while typically returning the outflow material, such as plasma, red blood cells, and granulocytes, back to the donor, although this returning would be optional in methods provided herein. Further processing may be necessary to remove residual red blood cells and granulocytes. Both methods include a time intensive purification of the PBMCs, and the leukapheresis method requires the presence and participation of the patient during the PBMC enrichment step.
- PBMCs are isolated using a Sepax or Sepax 2 cell processing system (BioSafe).
- the PBMCs are isolated using a CliniMACS Prodigy cell processor (Miltenyi Biotec).
- an automated apheresis separator is used which takes blood from the subject, passes the blood through an apparatus that sorts out a particular cell type (such as, for example, PBMCs), and returns the remainder back into the subject.
- Density gradient centrifugation can be performed after apheresis.
- the PBMCs are isolated using a leukoreduction filter assembly.
- magnetic bead activated cell sorting is then used for purifying a specific cell population from PBMCs, such as, for example, PBLs or a subset thereof, according to a cellular phenotype (i.e., positive selection), before they are used in a reaction mixture herein.
- Other methods for purification can also be used, such as, for example, substrate adhesion, which utilizes a substrate that mimics the environment that a T cell encounters during recruitment, to purify T cells before adding them to a reaction mixture, or negative selection can be used, in which unwanted cells are targeted for removal with antibody complexes that target the unwanted cells for removal before a reaction mixture for a contacting step is formed.
- substrate adhesion which utilizes a substrate that mimics the environment that a T cell encounters during recruitment
- negative selection can be used, in which unwanted cells are targeted for removal with antibody complexes that target the unwanted cells for removal before a reaction mixture for a contacting step is formed.
- red blood cell rosetting can be used to remove red blood cells before forming a reaction mixture.
- hematopoietic stem cells can be removed before a contacting step, and thus in these embodiments, are not present during the contacting step.
- an ABC transporter inhibitor and/or substrate is not present before, during, or both before and during the contacting (i.e., not present in the reaction mixture in which contacting takes place) with or without optional incubating, or any step of the method.
- contact between the T cells and/or NK cells and the replication incompetent recombinant retroviral particles can facilitate transduction of the T cells and/or NK cells by the replication incompetent recombinant retroviral particles.
- the replication incompetent recombinant retroviral particles RIPs
- identify and bind to T cells and/or NK cells and the T cells and NK cells are “modified” as the term is used herein.
- genetic material from the replication incompetent recombinant retroviral particles enters the T cells and/or NK cells at which time the T cells and/or NK cells are “genetically modified” as the phrase is used herein. It is noteworthy that such process might occur hours or even days after the contacting is initiated, and even after non-associated retroviral particles are rinsed away.
- the genetic material is typically integrated into the genomic DNA of the T cells and/or NK cells, at which time the T cells and/or NK cells are now “transduced” as the term is used herein.
- cells can be modified, genetically modified, and/or transduced by recombinant vectors other than replication incompetent recombinant retroviral particles. Cells may also internalize and integrate genetic material into the genomic DNA of the T cells and/or NK cells after transfection, at which time the T cells and/or NK cells are now “stably transfected” as the term is used herein.
- any method for modifying and/or genetically modifying lymphocytes is a method for transducing lymphocytes (e.g., T cells and/or NK cells). It is believed that by day 6 in vivo or ex vivo, after contacting is initiated, the vast majority of modified and genetically modified cells have been transduced. Methods of lentiviral transduction are known. Exemplary methods are described in, e.g., Wang et al. (2012) J. Immunother. 35(9): 689-701; Cooper et al. (2003) Blood. 101: 1637-1644; Verhoeyen et al. (2009) Methods Mol Biol.
- a transduced, or in some embodiments a stably transfected, T cell and/or NK cell includes progeny of ex vivo transduced cells that retain at least some of the nucleic acids or polynucleotides that are incorporated into the genome of a cell during the ex vivo transduction.
- methods herein that recite “reintroducing” a transduced cell it will be understood that such cell is typically not in a transduced state when it is collected from the blood of a subject.
- Introduction or reintroduction also referred to herein as administration and readministration, and also referred to as delivery of modified and in illustrative embodiments genetically modified lymphocytes, or in some embodiments, replication incompetent retroviral particles (“RIPs”), into a subject in methods provided herein can be via any route known in the art.
- RIPs replication incompetent retroviral particles
- Such introduction or reintroduction of genetically modified lymphocytes typically involves suspending i) modified and/or ii) genetically modified and/or iiia) transduced or iiib) transfected cells or iv) RIPs, in a delivery solution to form a cell formulation or a RIP formulation that can be introduced or reintroduced into a subject as discussed in further detail herein.
- Some embodiments that relate to introduction of RIPs can involve suspension of the RIPs in a delivery solution to form a transducing formulation that can be introduced into a subject.
- introduction or RIPS, lymphocytes or modified lymphocytes, or reintroduction for lymphocytes or modified lymphocytes can be delivery via infusion into a blood vessel of the subject.
- RIPS or modified lymphocytes e.g., T cells and/or NK cells
- Some administered cells are modified with a nucleic acid encoding a lymphoproliferative element.
- a nucleic acid encoding a lymphoproliferative element is not limited by theory, in non-limiting illustrative methods, the delivery of a polynucleotide encoding a lymphoproliferative element, to a resting T cell and/or NK cell ex vivo, which can integrate into the genome of the T cell or NK cell, provides that cell with a driver for in vivo expansion without the need for lymphodepleting the host.
- the subject is not exposed to a lymphodepleting agent within 1, 2, 3, 4, 5, 6, 7, 10, 14, 21, or 28 days, or within 1 month, 2 months, 3 months or 6 months of direct administration of RIPs, or of performing the contacting, during the contacting, and/or within 1, 2, 3, 4, 5, 6, 7, 10, 14, 21, or 28 days, or within 1 month, 2 months, 3 months or 6 months after either direct administration of RIPs or the modified T cells and/or NK cells are reintroduced back into the subject.
- methods provided herein can be performed without exposing the subject to a lymphodepleting agent during a step wherein a RIP is in contact in vivo or ex vivo, with T cells and/or NK cells (e.g., resting T cells and/or resting NK cells) of the subject and/or during the entire ex vivo method or the entire in vivo administration.
- T cells and/or NK cells e.g., resting T cells and/or resting NK cells
- methods of expanding modified and in illustrative embodiments genetically modified T cells and/or NK cells in a subject in vivo is a feature of some embodiments of the present disclosure. In illustrative embodiments, such methods are ex vivo propagation-free or substantially propagation-free.
- the present disclosure provides various treatment methods using a CAR.
- a CAR of the present disclosure when present in a T lymphocyte or an NK cell, can mediate cytotoxicity toward a target cell.
- a CAR of the present disclosure binds to an antigen present on a target cell, thereby mediating killing of a target cell by a T lymphocyte or an NK cell genetically modified to produce the CAR.
- the ASTR of the CAR binds to an antigen present on the surface of a target cell.
- the present disclosure provides methods of killing, or inhibiting the growth of, a target cell, the method involving contacting a cytotoxic immune effector cell (e.g., a cytotoxic T cell, or an NK cell) that is genetically modified to produce a subject CAR, such that the T lymphocyte or NK cell recognizes an antigen present on the surface of a target cell, and mediates killing of the target cell.
- a cytotoxic immune effector cell e.g., a cytotoxic T cell, or an NK cell
- the target cell can be a cancer cell, for example, and autologous cell therapy methods herein, can be methods for treating cancer, in some illustrative embodiments.
- the subject can be an animal or human suspected of having cancer, or more typically, a subject that is known to have cancer.
- genetically modified cells can be administered in combination with an anti-PDL-1 antibody or antibody mimetic.
- cells are introduced or reintroduced into the subject by infusion into a vein or artery, especially when neutrophils are not present in a preparation of lymphocytes that have been contacted with retroviral particles and are ready to be reintroduced, or by subcutaneous, intratumoral, or intramuscular administration, for embodiments where at least 1%, 2%, 3%, 4%, 5%,
- the number of lymphocytes, and in illustrative embodiments modified T cells and/or NK cells, present in cell formulations provided herein and optionally reinfused or in illustrative embodiments, subcutaneously delivered into a subject can be between 1 x 10 3 , 2.5 x 10 3 , 5 x 10 3 , 1 x 10 ⁇ 2.5 x 10 4 , 5 x 10 4 , 1 x 10 5 , 2.5 x 10 5 , 5 x 10 5 , 1 x 10 6 , 2.5 x 10 6 , 5 x 10 6 , and 1 x 10 7 cells/kg on the low end of the range and 5 x 10 4 , 1 x 10 5 , 2.5 x 10 5 , 5 x 10 5 , 1 x 10 6 , 2.5 x 10 6 , 5 x 10 6 , 1 x 10 7 , 2.5 x 10 7 , 5 x 10 7 , 1 x 10 8 , 1 x 10 9 , and
- the number of lymphocytes, and in illustrative embodiments modified T cells and/or NK cells, present in cell formulations herein and optionally reinfused or otherwise delivered into a subject can be between 1 x 10 4 , 2.5 x 10 4 , 5 x 10 4 , and 1 x 10 5 cells/kg on the low end of the range and 2.5 x 10 4 , 5 x 10 4 , 1 x 10 5 , 2.5 x 10 5 , 5 x 10 5 , 1 x 10 6 , 1 x 10 7 , 2.5 x 10 7 , 5 x 10 7 , and 1 x 10 8 cells/kg on the high end of the range, or between 1 x 10 4 cells/kg on the low end of the range and 2.5 x 10 4 , 5 x 10 4 , 1 x 10 5 , 2.5 x 10 5 , 5 x 10 5 , 1 x
- the number of lymphocytes, and in illustrative embodiments T cells and/or NK cells present in cell formulations herein and optionally reinfused, or delivered intratumorally, intramuscularly, subcutaneously, or otherwise delivered into a subject can be between 5 x 10 5 , 1 x 10 6 , 2.5 x 10 6 , 5 x 10 6 , 1 x 10 7 , 2.5 x 10 7 , 5 x 10 7 , and 1 x 10 8 cells on the low end of the range and 2.5 x 10 6 , 5 x 10 6 , 1 x 10 7 , 2.5 x
- the number of lymphocytes, and in illustrative embodiments T cells and/or NK cells, present in cell formulations herein and available for infusion, reinfusion, or other delivery means (e.g., subcutaneous delivery) into a 70 kg subject or patient is between 7 x 10 5 and 2.5 x 10 8 cells.
- the number of lymphocytes, and in illustrative embodiments T cells and/or NK cells present in cell formulations herein and available for transduction is approximately 7 x 10 6 plus or minus 10%.
- the cell can be an autologous cell or an allogeneic cell.
- the allogeneic cell can be a genetically engineered allogeneic cell. Allogeneic cells, such as allogeneic T cells, and methods for genetically engineering allogeneic cells, are known in the art.
- the allogeneic cell is a T cell
- the T cell has been genetically engineered such that at least one component of the TCR complex is functionally impaired and/or is at least partially deleted.
- the T cell has been genetically engineered such that the expression of at least one component of the TCR complex has been reduced or eliminated.
- the allogeneic cell can be modified such that it is missing all or part of the B2 microglobulin gene.
- allogeneic cells can include any of the lymphoproliferative elements and/or CLEs disclosed herein. The use of lymphoproliferative elements and CLEs can reduce the required number of cells and can facilitate cell manufacturing of T cells, NK cells, B cells, or stem cells.
- the allogeneic cell can be an immortalized cell. In any of the aspects or embodiments herein that include an allogeneic cell, steps that include collecting blood or contacting a cell with a replication incompetent recombinant retroviral particle can be eliminated.
- a T cell may have been previously genetically modified, and the genetically modified allogeneic CAR-T cell is administered to the subject without collecting blood from the subject.
- the allogeneic cell is administered subcutaneously.
- the allogeneic cell is administered intravenously.
- the allogeneic cell is administered intraperitoneally.
- lymphocytes e.g., T cells and/or NK cells
- RIPs replication incompetent recombinant retroviral particles
- the modified, genetically modified, and/or transduced lymphocyte (e.g., T cell and/or NK cell) or population thereof, or the RIPs in compositions provided herein without cells, such as GMP RIP compositions, are introduced or reintroduced into the subject.
- introduction or reintroduction of the modified and, in illustrative embodiments, genetically modified lymphocytes into a subject, and direct delivery or introduction of RIPs can be via any route known in the art.
- introduction or reintroduction can be delivery via infusion into a blood vessel of the subject.
- the modified, genetically modified, and/or transduced lymphocyte (e.g., T cell and/or NK cell) or population thereof undergo 4 or fewer cell divisions ex vivo prior to being introduced or reintroduced into the subject.
- the lymphocyte(s) used in such a method are resting T cells and/or resting NK cells that are in contact with the replication incompetent recombinant retroviral particles for between 1 hour and 12 hours. In some embodiments, no more than 12 hours, 10 hours, 8 hours, 6 hours, 4 hours, 2 hours, or 1 hour pass(es) between the time blood is collected from the subject and the time the unmodified, modified and/or genetically modified T cells and/or NK cells are formulated for delivery and/or are reintroduced into the subject. In some embodiments, all steps after the blood are collected and before the blood is reintroduced, are performed in a closed system in which a person monitors the closed system throughout the processing.
- any cell in a cell mixture, cell formulation, or reaction mixture that is useful in adoptive cell therapy can be enriched prior to formulation for delivery.
- the desired cells can be enriched by positive selection prior to being contacted with a recombinant nucleic acid vector, such as a replication incompetent retroviral particle.
- the desired cells can be enriched by positive selection after the cell mixture, cell formulation, or reaction mixture is contacted with a recombinant nucleic acid vector, such as a replication incompetent retroviral particle.
- enriching the one or more cell populations can be performed at the same time as any of the methods of genetic modification disclosed herein, and in illustrative embodiments genetic modification with a replication incompetent retroviral particle.
- Mononuclear cells such as PBMCs
- TNCs can be isolated from a more complex cell mixture such as whole blood by density-gradient centrifugation or reverse perfusion of a leukoreduction filter assembly, respectively, as described in more detail herein.
- the desired cells can have specific cell lineages, such as NK cells, T cells, and/or T cell subsets including naive, effector, memory, suppressor T-ceIIs, and/or regulatory T cells and can be enriched through the selection of cells expressing one or more surface molecules.
- the one or more surface molecules can include CD4, CD8, CD16, CD25, CD27, CD28, CD44, CD45RA, CD45RO, CD56, CD62L, CCR7, KIRs, FoxP3, and/or TCR components such as CD3.
- Methods using beads conjugated to antibodies directed to one or more surface molecules can be used to enrich for the desired cells using magnetic, density, and size-based separation.
- binding of the one or more cell surface molecules can lead to signal transduction and alteration of the biology of the bound cell.
- selection of T cells using beads with attached antibodies to CD3 may lead to CD3 signal transduction and T cell activation.
- binding and signal transduction may lead to further cell differentiation of cells such as naive or memory T cells.
- positive selection is not used to enrich for desired cells such as when it is preferred that the desired cells are not contacted but rather are left untouched.
- the desired cells can be enriched such that the desired cells comprise at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% of the cells in a cell mixture, cell formulation, or reaction mixture.
- the desired cells can be enriched such that the desired cells comprise between 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, or 40% of the cells in a cell mixture, cell formulation, or reaction mixture on the low end of the range and 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% of the cells in a cell mixture, cell formulation, or reaction mixture on the high end of the range.
- the desired cells can be enriched such that the desired cells comprise between 10% and 90%, 20% and 90%, 30% and 90%, 40% and 90%, 40% and 80%, 45% and 75%, 1% and 14%, 2% and 14%, 3% and 14%, 4% and 14%, 5% and 14%, 5 and 13%, 5% and 12%, 5% and 11%, or 5% and 10% of the cells in a cell mixture, cell formulation, or reaction mixture.
- any cell in a cell population, cell mixture, cell formulation, or reaction mixture from whole blood, isolated TNCs, or isolated PBMCs can contain one or more unwanted cell populations, referred to herein as unwanted cells, that can be depleted, such that the desired cells in the cell mixture, cell formulation, or reaction mixture are enriched.
- the unwanted cells can be depleted by negative selection prior to being contacted with a recombinant nucleic acid vector, such as a replication incompetent retroviral particle, for example as provided in methods for genetically modifying a T cell or NK cell provided herein.
- the unwanted cells can be depleted by negative selection after the cell mixture is contacted with a recombinant nucleic acid vector, such as a replication incompetent retroviral particle, for example as provided in methods for genetically modifying a T cell or NK cell provided herein.
- depleting the unwanted cells can be performed at the same time as any of the methods of genetic modification disclosed herein, and in illustrative embodiments genetic modification with a replication incompetent retroviral particle.
- the unwanted cells can include any non-T or non-NK cell.
- the unwanted cells can include T or NK cell subsets, such as regulatory T cells or suppressor T cells.
- the unwanted cells can include B cells.
- the unwanted cells include monocytes.
- the unwanted cells include granulocytes.
- the unwanted cells include cells that express the cognate antigen to a CAR that is or will be expressed on a population of the cells that will be formulated for delivery.
- the unwanted cells include cancer cells. Cancer cells from many types of cancer can enter the blood and could be unintentionally genetically modified at a low frequency along with the lymphocytes using the methods provided herein.
- the cancer cell can be derived from any cancer, including, but not limited to: renal cell carcinoma, gastric cancer, sarcoma, breast cancer, lymphoma, B cell lymphoma, diffuse large B cell lymphoma (DLBCL), Hodgkin’s lymphoma, non-Hodgkin’s B-cell lymphoma (B-NHL), neuroblastoma, glioma, glioblastoma, medulloblastoma, colorectal cancer, ovarian cancer, prostate cancer, mesothelioma, lung cancer (e.g., small cell lung cancer), melanoma, leukemia, chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (
- the CAR-cancer cell can be derived from a B-cell lymphoma.
- a cancer cell that expresses a CAR with an ASTR that binds to an antigen expressed on its own cell surface i.e., the CAR-expressing cancer cell is itself a target cell (CAR-cancer cell)
- CAR-cancer cell can block CAR- T cells from binding to the antigen, also known as epitope masking, and thereby prevent the killing of the CAR-cancer cell.
- the CAR-cancer cell can result in recurrence of the cancer, with immunity to CAR-T, even after initial successful treatment with CAR-T (see, e.g., Ruella et al. Nat Med. 2018 Oct;
- Methods and compositions provided herein for depleting unwanted cancer cells overcome this risk posed by genetically modifying cells, such as blood cells or PBMCs, isolated from a cancer patient.
- Monocytes can be depleted by incubation of the cell mixture with an immobilized monocyte binding substrate such as a standard plastic tissue culture plate, nylon or glass wool, or sephadex resin.
- an immobilized monocyte binding substrate such as a standard plastic tissue culture plate, nylon or glass wool, or sephadex resin.
- monocytes adhere preferentially to the immobilized monocyte-binding substrate versus other cells in the cell mixture, which adhere at a lower frequency or strength or do not adhere at all.
- the incubations can be performed at 37 °C for at least 1 hour or by passing the cell mixture through a resin After the incubation, the desired non-adherent cells in suspension are collected for further processing.
- the whole blood, TNCs, or PBMCs are not incubated for at least 8, 7, 6, 5, 4, 3, 2, or 1 hours with an immobilized monocyte-binding substrate and the monocytes are not depleted by such an incubation.
- methods herein include depleting unwanted cells by negative selection of cells expressing one or more surface molecules using methods known in the art for removing such cells.
- the surface molecule is a tumor-associated antigen, a tumor-specific antigen, or is otherwise expressed on cancer cells, for example, circulating tumor cells.
- the surface molecules can include Axl, ROR1, ROR2, Her2 (ERBB2), prostate stem cell antigen (PSCA), PSMA (prostate-specific membrane antigen), B cell maturation antigen (BCMA), alpha- fetoprotein (AFP), carcinoembryonic antigen (CEA), cancer antigen-125 (CA-125), CA19-9, calretinin, chromogranin, protein melan-A (melanoma antigen recognized by T lymphocytes; MART-1), myo-Dl, muscle-specific actin (MSA), neurofilament, neuron-specific enolase (NSE), MUC-1, epithelial membrane protein (EMA), epithelial tumor antigen (ETA), tyrosinase, melanoma-associated antigen (MAGE), MAGE-A1, high molecular weight-melanoma associated antigen (HMW-MAA), placental alkaline phosphatase, synaptophysin, thyroglob
- unwanted cells can be depleted from a cell mixture such as whole blood, PBMCs, or TNCs, by bead or column-based separation.
- ligand or antibody to a cell surface molecule is attached to the beads or column.
- the antibodies attached to the beads can bind the same antigen as a CAR that is used, for example expressed by T cells and/or NK cells, in a method in which the unwanted cells are removed.
- the antibodies attached to the beads can bind a different epitope of the same antigen as the CAR that will be expressed later in the patient.
- the antibodies attached to the beads can bind the same epitope of the same antigen as the CAR.
- the beads can have more than one attached antibody that binds to antigens on the surface of the unwanted cells.
- beads with different antibodies attached to them can be used in combination.
- the beads can be magnetic beads.
- the unwanted cells can be depleted by magnetic separation after incubation of the cell mixture with the magnetic beads with attached antibodies.
- the beads are not magnetic.
- unwanted cells expressing one or more surface molecules are depleted from a cell mixture such as whole blood, PBMCs, or TNCs, by antibody coated beads and separated by size.
- the beads are polystyrene.
- the beads are at least about 30 pm, about 35 pm, about 40 pm, about 50 pm, about 60 pm, about 70 pm, or about 80 pm in diameter.
- the antibody coated beads are added to the cell mixture during the time that the recombinant nucleic acid vectors, which in illustrative embodiments are replication incompetent recombinant retroviral particles, are incubated with the cell mixture.
- a reaction mixture is formed that includes: (A) a cell mixture, such as from whole blood, enriched TNCs, or enriched PBMCs; (B) recombinant nucleic acid vectors, such as replication incompetent recombinant retroviral particles, encoding a transgene of interest, such as a CAR; and (C) antibody coated beads that bind to one or more surface molecules, or antigens, expressed on the surfaces of the unwanted cells.
- the reaction mixture can be incubated for less than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, or 45 minutes or less than 1, 2, 3, 4, 5, 6, 7, or 8 hours.
- a density-gradient centrifugation -based cell enrichment procedure can be performed to enrich total mononuclear cells depleted of the unwanted cells complexed to the antibody coated beads which will pellet.
- the reaction mixture can be passed through a pre-filter of larger diameter mesh to deplete the unwanted cells complexed to the antibody coated beads.
- the filter can have a pore diameter that is or is about 5 pm, 10 pm, or 15 pm smaller than the diameter of the beads.
- the beads may be magnetic beads and the pre-filter can be a magnet. Such filters can capture the unwanted cells bound to the beads and allow the desired cells to flow through downstream to the leukoreduction filter assembly which has a smaller pore diameter.
- unwanted cells are depleted or removed from a cell mixture that contains lymphocytes and erythrocytes, such as whole blood, by erythrocyte antibody rosetting (EA-rosetting).
- EA-rosetting antibodies that bind to antigens on the cell surfaces of unwanted cells are incubated with the cell mixture to crosslink the unwanted cells to red blood cells, which are then separated from the desired cells by density gradient centrifugation, such as provided for in RosetteSepTM kits (Stemcell Technologies).
- the antibodies that mediate EA-rosetting are added to the cell mixture during the time that the recombinant nucleic acid vectors, which in illustrative embodiments are replication incompetent recombinant retroviral particles, are incubated with the cell mixture.
- a reaction mixture is formed that includes: (A) a cell mixture of lymphocytes and erythrocytes, such as from whole blood; (B) replication incompetent recombinant retroviral particles encoding a transgene of interest, and in further illustrative embodiments a CAR; (C) a first antibody to an antigen on the surface of the unwanted cells, for example a tumor antigen such as the blood cancer antigens CD19, CD20, CD22, CD25, CD32, CD34, CD38, CD123, BCMA, TACI, or TIM3; (D) a second antibody to an antigen on the surface of an erythrocyte, such as glycophorin A; and (E) a third antibody that cross links the first and second antibodies.
- A a cell mixture of lymphocytes and erythrocytes, such as from whole blood
- B replication incompetent recombinant retroviral particles encoding a transgene of interest
- CAR a CAR
- the reaction mixture can include antibodies to more than one antigen on the surface of unwanted cells.
- the antibodies can bind to the same antigen as does the CAR.
- this reaction mixture is incubated for less than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, or 45 minutes or less than 1, 2, 3, 4, 5, 6, 7, or 8 hours.
- a density-gradient centrifugation-based PBMC enrichment procedure is performed to isolate total PBMCs minus the population depleted or removed by EA-rosetting which will pellet with the erythrocytes.
- genetic modification of cancer cells with a recombinant nucleic acid vector encoding an engineered T cell receptor or a CAR can be minimized during cell processing by the enrichment of T and/or NK cells by including a step of positive selection or depletion of the cancer cells by negative selection from the cell mixture in methods provided herein, prior to formulation and/or delivery to a subject.
- Several additional methods to reduce the potential effects of cancer cells genetically modified with an engineered T cell receptor construct or a CAR construct are disclosed herein.
- T cell-specific promoters can be used to express the CAR and can help prevent non-T cells that contain an exogenous nucleic acid(s) encoding a CAR from actually expressing the CAR.
- the antigen will not be masked by a CAR expressed in cis, and CAR-T cells can bind to and kill the target cell containing an exogenous nucleic acid(s) encoding the CAR.
- a T cell-specific promoter for expressing an engineered T cell receptor or a CAR helps to reduce, minimize, or in illustrative embodiments substantially eliminate, or even eliminate expression of the engineered T cell receptor or CAR in a encapsulated nucleic acid vector such as a RIR retroviral particle or a virus-like particle because of reduced, low, negligible, substantially no, or no expression of the engineered T cell receptor or CAR in a cell line used to make the encapsulated nucleic acid vector.
- a encapsulated nucleic acid vector such as a RIR retroviral particle or a virus-like particle.
- Another method to reduce the potential effects of CAR-cancer cells is to use two or more separate CARs, and in illustrative embodiments, two CARs expressed in two populations of cells, to kill target cells that could mask one of the epitopes.
- a population of cells such as blood cells or PBMCs, are genetically modified separately so each population expresses either a first CAR or a second CAR.
- a target cell expressing the first or second CAR does not mask the epitope that the second and first CAR, respectively, bind to. Therefore, a target cell expressing the first or second CAR can be killed by an effector T or NK cell expressing the second or first CAR, respectively.
- the first and second CARs can bind to different epitopes of the same antigen expressed on a target cell. In other embodiments, the first and second CARs can bind to different antigens expressed on the same target cell, including any of the antigens disclosed elsewhere herein. In some embodiments, the first and second CARs can bind to different epitopes of, or different antigens selected from CD19, CD20, CD22, CD25, CD32, CD34, CD38, CD123, BCMA, TACI or TIM3. In further illustrative embodiments, the first CAR can bind to CD19 and the second CAR can bind to CD22, both of which are expressed on B cells.
- the CAR can be an extracellular ligand of a cancer antigen.
- the modified cell populations are formulated separately.
- the separate cell formulations are introduced or reintroduced back into the subject at different sites in the body.
- separate cell formulations are separately introduced or reintroduced back into the subject at the same site.
- the modified cell populations are combined into one formulation that is optionally introduced or reintroduced back into the subject together at the same site.
- the cell populations are not combined until after a washing step in which the cells are washed away from the recombinant nucleic acid vectors.
- a CAR-cancer cell expressing a first or second CAR that binds and masks its cognate epitope in cis will be killed by a CAR-T cell expressing the second or first CAR, respectively.
- the unwanted cells can be depleted such that the unwanted cells comprise at most 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%,
- the unwanted cells can be depleted such that the unwanted cells comprise between 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, or 40% of the cells in a cell mixture, cell formulation, or reaction mixture on the low end of the range and 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% of the cells in a cell mixture, cell formulation, or reaction mixture on the high end of the range.
- the unwanted cells can be depleted such that the unwanted cells comprise between 10% and 90%, 20% and 90%, 30% and 90%, 40% and 90%, 40% and 80%, 45% and 75%, 1% and 14%, 2% and 14%, 3% and 14%, 4% and 14%, 5% and 14%, 5 and 13%, 5% and 12%, 5% and 11%, or 5% and 10% of the cells in a cell mixture, cell formulation, or reaction mixture.
- Some embodiments of the method and composition aspects provided herein include a membrane- bound cytokine typically associated with and/or on the outer membrane or surface of a RIP or on the plasma membrane of a modified, genetically modified and/or transduced T cell and/or NK cell, or population thereof, or polynucleotides encoding a membrane-bound cytokine, in illustrative embodiments within a RIP, for example in the genome of a RIP, or a population thereof, or within a T cell and/or NK cell, or a population thereof.
- Cytokines are typically, but not always, secreted proteins. Cytokines that are naturally secreted can be engineered as fusion proteins to be membrane-bound.
- Membrane-bound cytokine fusion polypeptides are included in methods and compositions disclosed herein, and are also an aspect of the invention.
- RIPs have a membrane-bound cytokine fusion polypeptide on their surface that is capable of binding a T cell and/or NK cell and promoting proliferation and/or survival thereof, or capable of attracting or retaining an immune cell.
- Such RIPs can be used, for example, in RIP formulations provided herein for administration to a subject.
- membrane-bound polypeptides are incorporated into the membranes of replication incompetent recombinant retroviral particles, and when a cell is transduced by the replication incompetent recombinant retroviral particles, the fusion of the retroviral and host cell membranes results in the polypeptide, such as the cytokine fusion polypeptide, being bound to the membrane of the transduced cell.
- RIP formulations and/or a delivery solution comprises membrane-bound cytokine associated with the surface of RIP.
- the RIP formulation or a delivery solution including the RIP having membrane-bound cytokine associated with the surface as disclosed herein is administered in vivo to a subject in need thereof.
- RIP having membrane-bound cytokine associated with the surface as disclosed herein is contacted to T cells and/or NK cells in vivo (direct RIP administration). In some embodiments, RIP having membrane-bound cytokine associated with the surface as disclosed herein is contacted to T cells and/or NK cells, ex vivo.
- the cytokine fusion polypeptide includes one or more of IL-1, IL-2, IL-7, IL-12, IL-15, IL-18, IL-21, TNFa, IFNy, GM-CSF, CCL1, CCL2 (MCP-1), CCL3, CCL5, CCL7 (MCP- 3), CCL8 (MCP-2), CCL19, CCL20, CCL21, CCL22, CCL28, CXCL1, CXCL9, CXCL10, CXCL11, CXCL12, CXCL14 (BRAK), CX3CL1, or variants thereof, or an active fragment of any of the preceding.
- the cytokine fusion polypeptide does not include IL-2, IL-7, or IL-15.
- the cytokine fusion polypeptide comprises a cytokine capable of promoting T and/or NK cell proliferation and/or survival.
- the cytokine fusion polypeptide capable of promoting T and/or NK cell proliferation and/or survival includes one or more of IL-2, IL-7, IL-15, IL-21, or variants thereof, or an active fragment of any of the preceding.
- the cytokine fusion polypeptide comprises a cytokine capable of stimulating inflammation.
- the cytokine fusion polypeptide includes one or more of IL-1, IL-12, IL-18, TNFa, IHNg, GM-CSF, or variants thereof, or an active fragment of any of the preceding.
- the cytokine fusion polypeptide comprises a chemotactic cytokine (e.g., chemokine).
- a chemotactic cytokine is capable of attracting and optionally retaining an immune cell (for example, a T cell, NK cell, NK T cell, TIL (tumor-infiltrating T cell), MIL (marrow-infiltrating lymphocyte), TINK (tumor-infiltrating NK cell), or dendritic cell).
- the chemotactic cytokine comprises a C-C motif.
- the chemotactic cytokine comprising a C-C motif comprises one or more of CCL1, CCL2 (MCP-1), CCL3, CCL5, CCL7 (MCP-3), CCL8 (MCP-2), CCL19, CCL20, CCL21, CCL22, CCL28, or variants thereof, or an active fragment of any of the preceding.
- the chemotactic cytokine comprising a C-C motif comprises one or more of CCL19, CCL21, or variants thereof, or an active fragment of any of the preceding capable of binding to CCR7 or CXCR3.
- the chemotactic cytokine comprises a C-X-C motif.
- the chemotactic cytokine comprising a C-X-C motif comprises one or more of CXCL1, CXCL9, CXCL10, CXCL11, CXCL12, CXCL14 (BRAK), or variants thereof, or an active fragment of any of the preceding.
- the chemotactic cytokine comprises a C-X3-C motif.
- the chemotactic cytokine comprising a C-X3-C motif comprises one or more of CX3CL1, or variants thereof, or an active fragment of any of the preceding.
- the cytokine fusion polypeptide comprises one or more polypeptides capable of binding to CCR2, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CXCR3, CXCR4, CXCR5, CXCR6, or Cx3crl.
- the cytokine fusion polypeptide comprises one or more polypeptides capable of binding to CCR7, CXCR3, CXCR4, or CXCR6.
- the cytokine fusion polypeptide comprises one or more polypeptides capable of binding to CCR1, CC42, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CXCR3, CXCR4, CXCR5, or CXCR6.
- the membrane-bound cytokine fusion polypeptides are typically a cytokine fused to heterologous signal sequence and/or a heterologous membrane attachment sequence.
- the heterologous membrane attachment sequence is a GPI anchor attachment sequence.
- the heterologous GPI anchor attachment sequence can be derived from any known GPI-anchored protein (reviewed in Ferguson MAJ, Kinoshita T, Hart GW. Glycosylphosphatidylinositol Anchors. In: Varki A, Cummings RD, Esko JD, et al., editors. Essentials of Gly cobiology. 2nd edition. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2009. Chapter 11).
- the heterologous GPI anchor attachment sequence is the GPI anchor attachment sequence from CD14, CD16, CD48, CD55 (DAF), CD59, CD80, and CD87. In some embodiments, the heterologous GPI anchor attachment sequence is derived from CD 16. In an illustrative embodiment, the heterologous GPI anchor attachment sequence is derived from Fc receptor FcyRIIIb (CD16b). In some embodiments, the GPI anchor is the GPI anchor of DAF.
- the membrane-bound cytokine is a fusion polypeptide of a cytokine fused to DAF.
- DAF is known to accumulate in lipid rafts that are incorporated into the membranes of replication incompetent recombinant retroviral particles budding from packaging cells. Accordingly, not to be limited by theory, it is believed that DAF fusion proteins are preferentially targeted to portions of membranes of packaging cells that will become part of a recombinant retroviral membrane.
- the cytokine fusion polypeptide is an IL-7, or an active fragment thereof, fused to DAF.
- the fusion cytokine polypeptide includes in order: the DAF signal sequence (residues 1-31 of DAF), IL-7 without its signal sequence, and residues 36-525 of DAF.
- the membrane-bound cytokine fusion polypeptide comprises a cleavage site.
- the cleavage site can be within the sequence of the cytokine.
- the cleavage site can be within the sequence of the heterologous signal sequence.
- the cleavage site can be within the sequence of the heterologous membrane attachment sequence.
- the cleavage site can be between the cytokine and the heterologous signal sequence or the heterologous membrane attachment sequence.
- the membrane-bound cytokine fusion polypeptide can include linkers as disclosed elsewhere herein.
- the replication incompetent recombinant retroviral particles used to contact T cells and/or NK cells whether in vivo (e.g., in direct RIP administration aspects and embodiments) or ex vivo, have a polynucleotide or nucleic acid having one or more transcriptional units that encode one or more engineered signaling polypeptides.
- an engineered signaling polypeptide includes any combination of an extracellular domain (e.g., an antibody, an antigen-specific targeting region or ASTR), a stalk and a transmembrane domain, combined with one or more intracellular activating domains, optionally one or more modulatory domains (such as a co-stimulatory domain), and optionally one or more T cell survival motifs.
- an extracellular domain e.g., an antibody, an antigen-specific targeting region or ASTR
- a stalk and a transmembrane domain combined with one or more intracellular activating domains, optionally one or more modulatory domains (such as a co-stimulatory domain), and optionally one or more T cell survival motifs.
- at least one, two, or all of the engineered signaling polypeptides is a chimeric antigen receptor (CAR) or a lymphoproliferative element (LE) such as a chimeric lymphoproliferative element (CLE).
- CAR chimeric antigen receptor
- LE
- At least one, two, or all of the engineered signaling polypeptides is an engineered T cell receptor (TCR).
- TCR T cell receptor
- one encodes a lymphoproliferative element and the other encodes a chimeric antigen receptor (CAR) that includes an antigen-specific targeting region (ASTR), a transmembrane domain, and an intracellular activating domain.
- ASTR antigen-specific targeting region
- transmembrane domain a transmembrane domain
- intracellular activating domain exemplary sequences can be found in WO2019/055946, incorporated herein in its entirety by reference. A skilled artisan will recognize that such engineered polypeptides can also be referred to as recombinant polypeptides.
- the engineered signaling polypeptides such as CARs, engineered TCRs, LEs, and CLEs provided herein, are typically transgenes with respect to lymphocytes, especially T cells and NK cells, and most especially T cells and/or NK cells that are engineered using methods and compositions provided herein, to express such signaling polypeptides.
- an engineered signaling polypeptide includes an extracellular domain that is a member of a specific binding pair.
- the extracellular domain can be the extracellular domain of a cytokine receptor, or a mutant thereof, or a hormone receptor, or a mutant thereof.
- Such mutant extracellular domains in some embodiments have been reported to be constitutively active when expressed at least in some cell types.
- such extracellular and transmembrane domains do not include a ligand binding region. It is believed that such domains do not bind a ligand when present in an engineered signaling polypeptide and expressed in B cells, T cells, and/or NK cells.
- Mutations in such receptor mutants can occur in the extracellular juxtamembrane region.
- a mutation in at least some extracellular domains (and some extracellular- transmembrane domains) of engineered signaling polypeptides provided herein are responsible for signaling of the engineered signaling polypeptide in the absence of ligand, by bringing activating chains together that are not normally together.
- extracellular domains that comprise mutations in extracellular domains can be found, for example, in the Lymphoproliferative Element section herein.
- the extracellular domain comprises a dimerizing motif.
- the dimerizing motif comprises a leucine zipper.
- the leucine zipper is from a jun polypeptide, for example c-jun.
- extracellular domains that comprise a dimerizing motif can be found, for example, in the Lymphoproliferative Element section herein.
- the extracellular domain is an antigen-specific targeting region (ASTR), sometimes called an antigen binding domain herein. Specific binding pairs include, but are not limited to, antigen-antibody binding pairs; ligand-receptor binding pairs; and the like.
- a member of a specific binding pair suitable for use in an engineered signaling polypeptide of the present disclosure includes an ASTR that is an antibody, an antigen, a ligand, a receptor binding domain of a ligand, a receptor, a ligand binding domain of a receptor, and an alternative non-antibody scaffold, also referred to herein as an antibody mimetic.
- the ASTR can be a suitable antibody mimetic.
- the antibody mimetic can be an affibody, an afflilin, an affimer, an affitin, an alphabody, an alphamab, an anticalin, an armadillo repeat protein, an atrimer, an avimer (also known as avidity multimer), a C-type lectin domain, a cysteine-knot miniprotein, a cyclic peptide, a cytotoxic T-lymphocyte associated protein-4, a DARPin (Designed Ankyrin Repeat Protein), a fibrinogen domain, a fibronectin binding domain (FN3 domain) (e.g., adnectin or monobody), a fynomer, a knottin, a Kunitz domain peptide, a leucine -rich repeat domain, a lipocalin domain, a mAh 2 or FcabTM, a nanobody, a nanoCLAMP, an OBody, a Pronectin, a single-chain T
- An ASTR suitable for use in an engineered signaling polypeptide of the present disclosure can be any antigen-binding polypeptide.
- the ASTR is an antibody such as a full-length antibody, a single-chain antibody, a Fab fragment, a Fab' fragment, a (Fab')2 fragment, a Fv fragment, and a divalent single-chain antibody or a diabody.
- the ASTR is a single chain Fv (scFv).
- the heavy chain is positioned N-terminal of the light chain in the engineered signaling polypeptide.
- the light chain is positioned N-terminal of the heavy chain in the engineered signaling polypeptide.
- the heavy and light chains can be separated by a linker as discussed in more detail herein.
- the heavy or light chain can be at the N-terminus of the engineered signaling polypeptide and is typically C-terminal of another domain, such as a signal sequence or peptide.
- T cell receptor TCR based recognition domains.
- Naturally-occurring T cell receptors include an a-subunit and a b-subunit, separately produced by unique recombination events in a T cell's genome.
- TCRs may be screened for their selectivity to a target antigen, for example, any of the antigens disclosed herein. Screens of natural and/or engineered TCRs can identify TCRs with high avidities and/or reactivities towards a target antigen. Such TCRs can be selected, cloned, and a polynucleotide encoding such a TCR can be included in a replication incompetent recombinant retroviral particle to genetically modify a lymphocyte, or in illustrative embodiments, T cell or NK cell, such that the lymphocyte expresses the engineered TCR. In some embodiments, the TCR can be a single chain TCR (scTv, single chain two-domain TCR containing nanb).
- scTv single chain two-domain TCR containing nanb
- a CAR include CARs having extracellular domains engineered to co-opt the endogenous TCR signaling complex and CD3Z signaling pathway.
- a chimeric antigen receptor ASTR is fused to one of the endogenous TCR complex chains (e.g., TCR alpha, CD3E etc.) to promote incorporation into the TCR complex and signaling through the endogenous CD3Z chains.
- a CAR contains a first scFv or protein that binds to the TCR complex and a second scFv or protein that binds to the target antigen (e.g., tumor antigen).
- the TCR can be a single chain TCR (scTv, single chain two-domain TCR containing n ⁇ n ⁇ ).
- scFv single chain two-domain TCR containing n ⁇ n ⁇ .
- scFv single chain two-domain TCR containing n ⁇ n ⁇ .
- the ASTR can be multispecific, e.g., bispecific antibodies.
- Multispecific antibodies have binding specificities for at least two different sites. In certain embodiments, one of the binding specificities is for one target antigen and the other is for another target antigen.
- bispecific antibodies may bind to two different epitopes of a target antigen. Bispecific antibodies may also be used to localize cytotoxic agents to cells which express a target antigen. Bispecific antibodies can be prepared as full-length antibodies or antibody fragments.
- An ASTR suitable for use in an engineered signaling polypeptide of the present disclosure, or an engineered TCR, can have a variety of antigen-binding specificities.
- the antigen-binding domain is specific for an epitope present in an antigen that is expressed by (synthesized by) a target cell.
- the target cell is a cancer cell associated antigen.
- the cancer cell associated antigen can be an antigen associated with, e.g., a breast cancer cell, a B cell lymphoma cell, as a diffuse large B cell lymphoma (DLBCL) cell, a Hodgkin lymphoma cell, an ovarian cancer cell, a prostate cancer cell, a mesothelioma, a lung cancer cell (e.g., a small cell lung cancer cell), a lymphoma cell, a non-Hodgkin B- cell lymphoma (B-NHL) cell, an ovarian cancer cell, a prostate cancer cell, a mesothelioma cell, a lung cancer cell (e.g., a small cell lung cancer cell), a melanoma cell, a leukemia cell, a chronic myelogenous leukemia (CML) cell, a chronic lymphocytic leukemia (CLL) cell, an acute myelogenous leukemia (AML) cell, an acute lympho
- a cancer cell associated antigen may also be expressed by a non-cancerous cell.
- the cancer cell is a PDL-1 positive cancer cell.
- the cancer cell is a PDL-1 positive DLBCL cell.
- the cancer cell is a PDL-1 negative cell.
- the cancer cell is a PDL-1 negative DLBCL cell.
- Non-limiting examples of antigens to which an ASTR of an engineered signaling polypeptide can bind, or an engineered T cell receptor can bind include, e.g., In any of the aspects or embodiments herein that include an ASTR, the antigen can be a tumor-associated antigen or a tumor-specific antigen.
- the tumor-associated antigen or tumor-specific antigen is Axl, ROR1, ROR2, Her2 (ERBB2), prostate stem cell antigen (PSCA), PSMA (prostate-specific membrane antigen), B cell maturation antigen (BCMA), alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), cancer antigen- 125 (CA-125), CA19-9, calretinin, chromogranin, protein melan-A (melanoma antigen recognized by T lymphocytes; MART-1), myo-Dl, muscle-specific actin (MSA), neurofilament, neuron-specific enolase (NSE), MUC-1, epithelial membrane protein (EMA), epithelial tumor antigen (ETA), tyrosinase, melanoma-associated antigen (MAGE), MAGE-A1, high molecular weight-melanoma associated antigen (HMW-MAA), placental alkaline phosphatase, synaptophy
- a member of a specific binding pair suitable for use in an engineered signaling polypeptide is an ASTR that is a ligand for a receptor.
- Ligands include, but are not limited to, hormones (e.g., erythropoietin, growth hormone, leptin, etc.); cytokines (e.g., interferons, interleukins, certain hormones, etc.); growth factors (e.g., heregulin; vascular endothelial growth factor (VEGF); and the like); an integrin-binding peptide (e.g., a peptide comprising the sequence Arg-Gly-Asp (SEQ ID NO:l)); and the like.
- hormones e.g., erythropoietin, growth hormone, leptin, etc.
- cytokines e.g., interferons, interleukins, certain hormones, etc.
- growth factors e.g., heregulin;
- the engineered signaling polypeptide can be activated in the presence of a second member of the specific binding pair, where the second member of the specific binding pair is a receptor for the ligand.
- the second member of the specific binding pair can be a VEGF receptor, including a soluble VEGF receptor.
- the member of a specific binding pair that is included in an engineered signaling polypeptide is an ASTR that is a receptor, e.g., a receptor for a ligand, a co-receptor, etc.
- the receptor can be a ligand-binding fragment of a receptor.
- Suitable receptors include, but are not limited to, a growth factor receptor (e.g., a VEGF receptor); a killer cell lectin-like receptor subfamily K, member 1 (NKG2D) polypeptide (receptor for MICA, MICB, and ULB6); a cytokine receptor (e.g., an IL-13 receptor; an IL-2 receptor; etc.); CD27; a natural cytotoxicity receptor (NCR) (e.g., NKP30 (NCR3/CD337) polypeptide (receptor for F1LA-B -associated transcript 3 (BAT3) and B7-F16); etc.); etc.
- a growth factor receptor e.g., a VEGF receptor
- a killer cell lectin-like receptor subfamily K, member 1 (NKG2D) polypeptide receptor for MICA, MICB, and ULB6
- a cytokine receptor e.g., an IL-13 receptor; an IL-2 receptor;
- the ASTR can be directed to an intermediate protein that links the ASTR with a target molecule expressed on a target cell.
- the intermediate protein may be endogenously expressed or introduced exogenously and may be natural, engineered, or chemically modified.
- the ASTR can be an anti-tag ASTR such that at least one tagged intermediate, typically an antibody-tag conjugate, is included between a tag recognized by the ASTR and a target molecule, typically a protein target, expressed on a target cell. Accordingly, in such embodiments, the ASTR binds a tag and the tag is conjugated to an antibody directed against an antigen on a target cell, such as a cancer cell.
- Non-limiting examples of tags include fluorescein isothiocyanate (FITC), streptavidin, biotin, histidine, dinitrophenol, peridinin chlorophyll protein complex, green fluorescent protein, phycoerythrin (PE), horse radish peroxidase, palmitoylation, nitrosylation, alkaline phosphatase, glucose oxidase, and maltose binding protein.
- FITC fluorescein isothiocyanate
- streptavidin biotin
- biotin histidine
- dinitrophenol dinitrophenol
- peridinin chlorophyll protein complex green fluorescent protein
- PE phycoerythrin
- horse radish peroxidase palmitoylation
- nitrosylation alkaline phosphatase
- glucose oxidase glucose oxidase
- maltose binding protein a binds the tag.
- the engineered signaling polypeptide includes a stalk which is located in the portion of the engineered signaling polypeptide lying outside the cell and interposed between the ASTR and the transmembrane domain.
- the stalk has at least 85, 90, 95, 96, 97, 98, 99, or 100% identity to a wild-type CD 8 stalk region (TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGG AVF1TRGLDFA (SEQ ID NO:2), has at least 85, 90, 95, 96, 97, 98, 99, or 100% identity to a wild-type CD28 stalk region (FCKIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKP (SEQ ID NO:3)), or has at least 85, 90, 95, 96, 97, 98, 99, or 100% identity to a wild-type immunoglobulin heavy chain stalk region.
- the stalk employed allows the antigen-
- the stalk region can have a length of from about 4 amino acids to about 50 amino acids, e.g., from about 4 aa to about 10 aa, from about 10 aa to about 15 aa, from about 15 aa to about 20 aa, from about 20 aa to about 25 aa, from about 25 aa to about 30 aa, from about 30 aa to about 40 aa, or from about 40 aa to about 50 aa.
- the stalk of an engineered signaling polypeptide includes at least one cysteine.
- the stalk can include the sequence Cys-Pro-Pro-Cys (SEQ ID NO:4). If present, a cysteine in the stalk of a first engineered signaling polypeptide can be available to form a disulfide bond with a stalk in a second engineered signaling polypeptide.
- Stalks can include immunoglobulin hinge region amino acid sequences that are known in the art; see, e.g., Tan et al. (1990) Proc. Natl. Acad. Sci. USA 87:162; and Huck et al. (1986) Nucl. Acids Res. 14:1779.
- an immunoglobulin hinge region can include a domain with at least 50, 60, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99 or 100% sequence identity to a stretch of at least 10, 15, 20, or all of the amino acids of any of the following amino acid sequences: DKTHT (SEQ ID NO:5); CPPC (SEQ ID NO:4); CPEPKSCDTPPPCPR (SEQ ID NO:6) (see, e.g., Glaser et al. (2005) J. Biol. Chem.
- ELKTPLGDTTHT SEQ ID NO:7
- KSCDKTHTCP SEQ ID NO:8
- KCCVDCP SEQ ID NO:9
- KYGPPCP SEQ ID NO: 10
- EPKSCDKTHTCPPCP SEQ ID NO: 11
- ERKCCVECPPCP SEQ ID NO: 12
- ELKTPLGDTTHTCPRCP SEQ ID NO: 13
- SPNMVPHAHHAQ SEQ ID NO: 14
- the stalk can include a hinge region with an amino acid sequence of a human IgGl, IgG2, IgG3, or IgG4, hinge region.
- the stalk can include one or more amino acid substitutions and/or insertions and/or deletions compared to a wild-type (naturally-occurring) hinge region.
- Flis229 of human IgG 1 hinge can be substituted with Tyr, so that the stalk includes the sequence EPKSCDKTYTCPPCP (SEQ ID NO:15), (see, e.g., Yan et al. (2012) J. Biol. Chem. 287:5891).
- the stalk can include an amino acid sequence derived from human CD8; e.g., the stalk can include the amino acid sequence: TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD (SEQ ID NO: 16), or a variant thereof.
- An engineered signaling polypeptide of the present disclosure can include transmembrane domains for insertion into a eukaryotic cell membrane.
- the transmembrane domain can be interposed between the ASTR and the co-stimulatory domain.
- the transmembrane domain can be interposed between the stalk and the co-stimulatory domain, such that the chimeric antigen receptor includes, in order from the amino terminus (N-terminus) to the carboxyl terminus (C-terminus): an ASTR; a stalk; a transmembrane domain; and an activating domain.
- any transmembrane (TM) domain that provides for insertion of a polypeptide into the cell membrane of a eukaryotic (e.g., mammalian) cell is suitable for use in aspects and embodiments disclosed herein.
- the TM domain for any aspect provided herein that includes a CAR can include a transmembrane domain from BAFFR, C3Z, CEACAM1, CD2, CD3A, CD3B, CD3D, CD3E, CD3G, CD3Z, CD4, CD5, CD7, CD8A, CD8B, CD9, CD11A, CD11B, CD11C, CD11D, CD27, CD16, CD18, CD19, CD22, CD28, CD29, CD33, CD37, CD40, CD45, CD49A, CD49D, CD49F, CD64, CD79A, CD79B, CD80, CD84, CD86, CD96 (Tactile), CD100 (SEMA4D), CD103, C134, CD137,
- CD 154 CD 160 (BY55), CD162 (SELPLG), CD226 (DNAM1), CD229 (Ly9), CD247, CRLF2, CRTAM, CSF2RA, CSF2RB, CSF3R, EPOR, FCER1G, FCGR2C, FCGRA2, GHR, HVEM (LIGHTR), IA4,
- SLAM SLAMF1, CD150, IPO-3
- SLAMF4 CD244, 2B4
- SLAMF6 NTB-A, Lyl08
- SLAMF7 SLAMF8
- BLAME TNFR2, TNFRSF4, TNFRSF8, TNFRSF9, TNFRSF14, TNFRSF18, VLA1, or VLA-6, or functional mutants and/or fragments thereof.
- Non-limiting examples of TM domains suitable for any of the aspects or embodiments provided herein, include a domain with at least 50, 60, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99 or 100% sequence identity to a stretch of at least 10, 15, 20, or all of the amino acids of any of the following TM domains or combined stalk and TM domains: a) CD8 alpha TM (SEQ ID NO:17); b) CD8 beta TM (SEQ ID NO:18); c) CD4 stalk (SEQ ID NO: 19); d) CD3Z TM (SEQ ID NO:20); e) CD28 TM (SEQ ID NO:21); f) CD134 (0X40) TM: (SEQ ID NO:22); g) CD7 TM (SEQ ID NO:23); h) CD 8 stalk and TM (SEQ ID NO:24); and i) CD28 stalk and TM (SEQ ID NO:25).
- a transmembrane domain of an aspect of the present disclosure can have at least 80%, 90%, or 95% or can have 100% sequence identity to the SEQ ID NO: 17 transmembrane domain, or can have 100% sequence identity to any of the transmembrane domains from the following genes respectively: the CD8 beta transmembrane domain, the CD4 transmembrane domain, the CD3 zeta transmembrane domain, the CD28 transmembrane domain, the CD 134 transmembrane domain, or the CD7 transmembrane domain.
- Intracellular activating domain Intracellular activating domain
- Intracellular activating domains suitable for use in an engineered signaling polypeptide of the present disclosure when activated typically induce the production of one or more cytokines; increase cell death; and/or increase proliferation of CD8 + T cells, CD4 + T cells, NKT cells, gd T cells, and/or neutrophils.
- Activating domains can also be referred to as activation domains herein.
- Activating domains can be used in CARs or in lymphoproliferative elements provided herein.
- the intracellular activating domain includes at least one (e.g., one, two, three, four, five, six, etc.) IT AM motifs as described below.
- an intracellular activating domain of an aspect of the present disclosure can have at least 80%, 90%, or 95% or can have 100% sequence identity to the CD3Z, CD3D, CD3E, CD3G, CD79A, CD79B, DAP12, FCER1G, FCGR2A, FCGR2C, DAP10/CD28, ZAP70, NKp30 (B7-H6), NKG2D, NKp44, NKp46, FcR gamma (FCER1G), FcR beta (FCER1B), FcgammaRI, FcgammaRIIA, FcgammaRIIC, FcgammaRIIIA, and FcRL5 domains as described below.
- Intracellular activating domains suitable for use in an engineered signaling polypeptide of the present disclosure include immunoreceptor tyrosine-based activation motif (ITAM)-containing intracellular signaling polypeptides.
- ITAM immunoreceptor tyrosine-based activation motif
- An IT AM motif is YX1X2F/I, where X1 and X2 are independently any amino acid.
- the intracellular activating domain of an engineered signaling polypeptide includes 1, 2, 3, 4, or 5 IT AM motifs.
- an IT AM motif is repeated twice in an intracellular activating domain, where the first and second instances of the IT AM motif are separated from one another by 6 to 8 amino acids, e.g., (YX1X2L/I)(X3) n (YXiX2L/I), where n is an integer from 6 to 8, and each of the 6-8 X3 can be any amino acid.
- the intracellular activating domain of an engineered signaling polypeptide includes 3 IT AM motifs.
- a suitable intracellular activating domain can be an IT AM motif-containing portion that is derived from a polypeptide that contains an IT AM motif.
- a suitable intracellular activating domain can be an IT AM motif-containing domain from any IT AM motif-containing protein.
- a suitable intracellular activating domain need not contain the entire sequence of the entire protein from which it is derived.
- IT AM motif-containing polypeptides include, but are not limited to: CD3Z (CD3 zeta); CD3D (CD3 delta); CD3E (CD3 epsilon); CD3G (CD3 gamma); CD79A (antigen receptor complex-associated protein alpha chain); CD79B (antigen receptor complex-associated protein beta chain) DAP12; and FCER1G (Fc epsilon receptor I gamma chain).
- an intracellular activating domain can include a domain with at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a stretch of at least 10, 15, 20, or all the amino acids in the following IT AM motif-containing polypeptides or to a contiguous stretch of from about 100 amino acids to about 110 amino acids (aa), from about 110 aa to about 115 aa, from about 115 aa to about 120 aa, from about 120 aa to about 130 aa, from about 130 aa to about 140 aa, from about 140 aa to about 150 aa, or from about 150 aa to about 160 aa, of any of the following IT AM motif-containing polypeptides: CD3 zeta chain (also known as CD3Z, T cell receptor T3 zeta chain, CD247, CD3-ZETA, CD3H, CD3Q, T3Z, TCRZ, etc.)
- R VKFSRS AD AP A Y QQGQN QL [ YNELNLGRREE YD VL] DKRRGRDPEMGGKPRRKNPQEGL [ YNE LQKDKMAEAYSEI]GMKGERRRGKGHDGL[YQGLSTATKDTYDAL]HMQALPPR (SEQ ID NO:28),
- T cell surface glycoprotein CD3 gamma chain also known as CD3G, T cell receptor T3 gamma chain, CD3-GAMMA, T3G, gamma polypeptide (TiT3 complex), etc. with exemplary sequences: MEQGKGLAVLILAIILLQGTLAQSIKGNHLVKVYDYQEDGSVLLTCDAE
- FCER1G also known as FCRG; Fc epsilon receptor I gamma chain; Fc receptor gamma-chain; fc -epsilon Rl-gamma; fcRgamma; fceRI gamma; high affinity immunoglobulin epsilon receptor subunit gamma; immunoglobulin E receptor, high affinity, gamma chain; etc.
- Intracellular activating domains suitable for use in an engineered signaling polypeptide of the present disclosure include a DAP10/CD28 type signaling chain.
- An example of a DAP10 signaling chain is the amino acid SEQ ID NO:50.
- a suitable intracellular activating domain includes a domain with at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a stretch of at least 10, 15, 20, or all amino acids in SEQ ID NO:50.
- a CD28 signaling chain is the amino acid sequence is SEQ ID NO:51.
- a suitable intracellular domain includes a domain with at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a stretch of at least 10, 15, 20, or all amino acids of SEQ ID NO:51.
- Intracellular activating domains suitable for use in an engineered signaling polypeptide of the present disclosure include a ZAP70 polypeptide
- a suitable intracellular activating domain can include a domain with at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a stretch of at least 10, 15, 20, or all amino acids in the following sequences or to a contiguous stretch of from about 300 amino acids to about 400 amino acids, from about 400 amino acids to about 500 amino acids, or from about 500 amino acids to 619 amino acids, of SEQ ID NO:52.
- Modulatory domains can change the effect of the intracellular activating domain in the engineered signaling polypeptide, including enhancing or dampening the downstream effects of the activating domain or changing the nature of the response.
- Modulatory domains suitable for use in an engineered signaling polypeptide of the present disclosure include co-stimulatory domains.
- a modulatory domain suitable for inclusion in the engineered signaling polypeptide can have a length of from about 30 amino acids to about 70 amino acids (aa), e.g., a modulatory domain can have a length of from about 30 aa to about 35 aa, from about 35 aa to about 40 aa, from about 40 aa to about 45 aa, from about 45 aa to about 50 aa, from about 50 aa to about 55 aa, from about 55 aa to about 60 aa, from about 60 aa to about 65 aa, or from about 65 aa to about 70 aa.
- modulatory domain can have a length of from about 70 aa to about 100 aa, from about 100 aa to about 200 aa, or greater than 200 aa.
- Co-stimulatory domains typically enhance and/or change the nature of the response to an activation domain.
- Co-stimulatory domains suitable for use in an engineered signaling polypeptide of the present disclosure are generally polypeptides derived from receptors.
- costimulatory domains homodimerize.
- a subject co-stimulatory domain can be an intracellular portion of a transmembrane protein (i.e., the co-stimulatory domain can be derived from a transmembrane protein).
- any of the CAR provided herein can include a costimulatory domain.
- the co-stimulatory domain can include a domain with at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a stretch of at least 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids or an intracellular domain of 4-1BB (CD137), B7-H3, B7-HCDR3, BAFFR, BTLA, CIOO (SEMA4D), CD2, CD4, CD7, CD8A, CD8B, CD11A, CD11B, CD11C, CD11D, CD18, CD19, CD27, CD28, CD28 deleted for Lck binding (ICA), CD29, CD30, CD40, CD49A, CD49D, CD49F, CD69, CD84, CD96 (Tactile), CD103, CD160 (BY55), CD162 (SELPLG), CD226 (DNAM1), CD229 (Ly9), a ligand that specifically binds with CD83, CDS
- a co-stimulatory domain suitable for inclusion in an engineered signaling polypeptide can have a length of from about 30 amino acids to about 70 amino acids (aa), e.g., a co-stimulatory domain can have a length of from about 30 aa to about 35 aa, from about 35 aa to about 40 aa, from about 40 aa to about 45 aa, from about 45 aa to about 50 aa, from about 50 aa to about 55 aa, from about 55 aa to about 60 aa, from about 60 aa to about 65 aa, or from about 65 aa to about 70 aa.
- the co-stimulatory domain can have a length of from about 70 aa to about 100 aa, from about 100 aa to about 200 aa, or greater than 200 aa.
- a co-stimulatory domain can include a domain with at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a stretch of at least 10, 15, 20, or all the amino acids or from about 30 aa to about 35 aa, from about 35 aa to about 40 aa, from about 40 aa to about 45 aa, from about 45 aa to about 50 aa, from about 50 aa to about 55 aa, from about 55 aa to about 60 aa, from about 60 aa to about 65 aa, or from about 65 aa to about 70 aa, from about 70 aa to about 75 aa, from about 75 aa to about 80 aa, from about 80 aa to about 85 aa, from about 85 aa to about 90 aa, from about 90 aa to about 95 aa, from about 95 aa to about 100
- 0X40 contains a p85 PI3K binding motif at residues 34-57 and a TRAF binding motif at residues 76-102, each of SEQ ID NO: 296 (of Table 1).
- the costimulatory domain can include the p85 PI3K binding motif of 0X40.
- the costimulatory domain can include the TRAF binding motif of 0X40.
- Lysines corresponding to amino acids 17 and 41 of SEQ ID NO: 296 are potentially negative regulatory sites that function as parts of ubiquitin targeting motifs. In some embodiments, one or both of these Lysines in the costimulatory domain of 0X40 are mutated Arginines or another amino acid.
- the engineered signaling polypeptide includes a linker between any two adjacent domains.
- a linker can be between the transmembrane domain and the first co stimulatory domain.
- the ASTR can be an antibody and a linker can be between the heavy chain and the light chain.
- a linker can be between the ASTR and the transmembrane domain and a co-stimulatory domain.
- a linker can be between the co-stimulatory domain and the intracellular activating domain of the second polypeptide.
- the linker can be between the ASTR and the intracellular signaling domain.
- the linker peptide may have any of a variety of amino acid sequences. Proteins can be joined by a spacer peptide, generally of a flexible nature, although other chemical linkages are not excluded.
- a linker can be a peptide of between about 1 and about 100 amino acids in length, or between about 1 and about 25 amino acids in length. These linkers can be produced by using synthetic, linker-encoding oligonucleotides to couple the proteins. Peptide linkers with a degree of flexibility can be used.
- the linking peptides may have virtually any amino acid sequence, bearing in mind that suitable linkers will have a sequence that results in a generally flexible peptide. The use of small amino acids, such as glycine and alanine, are of use in creating a flexible peptide. The creation of such sequences is routine to those of skill in the art.
- Suitable linkers can be readily selected and can be of any of a suitable of different lengths, such as from 1 amino acid (e.g., Gly) to 20 amino acids, from 2 amino acids to 15 amino acids, from 3 amino acids to 12 amino acids, including 4 amino acids to 10 amino acids, 5 amino acids to 9 amino acids, 6 amino acids to 8 amino acids, or 7 amino acids to 8 amino acids, and may be 1, 2, 3, 4, 5, 6, or 7 amino acids.
- Exemplary flexible linkers include glycine polymers (G) n , glycine-serine polymers (including, for example, (GS) n , (GSGGS) n , (GGS) n , (GGGS) n , and (GGGGS) n where n is an integer of at least one), glycine-alanine polymers, alanine-serine polymers, and other flexible linkers known in the art. Glycine and glycine-serine polymers are of interest since both of these amino acids are relatively unstructured, and therefore may serve as a neutral tether between components.
- Glycine polymers are of particular interest since glycine accesses significantly more phi-psi space than even alanine, and is much less restricted than residues with longer side chains (see Scheraga, Rev. Computational Chem. 11173-142 (1992)).
- Exemplary flexible linkers include, but are not limited to, GGGGSGGGGS (SEQ ID NO:674), GGGGSGGGGSGGGGS (SEQ ID NO:63), GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:372), GGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO:675),
- GGGGSGGGGSGGGGSGGGGSGGGGGGSGGGGS (SEQ ID NO:64), GGSSRSS (SEQ ID NO:673), GGGGSGGGSGGGGS (SEQ ID NO:65), GGSG (SEQ ID NO:66), GGSGG (SEQ ID NO:67), GSGSG (SEQ ID NO:68), GSGGG (SEQ ID NO:69), GGGSG (SEQ ID NO:70), GSSSG (SEQ ID NO:71), and the like.
- linkers that are all or partially flexible, such that the linker can include a flexible linker as well as one or more portions that confer less flexible structure.
- a polynucleotide provided by the replication incompetent recombinant retroviral particles has one or more transcriptional units that encode certain combinations of the one or more engineered signaling polypeptides.
- modified and in illustrative embodiments genetically modified T cells include the combinations of the one or more engineered signaling polypeptides after transduction of T cells by the replication incompetent recombinant retroviral particles. It will be understood that the reference of a first polypeptide, a second polypeptide, a third polypeptide, etc. is for convenience and elements on a “first polypeptide” and those on a “second polypeptide” means that the elements are on different polypeptides that are referenced as first or second for reference and convention only, typically in further elements or steps to that specific polypeptide.
- the first engineered signaling polypeptide includes an extracellular antigen binding domain, which is capable of binding an antigen, and an intracellular signaling domain. In other embodiments, the first engineered signaling polypeptide also includes a T cell survival motif and/or a transmembrane domain. In some embodiments, the first engineered signaling polypeptide does not include a co-stimulatory domain, while in other embodiments, the first engineered signaling polypeptide does include a co-stimulatory domain.
- a second engineered signaling polypeptide includes a lymphoproliferative gene product and optionally an extracellular antigen binding domain.
- the second engineered signaling polypeptide also includes one or more of the following: a T cell survival motif, an intracellular signaling domain, and one or more co-stimulatory domains.
- at least one is a CAR.
- the one or more engineered signaling polypeptides are expressed under a T cell specific promoter or a general promoter under the same transcript wherein in the transcript, nucleic acids encoding the engineered signaling polypeptides are separated by nucleic acids that encode one or more internal ribosomal entry sites (IREs) or one or more protease cleavage peptides.
- IREs internal ribosomal entry sites
- the polynucleotide encodes two engineered signaling polypeptides wherein the first engineered signaling polypeptide includes a first extracellular antigen binding domain, which is capable of binding to a first antigen, and a first intracellular signaling domain but not a co stimulatory domain, and the second polypeptide includes a second extracellular antigen binding domain, which is capable of binding VEGF, and a second intracellular signaling domain, such as for example, the signaling domain of a co-stimulatory molecule.
- the first antigen is PSCA, PSMA, or BCMA.
- the first extracellular antigen binding domain comprises an antibody or fragment thereof (e.g., scFv), e.g., an antibody or fragment thereof specific to PSCA, PSMA, or BCMA.
- the second extracellular antigen binding domain that binds VEGF is a receptor for VEGF, i.e., VEGFR.
- the VEGFR is VEGFR1, VEGFR2, or VEGFR3. In a certain embodiment, the VEGFR is VEGFR2.
- the polynucleotide encodes two engineered signaling polypeptides wherein the first engineered signaling polypeptide includes an extracellular tumor antigen binding domain and a CD3z signaling domain, and the second engineered signaling polypeptide includes an antigen binding domain, wherein the antigen is an angiogenic or vasculogenic factor, and one or more co stimulatory molecule signaling domains.
- the angiogenic factor can be, e.g., VEGF.
- the one or more co- stimulatory molecule signaling motifs can comprise, e.g., co-stimulatory signaling domains from each of CD27, CD28, 0X40, ICOS, and 4-1BB.
- the polynucleotide encodes two engineered signaling polypeptides wherein the first engineered signaling polypeptide includes an extracellular tumor antigen-binding domain and a O ⁇ 3z signaling domain, the second polypeptide comprises an antigen-binding domain, which is capable of binding to VEGF, and co-stimulatory signaling domains from each of CD27, CD28, 0X40, ICOS, and 4- IBB.
- the first signaling polypeptide or second signaling polypeptide also has a T cell survival motif.
- the T cell survival motif is, or is derived from, an intracellular signaling domain of IL-7 receptor (IL-7R), an intracellular signaling domain of IL-12 receptor, an intracellular signaling domain of IL-15 receptor, an intracellular signaling domain of IL-21 receptor, or an intracellular signaling domain of transforming growth factor b (TOHb) receptor or the T ⁇ Rb decoy receptor (TGF-b — dominant-negative receptor II (DNRII)).
- IL-7R IL-7 receptor
- TOHb transforming growth factor b
- the polynucleotide encodes two engineered signaling polypeptides wherein the first engineered signaling polypeptide includes an extracellular tumor antigen-binding domain and a CD3z signaling domain, and the second engineered signaling polypeptide includes an antigen-binding domain, which is capable of binding to VEGF, an IF-7 receptor intracellular T cell survival motif, and co-stimulatory signaling domains from each of CD27, CD28, 0X40, ICOS, and 4- 1BB.
- more than two signaling polypeptides are encoded by the polynucleotide.
- only one of the engineered signaling polypeptides includes an antigen binding domain that binds to a tumor-associated antigen or a tumor-specific antigen; each of the remainder of the engineered signaling polypeptides comprises an antigen binding domain that binds to an antigen that is not a tumor-associated antigen or a tumor-specific antigen.
- two or more of the engineered signaling polypeptides include antigen binding domains that bind to one or more tumor- associated antigens or tumor-specific antigens, wherein at least one of the engineered signaling polypeptides comprises an antigen binding domain that does not bind to a tumor-associated antigen or a tumor-specific antigen.
- the antigen can be a tumor- associated antigen or a tumor-specific antigen.
- the tumor-associated antigen or tumor-specific antigen is Axl, ROR1, ROR2, Her2 (ERBB2), prostate stem cell antigen (PSCA), PSMA (prostate-specific membrane antigen), B cell maturation antigen (BCMA), alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), cancer antigen-125 (CA-125), CA19-9, calretinin, chromogranin, protein melan-A (melanoma antigen recognized by T lymphocytes; MART-1), myo-Dl, muscle-specific actin (MSA), neurofilament, neuron-specific enolase (NSE), MUC-1, epithelial membrane protein (EMA), epithelial tumor antigen (ETA), tyrosinase, melanoma-associated antigen (MAGE), MUC-1, epithelial membrane protein (EMA), epithelial tumor antigen (ETA),
- the first engineered signaling polypeptide includes a first extracellular antigen binding domain that binds a first antigen, and a first intracellular signaling domain; and a second engineered signaling polypeptide includes a second extracellular antigen binding domain that binds a second antigen, or a receptor that binds the second antigen; and a second intracellular signaling domain, wherein the second engineered signaling polypeptide does not comprise a co-stimulatory domain.
- the first antigen-binding domain and the second antigen-binding domain are independently an antigen-binding portion of a receptor or an antigen-binding portion of an antibody.
- first antigen binding domain or the second antigen binding domain are scFv antibody fragments.
- first engineered signaling polypeptide and/or the second engineered signaling polypeptide additionally comprises a transmembrane domain.
- the first engineered signaling polypeptide or the second engineered signaling polypeptide comprises a T cell survival motif, e.g., any of the T cell survival motifs described herein.
- the first engineered signaling polypeptide includes a first extracellular antigen binding domain that binds HER2 and the second engineered signaling polypeptide includes a second extracellular antigen binding domain that binds MUC-1.
- the second extracellular antigen binding domain of the second engineered signaling polypeptide binds an interleukin.
- the second extracellular antigen binding domain of the second engineered signaling polypeptide binds a damage associated molecular pattern molecule (DAMP; also known as an alarmin).
- DAMP is a heat shock protein, chromatin-associated protein high mobility group box 1 (HMGB1), S100A8 (also known as MRP8, or calgranulin A), S100A9 (also known as MRP14, or calgranulin B), serum amyloid A (SAA), deoxyribonucleic acid, adenosine triphosphate, uric acid, or heparin sulfate.
- HMGB1 chromatin-associated protein high mobility group box 1
- S100A8 also known as MRP8, or calgranulin A
- S100A9 also known as MRP14, or calgranulin B
- SAA serum amyloid A
- said second antigen is an antigen on an antibody that binds to an antigen presented by a tumor cell.
- signal transduction activation through the second engineered signaling polypeptide is non-antigenic, but is associated with hypoxia.
- hypoxia is induced by activation of hypoxia-inducible factor-la (HIF-la), HIF-Ib, FlIF-2a, HIH-2b, FlIF-3a, or R1IR-3b.
- HIF-la hypoxia-inducible factor-la
- HIF-Ib HIF-Ib
- FlIF-2a HIH-2b
- FlIF-3a HIH-2b
- R1IR-3b R1IR-3b
- the engineered signaling polypeptides can further include one or more additional polypeptide domains, where such domains include, but are not limited to, a signal sequence; an epitope tag; an affinity domain; and a polypeptide whose presence or activity can be detected (detectable marker), for example by an antibody assay or because it is a polypeptide that produces a detectable signal.
- Non limiting examples of additional domains for any of the aspects or embodiments provided herein include a domain with at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any of the following sequences as described below: a signal sequence, an epitope tag, an affinity domain, or a polypeptide that produces a detectable signal.
- Signal sequences that are suitable for use in a subject CAR include any eukaryotic signal sequence, including a naturally-occurring signal sequence, a synthetic (e.g., man-made) signal sequence, etc.
- the signal sequence can be the CD8 signal sequence MALPVTALLLPLALLLHAARP (SEQ ID NO:72).
- Suitable epitope tags include, but are not limited to, hemagglutinin (F1A; e.g., YPYDVPDYA; SEQ ID NO:73); FLAG (e.g., DYKDDDDK; SEQ ID NO:74); c-myc (e.g., EQKLISEEDL; SEQ ID NO:75), and the like.
- Affinity domains include peptide sequences that can interact with a binding partner, e.g., such as one immobilized on a solid support, useful for identification or purification.
- DNA sequences encoding multiple consecutive single amino acids, such as histidine, when fused to the expressed protein, may be used for one-step purification of the recombinant protein by high affinity binding to a resin column, such as nickel sepharose.
- affinity domains include His5 (HHHHH; SEQ ID NO:76), FlisX6 (HHHHHH; SEQ ID NO:77), c-myc (EQKLISEEDL; SEQ ID NO:75), Flag (DYKDDDDK; SEQ ID NO:74), Strep Tag (WSHPQFEK; SEQ ID NO:78), hemagglutinin, e.g., HA Tag (YPYDVPDYA; SEQ ID NO:73), GST, thioredoxin, cellulose binding domain, RYIRS (SEQ ID NO:79), Phe-His-His-Thr (SEQ ID NO: 80), chitin binding domain, S-peptide, T7 peptide, SH2 domain, C-end RNA tag, WEAAAREACCRECCARA (SEQ ID NO:81), metal binding domains, e.g., zinc binding domains or calcium binding domains such as those from calcium-binding proteins, e.g., calmodulin, troponin C,
- Suitable detectable signal-producing proteins include, e.g., fluorescent proteins; enzymes that catalyze a reaction that generates a detectable signal as a product; and the like.
- Suitable fluorescent proteins include, but are not limited to, green fluorescent protein (GFP) or variants thereof, blue fluorescent variant of GFP (BFP), cyan fluorescent variant of GFP (CFP), yellow fluorescent variant of GFP (YFP), enhanced GFP (EGFP), enhanced CFP (ECFP), enhanced YFP (EYFP), GFPS65T, Emerald, Topaz (TYFP), Venus, Citrine, mCitrine, GFPuv, destabilized EGFP (dEGFP), destabilized ECFP (dECFP), destabilized EYFP (dEYFP), mCfPm, Cerulean, T-Sapphire, CyPet, YPet, mKO, HcRed, t-HcRed, DsRed, DsRed2, DsRed-monomer, J-Red, dimer2, t-dimer2(12), mRFPl, pocilloporin, Renilla GFP, Monster GFP, paGF
- fluorescent proteins include mHoneydew, mBanana, mOrange, dTomato, tdTomato, mTangerine, mStrawberry, mCherry, mGrapel, mRaspberry, mGrape2, m PI urn (Shaner et al. (2005) Nat. Methods 2:905-909), and the like. Any of a variety of fluorescent and colored proteins from Anthozoan species, as described in, e.g., Matz et al. (1999) Nature Biotechnol. 17:969-973, is suitable for use.
- Suitable enzymes include, but are not limited to, horse radish peroxidase (HRP), alkaline phosphatase (AP), beta-galactosidase (GAL), glucose-6-phosphate dehydrogenase, beta-N- acetylglucosaminidase, b-glucuronidase, invertase, Xanthine Oxidase, firefly luciferase, glucose oxidase (GO), and the like.
- HRP horse radish peroxidase
- AP alkaline phosphatase
- GAL beta-galactosidase
- glucose-6-phosphate dehydrogenase beta-N- acetylglucosaminidase
- b-glucuronidase invertase
- Xanthine Oxidase firefly luciferase
- glucose oxidase GO
- Safety switches have been developed for use with cellular therapies to affect the reduction or elimination of infused cells in the case of adverse events.
- Any of the recombinant viral vectors (e.g., RIPs) provided herein, including those that comprise, for example, membrane-bound cytokines, can include nucleic acids that encode a safety switch as part of, or separate from, nucleic acids encoding any of the engineered signaling polypeptides provided herein.
- any of the RIPs that are delivered directly to a subject can comprise nucleic acids that encode safety switches, including for example, anti-idiotype safety switches.
- any of the engineered signaling polypeptides provided herein for example engineered signaling polypeptides in modified, genetically modified, and/or transduced lymphocytes to be introduced or reintroduced into a subject, can include a safety switch.
- any of the engineered T cells disclosed herein can include a safety switch.
- Safety switch technologies can be broadly categorized into three groups based on their mechanism of action, antibody- or antibody mimetic-mediated cytotoxicity, pro-apoptotic signaling, and metabolic (gene-directed enzyme prodrug therapy, GDEPT).
- Previously disclosed safety switches include cell surface molecules that are truncated tyrosine kinase receptors.
- the truncated tyrosine kinase receptor is a member of the epidermal growth factor receptor (EGFR) family (e.g., ErbBl (HER1), ErbB2, ErbB3, and ErbB4), for example as disclosed in U.S. Patent 8,802,374 or WO2018226897.
- EGFR epidermal growth factor receptor
- eTags are recognized by monoclonal antibodies that are commercially available such as matuzumab, necitumumab panitumumab, and in illustrative embodiments, cetuximab.
- eTag was demonstrated to have a cell killing potential through Erbitux® mediated antibody dependent cellular cytotoxicity (ADCC) pathways.
- ADCC antibody dependent cellular cytotoxicity
- the inventors of the present disclosure have successfully expressed eTag in PBMCs using lentiviral vectors, and have found that expression of eTag in vitro by PBMCs exposed to Cetuximab, provided an effective elimination mechanism for PBMCs.
- eTags can be used in some embodiments of the present disclosure, but in such embodiments, typically an anti-idiotype extracellular domain is present as well.
- the extracellular recognition domain i.e., cell tag
- the extracellular recognition domain is itself an antibody, which as disclosed herein includes a functional antibody fragment, that binds a predetermined binding partner antibody (e.g., a target antibody).
- the cell tag antibody is specific for the target antibody, and for example, does not bind antibody constant regions exclusively, or in some embodiments, at all, or in illustrative embodiments, unless they interact with the target antibody (Abl) to cell tag (extracellular recognition domain) (Ab2) binding.
- the cell tag antibody i.e., extracellular recognition domain that includes the variable region of an antibody
- the anti-idiotypic antibody recognizes an epitope on the predetermined binding partner antibody (i.e., target antibody) (Abl) that is distinct from the antigen binding site on Abl.
- Ab2 binds the variable region of Abl.
- Ab2 binds the antigen-binding site of Abl, and, in illustrative embodiments, competes with Abl for binding to the antigen-binding site of Abl.
- Ab2 may be from any animal including human and murine, or humanized or a chimeric antibody or an antibody derivative included within the definition of “antibody” herein, including, for example antibody fragments (Fab, Fab’, F(ab’)2, scFv, diabodies, bispecific antibodies, and antibody fusion proteins.
- Ab2 is typically associated with a membrane through a membrane association domain.
- Ab2 is associated with the cell surface via its endogenous transmembrane domain.
- Ab2 is associated with the cell surface via a heterologous transmembrane domain or membrane attachment sequence such as GPI.
- Abl is a commercially available monoclonal antibody.
- Abl is a commercially available monoclonal antibody therapeutic. In further illustrative embodiments, Abl is capable of mediating ADCC and/or CDC as described below.
- safety switches can also function as flags that label or mark polynucleotides, polypeptides, or cells as being engineered.
- Such safety switches can be detected using standard laboratory techniques including PCR, Southern Blots, RT-PCR, Northern Blots, Western Blots, histology, and flow cytometry.
- detection of eTAG by flow cytometry has been used by at least one of the inventors as an in vivo backing marker for T cell engraftment in mice.
- cell tags are used to enrich for engineered cells using antibodies or ligands optionally bound to a solid substrate such as a column or beads.
- biotinylated-cetuximab to immunomagnetic selection in combination with anti-biotin microheads successfully enriches T cells that have been lentivirally transduced with eTAG containing constructs from as low as 2% of the population to greater than 90% purity without observable toxicity to the cell preparation.
- the anti-idiotype polypeptide is a safety switch (also called a safety switch polypeptide or an anti-idiotype polypeptide safety switch herein) comprising a recognition domain of an anti-idiotype antibody or anti-idiotype antibody mimetic and a membrane association domain.
- a safety switch polypeptide or an anti-idiotype polypeptide safety switch herein
- Such safety switch polypeptides can be designed much more efficiently and with many more optional sequences and designs, than prior art safety switches.
- Such a safety switch polypeptide in one aspect is designed such that the extracellular recognition domain recognizes an idiotype of an antibody or antibody mimetic capable of inducing cytotoxicity.
- the safety switch is based on antibody mediated cytotoxicity upon antibody or antibody mimetic binding to an anti-idiotype polypeptide expressed on the surface of a cell, and more specifically binding to an extracellular recognition domain (also referred to herein as a cell tag or more specifically, an anti-idiotype cell tag) of an anti-idiotype polypeptide.
- the antibody or antibody mimetic binds to the cell tag and induces complement-dependent cytotoxicity (CDC) and/or antibody-dependent cell-mediated cytotoxicity (ADCC).
- binding of the antibody or antibody mimetic to the anti-idiotype polypeptide induces, promotes, and/or activates one or more of ADCC, CDC, antibody-mediated complement activation, antibody-dependent cellular phagocytosis, and antibody-dependent enhancement of diseases. Details related to other antibody and antibody mimetic functions, including corresponding Fc domains for eliciting such responses, are discussed in the “Antibody and antibody mimetic effector functions” herein.
- the anti-idiotype polypeptide can be immunogenic, to further stimulate the immune system.
- the cell tag is immunogenic.
- the cell tag polypeptide is non-immunogenic.
- a safety switch polypeptide is designed such that the anti-idiotype polypeptide includes an intracellular domain having one or more cell-death inducing signals, and the polypeptide is capable of inducing a cell death signal upon binding of the anti-idiotype polypeptide to a target antibody or antibody mimetic that comprises the idiotype recognized by the anti-idiotype polypeptide.
- the cell-death inducing signals can be induced based on dimerization-induced apoptotic signaling.
- the safety switch is based on dimerization induced apoptotic signals.
- such a safety switch comprises an extracellular dimerization domain comprising a recognition domain of an anti-idiotype antibody or antibody mimetic linked in frame with a membrane association domain and an intracellular domain comprising components of an apoptotic pathway.
- dimerization mediated by the binding of an antibody or antibody mimetic to the anti-idiotype polypeptide results in apoptosis of the cell.
- the safety switch includes inducible FAS (iFAS) comprised of one or more inducible dimerization domains, i.e., the anti-idiotype polypeptides, fused to the cytoplasmic tail of the Fas receptor and localized to the membrane by a membrane association domain.
- the safety switch includes one or more domains from a Caspase, such as caspase-1 or caspase-9.
- the anti-idiotype polypeptides can be expressed as fusions with other polypeptides disclosed herein, including a lymphoproliferative element, a CAR, and/or a recombinant TCR. In other embodiments, the anti-idiotype polypeptides are expressed as polypeptides by themselves. In any of these embodiments, the anti-idiotype polypeptides can include any of the domains disclosed herein to be included in a lymphoproliferative element, CAR, and/or TCR, such as the extracellular domains, stalks, transmembrane domains, intracellular activating domains, modulatory domains, linkers, or intracellular domains.
- the safety switch is based on dimerization induced apoptotic signals.
- the safety switch is a chimeric protein comprised of an inducible dimerization domain linked in frame with components of an apoptotic pathway, such that conditional dimerization mediated by the binding of a cell-permeable chemical inducer of dimerization (CID) results in apoptosis of the cell.
- the safety switch is inducible FAS (iFAS) comprised of one or more inducible dimerization domains fused to the cytoplasmic tail of the Fas receptor and localized to the membrane by a myristoyl group.
- the safety switch is an inducible Caspase comprised of one or more inducible dimerization domains fused to a caspase, such as caspase- 1 or caspase-9.
- the inducible dimerization domain is a cyclophilin and the CID is cyclosporin or a cyclosporin derivative.
- the inducible dimerization domain is a FKBP and the CID is an FK-506 dimer or derivative thereof, such as AP1903.
- the cell tag is a myc or FLAG tag.
- the cell tag polypeptide is non-immunogenic.
- the modified endogenous cell-surface molecule is a truncated version of a member of the TNF receptor superfamily. For example, a truncated version of the low affinity nerve growth factor receptor (LNGFR or TNFRSF16).
- Fiuman LNGFR is a single pass type I transmembrane glycoprotein with the amino acid sequence of (SEQ ID NO:369) that comprises a 28 aa residue signal peptide, a 222 aa extracellular domain comprising 4 cysteine rich domains, a 22 aa transmembrane domain and a 155aa intracellular domain.
- the cell-surface molecule comprises an epitope has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identify to the amino acid sequence of the entire extracellular domain of LNGFR or to a truncated fragment of the extracellular domain such as residues 29-250, 65-250, or 108-250 of SEQ ID NO:369.
- the modified endogenous cell-surface molecule is a version of CD20.
- the human CD20 polypeptide is a multi-pass transmembrane protein encoded by a membrane-spanning 4- domains subfamily A member (MS4A1) gene with the amino acid sequence of SEQ ID NO:370.
- CD20 comprises 4 transmembrane domain passes encompassing amino acids 57-78, 85- 105, 121-141, and 189-209.
- CD20 comprises 2 extracellular domains encompassing amino acids 79-84 and 142-188.
- CD20 comprises 3 cytoplasmic domains encompassing amino acids 1-56, 106-120 and 210-297.
- a CD20 polypeptide can be missing multiple domains or multiple portions of a domain relative to the wildtype polypeptide.
- a CD20 polypeptide comprises M1-E263, M117-N214, M1-N214, V82- N214, or V82-I186 of endogenous CD20.
- a CD20 polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to an amino acid sequence selected from K142-S185, P160-S185, or C167-C183 of SEQ ID NO:370.
- the truncated CD20 version comprises at least one copy of an epitope recognized by a monoclonal antibody such as ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, ublituximab, and in further illustrative embodiments rituximab.
- a monoclonal antibody such as ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, ublituximab, and in further illustrative embodiments rituximab.
- the modified endogenous cell-surface molecule is a version of CD52.
- CD52 occurs endogenously in humans as a peptide of 12 amino acids linked at its C-terminus to a GPI anchor.
- GPI can be used to anchor the polypeptide to the cell surface.
- CD52 can be attached to the cell surface using a heterologous transmembrane domain.
- the truncated CD52 polypeptide can incorporate one or more epitopes recognized by an antibody such as HI186 (BioRad), YTH34.5 (BioRad), YTH66.9 (BioRad), or in illustrative embodiments, alemtuzumab.
- the CD52 epitope has at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identify to the amino acid sequence of SEQ ID NO:371.
- safety switches also function as flags that label or mark polynucleotides, polypeptides, or cells as being engineered.
- Such safety switches can be detected using standard laboratory techniques including PCR, Southern Blots, RT-PCR, Northern Blots, Western Blots, histology, and flow cytometry.
- detection of eTAG by flow cytometry was used herein as an in vivo tracking marker for T cell engraftment in mice.
- cell tags are used to enrich for engineered cells using antibodies or ligands optionally bound to a solid substrate such as a column or beads.
- biotinylated-cetuximab to immunomagnetic selection in combination with anti-biotin microheads successfully enriches T cells that have been lentivirally transduced with eTAG containing constructs from as low as 2% of the population to greater than 90% purity without observable toxicity to the cell preparation.
- the safety switch is expressed as part of a single polynucleotide that also includes the CAR, or as part of a single polynucleotide that includes the lymphoproliferative element, or as a single polynucleotide that encodes both the CAR and the lymphoproliferative element.
- the polynucleotide encoding the safety switch is separated from the polynucleotide encoding the CAR and/or the polynucleotide encoding the lymphoproliferative element, by an internal ribosome entry site (IRES) or a ribosomal skip sequence and/or cleavage signal.
- the ribosomal skip and/or cleavage signal can be any ribosomal skip sequence and/or cleavage signal known in the art.
- the ribosomal skip sequence can be, for example, T2A with amino acid sequence
- cleavage signals and ribosomal skip sequences include FMDV 2 A (F2A); equine rhinitis A virus 2 A (abbreviated as E2A); porcine teschovirus-1 2A (P2A); and Thoseaasigna virus 2A (T2A).
- F2A FMDV 2 A
- E2A equine rhinitis A virus 2 A
- P2A porcine teschovirus-1 2A
- T2A Thoseaasigna virus 2A
- a safety switch and in illustrative embodiments, a cell tag, is expressed as part of a fusion polypeptide, fused to a CAR.
- a safety switch and as exemplified empirically herein, a cell tag, is expressed fused to a lymphoproliferative element.
- an eTag is expressed as a fusion polypeptide, fused the 5’ terminus of the c-Jun domain (SEQ ID NO: 104), a transmembrane domain from CSF2RA (SEQ ID NO: 129), a first intracellular domain from MPL (SEQ ID NO:283), and a second intracellular domain from CD40 (SEQ ID NO:208).
- the cell tag When expressed as a polypeptide not fused to a CAR or lymphoproliferative element, the cell tag may be associated with the cell membrane via its natural membrane attachment sequence or via a heterologous membrane attachment sequence such as a GPI-anchor or transmembrane sequence.
- cell tags are expressed on the T cell and/or NK cell but are not expressed on the replication incompetent recombinant retroviral particles.
- polynucleotides, polypeptides, and cells comprise 2 or more safety switches.
- an engineered signaling polypeptide is a chimeric antigen receptor (CAR) or a polynucleotide encoding a CAR, which, for simplicity, is referred to herein as “CAR.”
- a CAR of the present disclosure includes: a) at least one antigen-specific targeting region (ASTR); b) a transmembrane domain; and c) an intracellular activating domain.
- the antigen-specific targeting region of the CAR is an scFv portion of an antibody to the target antigen.
- the intracellular activating domain is from CD3Z, CD3D, CD3E, CD3G, CD79A, CD79B, DAP12, FCER1G, FCGR2A, FCGR2C, DAP10/CD28, or ZAP70, and some further illustrative embodiments, from CD3z.
- the CAR further comprises a co-stimulatory domain, for example any of the co-stimulatory domains provided above in the Modulatory Domains section, and in further illustrative embodiments the co-stimulatory domain is the intracellular co-stimulatory domain of 4-1BB (CD137), CD28, ICOS, OX-40, BTLA, CD27, CD30, GITR, and HVEM.
- the CAR includes any of the transmembrane domains listed in the Transmembrane Domain section above.
- any of the RIPs (RIP formulation and/or a delivery solution) that are delivered directly to a subject can comprise nucleic acids that encode a CAR as disclosed in this section, and in any embodiments herein.
- a CAR of the present disclosure can be present in the plasma membrane of a eukaryotic cell, e.g., a mammalian cell, where suitable mammalian cells include, but are not limited to, a cytotoxic cell, a T lymphocyte, a stem cell, a progeny of a stem cell, a progenitor cell, a progeny of a progenitor cell, and an NK cell, an NK-T cell, and a macrophage.
- a CAR of the present disclosure is active in the presence of one or more target antigens that, in certain conditions, binds the ASTR.
- the target antigen is the second member of the specific binding pair.
- the target antigen of the specific binding pair can be a soluble (e.g., not bound to a cell) factor; a factor present on the surface of a cell such as a target cell; a factor presented on a solid surface; a factor present in a lipid bilayer; and the like.
- the antigen can be a soluble (e.g., not bound to a cell) antigen; an antigen present on the surface of a cell such as a target cell; an antigen presented on a solid surface; an antigen present in a lipid bilayer; and the like.
- the ASTR of a CAR is expressed as a separate polypeptide from the intracellular signaling domain.
- one or both of the polypeptides can include any of the transmembrane domains disclosed herein.
- one or both of the polypeptides can include a heterologous signal sequence and/or a heterologous membrane attachment sequence.
- the heterologous membrane attachment sequence is a GPI anchor attachment sequence.
- a CAR of the present disclosure when present in the plasma membrane of a eukaryotic cell, and when activated by the one or more target antigens, increases expression of at least one nucleic acid in the cell by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 75%, at least about 2-fold, at least about 2.5-fold, at least about 5-fold, at least about 10-fold, or more than 10- fold, compared with the level of transcription of the nucleic acid in the absence of the one or more target antigens.
- the CAR of the present disclosure can include an immunoreceptor tyrosine-based activation motif (IT AM) -containing intracellular signaling polypeptide.
- IT AM immunoreceptor tyrosine-based activation motif
- a CAR of the present disclosure when present in the plasma membrane of a eukaryotic cell, and when activated by one or more target antigens, can, in some instances, result in increased production of one or more cytokines by the cell.
- a CAR of the present disclosure when present in the plasma membrane of a eukaryotic cell, and when activated by the one or more target antigens, can increase production of a cytokine by the cell by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 75%, at least about 2-fold, at least about 2.5-fold, at least about 5-fold, at least about 10-fold, or more than 10- fold, compared with the amount of cytokine produced by the cell in the absence of the one or more target antigens.
- Cytokines whose production can be increased include, but are not limited to, interferon gamma (IFN-g), tumor necrosis factor-alpha (TNF-a), IL-2, IL-15, IL-12, IL-4, IL-5, IL-10; a chemokine; a growth factor; and the like.
- IFN-g interferon gamma
- TNF-a tumor necrosis factor-alpha
- IL-2 tumor necrosis factor-alpha
- IL-15 IL-12
- IL-4 IL-5
- IL-10 a chemokine
- chemokine a growth factor
- a CAR of the present disclosure when present in the plasma membrane of a eukaryotic cell, and when activated by one or more target antigens, can result in both an increase in transcription of a nucleic acid in the cell and an increase in production of a cytokine by the cell.
- a CAR of the present disclosure when present in the plasma membrane of a eukaryotic cell, and when activated by one or more target antigens, results in cytotoxic activity by the cell toward a target cell that expresses on its cell surface an antigen to which the antigen-binding domain of the first polypeptide of the CAR binds.
- a CAR of the present disclosure when present in the plasma membrane of the cell, and when activated by the one or more target antigens, increases cytotoxic activity of the cell toward a target cell that expresses on its cell surface the one or more target antigens.
- a CAR of the present disclosure when present in the plasma membrane of the cell, and when activated by the one or more target antigens, increases cytotoxic activity of the cell by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 75%, at least about 2-fold, at least about 2.5-fold, at least about 5-fold, at least about 10-fold, or more than 10-fold, compared to the cytotoxic activity of the cell in the absence of the one or more target antigens.
- a CAR of the present disclosure when present in the plasma membrane of a eukaryotic cell, and when activated by one or more target antigens, can result in other CAR activation related events such as proliferation and expansion (either due to increased cellular division or anti- apoptotic responses).
- a CAR of the present disclosure when present in the plasma membrane of a eukaryotic cell, and when activated by one or more target antigens, can result in other CAR activation related events such as intracellular signaling modulation, cellular differentiation, or cell death.
- CARs of the present disclosure are microenvironment restricted. This property is typically the result of the microenvironment restricted nature of the ASTR domain of the CAR.
- CARs of the present disclosure can have a lower binding affinity or, in illustrative embodiments, can have a higher binding affinity to one or more target antigens under a condition(s) in a microenvironment than under a condition in a normal physiological environment.
- CARs provided herein comprise a co-stimulatory domain in addition to an intracellular activating domain, wherein the co-stimulatory domain is any of the intracellular signaling domains provided herein for lymphoproliferative elements (LEs), such as, for example, intracellular domains of CLEs.
- Ls lymphoproliferative elements
- the co-stimulatory domains of CARs herein are first intracellular domains (P3 domains) identified herein for CLEs or P4 domains that are shown as effective intracellular signaling domains of CLEs herein in the absence of a P3 domain.
- co-stimulatory domains of CARs can comprise both a P3 and a P4 intracellular signaling domain identified herein for CLEs.
- Certain illustrative subembodiments include especially effective P3 and P4 partner intracellular signaling domains as identified herein for CLEs.
- the co-stimulatory domain is other than an ITAM-containing intracellular domain of a CAR either as part of the co-stimulatory domain, or in further illustrative embodiments as the only co-stimulatory domain.
- the co-stimulatory domain of a CAR can be any intracellular signaling domain in Table 1 provided herein. Active fragments of any of the intracellular domains in Table 1 can be a co-stimulatory domain of a CAR.
- the ASTR of the CAR comprises an scFV.
- these CARs comprise an intracellular activating domain that in illustrative embodiments is a CD3Z, CD3D, CD3E, CD3G, CD79A, CD79B, DAP12, FCER1G, FCGR2A, FCGR2C.
- DAP10/CD28, or ZAP70 intracellular activating domain or in further illustrative embodiments is a CD3z intracellular activating domain.
- the co-stimulatory domain of a CAR can comprise an intracellular domain or a functional signaling fragment thereof that includes a signaling domain from CSF2RB, CRLF2, CSF2RA, CSF3R, EPOR, GHR, IFNAR1, IFNAR2, IFNGR1, IFNGR2, IFNLR1, IL1R1, IL1RAP, IL1RL1, IL1RL2, IL2RA, IL2RB, IL2RG, IL3RA, IL5RA, IL6R, IL6ST, IL7RA, IL9R, IL10RA, IL10RB, IL11RA, IL12RB1, IL12RB2, IL13RA1, IL13RA2, IL15RA, IL17RB, IL17RC, IL17RD, IL18R1, IL18RAP, IL20RA, IL20RB, IL21R, IL22RA1, IL23R, IL27RA,
- the co-stimulatory domain of a CAR can include an intracellular domain or a functional signaling fragment thereof that includes a signaling domain from CSF2RB, CRLF2, CSF2RA, CSF3R, EPOR, GHR, IFNAR1, IFNAR2, IFNGR1, IFNGR2, IFNLR1, IL1R1, IL1RAP, IL1RL1, IL1RL2, IL2RA, IL2RB, IL2RG, IL3RA, IL5RA, IL6R, IL6ST, IL9R, IL10RA, IL10RB, IL11RA, IL13RA1, IL13RA2, IL17RB, IL17RC, IL17RD, IL18R1, IL18RAP, IL20RA, IL20RB, IL22RA1, IL31RA, LEPR, LIFR, LMP1, MPL, MyD88, OSMR, or PRLR.
- the co-stimulatory domain of a CAR can include an intracellular domain or a functional fragment thereof that includes a signaling domain from CSF2RB, CSF2RA, CSF3R, EPOR, IFNGR1, IFNGR2, IL1R1, IL1RAP, IL1RL1, IL2RA, IL2RG, IL5RA, IL6R, IL9R, IL10RB, IL11RA, IL12RB1, IL12RB2, IL13RA2, IL15RA, IL17RD, IL21R, IL23R, IL27RA, IL31RA, LEPR, MPL, MyD88, or OSMR.
- the co-stimulatory domain of a CAR can include an intracellular domain or a fragment thereof that includes a signaling domain from CSF2RB, CSF2RA, CSF3R, EPOR, IFNGR1, IFNGR2, IL1R1, IL1RAP, IL1RL1, IL2RA, IL2RG, IL5RA, IL6R, IL9R, IL10RB, IL11RA, IL13RA2, IL17RD, IL31RA, LEPR, MPL, MyD88, or OSMR.
- the co-stimulatory domain of a CAR can include an intracellular domain or a functional signaling fragment thereof that includes a signaling domain from CSF2RB, CSF3R, IFNAR1, IFNGR1, IL2RB, IL2RG, IL6ST, IL10RA, IL12RB2, IL17RC, IL17RE, IL18R1, IL27RA, IL31RA, MPL, MyD88,
- the co-stimulatory domain of a CAR can include an intracellular domain or a functional signaling fragment thereof that includes a signaling domain from CSF2RB,
- CSF3R CSF3R, IFNGR1, IL2RB, IL2RG, IL6ST, IL10RA, IL17RE, IL31RA, MPL, or MyD88.
- the co-stimulatory domain of a CAR can include an intracellular domain or a fragment thereof that includes a signaling domain from CSF3R, IL6ST, IL27RA, MPL, and MyD88.
- the intracellular activating domain of the CAR is derived from CD3z.
- TCRs T Cell Receptors
- T Cell Receptors recognize specific protein fragments derived from intracellular as well as extracellular proteins. When proteins are broken into peptide fragments, they are presented on the cell surface with another protein called major histocompatibility complex, or MF1C, which is called the F1LA (human leukocyte antigen) complex in humans.
- MF1C major histocompatibility complex
- F1LA human leukocyte antigen
- Such combinations are formed by dimerization between members of dimerizing subtypes, such as an a TCR subunit and a b TCR subunit, a g TCR subunit and a d TCR subunit, and for pre-TCRs, a pT ⁇ subunit and a b TCR subunit.
- a set of TCR subunits dimerize and recognize a target peptide fragment presented in the context of an MF1C.
- the pre-TCR is expressed only on the surface of immature ⁇ T cells while the ⁇ TCR is expressed on the surface of mature ⁇ T cells and NK T cells, and ⁇ dTCR is expressed on the surface of gdT cells.
- ⁇ TCRs on the surface of a T cell recognize the peptide presented by MF1CI or MF1CII and the ⁇ TCR on the surface of NK T cells recognize lipid antigens presented by CD1.
- ⁇ dTCRs can recognize MF1C and MFIC-like molecules, and can also recognize non-MFIC molecules such as viral glycoproteins.
- o ⁇ TCRs and ⁇ dTCRs transmit activation signals through the CD3zeta chain that stimulate T cell proliferation and cytokine secretion.
- TCR molecules belong to the immunoglobulin superfamily with its antigen-specific presence in the V region, where CDR3 has more variability than CDR1 and CDR2, directly determining the antigen binding specificity of the TCR.
- CDR3 has more variability than CDR1 and CDR2 directly determining the antigen binding specificity of the TCR.
- the CDR1 and CDR2 recognize and bind the sidewall of the MF1C molecule antigen binding channel, and the CDR3 binds directly to the antigenic peptide.
- Recombinant TCRs may thus be engineered that recognize a tumor-specific protein fragment presented on MHC.
- Recombinant TCR such as those derived from human TCR ⁇ and TCR ⁇ pairs that recognize specific peptides with common HLAs can thus be generated with specificity to a tumor specific protein (Schmitt, TM et al., 2009).
- the target of recombinant TCRs may be peptides derived from any of the antigen targets for CAR ASTRs provided herein, but are more commonly derived from intracellular tumor specific proteins such as oncofetal antigens, or mutated variants of normal intracellular proteins or other cancer specific neoepitopes. Libraries of TCR subunits may be screened for their selectivity to a target antigen.
- TCR subunits Screens of natural and/or recombinant TCR subunits can identify sets of TCR subunits with high avidities and/or reactivities towards a target antigen. Members of such sets of TCR subunits can be selected and cloned to produce one or more polynucleotide encoding the TCR subunit.
- Polynucleotides encoding such a set of TCR subunits can be included in a replication incompetent recombinant retroviral particle to genetically modify a lymphocyte, or in illustrative embodiments, a T cell or an NK cell, such that the lymphocyte expresses the recombinant TCR.
- RIP comprising nucleic acids that encode a TCR as disclosed in this section, and in any embodiments herein modifies a lymphocyte, such as, a T cell and/or a NK cell, in vivo.
- the RIP comprising nucleic acids that encode TCR modifies a lymphocyte, such as, a T cell and/or a NK cell, ex vivo.
- a lymphocyte such as, a T cell and/or a NK cell, ex vivo.
- the CAR can be replaced by a set of ydTCR chains, or in illustrative embodiments aPTCR chains.
- TCR chains that form a set may be co-expressed using a number of different techniques to co-express the two TCR chains as is disclosed herein for expressing two or more other engineered signaling polypeptides such as CARs and lymphoproliferative elements.
- protease cleavage epitopes such as 2A protease, internal ribosomal entry sites (IRES), and separate promoters may be used.
- any of the RIP (RIP formulation and/or a delivery solution) that are delivered directly to a subject can comprise nucleic acids that encode a TCR as disclosed in this section, and in any embodiments herein.
- this involves modification of the constant (C) domains of the TCRa and TCR ⁇ chains to promote the preferential pairing of the introduced TCR chains with each other, while rendering them less likely to successfully pair with endogenous TCR chains.
- C constant domains of the TCRa and TCR ⁇ chains
- One approach that has shown some promise in vitro involves replacement of the C domain of human TCRa and TCR ⁇ chains with their mouse counterparts.
- Another approach involves mutation of the human TCRa common domain and TCR ⁇ chain common regions to promote self-pairing, or the expression of an endogenous TCR alpha and TCR beta miRNA within the viral gene construct.
- each member of the set of TCR chains in illustrative embodiments o ⁇ TCR chains, comprises a modified constant domain that promotes preferential pairing with each other.
- each member of a set of TCR chains in illustrative embodiments o ⁇ TCR chains, comprises a mouse constant domain from the same TCR chain type, or a constant domain from the same TCR chain subtype with enough sequences derived from a mouse constant domain from the same TCR chain subtype, such that dimerization of the set of TCR chains to each other is preferred over, or occurs to the exclusion of, dimerization with human TCR chains.
- each member of a set of TCR chains in illustrative embodiments o ⁇ TCR chains, comprises corresponding mutations in its constant domain, such that dimerization of the set of TCR chains to each other is preferred over, or occurs to the exclusion of, dimerization with TCR chains that have human constant domains.
- dimerization in illustrative embodiments, is under physiological conditions.
- the constant regions of the members of each of the one or more sets of TCR chains are swapped.
- the a TCR subunit of the set has a b TCR constant region
- the b TCR subunit of the set has a a TCR constant region.
- an engineered signaling polypeptide is a lymphoproliferative element (LE) such as a chimeric lymphoproliferative element (CLE).
- L lymphoproliferative element
- CLE chimeric lymphoproliferative element
- any of the RIP (RIP formulation and/or a delivery solution) that are delivered directly to a subject comprises nucleic acid encoding an LE, such as a CLE.
- such an in vivo delivery of the RIP provides in vivo modification of lymphocytes.
- the LE comprises an extracellular domain, a transmembrane domain, and at least one intracellular signaling domain that drives proliferation, and in illustrative embodiments a second intracellular signaling domain.
- the extracellular domains, transmembrane domains, and intracellular domains of LEs can vary in their respective amino acid lengths.
- the overall length of the LE can be between 3 and 4000 amino acids, for example between 10 and 3000, 10 and 2000, 50 and 2000, 250 and 2000 amino acids, and, in illustrative embodiments between 50 and 1000, 100 and 1000 or 250 and 1000 amino acids.
- the extracellular domain when present to form an extracellular and transmembrane domain, can be between 1 and 1000 amino acids, and is typically between 4 and 400, between 4 and 200, between 4 and 100, between 4 and 50, between 4 and 25, or between 4 and 20 amino acids.
- the extracellular region is GGGS for an extracellular and transmembrane domain of this aspect of the invention.
- the transmembrane domains, or transmembrane regions of extracellular and transmembrane domains can be between 10 and 250 amino acids, and are more typically at least 15 amino acids in length, and can be, for example, between 15 and 100, 15 and 75, 15 and 50, 15 and 40, or 15 and 30 amino acids in length.
- the intracellular signaling domains can be, for example, between 10 and 1000, 10 and 750, 10 and 500, 10 and 250, or 10 and 100 amino acids.
- the intracellular signaling domain can be at least 30, or between 30 and 500, 30 and 250, 30 and 150, 30 and 100, 50 and 500, 50 and 250, 50 and 150, or 50 and 100 amino acids.
- an intracellular signaling domain for a particular gene is at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to at least 10, 25, 30, 40, 50, or all the amino acids from a sequence of that intracellular signaling domain, such as a sequence provided herein for that intracellular domain, up to the size of the entire intracellular domain sequence, and can include for example, up to an additional 1, 2, 3, 4, 5, 10, 20, or 25 amino acids, provided that such sequence still is capable of providing any of the properties of LEs disclosed herein.
- the lymphoproliferative element can include a first and/or second intracellular signaling domain.
- the first and/or second intracellular signaling domain can include CD2, CD3D, CD3E, CD3G, CD4, CD8A, CD8B, CD27, mutated Delta Lck CD28, CD28, CD40, CD79A, CD79B, CRLF2, CSF2RB, CSF2RA, CSF3R, EPOR, FCER1G, FCGR2C, FCGRA2, GHR, ICOS, IFNAR1, IFNAR2, IFNGR1, IFNGR2, IFNLR1, IL1R1, IL1RAP, IL1RL1, IL1RL2, IL2RA, IL2RB, IL2RG, IL3RA, IL4R, IL5RA, IL6R, IL6ST, IL7RA, IL9R, IL10RA, IL10RB, IL11RA, IL12RB1,
- the first intracellular signaling domain can include MyD88, or a functional mutant and/or fragment thereof.
- the first intracellular signaling domain can include MyD88, or a functional mutant and/or fragment thereof
- the second intracellular signaling domain can include ICOS, TNFRSF4, or TNSFR18, or functional mutants and/or fragments thereof.
- the first intracellular domain is MyD88 and the second intracellular domain is an ITAM-containing intracellular domain, for example, an intracellular domain from CD3Z, CD3D, CD3E, CD3G, CD79A, CD79B, DAP12, FCER1G, FCGR2A, FCGR2C, DAP10/CD28, or ZAP70.
- the second intracellular signaling domain can include TNFRSF18, or a functional mutant and/or fragment thereof.
- the lymphoproliferative element can include a fusion of an extracellular domain and a transmembrane domain.
- the fusion of an extracellular domain and a transmembrane domain can include eTAG IL7RA Ins PPCL (interleukin 7 receptor), Myc LMP1, LMP1, eTAG CRLF2, eTAG CSF2RB, eTAG CSF3R, eTAG EPOR, eTAG GHR, eTAG truncated after Fn F523C IL27RA, or eTAG truncated after Fn S505N MPF, or functional mutants and/or fragments thereof.
- the lymphoproliferative element can include an extracellular domain.
- the extracellular domain can include cell tag with 0, 1, 2, 3, or 4 additional alanines at the carboxy terminus.
- the extracellular domain can include Myc or an eTAG with 0, 1, 2, 3, or 4 additional alanines at the carboxy terminus, or functional mutants and/or fragments thereof.
- a lymphoproliferative element disclosed herein that includes a cell tag there is a corresponding embodiment that is identical but lacks the cell tag and optionally lacks any linker sequence that connected the cell tag to the lymphoproliferative element.
- the lymphoproliferative element can include a transmembrane domain.
- the transmembrane domain can include a transmembrane domain from BAFFR,
- CD3Z CEACAM1, CD2, CD3A, CD3B, CD3D, CD3E, CD3G, CD3Z, CD4, CD5, CD7, CD8A, CD8B, CD9, CD11A, CD11B, CD11C, CD11D, CD27, CD16, CD18, CD19, CD22, CD28, CD29, CD33, CD37, CD40, CD45, CD49A, CD49D, CD49F, CD64, CD79A, CD79B, CD80, CD84, CD86, CD96 (Tactile), CD 100 (SEMA4D), CD103, C134, CD137, CD154, CD160 (BY55), CD162 (SEFPFG), CD226 (DNAM1), CD229 (Ly9), CD247, CRLF2, CRTAM, CSF2RA, CSF2RB, CSF3R, EPOR, FCER1G, FCGR2C, FCGRA2, GHR, HVEM (LIGHTR), IA4, ICOS, IFN
- CLEs for use in any aspect or embodiment herein can include any CLE disclosed in WO2019/055946 (incorporated by reference herein, in its entirety), the vast majority of which were designed to be and are believed to be constitutively active, typically because they constitutively activate a signaling pathway, typically through functional domains on their intracellular domains.
- the constitutively active signaling pathways include activation of a Jak pathway, a Stat pathway, or Jak/Stat pathways including Jakl, Jak2, Jak3, and Tyk2 and STATs such as STAT1, STAT2, STAT3, STAT4, STAT5, STAT6, and in illustrative embodiments, STAT3 and/or STAT5.
- Illustrative embodiments of LEs herein include a JAK-binding domain and/or a STAT-recruiting domain. Accordingly, provided herein, in certain embodiments, are lymphoproliferative elements that comprise a means for activating any one or more of these pathways, which typically comprises an intracellular domain that is a means for activating any one or more of these pathways. In certain embodiments, lymphoproliferative elements comprise a means, such as an intracellular domain, that is a means for transmitting a signal that promotes proliferation and/or survival of a T cell and/or NK cell, in illustrative embodiments when part of a dimerized lymphoproliferative element. In some embodiments, a CLE includes one or more Jak binding domains.
- a CLE includes one or more Stat recruitment domains.
- an LE herein that includes a JAK-binding domain and a STAT-recruiting domain dimerizes and/or clusters and allows for two bound JAK-proteins to become activated, which in turn phosphorylate tyrosine residues on a recruiting domain of the LE.
- the phosphorylated recruiting domains are then capable of binding the recruited proteins (e.g., a phosphorylated STAT-recruiting domain binds a STAT protein), the STAT protein is activated (e.g., by phosphorylation), dissociates from the STAT-recruiting domain, and translocates to the nucleus where the STAT protein affects transcription events.
- a phosphorylated STAT-recruiting domain binds a STAT protein
- the STAT protein is activated (e.g., by phosphorylation), dissociates from the STAT-recruiting domain, and translocates to the nucleus where the STAT protein affects transcription events.
- a CLE includes one or more STAT-activation domains. In some embodiments, a CLE includes two or more, three or more, four or more, five or more, or six or more STAT-activation domains. In some embodiments, at least one of the one or more STAT-activation domains is, or is derived from BLNK, IL2RG, EGFR, EpoR, GHR, IFNAR1, IFNAR2, IFNAR1/2, IFNLR1, IL10R1, IL12Rbl, IL12Rb2, IL21R, IL2Rb, IL2smah, IL7R, IL7Ra, IL9R, IL15R, and IL21R, as are known in the art.
- two or more STAT-activation domains are, or are derived from two or more different receptors.
- Other STAT-activation domains that can be included in aspects and embodiments herein that include an LE include one or more of IL7R (316-459), IL2Rb (333-551), IFNAR1 (508-557), IFNAR2 (310-515), IFNAR1/2 (IFNAR1 residues 508-557-IFNAR2 residues 310- 515), IFNLR1 (300-520), Common Gamma Chain (335-369), IL9R (356-521), IL21R (322-538), GHR (353-638), EpoR (339-508), murine IL2Rb (337-539), murine IL7Ra (316-459), EGFR (955-1186), EGFR (955-1186; Y974F, dl045-1057), EGFR (955-1009; Y974F), EGFR (1019-1085), EGFR (10
- STAT-activation domains which can also be called STAT-recruiting domains herein, can be linked in tandem to stimulate multiple pathways (e.g., the IL7R(316-459)- IL12Rb2(775-825) fragment fusion for pro-persistence STAT5 and pro-inflammatory STAT4; IL7R(316- 459)-IL2Rbsmall(393-433,518-551) for pro-persistence; IL7R(316-459)- EGFR(1122-1165) for pro persistence and anti-exhaustion; IL2Rbsmall(393-433,518-551)- EGFR(1122-1165) for pro-persistence and anti-exhaustion).
- multiple pathways e.g., the IL7R(316-459)- IL12Rb2(775-825) fragment fusion for pro-persistence STAT5 and pro-inflammatory STAT4; IL7R(316- 459)-IL2Rbsmall(393-433,518
- the constitutively active signaling pathways include activation of a TRAF pathway through activation of TNF receptor associated factors such as TRAF3, TRAF4, TRAF7, and in illustrative embodiments TRAF1, TRAF2, TRAF5, and/or TRAF6.
- TRAF3, TRAF4, TRAF7 TNF receptor associated factors
- TRAF1, TRAF2, TRAF5, and/or TRAF6 TNF receptor associated factors
- lymphoproliferative elements for use in any of the kits, methods, uses, or compositions herein are constitutively active and comprise an indacellular signaling domain that activates a Jak/Stat pathway and/or a TRAF pathway.
- the constitutively active signaling pathways include activation of PI3K pathways.
- the constitutively active signaling pathways include activation of PLC pathways.
- lymphoproliferative elements for use in any of the kits, methods, uses, or compositions herein are constitutively active and comprise an intracellular signaling domain that activates a Jak/Stat pathway a TRAF pathway, a PI3K pathway, and/or a PLC pathway.
- the first intracellular signaling domain is positioned between the membrane associating motif, for example, a transmembrane domain, and the second intracellular domain.
- the lymphoproliferative elements provided herein include one or more, or ah of the binding domains, including those disclosed herein, responsible for signaling found in the corresponding lymphoproliferative element in nature.
- the lymphoproliferative elements provided herein include one or more JAK binding domains.
- the JAK- binding domain is, or is derived from, EPOR, GP130, PRLR, GHR, GCSFR, or TPOR/MPL. JAK- binding domains from these proteins are known in the art and a skilled artisan will understand how to use them.
- residues 273-338 of EpoR and residues 478-582 of TpoR are known to be JAK- binding domains.
- conserveed motifs that are found in intracellular domains of cytokine receptors that are responsible for this signaling are known and are present in certain illustrative lymphoproliferative elements provided herein (see e.g., Morris et al., “The molecular details of cytokine signaling via the JAK/STAT pathway,” Protein Science (2018) 27:1984-2009).
- the Boxl and Box2 motifs are involved in binding to JAKs and signal transduction, although the Box2 motif presence is not always required for a proliferative signal (Murakami et al. Proc Natl Acad Sci U S A. 1991 Dec 15; 88(24): 11349-53;
- a lymphoproliferative element herein is a transgenic Boxl -containing cytokine receptor that includes an intracellular domain of a cytokine receptor comprising a Boxl Janus kinase (JAK)-binding motif, optionally a Box2 JAK-binding motif, and a Signal Transducer and Activator of Transcription (STAT) binding motif comprising a tyrosine residue.
- a cytokine receptor comprising a Boxl Janus kinase (JAK)-binding motif, optionally a Box2 JAK-binding motif, and a Signal Transducer and Activator of Transcription (STAT) binding motif comprising a tyrosine residue.
- JAK Boxl Janus kinase
- STAT Signal Transducer and Activator of Transcription
- a lymphoproliferative element includes two or more JAK-binding motifs, for example three or more or four or more JAK-binding motifs, which in illustrative are the binding motifs found in natural versions of the corresponding lymphoproliferative element.
- Intracellular domains from IFNAR1, IFNGR1, IFNLR1, IL2RB, IL4R, IL5RB, IL6R, IL6ST, IL7RA, IL9R, IL10RA, IL21R, IL27R, IL31RA, LIFR, and OSMR are known in the art to activate JAK1 signaling and thus comprise a JAK1 binding motif.
- Intracellular domains from CRLF2, CSF2RA, CSF2RB, CSF3R, EPOR, GHR, IFNGR2, IL3RA, IL5RA, IL6ST, IL20RA, IL20RB, IL23R, IL27R, LEPR, MPL, and PRLR are known in the art to activate JAK2 and thus comprise a JAK2 binding motif.
- Intracellular domains from IL2RG are known in the art to activate JAK3 and thus comprise a JAK3 binding motif.
- Intracellular domains from GHR, IFNAR1, IFNAR2, IFNGR1, IFNGR2, IL2RB, IL2RG, IL4R, IL5RA, IL5RB, IL7RA, IL9R, IL21R, IL22RA1, IL31RA, LIFR, MPL, and OSMR are known in the art to activate STAT1.
- Intracellular domains from IFNAR1 and IFNAR2 are known in the art to activate STAT2.
- Intracellular domains from GHR, IL2RB, IL2RG, IL6R, IL7RA, IL9R, IL10RA, IL10RB, IL21R, IL22RA1, IL23R, IL27R, IL31RA, LEPR, LIFR, MPL, and OSMR are known in the art to activate STAT3.
- Intracellular domains from IL12RB1 are known in the art to activate STAT4.
- Intracellular domains from CSF2RA, CSF2RB, CSF3R, EPOR, GHR, IL2RB, IL2RG, IL3RA, IL4R, IL5RA, IL5RB, IL7RA, IL9R, IL15RA, IL20RA, IL20RB, IL21R, IL22RA1, IL31RA, LIFR, MPL, OSMR, and PRLR are known in the art to activate STAT5.
- Intracellular domains from IL4R and OSMR are known in the art to activate STAT6.
- a lymphoproliferative element herein can include one or more intracellular signaling domains that include one or more Boxl motifs.
- the one or more intracellular signaling domains that include one or more Boxl motifs can be IL7RA (Boxl motif at residues 9-17 of SEQ ID NOs:248 and 249), IL12RB ((Boxl motifs at residues 10-12 of SEQ ID NOs:254 and 255; and residues 107-110 and 139-142 of SEQ ID NO:256), IL31RA (Boxl motifs at residues 12-15 of SEQ ID NOs:275 and 276), CSF2RB (Boxl motif at residues 14-22 of SEQ ID NO:213), IL2RB (Boxl motif at residues 13-21 of SEQ ID NO:240), IL6ST (Boxl motif at residues 10- 18 of SEQ ID NO:247), IL2RG (Boxl motif at residues 3-11 of SEQ ID NO:241), IL27RA (Boxl motif at residues 17-25 of SEQ ID NO:273), MPL (Boxl motif at residues 17-20 of SEQ ID NO:283),
- a lymphoproliferative element herein can include one or more intracellular signaling domains that include one or more Box2 motifs.
- the one or more intracellular signaling domains that include one or more Box2 motifs can be MPL (Box2 motif at residues 46-64 in SEQ ID NO:283), IFNAR2 (Boxl motif at residues 37-46 of SEQ ID NO:227), CSF3R, or EPOR (Box2 motif at residues 303-313 of full-length EPOR).
- EPOR also contains an extended Box2 motif (residues 329-372 of full-length EPOR) important for binding tyrosine kinase receptor KIT, which, in some embodiments, a lymphoproliferative element can include.
- CSF3R also contains a Box3 motif, which, in some embodiments, a lymphoproliferative element can include.
- the Boxl motif-containing lymphoproliferative element has a switch motif, which in illustrative embodiments has one or more, and preferably ah hydrophobic residues at positions -1, -2, and -6 relative to the Boxl motif.
- the Boxl motif an ICD of a lymphoproliferative element is located proximal to the transmembrane (TM) domain (for example between 5 and 15 or about 10 residues downstream from the TM domain) relative to the Box2 motif, which is located proximal to the transmembrane domain (for example between 10 and 50 residues downstream from the TM domain) relative to the STAT binding motif.
- the STAT binding motif typically comprising a tyrosine residue, the phosphorylation of which affects binding of a STAT to the STAT binding motif of the lymphoproliferative element.
- the ICDs comprising multiple STAT binding motifs where multiple STAT binding motifs are present in a native ICD (e.g., EPO receptor and IL-6 receptor signaling chain (gpl30).
- the switch motif containing intracellular signaling domain can be MPL (switch motif at residues 11, 15, and 16 of SEQ ID NO:283).
- a lymphoproliferative element herein can include one or more intracellular signaling domains that include one or more phosphorylatable residues, for example, a phosphorylatable serine, threonine, or tyrosine.
- the one or more intracellular signaling domains that include one or more phosphorylatable residues can be IL31RA (phosphorylatable tyrosines at residues Y96, Y237, and Y165 of SEQ ID NO:275; not present in SEQ ID NO:276), CD27 (phosphorylatable serine at residue S6 of SEQ ID NO:205), CSF2RB (phosphorylatable tyrosine at residue Y306 of SEQ ID NO:213), IL6ST (phosphorylatable serines at residues S20, S26, S 141 , S148, S188, and S198 of SEQ ID NO:247), MPL (phosphorylatable tyrosines at residues Y8, Y29, Y78, Y113, and Y118 of SEQ ID NO: 283), CD79B (phosphorylatable tyrosines at residues Y16 and Y27 of SEQ ID NO: 211), OSMR (phosphorylatable serines at residues
- a lymphoproliferative element that includes a CSF3R intracellular domain can include one, two, three, or ah of the tyrosine residues corresponding to Y704, Y729, Y744, and Y764 of full-length CSF3R, various combinations of which have been shown to be important for binding Stat3, SOCS3, Grb2, and p21Ras.
- a lymphoproliferative element herein can include one or more intracellular signaling domains that has one or more of its phosphorylatable residues mutated to a phosphomimetic residue, for example, aspartic acid or glutamic acid.
- a lymphoproliferative element herein can include one or more intracellular signaling domains that has one or more of its phosphorylatable tyrosines mutated to a non-phosphorylatable residue, for example, alanine, valine, or phenylalanine.
- a lymphoproliferative element that includes a CSF3R intracellular domain can include one or more mutations corresponding to T615A and T618I of full-length CSF3R, which have been shown to increase receptor dimerization and activity.
- a lymphoproliferative element herein can include one or more intracellular signaling domains that include one or more ubiquitination targeting motif residues.
- the one or more intracellular signaling domains that include one or more ubiquitination targeting motif residues can be MPL (residues at K40 and K60 of SEQ ID NO:283) or 0X40 (residues at K17 and K41 of SEQ ID NO:296).
- an intracellular domain including ubiquitination targeting motif residues can have one or more of the lysines mutated to arginine or another amino acid.
- a lymphoproliferative element herein can include one or more intracellular signaling domains that include one or more TRAF binding sites.
- TRAF1, TRAF2, and TRAF3 binding sites include the amino acid sequence PXQXT (SEQ ID NO:303), where each X can be any amino acid, a distinct TRAF2 binding site includes the consensus sequence SXXE (SEQ ID NO:304) where each X can be any amino acid, and a TRAF6 binding site includes the consensus sequence QXPXEX (SEQ ID NO:305).
- the one or more intracellular signaling domains that include one or more TRAF binding sites can be CD40 (binding sites for TRAF1, TRAF2, and TRAF3 at residues 35-39 of SEQ ID NO:208; TRAF2 binding site at residues 57-60 of SEQ ID NO:208; TRAF6 binding site at residues 16-21 of SEQ ID NO:208), or 0X40 (TRAF1, TRAF2,
- TRAF3, and TRAF5 binding motif at residues 20-27 of SEQ ID NO:296) are amino acids 20-27 of SEQ ID NO:296).
- a lymphoproliferative element herein can include one or more intracellular signaling domains that include a TIR domain.
- the one or more intracellular signaling domains that include a TIR domains can be IL17RE (TIR domain at residues 13-136 of SEQ ID NO:265), IL18R1 (TIR domain at residues 28-170 of SEQ ID NO:266), or MyD88 (TIR domain at residues 160-304 of SEQ ID NO:284).
- a lymphoproliferative element herein can include one or more intracellular signaling domains that include a PI3K binding motif domain.
- the one or more intracellular signaling domains that include a PI3K binding motif can be CD28 (PI3K binding motifs at residues 12-15 of SEQ ID NOs:206 and 207, which also binds Grb2), ICOS (PI3K binding motif at residues 19-22 of SEQ ID NO:225, which can be mutated F21Q to increase IL-2 production and/or to bind Grb2), 0X40 (p85 PI3K binding motif at residues 34-57 of full-length 0X40)
- a lymphoproliferative element herein can include one or more intracellular signaling domains that include a dileucine motif.
- the one or more intracellular signaling domains that include a dileucine motif can be IFNGR2 (dileucine motif at residues 8-9 of SEQ ID NO:230) or CD3G (dileucine motif at residues 131-132 of full-length CD3G).
- one or both of the residues in the dileucine motif can be mutated.
- a lymphoproliferative element herein can include one or more intracellular signaling domains that include one or more N-terminal death domains.
- the one or more intracellular signaling domains that include one or more N-terminal death domains can be MyD88 (N-terminal death domain at residues 29-106 of SEQ ID NO:284) or a TNFR.
- TNFRs TNF receptors
- TNFRSF4 TNF receptors
- TNFRSF8 TNF receptor-associated factors
- DD death domain
- the domains, motifs, and point mutations of TNFRs that induce proliferation and/or survival of T cells and/or NK cells are known in the art and a skilled artisan can identify corresponding domains, motifs, and point mutations in TNFR polypeptides.
- a lymphoproliferative element that includes a TNFR intracellular domain can include one or more TRAF-binding motifs.
- a lymphoproliferative element that includes a TNFR intracellular domain does not include a DD-binding motif, or has one or more DD-binding motifs deleted or mutated within the intracellular domain.
- a lymphoproliferative element that includes a TNFR intracellular domain can recruit TRADD and/or TRAF2.
- TNFRs also include cysteine -rich domains (CRDs) that are important for ligand binding (Locksley RM et al. Cell. 2001 Feb 23;104(4):487-501).
- CRDs cysteine -rich domains
- a lymphoproliferative element that includes a TNFR intracellular domain does not include a TNFR CRD.
- a lymphoproliferative element herein can include one or more intracellular signaling domains that include one or more intermediate domains that interact with IL-1R associated kinase.
- the one or more intracellular signaling domains that include one or more intermediate domains can be MyD88 (intermediate domain at residues 107-156 of SEQ ID NO:284),
- a lymphoproliferative element that includes an intracellular domain from IL7RA can include one or more of the S region or T region (S region at residues 359-394 and T region at residues Y401, Y449, and Y456 of full-length IL7RA).
- the lymphoproliferative element comprises a second intracellular domain from a receptor other than IL7RA.
- the second intracellular domain is derived from TNFRSF8.
- the second intracellular domain is derived from IL2R .
- the second intracellular domain is derived from IL12R ⁇ 2.
- the transmembrane domain is derived from EpoR, GP130, PrlR, GF1R, GCSFR, or TPOR/MPL.
- the transmembrane domain is derived from EpoR, GP130, PrlR, GF1R, GCSFR, or TPOR/MPL. In some embodiments of lymphoproliferative elements that comprise an intracellular domain from IL12bb2, the transmembrane domain is derived from EpoR, GP130, PrlR, GF1R, GCSFR, or TPOR/MPL. In some embodiments of lymphoproliferative elements that comprise an intracellular domain from IL2Rb, IL7RA, or IL2Rb, the transmembrane domain comprises amino acids 478-582 of the naturally occurring TPOR/MPL.
- the second intracellular domain can be other than an intracellular domain derived from MyD88, a CD28 family member (e.g., CD28, ICOS), Pattern Recognition Receptor, a C- reactive protein receptor (i.e., Nodi, Nod2, PtX3-R), a TNF receptor, CD40, RANK/TRANCE-R, 0X40, 4-1BB), an F1SP receptor (Lox-1 and CD91), or CD28.
- a CD28 family member e.g., CD28, ICOS
- Pattern Recognition Receptor e.e., a C- reactive protein receptor (i.e., Nodi, Nod2, PtX3-R), a TNF receptor, CD40, RANK/TRANCE-R, 0X40, 4-1BB), an F1SP receptor (Lox-1 and CD91), or CD28.
- Pattern Recognition Receptors include, but are not limited to endocytic pattern-recognition receptors (i.e., mannose receptors, scavenger receptors (i.e., Mac- 1, LRP, peptidoglycan, teichoic acids, toxins, CD1 1 c/CR4)); external signal pattern-recognition receptors (Toll-like receptors (TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10), peptidoglycan recognition protein, (PGRPs bind bacterial peptidoglycan, and CD 14); internal signal pattern-recognition receptors (i.e., NOD-receptors 1 & 2), and RIG1.
- endocytic pattern-recognition receptors i.e., mannose receptors, scavenger receptors (i.e., Mac- 1, LRP, peptidoglycan, teichoic acids,
- a lymphoproliferative element that includes an intracellular domain from MyD88 can include one or more of the mutations L93P, R193C, and L265P in full-length MyD88 (mutations L93P, R196C, and L260P of SEQ ID NO:284).
- the second intracellular domain can be derived from TNFRSF4 or TNFRSF8.
- the second intracellular domain can be other than an intracellular domain derived from a CD28 family member (e.g., CD28, ICOS), Pattern Recognition Receptor, a C-reactive protein receptor, a TNF receptor, or an HSP receptor.
- a CD28 family member e.g., CD28, ICOS
- Pattern Recognition Receptor e.g., a C-reactive protein receptor, a TNF receptor, or an HSP receptor.
- a cell expressing the lymphoproliferative element comprising an intracellular and transmembrane domain of MPF can be contacted with or exposed to eltrombopag, or a patient or subject to which such a cell has been infused can be treated with eltrombopag.
- eltrombopag binds to the transmembrane domain of MPF and induces the activation of the intracellular domain of MPF.
- a MPF intracellular signaling domain does not comprise the region comprising amino acids 70-95 in SEQ ID NO:283.
- Fee et al. found clinically relevant mutations in the transmembrane domain of MPF should activate MPF with the following order of activating effects: W515K (corresponding to the amino acid substitution W2K of SEQ ID NO: 283) > S505A (corresponding to the amino acid substitution S14A of SEQ ID NO:187) > W515I (corresponding to the amino acid substitution W2I of SEQ ID NO: 283) > S505N (corresponding to the amino acid substitution S14N of SEQ ID NO:187, which was tested as part T075 (SEQ ID NO:188)) (Fee et.
- the intracellular portion of MPL can include one or more, or all the domains and motifs described herein that are present in SEQ ID NO: 283.
- a transmembrane portion of MPL can include one or more, or all the domains and motifs described herein that are present in SEQ ID NO: 187.
- the second intracellular domain can be derived from CD79B.
- the first intracellular domain can be derived from CSF3R.
- a lymphoproliferative element that includes an PRLR intracellular domain can include the growth hormone receptor binding domain of PRLR and any known mutations (growth hormone receptor binding domain at residues 28-104 of SEQ ID NO:295).
- a lymphoproliferative element that includes an ICOS intracellular domain can include a calcium-signaling motif (calcium-signaling motif at residues 5-8 of SEQ ID NO:225). In some embodiments, a lymphoproliferative element that includes an ICOS intracellular domain can include at least one of a first and second conserved motif (first and second conserved motifs at residues 9- 18 and 24-30, respectively, of SEQ ID NO:225). In some embodiments, a lymphoproliferative element that includes an ICOS intracellular domain does not include at least one of the first and second conserved motif.
- EPOR also contains a short segment important for EPOR internalization (residues 267-276 of full-length EPOR).
- a lymphoproliferative element that includes an EPOR intracellular domain does not include the internalization segment.
- domains, motifs, and point mutations of intracellular signaling domains that induce proliferation and/or survival of T cells and/or NK cells are known in the art and a skilled artisan can identify corresponding domains, motifs, and point mutations in polypeptides, some of which are above, and a skilled artisan can identify corresponding domains, motifs, and point mutations in other polypeptides. A skilled artisan will be able to identify these domains, motifs, and point mutations in similar polypeptides using, for example, sequence alignments to known binding motifs.
- a lymphoproliferative element herein can include any, for example, one or more up to all of the domains, motifs, and mutations of an intracellular signaling domain disclosed herein or otherwise known to induce proliferation and/or survival of T cells and/or NK cells.
- the LE provides, is capable of providing and/or possesses the property of (or a cell modified, genetically modified, and/or transduced with the LE is capable of providing, is adapted for, possesses the property of, and/or is modified for) driving T cell expansion in vivo.
- the lymphoproliferative element can include any of the sequences listed in Table 1 (SEQ ID NOs: 84-302).
- Table 1 shows the parts, names (including gene names), and amino acid sequences for domains that were tested in CLEs.
- CLEs can include in certain illustrative embodiments, an extracellular domain (ECD) (denoted PI), a transmembrane (TM) domain (denoted P2), a first intracellular domain (ICD) (denoted P3), and a second ICD (denoted P4).
- ECD extracellular domain
- TM transmembrane
- ICD intracellular domain
- P4 second ICD
- CLEs provided herein can be heterodimeric CLEs comprised of two different LE or CLE polypeptides that each comprise a TM domain and an ICD and, in illustrative embodiments, an ECD, wherein the TM or ECD of each LE polypeptide of the heterodimer comprises a dimerizing motif that can bind to the other (i.e., complementary dimerizing motifs).
- the ICD of one polypeptide is any of the first ICDs called out herein and the ICD of the other polypeptide of the homodimer is any of the second ICDs called out herein.
- the ICD of one polypeptide is one of the P3 ICDs in Table 1, and the ICD of the other polypeptide of the heterodimer comprises a corresponding P4 ICD of Table 1.
- retroviruses encoding such heterodimeric CLEs can be directly administered to a subject.
- retroviruses encoding such heterodimeric CLEs can comprise membrane-bound cytokines.
- the lymphoproliferative element includes a first intracellular domain.
- the first intracellular domain can include any of the parts listed as S036 to S0216 or in Table 1, or functional mutants and/or fragments thereof.
- the lymphoproliferative element can include a second intracellular domain.
- the second intracellular domain can include any of the parts listed as S036 to S0216 or in Table 1, or functional mutants and/or fragments thereof.
- the lymphoproliferative element can include an extracellular domain.
- the extracellular domain can include any of the sequences of parts listed as M001 to M049 or E006 to E015 in Table 1, or functional mutants and/or fragments thereof.
- the lymphoproliferative element can include a transmembrane domain.
- the transmembrane domain can include any of the parts listed as M001 to M049 or T001 to T082 in Table 1, or functional mutants and/or fragments thereof.
- the lymphoproliferative element can be a fusion of an extracellular/transmembrane domain (M001 to M049 in Table 1), a first intracellular domain (S036 to S0216 in Table 1), and a second intracellular domain (S036 to S216 in Table 1).
- the lymphoproliferative element can be a fusion of an extracellular domain (E006 to E016 in Table 1), a transmembrane domain (T001 to T082 in Table 1), a first intracellular domain (S036 to S0216 in Table 1), and a second intracellular domain (S036 to S0216 in Table 1).
- the lymphoproliferative element can be a fusion of E006, T001, S036, and S216, also written as E006-T001-S036-S216).
- the lymphoproliferative element can be the fusion E010-T072-S192-S212, E007-T054-S197-S212, E006-T006-S194-S211, E009- T073-S062-S053, E008-T001-S121-S212, E006-T044-S186-S053, or E006-T016-S186-S050.
- the intracellular domain of an LE is other than a functional intracellular activating domain from an ITAM-containing intracellular domain, for example, an intracellular domain from CD3Z, CD3D, CD3E, CD3G, CD79A, CD79B, DAP12, FCER1G, FCGR2A, FCGR2C, DAP10/CD28, or ZAP70, and in a further illustrative subembodiment, CD3z.
- the extracellular domain of an LE does not comprise a single-chain variable fragment (scFv).
- the extracellular domain of an LE that upon binding to a binding partner activates an LE does not comprise a single -chain variable fragment (scFv).
- a CLE does not comprise both an ASTR and an activation domain from CD3Z, CD3D, CD3E, CD3G, CD79A, CD79B, DAP12, FCER1G, FCGR2A, FCGR2C, DAP10/CD28, or ZAP70. If an LE does include an ASTR (and not an activation domain in the previous list), the ASTR of an LE in illustrative embodiments does not include an scFv. In some embodiments, a lymphoproliferative element does not include an extracellular domain.
- the lymphoproliferative element, and in illustrative embodiments CLE is not covalently attached to a cytokine.
- a lymphoproliferative element, and in illustrative embodiments CLE comprises a cytokine polypeptide covalently linked to its cognate receptor.
- the CLE can be constitutively active and typically constitutively activates the same Jak/STAT and/or TRAF pathways as the corresponding activated wild-type cytokine receptor.
- the chimeric cytokine receptor is an interleukin.
- the CLE is IL-7 covalently linked to IL7RA or IL-15 covalently linked to IL15RA. In other embodiments, the CLE is other than IL-15 covalently linked to IL15RA. In other aspects, the CLE comprises a cytokine polypeptide covalently linked to only a portion of its cognate receptor that includes a functional portion of the extracellular domain capable of binding the cytokine polypeptide, the transmembrane domain and/or intracellular domain are from heterologous polypeptides, and the CLE is constitutively active. In one embodiment, the CLE is IL-7 covalently linked to the extracellular and transmembrane domains of IL7RA, and the intracellular domain from IL2RB.
- the CLE is a cytokine polypeptide covalently linked to a portion of its cognate receptor that includes a functional portion of the extracellular domain capable of binding the cytokine polypeptide, a heterologous transmembrane domain, and lymphoproliferative element intracellular domain provided herein.
- the lymphoproliferative element is a cytokine receptor that is not tethered to a cytokine. [0398] In some aspects, the lymphoproliferative element is capable of binding to soluble cytokines or growth factors and such binding is required for activity.
- the lymphoproliferative element is constitutively active, and thus does not require binding to a soluble growth factor or cytokine for activity. Typically, constitutively active lymphoproliferative elements do not bind soluble cytokines or growth factors.
- the lymphoproliferative element is a chimera comprising an extracellular binding domain from one receptor and the intracellular signaling domain from a different receptor.
- the CLE is an inverted receptor that is activated upon binding of a ligand that would inhibit proliferation and/or survival when bound to its natural receptor, but instead leads to proliferation and/or survival upon activating the CLE.
- inverted receptors include chimeras that comprise an extracellular ligand binding domain from IL4Ra and an intracellular domain from IL7Ra or IL21.
- Other embodiments of inverted cytokine receptors include chimeras that comprise an extracellular ligand binding domain from a receptor that would inhibit proliferation and/or survival when bound to its natural ligand, such as receptors for IL-4, IL-10, IL-13, or TGFb, and any lymphoproliferative element intracellular domain disclosed herein.
- the lymphoproliferative element does not bind a cytokine. In further illustrative aspects, the lymphoproliferative element does not bind any ligand.
- the lymphoproliferative elements that do not bind any ligand are constitutively dimerized or otherwise multimerized and are constitutively active.
- the intracellular domain can be derived from an intracellular portion of the transmembrane protein of the TNF receptor family, CD40.
- the domains, motifs, and point mutations of CD40 that induce proliferation and/or survival of T cells and/or NK cells are known in the art and a skilled artisan can identify corresponding domains, motifs, and point mutations in CD40 polypeptides, some of which are discussed in this paragraph.
- the CD40 protein contains several binding sites for TRAF proteins. Not to be limited by theory, binding sites for TRAF1, TRAF2, and TRAF3 are located at the membrane distal domain of the intracellular portion of CD40 and include the amino acid sequence PXQXT (SEQ ID NO:303) where each X can be any amino acid, (corresponding to amino acids 35-39 of SEQ ID NO:208) (Elgueta et al. Immunol Rev. 2009 May;
- TRAF2 has also been shown to bind to the consensus sequence SXXE (SEQ ID NO:304) where each X can be any amino acid, (corresponding to amino acids 57-60 of SEQ ID NO:208) (Elgueta et al. Immunol Rev. 2009 May; 229(1): 152-72).
- SXXE consensus sequence
- a distinct binding site for TRAF6 is situated at the membrane proximal domain of intracellular portion of CD40 and includes the consensus sequence QXPXEX (SEQ ID NO:305) where each X can be any amino acid (corresponding to amino acids 16-21 of SEQ ID NO:208) (Lu et al. J Biol Chem. 2003 Nov 14; 278(46):45414-8).
- the intracellular portion of the transmembrane protein CD40 can include all the binding sites for the TRAF proteins.
- the TRAF binding sites are known in the art and a skilled artisan will be able to identify corresponding TRAF binding sites in similar CD40 polypeptides.
- a suitable intracellular domain can include a domain with at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a stretch of at least 10, 15, 20, or all of the amino acids in SEQ ID NO:208 or SEQ ID NO:209.
- the intracellular domain derived from CD40 has a length of from about 30 amino acids (aa) to about 35 aa, from about 35 aa to about 40 aa, from about 40 aa to about 45 aa, from about 45 aa to about 50 aa, from about 50 aa to about 55 aa, from about 55 aa to about 60 aa, or from about 60 aa to about 65 aa.
- the intracellular domain derived from CD40 has a length of from about 30 aa to about 66 aa, for example, 30 aa to 65 aa, or 50 aa to 66 aa.
- the second intracellular domain can be other than an intracellular domain derived from MyD88, a CD28 family member (e.g., CD28, ICOS), Pattern Recognition Receptor, a C-reactive protein receptor (i.e., Nodi, Nod2, PtX3-R), a TNF receptor, CD40, RANK/TRANCE-R, 0X40, 4-1BB), an HSP receptor (Lox-1 and CD91), or CD28.
- a CD28 family member e.g., CD28, ICOS
- Pattern Recognition Receptor e., a C-reactive protein receptor (i.e., Nodi, Nod2, PtX3-R), a TNF receptor, CD40, RANK/TRANCE-R, 0X40, 4-1BB), an HSP receptor (Lox-1 and CD91), or CD28.
- one intracellular domain of a CLE herein is the intracellular domain from CD40, or a functional fragment thereof, and another intracellular domain of the CLE is the intracellular domain of MPL, or a functional fragment thereof.
- Pattern Recognition Receptors include, but are not limited to endocytic pattern-recognition receptors (i.e., mannose receptors, scavenger receptors (i.e., Mac-1, LRP, peptidoglycan, teichoic acids, toxins, CD1 1 c/CR4)); external signal pattern-recognition receptors (Toll like receptors (TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10), peptidoglycan recognition protein, (PGRPs bind bacterial peptidoglycan, and CD 14); internal signal pattern-recognition receptors (i.e., NOD-receptors 1 & 2), and RIG1.
- the intracellular domain can be derived from a portion of the transmembrane protein MPL.
- the lymphoproliferative element comprises MPL, or is MPL, or a variant and/or fragment thereof, including a variant and/or fragment that includes at least 75, 80, 85, 90, 95, 96, 97, 98, 99, or 100% of the intracellular domain of MPL, with or without a transmembrane and/or extracellular domain of MPL, wherein the variant and/or fragment retains the ability to promote cell proliferation of PBMCs, and in some embodiments T cells.
- a cell expressing the lymphoproliferative element comprising an intracellular and transmembrane domain of MPL can be contacted with, exposed to, or treated with eltrombopag.
- eltrombopag binds to the transmembrane domain of MPL and induces the activation of the intracellular domain of MPL.
- the domains, motifs, and point mutations of MPL that induce proliferation and/or survival of T cells and/or NK cells are known in the art and a skilled artisan can identify corresponding domains, motifs, and point mutations in MPL polypeptides, some of which are discussed in this paragraph.
- the transmembrane MPL protein contains the Boxl motif PXXP (SEQ ID NO:306) where each X can be any amino acid (corresponding to amino acids 17-20 in SEQ ID NO:283) and the Box2 motif, a region with increased serine and glutamic acid content (corresponding to amino acids 46-64 in SEQ ID NO:283) (Drachman and Kaushansky. Proc Natl Acad Sci U S A. 1997 Mar 18; 94(6):2350-5).
- the Boxl and Box2 motifs are involved in binding to JAKs and signal transduction, although the Box2 motif presence is not always required for a proliferative signal (Murakami et al. Proc Natl Acad Sci U S A.
- cytokine receptors have hydrophobic residues at positions -1, -2, and -6 relative to the Boxl motif (corresponding to amino acids 16, 15, and 11, respectively, of SEQ ID NO:283), that form a “switch motif,” which is required for cytokine-induced JAK2 activation but not for JAK2 binding (Constantinescu et al. Mol Cell. 2001 Feb; 7(2):377-85; and Huang et al. Mol Cell.
- a MPL intracellular signaling domain does not comprise the region comprising amino acids 70-95 in SEQ ID NO:283.
- the lysines K553 corresponding to K40 of SEQ ID NO: 283
- K573 corresponding to K60 of SEQ ID NO: 283
- a MPL intracellular signaling domain does not comprise these ubiquitination targeting motif residues.
- the tyrosines Y521 (corresponding to Y8 of SEQ ID NO: 283), Y542 (corresponding to Y29 of SEQ ID NO:283), Y591 (corresponding to Y78 of SEQ ID NO: 283), Y626 (corresponding to Y113 of SEQ ID NO: 283), and Y631 (corresponding to Y118 of SEQ ID NO: 283) have been shown to be phosphorylated (Varghese et al. Front Endocrinol (Lausanne). 2017 Mar 31; 8:59).
- Y521 and Y591 of full-length MPL are negative regulatory sites that function either as part of a lysosomal targeting motif (Y521) or via an interaction with adaptor protein AP2 (Y591) (Drachman and Kaushansky. Proc Natl Acad Sci U S A. 1997 Mar 18; 94(6):2350-5; and Hitchcock et al. Blood. 2008 Sep 15; 112(6):2222-31).
- Y626 and Y631 of full-length MPL are positive regulatory sites (Drachman and Kaushansky. Proc Natl Acad Sci U S A.
- MPL contains the She phosphotyrosine-binding binding motif NXXY (SEQ ID NO:307) where each X can be any amino acid (corresponding to amino acids 110-113 of SEQ ID NO: 283), and this tyrosine is phosphorylated and important for the TPO- dependent phosphorylation of She, SHIP, and STAT3 (Laminet et al. J Biol Chem. 1996 Jan 5; 271(l):264-9; and van der Geer et al. Proc Natl Acad Sci U S A. 1996 Feb 6; 93(3):963-8).
- MPL also contains the STAT3 consensus binding sequence YXXQ (SEQ ID NO:308) where each X can be any amino acid (corresponding to amino acids 118-121 of SEQ ID NO: 283) (Stahl et al. Science. 1995 Mar 3; 267(5202): 1349-53).
- the tyrosine of this sequence can be phosphorylated and MPL is capable of partial STAT3 recruitment (Drachman and Kaushansky. Proc Natl Acad Sci U S A. 1997 Mar 18; 94(6):2350-5).
- MPL also contains the sequence YLPL (SEQ ID NO: 309) (corresponding to amino acid 113-116 of SEQ ID NO: 283), which is similar to the consensus binding site for STAT5 recruitment pYLXL (SEQ ID NOG 10) where pY is phosphotyrosine and X can be any amino acid (March et al. FEBS Lett. 1996 Sep 30; 394(2):221-6). Using computer simulations, Lee et al.
- the MPL ICD comprises domains that bind, either directly or indirectly, and induce tyrosine phosphorylation of itself, She, SHIP, JAK2, TYK2, STAT3, STAT5, and other proteins that comprise SH2-binding and/or phosphotyrosine- binding domains. Binding to MPL of these proteins causes the phosphorylation and formation of the Shc- Grb2-SOS adaptor protein complex, activation of phosphatases SHIP and SHPTP-2 and stimulation of both the phosphoinositide3 kinase (PI3K)/AKT and Raf- 1/MAP kinase pathways.
- PI3K phosphoinositide3 kinase
- the intracellular portion of MPL can include one or more, or all the domains and motifs described herein that are present in SEQ ID NO 283. These include but are not limited to the MPL domains responsible for binding to the proteins and/or activation of the pathways indicated herein in this paragraph, this LE section, and this specification, in illustrative embodiments that promote proliferation and/or survival.
- a transmembrane portion of MPL can include one or more, or all the domains and motifs described herein that are present in SEQ ID NO: 187.
- MPL intracellular signaling domains herein in illustrative embodiments would include one or more corresponding domains, motifs, and point mutations in that have been shown to promote proliferative activity and would not include that that have been shown to inhibit MPLs proliferative activity. Any or all of these domains, motifs, and point mutations of MPL can be present in an intracellular signaling domain can be included in any of the aspects and embodiments disclosed herein.
- a suitable intracellular domain can include a domain with at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a stretch of at least 10, 15, 20, or all of the amino acids in SEQ ID NO:283.
- the intracellular domain derived from MPL has a length of from about 30 aa to about 35 aa, from about 35 aa to about 40 aa, from about 40 aa to about 45 aa, from about 45 aa to about 50 aa, from about 50 aa to about 55 aa, from about 55 aa to about 60 aa, from about 60 aa to about 65 aa, from about 65 aa to about 70 aa, from about 70 aa to about 100 aa, from about 100 aa to about 125 aa, from about 125 aa to 150 aa, from about 150 to about 175 aa, from about 175 aa to about 200 aa, from about 200 aa to about 250 aa, from about 250 aa to 300 aa, from about 300 aa to 350 aa, from about 350 aa to about 400 aa, from about 400 aa to about 450 aa, from about
- the intracellular domain derived from MPL has a length of from about 30 aa to about 200 aa, for example, 30 aa to 150 aa, 30 aa to 119 aa, 30 aa to 121 aa, 30 aa to 122 aa, or 50 aa to 125 aa.
- the second intracellular domain can be derived from CD79B.
- Lymphoproliferative elements and CLEs that can be included in any of the aspects disclosed herein, can be any of the LEs or CLEs disclosed in WO2019/055946.
- CLEs were disclosed therein that promoted proliferation in cell culture of PBMCs that were transduced with lentiviral particles encoding the CLEs between day 7 and day 21, 28, 35 and/or 42 after transduction.
- Lurthermore CLEs were identified therein, that promoted proliferation in vivo in mice in the presence or absence of an antigen recognized by a CAR, wherein T cells expressing one of the CLEs and the CAR were introduced into the mice.
- tests and/or criteria can be used to identify whether any test polypeptide, including LEs, or test domains of an LE, such as a first intracellular domain, or a second intracellular domain, or both a first and second intracellular domain, are indeed LEs or effective intracellular domains of LEs, or especially effective LEs or intracellular domains of LEs.
- any aspect or other embodiment provided herein that includes an LE or a polynucleotide or nucleic acid encoding an LE can recite that the LE meets, or provides the property of, or is capable of providing and/or possesses the property of, any one or more of the identified tests or criteria for identifying an LE provided herein, or that a cell genetically modified, transduced, and/or stably transfected with a recombinant nucleic acid vector, such as a cell that is transduced with a lentiviral particle encoding the LE, is capable of providing, is adapted for, possesses the property of, and/or is modified for achieving the results of one or more of the recited tests.
- the LE provides, is capable of providing and/or possesses the property of, (or a cell genetically modified and/or transduced with a retroviral particle encoding the LE is capable of providing, is adapted for, possesses the property of, and/or is modified for) improved expansion to pre-activated PBMCs transduced with a lentivirus comprising a nucleic acid encoding the LE and an anti-CD 19 CAR comprising a CD3 zeta intracellular activating domain but no co-stimulatory domain, between day 7 and day 21, 28, 35, and/or 42 of in vitro culturing post-transduction in the absence of exogenously added cytokines, compared to a control retroviral particle, e.g., lentiviral particle under identical conditions.
- a control retroviral particle e.g., lentiviral particle under identical conditions.
- a lymphoproliferative element test for improved or enhanced survival, expansion, and/or proliferation of cells transduced with a retroviral particle e.g., lentiviral particle
- a retroviral particle e.g., lentiviral particle
- test cells can be, for example, either untransduced cells or cells transduced with a control retroviral (e.g., lentiviral) particle identical to the lentiviral particle comprising the nucleic acid encoding the lymphoproliferative element, but lacking the lymphoproliferative element, or lacking the intracellular domain or domains of the test polypeptide construct but comprising the same extracellular domain, if present, and the same transmembrane region or membrane targeting region of the respective test polypeptide construct.
- lentiviral particle e.g., lentiviral particle having a genome encoding a test construct encoding a putative LE (test cells)
- control cells which can be, for example, either untransduced cells or cells trans
- control cells are transduced with a retroviral particle (e.g., lentiviral particle) having a genome encoding a lymphoproliferative element or intracellular domain(s) thereof, identified herein as exemplifying a lymphoproliferative element.
- the test criteria can include that there is at least as much enrichment, survival and/or expansion, or no statistical difference of enrichment, survival, and/or expansion when the test is performed using a retroviral particle (e.g., lentiviral particle) having a genome encoding a test construct versus encoding the control lymphoproliferative element, typically by analyzing cells transcribed therewith.
- exemplary or illustrative embodiments of lymphoproliferative elements herein, in some embodiments are illustrative embodiments of control lymphoproliferative elements for such a test.
- this test for an improved property of a putative or test lymphoproliferative element is performed by performing replicates and/or performing a statistical test.
- a skilled artisan will recognize that many statistical tests can be used for such a lymphoproliferative element test.
- the statistical test can be a T-test or a Mann-Whitney-Wilcoxon test.
- the normalized enrichment level of a test construct is significant at a p-value of less than 0.1 , or less than 0.05, or less than 0.01.
- the LE provides, is capable of providing and/or possesses the property of (or a cell genetically modified and/or transduced with the LE is capable of providing, is adapted for, possesses the property of, and/or is modified for) at least a 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold expansion, or between 1.5 fold and 25-fold expansion, or between 2-fold and 20-fold expansion, or between 2-fold and 15-fold expansion, or between 5-fold and 25-fold expansion, or between 5-fold and 20-fold expansion, or between 5-fold and 15-fold expansion, of pre activated PBMCs transduced with a nucleic acid encoding the LE when transduced along with an anti- CD 19 CAR comprising a CD3 zeta intracellular activating domain but no co-stimulatory domain, between day 7 and day 21, 28, 35, and/or 42 of in vitro culturing in the absence of exogenously added cyto
- the test is performed in the presence of PBMCs, for example at a 1:1 ratio of transduced cells to PBMCs, which can be for example, from a matched donor, and in some embodiments, the test is performed in the absence of PBMCs.
- the analysis of expansion for any of these tests is performed as illustrated in WO2019/055946.
- the test can include a further statistical test and a cut-off such as a P value below 0.1, 0.05, or 0.01, wherein a test polypeptide or nucleic acid encoding the same, needs to meet one or both thresholds (i.e., fold expansion and statistical cutoff).
- the number of test cells and the number of control cells can be compared between day 7 and day 14, 21, 28, 35, 42 or 60 post transduction.
- the numbers of test and control cells can be determined by sequencing DNA and counting the occurrences of unique identifiers present in each construct.
- the numbers of test and control cells can be counted directly, for example with a hemocytometer or a cell counter.
- all the test cells and control cells can be grown within the same vessel, well or flask.
- test cells can be seeded in one or more wells, flasks or vessels, and the control cells can be seeded in one or more flasks or vessels.
- test and control cells can be seeded individually into wells or flasks, e.g., one cell per well.
- the numbers of test cells and control cells can be compared using enrichment levels.
- the enrichment level for a test or control construct can be calculated by dividing the number of cells at a later time point (day 14, 21, 28, 35, or day 45) by the number of cells at day 7 for each construct.
- the enrichment level for a test or control construct can be calculated by dividing the number of cells at a time point (day 14, 21, 28, 35, or day 45) by the number of cells at that time point for untransduced cells.
- the enrichment level of each test construct can be normalized to the enrichment level of the respective control construct to generate a normalized enrichment level.
- a LE encoded in the test construct provides (or a cell genetically modified and/or transduced with a retroviral particle (e.g., lentiviral particle) having a genome encoding the LE is capable of providing, is adapted for, possesses the property of, and/or is modified for) at least a 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold normalized enrichment level, or between 1.5 fold and 25-fold normalized enrichment level, or between 3-fold and 20- fold normalized enrichment level, or between 5-fold and 25-fold normalized enrichment level, or between 5-fold and 20-fold normalized enrichment level, or between 5-fold and 15-fold normalized enrichment level.
- a retroviral particle e.g., lentiviral particle
- Enrichment can be measured, for example, by direct cell counting. Cutoff values can be based on a single test, or two, three, four, or five repeats, or based on many repeats. The cutoff can be met when a lymphoproliferative element meets one or more repeat tests, or meets or exceeds a cutoff for all repeats.
- the enrichment is measured as log2((normalized count data on the test day + l)/(normalized count data on day 7 + 1)).
- test constructs were identified as CLEs because the CLEs induced proliferation/expansion in these fed or unfed cultures without added cytokines such as IL-2 between days 7 and day 21, 28, 35, and/or 42.
- effective CLEs were identified by identifying test CLEs that provided increased expansion of these in vitro cultures, whether fed or unfed with untransduced PBMCs, between day 7 and day 21, 28, 35, and/or 42 post-transduction, compared to control constructs that did not include any intracellular domains.
- WO2019/055946 discloses that at least one and typically more than one test CLE that included an intracellular domain from a test gene provided more expansion than every control construct that was present at day 7 post-transduction, that did not include an intracellular domain.
- WO2019/055946 further provides a statistical method that was used to identify exceptionally effective genes with respect to a first intracellular domain, and one or more exemplary intracellular domain(s) from these genes. The method used a Mann-Whitney-Wilcoxon test and a false discovery cutoff rate of less than 0.1 or less than 0.05.
- WO2019/055946 identified especially effective genes for the first intracellular domain or the second intracellular domain, for example, by analyzing scores for genes calculated as combined score for all constructs with that gene. Such analysis can use a cutoff of greater than 1 , or greater than negative control constructs without any intracellular domains, or greater than 2, as shown for some of the tests disclosed in WO2019/055946.
- the LE provides, is capable of providing and/or possesses the property of (or a cell genetically modified and/or transduced with the LE is capable of providing, is adapted for, possesses the property of, and/or is modified for) driving T cell expansion in vivo.
- the in vivo test can utilize a mouse model and measure T cell expansion at 15 to 25 days in vivo, or at 19 to 21 days in vivo, or at approximately 21 days in vivo, after T cells are contacted with lentiviral vectors encoding the LEs, are introduced into the mice, as disclosed in WO2019/055946, [0407]
- a LE which typically include a CAR, such as methods provided herein for modifying, genetically modifying and/or transducing cells, and uses thereof
- the genetically modified cell is modified so as to possess new properties not previously possessed by the cell before genetic modification and/or transduction.
- Such a property can be provided by genetic modification with a nucleic acid encoding a CAR or a LE, and in illustrative embodiments both a CAR and a LE.
- the genetically modified and/or transduced cell is capable of, is adapted for, possesses the property of, and/or is modified for survival and/or proliferation in ex vivo culture for at least 7, 14, 21, 28, 35, 42, or 60 days or from between day 7 and day 14, 21, 28, 35, 42 or 60 post-transduction, in the absence of added IL-2 or in the absence of added cytokines such as IL-2, IL-15, or IL-7, and in certain illustrative embodiments, in the presence of the antigen recognized by the CAR where the method comprises modifying using a retroviral particle having a pseudotyping element and optionally a separate or fused activation domain on its surface and typically does not require pre activation.
- the genetically modified and/or transduced cell exhibits, is capable of, is adapted for, possesses the property of, and/or is modified for improved survival or expansion in ex vivo or in vitro culture in culture media in the absence of one or more added cytokines such as IL-2, IL-15, or IL-7, or added lymphocyte mitogenic agent, compared to a control cell(s) identical to the genetically modified and/or transduced cell(s) before it was genetically modified and/or transduced or to a control cell that was transduced with a retroviral particle identical to an on-test retroviral particle that comprises an LE or a putative LE, but without the LE or the intracellular domains of the LE, wherein said survival or proliferation of said control cell(s) is promoted by adding said one or more cytokines, such as IL-2, IL-15, or IL-7, or said lymphocyte mitogenic agent to the culture media.
- cytokines such as IL-2, IL-15, or IL-7
- cytokine or lymphocyte mitogenic agent By added cytokine or lymphocyte mitogenic agent, it is meant that cytokine or lymphocyte mitogenic agent is added from an exogenous source to a culture media such that the concentration of said cytokine or lymphocyte mitogenic agent is increased in the culture media during culturing of the cell(s) compared to the initial culture media, and in some embodiments can be absent from the initial culture media before said adding.
- added or exogenously added it is meant that such cytokine or lymphocyte mitogenic agent is added to a lymphocyte media used to culture the modified, genetically modified, and/or transduced cell after the modifying, where the culture media may or may not already possess the cytokine or lymphocyte mitogenic agent.
- All or a portion of the media that includes a mixture of multiple media components is typically stored and in illustrative embodiments has been shipped to a site where the culturing takes place, without the exogenously added cytokine(s) or lymphocyte mitogenic agent(s).
- the lymphocyte media in some embodiments is purchased from a supplier, and a user such as a technician not employed by the supplier and not located within a supplier facility, adds the exogenously added cytokine or lymphocyte mitogenic agent to the lymphocyte media and then the genetically modified and/or transduced cells are cultured in the presence or absence of such exogenously added cytokine or lymphocyte mitogenic agent.
- improved or enhanced survival, expansion, and/or proliferation can be shown as an increase in the number of cells determined by sequencing DNA from cells transduced with retroviral particle (e.g., lentiviral particle) having a genome encoding CLEs and counting the occurrences of sequences present in unique identifiers from each CLE.
- retroviral particle e.g., lentiviral particle
- improved survival and/or improved expansion can be determined by counting the cells directly, for example with a hemocy tome ter or a cell counter, at each time point.
- improved survival and/or improved expansion and/or enrichment can be calculated by dividing the number of cells at the later time point (day 21, 28, 35, and/or day 45) by the number of cells at day 7 for each construct.
- the cells can be counted by hemocy tome ter or cell counters.
- the enrichment level determined using the nucleic acid counts or the cell counts of each specific test construct can be normalized to the enrichment level of the respective control construct, i.e., the construct with the same extracellular domain and transmembrane domain but lacking the intracellular domains present in the test construct.
- the LE encoded in the construct provides (or a cell genetically modified and/or transduced with a retroviral particle (e.g., lentiviral particle) having a genome encoding the LE is capable of providing, is adapted for, possesses the property of, and/or is modified for) at least a 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold normalized enrichment level, or between 1.5 fold and 25-fold normalized enrichment level, or between 3-fold and 20-fold normalized enrichment level, or between 5-fold and 25-fold normalized enrichment level, or between 5- fold and 20-fold normalized enrichment level, or between 5-fold and 15-fold normalized enrichment level.
- a retroviral particle e.g., lentiviral particle
- the lymphoproliferative element can include a cytokine receptor or a fragment that includes a signaling domain thereof.
- the cytokine receptor can be CD27, CD40, CRLF2, CSF2RA, CSF2RB, CSF3R, EPOR, GHR, IFNAR1, IFNAR2, IFNGR1, IFNGR2, IFNLR1, IL1R1, IL1RAP, IL1RL1, IL1RL2, IL2R, IL2RA, IL2RB, IL2RG, IL3RA, IL4R, IL5RA, IL6R, IL6ST, IL7R, IL7RA, IL9R, IL10RA, IL10RB, IL11RA, IL12RB1, IL13R, IL13RA1, IL13RA2, IL15R, IL15RA, IL17RA, IL17RB, IL17RC, IL17RE, IL18R1,
- a lymphoproliferative element comprises an intracellular activating domain as disclosed hereinabove.
- a lymphoproliferative element is a CLE comprising an intracellular activating domain comprising an ITAM-containing domain, as such, the CLE can comprise an intracellular activating domain having at least 80%, 90%, 95%, 98%, or 100% sequence identity to the CD3Z, CD3D, CD3E, CD3G, CD79A, CD79B, DAP12, FCER1G, FCGR2A, FCGR2C, DAP10/CD28, or ZAP70 domains provided herein wherein the CLE does not comprise an ASTR.
- one or more domains of a lymphoproliferative element is fused to a modulatory domain, such as a co-stimulatory domain, and/or an intracellular activating domain of a CAR.
- a modulatory domain such as a co-stimulatory domain
- an intracellular activating domain of a CAR can be part of the same polypeptide as a CAR or can be fused and optionally functionally connected to some components of CARs.
- an engineered signaling polypeptide can include an ASTR, an intracellular activation domain (such as a CD3 zeta signaling domain), a co-stimulatory domain, and a lymphoproliferative domain. Further details regarding co-stimulatory domains, intracellular activating domains, ASTRs and other CAR domains, are disclosed elsewhere herein.
- Lymphoproliferative elements typically include a transmembrane domain.
- the transmembrane domain can have 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% sequence identity to any one of the transmembrane domains from the following genes and representative sequences disclosed in WO2019/055946: CD 8 beta, CD4, CD3 zeta, CD28, CD134, CD7, CD2, CD3D, CD3E, CD3G, CD3Z, CD4, CD8A CD8B, CD27, CD28, CD40, CD79A, CD79B, CRLF2, CRLF2, CSF2RA, CSF2RB, CSF2RB, CSF3R, EPOR, FCER1G, FCGR2C, FCGRA2, GHR, ICOS, IFNAR, IFNAR1, IFNAR2, IFNGR1, IFNGR2, IFNLR1, IL1R1, IL1RAP, IL1RL1, IL1RL2,
- Transmembrane (TM) domains suitable for use in any engineered signaling polypeptide include, but are not limited to, constitutively active cytokine receptors, the TM domain from LMP1, and TM domains from type 1 TM proteins comprising a dimerizing motif, as discussed in more detail herein.
- the transmembrane domain can be a Type I growth factor receptor, a hormone receptor, a T cell receptor, or a TNF-family receptor.
- CLEs include both an extracellular portion and a transmembrane portion that is from the same protein, in illustrative embodiments the same receptor, either of which in illustrative embodiments is a mutant, thus forming an extracellular and transmembrane domain.
- These domains can be from a cytokine receptor, or a mutant thereof, or a hormone receptor, or a mutant thereof in some embodiments that have been reported to be constitutively active when expressed at least in some cell types.
- such extracellular and transmembrane domains do not include a ligand binding region.
- a mutation in at least some extracellular - transmembrane domains of CLEs provided herein are responsible for signaling of the CLE in the absence of ligand, by bringing activating chains together that are not normally together, or by changing the confirmation of a linked transmembrane and/or intracellular domain.
- Exemplary extracellular and transmembrane domains for CLEs of embodiments that include such domains are extracellular regions, typically less than 30 amino acids of the membrane -proximal extracellular domains along with transmembrane domains from mutant receptors that have been reported to be constitutive, that is not require ligand binding for activation of an associated intracellular domain.
- extracellular and transmembrane domains include IL7RA Ins PPCL, CRLF2 F232C, CSF2RB V449E, CSF3R T640N, EPOR L251C I252C, GHR E260C I270C, IL27RA F523C, and MPL S505N.
- the extracellular and transmembrane domain does not comprise more than 10, 20, 25 30 or 50 consecutive amino acids that are identical in sequence to a portion of the extracellular and/or transmembrane domain of IL7RA, or a mutant thereof.
- the extracellular and transmembrane domain is other than IL7RA Ins PPCL.
- the extracellular and transmembrane does not comprise more than 10, 20, 25, 30, or 50 consecutive amino acids that are identical in sequence to a portion of the extracellular and/or transmembrane domain of IL15R.
- the transmembrane domain is a type I transmembrane protein
- the transmembrane domain can be a Type I growth factor receptor, a hormone receptor, a T cell receptor, or a TNF-family receptor.
- the chimeric polypeptide comprises an extracellular domain and wherein the extracellular domain comprises a dimerizing motif
- the transmembrane domain can be a Type I cytokine receptor, a hormone receptor, a T cell receptor, or a TNF-family receptor.
- the extracellular and transmembrane domain is the viral protein LMP1, or a mutant and/or fragment thereof.
- LMP1 is a multispan transmembrane protein that is known to activate cell signaling independent of ligand when targeted to lipid rafts or when fused to CD40 (Kaykas et al. EMBO J. 20: 2641 (2001)).
- a fragment of LMP1 is typically long enough to span a plasma membrane and to activate a linked intracellular domain(s).
- the LMP1 can be between 15 and 386, 15 and 200, 15 and 150, 15 and 100, 18 and 50, 18 and 30, 20 and 200, 20 and 150, 20 and 50, 20 and 30, 20 and 100, 20 and 40, or 20 and 25 amino acids.
- the extracellular domain includes at least 1 , but typically at least 4 amino acids and is typically linked to another functional polypeptide, such as a clearance domain, for example, an eTag.
- the lymphoproliferative element comprises an LMP1 transmembrane domain.
- the lymphoproliferative element comprises an LMP1 transmembrane domain and the one or more intracellular domains do not comprise an intracellular domain from TNFRSF proteins (i.e. CD40, 4- IBB, RANK, TACI, 0X40, CD27, GITR, FTR, and BAFFR), TFR1 to TFR13, integrins, FcyRIII, Dectinl, Dectin2, NODI, NOD2, CD 16, IF-2R, Type I II interferon receptor, chemokine receptors such as CCR5 and CCR7, G-protein coupled receptors, TREM1, CD79A, CD79B, Ig-alpha, IPS-1, MyD88, RIG- 1, MDA5, CD3Z, MyD88ATIR, TRIF, TRAM, TIRAP, MAE, BTK, RTK, RAC1, SYK, NAFP3 (NFRP3), NAFP3AFRR, NAFP1, CARD9, DAI
- TNFRSF proteins
- the extracellular domain includes a dimerizing moiety.
- dimerizing moieties disclosed herein can be used for these embodiments.
- the dimerizing moieties are capable of homodimerizing.
- dimerizing moieties can provide an activating function on intracellular domains connected thereto via transmembrane domains.
- an EE polypeptide such as a CLE polypeptide, comprises a first lymphoproliferative element polypeptide (“LE polypeptide”) and a second LE polypeptide, wherein the first LE polypeptide has a different amino acid sequence from the second LE polypeptide and the first LE polypeptide and the second LE polypeptide are capable of, adapted to, and/or are configured to dimerize with each other.
- L polypeptide lymphoproliferative element polypeptide
- second LE polypeptide a different amino acid sequence from the second LE polypeptide and the first LE polypeptide and the second LE polypeptide are capable of, adapted to, and/or are configured to dimerize with each other.
- heterodimeric LEs Such embodiments can be referred to herein as heterodimeric LEs.
- first LE polypeptide and the second LE polypeptide comprise a first extracellular dimerizing moiety and a second extracellular dimerizing moiety, respectively, that are capable of, adapted to, and/or configured to dimerize with each other.
- first LE polypeptide and the second LE polypeptide comprise a first intracellular dimerizing moiety and a second intracellular dimerizing moiety, respectively, that are capable of, adapted to, and/or configured to dimerize with each other.
- dimerization between the first LE polypeptide and the second LE polypeptide activates an intracellular signaling domain of the first and/or second LE polypeptide, or activates an intracellular signaling domain that is formed by an interaction, for example a binding between the first LE polypeptide and the second LE polypeptide.
- embodiments herein that include one or more LEs include embodiments that include a first LE polypeptide and a second LE polypeptide, wherein the first LE polypeptide and the second LE polypeptide are capable of, adapted to, and/or configured to form heterodimers and to activate a signaling pathway upon dimerization, typically promoting proliferation and/or cell survival.
- the ICDs of heterodimeric LEs can include any of the ICDs herein.
- Heterodimeric LEs can be constitutively active, but in illustrative embodiments they are inducible.
- the first LE polypeptide and the second LE polypeptide can be transcribed from a single polynucleotide or from separate polynucleotides.
- first LE polypeptide and the second LE polypeptide are encoded on the same polynucleotide and are separated by an IRES. In some embodiments, the first LE polypeptide and the second LE polypeptide are encoded on the same polynucleotide and are separated by a cleavage signal or ribosomal skip sequence such as P2A or T2A.
- the first LE polypeptide and the second LE polypeptide can be expressed from a single transcript or from separate transcripts.
- the ICD pair of a heterodimeric LE is a pair of ICDs that are activated upon dimerization in a cell in nature that has not been genetically modified.
- at least one domain of at least one of the first LE polypeptide and/or the second LE polypeptide is chimeric.
- the heterodimeric LE comprises a first LE polypeptide and a second LE polypeptide comprising intracellular signaling domains derived from the following pairs of genes: IL2R and IL2R ⁇ ; IL7RA and IL2R ⁇ ; IL7RA and IL2R ; LIFR and GP130, CSF2RA and TNFRSF4; CSF2RA and CD28; CSF2RA and TNFRSF8; CSF2RA and CD27; CSFR3 and CD79B; IFNAR2 and TNFRSF14; IL1RAP and CD79A; IL3RA and CD40; IL10RA and CD79B; IL11RA and FCGRA2; IL13RA2 and TNFRSF14; IL18RAP and CD3G; IL27RA and FCGRA2; LEPR and CD3G; LIFR and TNFRSF18; MPL and CD40; MPL
- a first LE polypeptide and a second LE polypeptide of a heterodimeric LE can include an FK506-binding protein (FKBP), an FKBP-rapamycin binding (FRB) domain, and variants thereof that are well known in the art.
- FKBP FK506-binding protein
- FKBP-rapamycin binding domain FK506-binding protein
- variants thereof that are well known in the art.
- ECDs of the first LE polypeptide and the second LE polypeptide comprise such FKBP, FRBs, or variants thereof.
- the ICDs of the first LE polypeptide and the second LE polypeptide comprise such FKbP, FRBs, or variants thereof.
- Such heterodimeric LEs can be activated by rapamycin or a rapalog, which can be administered to a subject who has been administered CAR-T cells or a viral vector encoding such an LE, in exemplary methods provided herein.
- the dimerizing moiety of a CLE can comprise an epitope recognized by an antibody, such as, for example, a clinical antibody, which in illustrative embodiments can be an approved biologic.
- an ECD of an LE herein can include an ECD that includes one or multiple tandem copies of a PD-1 epitope and/or a CTLA-4 epitope.
- an anti-PD-1 antibody and/or an anti-CTLA-4 antibody respectively for example a clinical anti-PD-1 antibody or a clinical anti- CTLA-4 antibody, can be used to dimerize and activate such an LE.
- such embodiments might provide an advantage for anti-PD-1 administration in both blocking interactions of PD-1 for example expressed on CAR-T cells, with PDL-1 expressed on tumor cells, and driving proliferation and/or survival signal in the CAR-T cells through dimerization of a homodimeric or a heterodimeric LE.
- an anti-PDl antibody for example, nivolumab or pembrolizumab
- the ECD can be referred to herein as the ectodomain.
- the ectodomain can comprise a PD-1 polypeptide, such as any of the polypeptides of Table
- the dimerizing moiety of a CLE can comprise an anti-idiotype extracellular recognition domain of any of the anti-idiotype polypeptides herein.
- anti-idiotype polypeptides containing an anti-idiotype extracellular domain can be CLEs.
- the extracellular recognition domain attached to such a CLE can dimerize upon binding of the target antibody or antibody mimetic, as disclosed elsewhere herein.
- the CLE is part of a fusion polypeptide including an anti-idiotype polypeptide, and the fusion polypeptide is dimeri ed through binding of the target antibody or antibody mimetic to the anti-idiotype extracellular recognition domain.
- the CLE is not constitutively active, but rather is activated upon dimerization induced by binding of a target antibody to 2 anti-idiotype polypeptides that bind the idiotype of the target antibody.
- the target antibody typically does not induce cytotoxicity.
- a lymphoproliferative element provided herein comprises an extracellular domain, and in illustrative embodiments, the extracellular domain comprises a dimerizing motif.
- the extracellular domain comprises a leucine zipper.
- the leucine zipper is from a jun polypeptide, for example c-jun.
- the c-jun polypeptide is the c-jun polypeptide region of ECD-11.
- An extracellular domain with a dimerizing moiety can also serve a function of connecting a cell tag polypeptide, such as an anti-idiotype extracellular recognition domain of an anti-idiotype polypeptide to a cell expressing a CLE.
- the dimerizing motif can serve the function of a stalk connecting an anti-idiotype extracellular recognition domain to a membrane association domain, which in LEs and CLEs is typically a transmembrane domain.
- Such embodiments provide an advantage of having a transmembrane domain and dimerization motif that anchor an anti idiotype domain to a cell, while retaining their function in an LE.
- such embodiments provide the advantage of providing for tetramerization of an intracellular domain by constitutive dimerization through an LE dimerization motif and inducible dimerization, which would form tetramers, upon binding of a target antibody that has the idiotype recognized by the anti-idiotype extracellular recognition domain.
- the target antibody typically does not induce cytotoxicity but rather serves to tetramerize dimerized ICDs.
- the dimerizing agent can be located intracellularly rather than extracellularly. In some embodiments, more than one or multiples of dimerizing domains can be used. In any aspects or embodiments wherein the extracellular domain of a CLE comprises a dimerizing motif, the dimerizing motif can be selected from the group consisting of: a leucine zipper motif-containing polypeptide, CD69, CD71, CD72, CD96, Cdl05, Cdl61, Cdl62, Cd249, CD271, and Cd324, as well as mutants and/or active fragments thereof that retain the ability to dimerize.
- a leucine zipper motif-containing polypeptide CD69, CD71, CD72, CD96, Cdl05, Cdl61, Cdl62, Cd249, CD271, and Cd324, as well as mutants and/or active fragments thereof that retain the ability to dimerize.
- the dimerizing motif can require a dimerizing agent, and the dimerizing motif and associated dimerizing agent can be selected from the group consisting of: FKBP and rapamycin or analogs thereof (e.g., AP1903), GyrB and coumermycin or analogs thereof, DHFR and methotrexate or analogs thereof, or DmrB and AP20187 or analogs thereof, as well as mutants and/or active fragments of the recited dimerizing proteins that retain the ability to dimerize.
- a lymphoproliferative element is constitutively active, and is other than a lymphoproliferative element that requires a dimerizing agent for activation.
- Internally dimerizing and/or multimerizing lymphoproliferative elements in one embodiment are an integral part of a system that uses a dimeric analog of the lipid permeable immunosuppressant drug, FK506, which loses its normal bioactivity while gaining the ability to crosslink molecules genetically fused to the FK506-binding protein, FKBP12.
- FKBPs which can be considered FKB-binding polypeptide domains
- a membrane targeting sequence such as a myristoylation sequence or transmembrane domain to the cytoplasmic signaling domain of a target receptor, one can stimulate signaling in a dimerizer drug-dependent, but ligand and ectodomain-in dependent manner.
- FKBP 12 third- generation AP20187/AP1903 dimerizer drugs for their binding domain, FKBP 12 permits specific activation of the recombinant receptor in vivo without the induction of non-specific side effects through endogenous FKBP12.
- the synthetic ligands are resistant to protease degradation, making them more efficient at activating receptors in vivo than most delivered protein agents.
- Extracellular domains for embodiments where extracellular domains have a dimerizing motif are long enough to form dimers, such as leucine zipper dimers.
- extracellular domains that include a dimerizing moiety can be from 15 to 100, 20 to 50, 30 to 45, or 35 to 40 amino acids, of in illustrative embodiments is a c-Jun portion of a c-Jun extracellular domain.
- Extracellular domains of polypeptides that include a dimerizing moiety may not retain other functionalities.
- leucine zippers embodiments such leucine zippers are capable of forming dimers because they retain a motif of leucines spaced 7 residues apart along an alpha helix.
- leucine zipper moieties of certain embodiments of CLEs provided herein may or may not retain their DNA binding function.
- a spacer of between 1 and 4 alanine residues can be included in CLEs between the extracellular domain that has a dimerizing moiety, and the transmembrane domain. Not to be limited by theory, it is believed that the alanine spacer affects signaling of intracellular domains connected to the leucine zipper extracellular region via the transmembrane domain, by changing the orientation of the intracellular domains.
- CLEs include a cell tag domain. Details regarding cell tags are provided in other sections herein. Any of the cell tags provided herein can be part of a CLE. Typically, the cell tag is linked to the N terminus of the extracellular domain. Not to be limited by theory, in some embodiments, the extracellular domain includes the function of providing a linker, in illustrative embodiments a flexible linker, linking a cell tag domain to a cell that expresses the CLE.
- polynucleotides that include a nucleic acid sequence encoding a CLE provided herein also typically comprise a signal sequence to direct expression to the plasma membrane.
- Exemplary signal sequences are provided herein in other sections. Elements can be provided on the transcript such that both a CAR and CLE are expressed from the same transcript in certain embodiments.
- anti-idiotype polypeptides and polynucleotides encoding these polypeptides are especially useful in modified cells, for example for use in cell and gene therapy.
- Anti-idiotype polypeptides expressed on the surface of cells can recognize target antibodies or target antibody mimetics that come in contact with these cells.
- antibodies and antibody mimetics can be used to, for example, mark cells expressing the anti-idiotype polypeptides for killing by the immune system, modulate a property (such as, for example, a proliferative state or an apoptotic state) or activity of the cells, label the cells, provide a target for enrichment and/or purification, enrich the cells, or cause the cells to aggregate.
- a property such as, for example, a proliferative state or an apoptotic state
- a person skilled in the art will understand how to use the anti-idiotype polypeptides for these and other methods in view of the present disclosure.
- provided herein are methods for providing any of the above-mentioned uses, by expressing any of the polynucleotides that are disclosed herein and/or in PCT/US21/48532, that include nucleic acids encoding anti-idiotype polypeptides disclosed herein/therein.
- Anti-idiotype polypeptides herein include an extracellular recognition domain (sometimes referred to as an anti-idiotype extracellular recognition domain, anti-id ERD, or anti- id ECD) and typically include a membrane association domain (MAD), which is separated from the anti- id ECD, in illustrative embodiments, by a stalk.
- the anti-id ERD in illustrative embodiments, includes a recognition domain of an anti-idiotype antibody or anti-idiotype antibody mimetic.
- the recognition domain of an anti-idiotype polypeptide recognizes the idiotype of a target antibody or the idiotype of a target antibody mimetic.
- an anti-idiotype extracellular recognition domain includes an idiotype-binding variable region of an anti-idiotype antibody or anti-idiotype antibody mimetic.
- a stalk separates the MAD and the anti-idiotype extracellular recognition domain.
- an extracellular recognition domain recognizes the idiotype of any antibody or antibody mimetic known in the art.
- the extracellular recognition domain recognizes the idiotype of a clinical antibody or clinical antibody mimetic.
- a clinical antibody in some illustrative embodiments, is a regulatory agency (e.g., U.S. FDA) approved biologic.
- binding of the anti-idiotype polypeptide to the target antibody does not block or prevent binding between the target antibody and its cognate antigen.
- binding of the anti-idiotype polypeptide to the target antibody blocks or prevents binding between the target antibody and its cognate antigen.
- anti-idiotype polypeptides include a membrane association domain (sometimes referred to herein as a MAD).
- the membrane association domain of the anti-idiotype polypeptide attaches, tethers, or anchors the recognition domain from an anti-idiotype antibody or antibody mimetic to a cell membrane.
- the membrane association domain comprises one or more of a transmembrane domain and a GPI anchor, as further disclosed elsewhere herein.
- the transmembrane domain can be a heterologous transmembrane domain or an endogenous transmembrane domain, either of which could be the transmembrane domain of an antibody.
- anti-idiotype polypeptides provided herein further include one or more intracellular domains (sometimes referred to herein as ICD).
- the MAD of such anti-idiotype polypeptides that include ICDs in certain illustrative embodiments is a transmembrane.
- the one or more intracellular domains can activate or inhibit pro-apoptotic or anti-apoptotic pathways and/or pro-survival or anti-survival pathways, and in certain embodiments modulate other cellular processes/pathways. Details are provided throughout this specification regarding these various embodiments and other embodiments wherein an anti-idiotype polypeptide herein, includes an ICD.
- the ICD serves a structural role to assure the anti-id ERD is stably expressed on and remains bound to the cell membrane.
- an ICD can have functional properties that are regulated by binding dimerization or multimerization that is induced by binding of the anti-id ERD by its target antibody or antibody mimetic.
- the anti-id ERD acts as an inducible extracellular dimerizing domain of an LE herein.
- dimerization of an LE by binding of a target antibody to the anti-id ERD can activate signaling domains in the ICD, driving proliferation and/or cell survival.
- the ICD of an LE can include P3 and optionally P4 domains, as disclosed herein with respect to LE ICDs.
- the intracellular domains can activate one or more of a Jak/Stat pathway, a TRAF pathway, a PI3K pathway, or a PLC pathway. Disclosure related to mechanisms for activating these pathways is provided in the “Lymphoproliferative section” herein. Illustrative examples of these embodiments are inducible chimeric lymphoproliferative elements, which are inducible upon binding of a target antibody to an extracellular domain that recognizes the idiotype of a target antibody.
- the anti-id ERD acts as the ASTR of a CAR or TCR.
- the CAR or TCR includes the anti-id ERD, a stalk attaching the ERD to a transmembrane domain, and an ICD of a CAR or TCR.
- binding of a target antibody to the anti-id ERD can activate signaling domains in the ICD of the CAR or TCR.
- the intracellular domain is pro-apoptotic, and can include one or more intracellular signaling domains from a caspase protein and/or one or more intracellular signaling domains from tumor necrosis factor receptor superfamily members.
- Such embodiments are specific examples of safety switches provided herein.
- Such embodiments can include an anti-idiotype polypeptide wherein the ICD includes a death domain.
- Such ICDs can include all or in certain illustrative embodiments, include a portion of an ICD from a TNF receptor superfamily member, that includes a death domain, such as FAS.
- Illustrative embodiments of such an ant-idiotype polypeptide includes a constitutive dimerization domain in the extracellular domain, that can be all or part of the stalk or transmembrane domain, thus providing such anti-idiotype polypeptide, the ability to form higher order multimers, such as tetramers.
- ICDs for these embodiments can include death domains, or other functional domains from initiator caspases, such as for example, caspases 2, 8, 9, and 10.
- the anti-id ERD acts as one of the ASTRs of a bi-specific CAR or TCR, wherein a second ASTR is present that typically binds to an antigen expressed by a cancer cell.
- a second ASTR is present that typically binds to an antigen expressed by a cancer cell.
- the CAR or TCR includes the anti-id ERD, a second ASTR, a stalk attaching the anti-id ERD and the 2 nd ASTR to a transmembrane domain, and an ICD of a CAR or TCR. Accordingly, binding of a target antibody to the anti-id ERD or binding of the 2 nd ASTR to its antigen, can activate signaling domains in the ICD of the CAR or TCR.
- anti-idiotype polypeptides herein that includes an ICD
- a cleavage site typically that is activated by dimerization, is added to the anti-idiotype polypeptide between or as part of the transmembrane domain and the ICD.
- these anti-idiotype polypeptides include a transmembrane domain that includes an amino acid sequence that serves as a substrate cleavage site upon dimerization, by certain proteases.
- Such cleavage site can be, in certain embodiments, a substrate cleavage site for gamma-secretase complex, as discussed in more detail herein.
- the intracellular domain for such embodiments can encode various intracellular polypeptides including certain caspases, including initiator caspases, for example caspases 2, 8, 9, and 10.
- the ICD is a transcription factor.
- the transcription factor is sequestered outside the nucleus until binding of the anti-id ERD by its target antibody inducing dimerization and cleavage, which releases the transcription factor such that it can enter the nucleus to become active in regulating gene expression.
- polynucleotides that include nucleic acids that encode anti idiotype polypeptides, which can be referred to herein as anti-idiotype polynucleotides.
- the encoded anti-idiotype polypeptide includes an anti-idiotype extracellular recognition domain (“Anti-idiotype”), a stalk, and a membrane association domain (MAD).
- Anti-idiotype an anti-idiotype extracellular recognition domain
- MAD membrane association domain
- Nucleic acids that encode an anti-idiotype polypeptide in some embodiments, encode a membrane association domain (MAD) and an anti-idiotype extracellular recognition domain.
- nucleic acids encoding a stalk separate and are in frame with nucleic acids encoding the MAD and nucleic acids encoding the anti idiotype extracellular recognition domain.
- polynucleotides that encode additional functionalities expressed from the same promoter (i.e., on the same transcription unit) or from different promoters (i.e. different transcriptional units).
- polynucleotides that include nucleic acids that encode an anti-idiotype extracellular recognition domain can include nucleic acids that encode, in addition to an anti-idiotype extracellular recognition domain, an engineered signaling polypeptide, a cytokine, and/or an inhibitory RNA.
- a polynucleotide comprising: one or more transcriptional units, wherein each of the one or more transcriptional units is operatively linked to a promoter, wherein the one or more transcriptional units comprise: a) a polynucleotide sequence encoding one or more inhibitory RNA molecules, a first engineered signaling polypeptide, and/or a cytokine, and b) a polynucleotide sequence encoding an anti-idiotype polypeptide comprising an anti-idiotype extracellular recognition domain that recognizes an idiotype of a target antibody or a target antibody mimetic.
- such polynucleotide is in a viral vector such as a RIP.
- the RIP further comprises membrane-bound chemokines.
- viral vectors e.g., RIPs
- Polynucleotides that include nucleic acids that encode anti-idiotype polypeptides can be DNA or RNA. In some illustrative embodiments, they are rnRNA. Such embodiments can include embodiments wherein the anti-idiotype antibody is directed against the antibody that forms the ASTR of a CAR. As such, rnRNA that encode an anti-idiotype antibody can be directly delivered to a subject and when taken up and expressed by cells in the subject, such cells can form artificial antigen presenting cells that drive proliferation of CAR-T cells administered to the subject that express a CAR with an ASTR that is the target antibody recognized by the anti-idiotype polypeptide. Methods for making synthetic rnRNA are well known in the art.
- polynucleotides can be polynucleotide vectors, such as expression vectors. Further details regarding polynucleotides and polynucleotide vectors, such as RIPs, including lentiviral particles, are provided throughout this disclosure, including the claims.
- Nucleic acids encoding the anti-idiotype polypeptide can be upstream or downstream (i.e., 5’or 3’) from those encoding other functionalities.
- anti-idiotype polynucleotides are expressed as a separate polypeptide from other functional polypeptides.
- polynucleotides herein encode an anti-idiotype polypeptide and are adapted for, structured for, and/or effective for expression in T cells and/or NK cells, and thus for T cell and/or NK cell therapies or therapies that include direct delivery of viral vectors (e.g., RIPs) to a subject.
- examples of such polynucleotides typically include a promoter that is active in T cells and/or NK cells, that drives expression of the anti-idiotype extracellular recognition domain and a membrane association domain, which thus are on the same transcriptional unit whose expression is driven by the promoter.
- an anti-idiotype polypeptide is expressed as part of a single polynucleotide that also encodes a chimeric antigen receptor (CAR), an engineered T cell receptor (TCR), a lymphoproliferative element, or a cytokine.
- CAR chimeric antigen receptor
- TCR engineered T cell receptor
- a lymphoproliferative element or a cytokine.
- an anti-idiotype polypeptide is expressed as part of a single polynucleotide that encodes a CAR or a TCR, an anti-idiotype polypeptide, and a lymphoproliferative element, or a cytokine, or both a lymphoproliferative element and a cytokine.
- the polynucleotide encoding the anti-idiotype polypeptide is separated from the polynucleotide encoding the CAR, the TCR, the cytokine, and/or the polynucleotide encoding the lymphoproliferative element by an internal ribosome entry site (IRES) or a ribosomal skip sequence and/or cleavage signal.
- IRES internal ribosome entry site
- ribosomal skip and/or cleavage signal can be any IRES or ribosomal skip sequence and/or cleavage signal known in the art.
- polynucleotides referred to herein as “self-driving CARs” that encode a membrane-bound lymphoproliferative element whose expression in a T cell or NK cell is under the control of an inducible promoter that is induced by the binding of an antigen to an extracellular binding pair member polypeptide that is expressed by the T cell or NK cell and is functionally linked to a intracellular activating domain, for example a CD3 zeta intracellular activating domain or any of the intracellular activating domains disclosed elsewhere herein.
- an anti idiotype polypeptide is co-expressed by the T cell or NK cell to provide additional functional optionality for self-driving CARs.
- the co-expressed anti-idiotype polypeptide is a safety switch.
- such a binding pair member polypeptide is a CAR.
- such a binding pair member polypeptide is a TCR.
- polynucleotides that include an inducible promoter operably linked to a nucleic acid encoding a membrane-bound lymphoproliferative element, that is induced by CAR-binding to its target.
- Self-driving CAR-T cells genetically modified or transduced T cells referred to herein as “self-driving CAR-T cells” that include a self-driving CAR.
- Any of the embodiments that include a self-driving CAR-T cell could include a “self-driving CAR NK cell,” which is a genetically modified or transduced NK cell that includes a self-driving CAR.
- the self-driving CAR NK cell is present in addition to the self-driving CAR-T cell.
- the self-driving CAR NK cell is present instead of the self-driving CAR-T cell.
- Various embodiments that include a self-driving CAR are disclosed in the Exemplary Embodiments section herein and can be combined with any of the embodiments or details of this section.
- an isolated polynucleotide that includes a first sequence comprising one or more first transcriptional units operably linked to an inducible promoter inducible in at least one of a T cell or an NK cell, wherein at least one of the one or more first transcriptional units comprises a first polynucleotide sequence encoding a first polypeptide comprising a lymphoproliferative element and in illustrative embodiments, a second transcriptional unit encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen-specific targeting region (ASTR), a transmembrane domain, and an intracellular activating domain.
- ASTR antigen-specific targeting region
- the lymphoproliferative element is constitutively active in at least one of a T cell or an NK cell, and the lymphoproliferative element comprises a transmembrane domain.
- the one or more first transcriptional units of a self-driving CAR does not encode a polypeptide that comprises a signal peptide sequence comprising a signal peptidase cleavage site, or other sequence that would result in the encoded polypeptide, once expressed, being secreted or otherwise released from the T or NK cell.
- an isolated polynucleotide that includes a first sequence in a reverse orientation comprising one or more first transcriptional units operably linked to an inducible promoter inducible in at least one of a T cell or an NK cell, and further includes a second sequence in a forward orientation comprising one or more second transcriptional units operably linked to a constitutive T cell or NK cell promoter, wherein the number of nucleotides between the 5’ end of the one or more first transcriptional units and the 5’ end of the one or more second transcriptional units is less than the number of nucleotides between the 3’ end of the one or more first transcriptional units and the 3’ end of the one or more second transcriptional units, wherein at least one of the one or more first transcriptional units encodes a lymphoproliferative element, and wherein at least one of the one or more second transcriptional units encodes a chimeric antigen receptor (CAR), wherein the CAR comprises an
- the distances between the 5’ end of the one or more first transcriptional units and the 5’ or 3’ end of the one or more second transcriptional units can be measured, for example, as the number of nucleotides between the 5’ nucleotide of the one or more first transcriptional units and the 5’ or 3’ nucleotide of the one or more second transcriptional units.
- the one or more first transcriptional units and the one or more second transcriptional units are transcribed divergently, and such transcriptional units are said to be arrange divergently, i.e., in opposite directions, wherein the 3’ ends of the one or more first and one or more second transcriptional units are farther away from each other than the 5’ ends of the one or more first and one or more second transcriptional units.
- the polynucleotides or vectors containing two transcriptional units i.e., a first and second one or more transcriptional units, can be referred to herein as bicistronic polynucleotides or vectors.
- a divergent bicistronic polynucleotide may encode 2, 3, 4 or more polypeptides and/or inhibitory RNAs.
- lymphocyte(s) in illustrative embodiments genetically modified T ceh(s) and/or NK ceh(s), that have been transduced and/or genetically modified with a polynucleotide disclosed above.
- a replication incompetent recombinant retroviral particle(s) in the manufacture of a kit for genetically modifying and/or transducing a lymphocyte, in illustrative embodiments a T cell and/or NK cell of a subject, wherein the use of the kit comprises transducing and/or genetically modifying the T cell or NK cell with a polynucleotide disclosed above, in vivo or in vitro.
- kits for administering a genetically modified lymphocyte to a subject wherein the genetically modified lymphocyte is produced by transducing and/or genetically modifying lymphocytes with a polynucleotide disclosed in this Self-Driving CAR section.
- the administration of the genetically modified lymphocytes or the replication incompetent retroviral particles can be performed by intravenous injection, intraperitoneal administration, subcutaneous administration, or intramuscular administration.
- the modified lymphocytes introduced into the subject can be allogeneic lymphocytes. In such embodiments, the lymphocytes are from a different person, and the lymphocytes from the subject are not modified.
- any of the RIP formulation (such as, a delivery solution) for direct administration to a subject can include polynucleotides encoding Self-Driving CAR as disclosed herein.
- the direct administration (in vivo ) of such RIP leads to the modification of lymphocytes in vivo.
- the polynucleotide can include a constitutive T cell or NK cell promoter.
- Constitutive T cell or NK cell promoters that constitutively express a polynucleotide in a T cell or NK cell are known in the art and disclosed elsewhere herein.
- a transcriptional unit is a constitutive expression unit or construct, which in illustrative embodiments of self-driving CAR embodiments, encodes a CAR.
- a constitutive expression construct is or is part of a recombinant expression vector described herein.
- a transcriptional unit is an inducible expression unit or construct, which in illustrative embodiments of self-driving CAR embodiments, can encode a lymphoproliferative element.
- An inducible expression construct can comprise regulatory sequences, such as transcription and translation initiation and termination codons. In some embodiments, such regulatory sequences are specific to the type of cell into which the inducible promoter is to be introduced, i.e., a T cell and/or an NK cell.
- An inducible expression construct can comprise a native or non-native promoter operably linked to a nucleotide sequence of interest.
- the inducible or activatable promoter can be an NFAT-responsive, ATF2 -responsive, AP-1 responsive, or NF-KB -responsive promoter.
- Other promoters that are induced upon T cell activation and can be used as inducible promoters in embodiments herein, especially embodiments for self-driving CARs, include an IL-2, IFNg, CD25, CD40L, CD69,
- CD 107a TNF, VLA1, or LFA1 promoter, or a functional and inducible fragment of any of these promoters. As discussed herein, such inducibility can result from the presence of one or more NFAT- binding elements.
- the first sequence can be in the reverse orientation and the second sequence can be in the forward orientation.
- the orientations of the first and second sequences are relative to the 5’ to 3’ orientation established by the 5’ LTR and the 3’ LTR of the polynucleotide when present in a recombinant retroviral particle capable of genetically modifying a T cell or NK cell.
- a sequence for example a transcriptional unit, a promoter, a coding sequence, a miRNA, whose 5’ end is closer to the 5’ LTR than its 3’ end is to the 5’ LTR, is in forward orientation and a sequence whose 3’ end is closer to the 5’ LTR than its 5’ end is to the 5’ LTR, is in reverse orientation.
- the distance between either end of a sequence and the 5’ LTR is typically measured, for example, as the number of nucleotides between the 5’ or 3’ nucleotide of the sequence and the 3’ nucleotide of the 5’ LTR.
- the polynucleotide can further include a riboswitch in reverse orientation as disclosed elsewhere herein.
- the number of nucleotides between the 5’ end of the one or more first transcriptional units and the 5’ end of the one or more second transcriptional units is less than the number of nucleotides between the 3’ end of the one or more first transcriptional units and the 3’ end of the one or more second transcriptional units.
- the inducible promoter is an NFAT-responsive promoter.
- the inducible or activatable promoter can be an NFAT-responsive promoter and include one or more NFAT-binding sites.
- the one or more NFAT-binding sites can be derived from promoters known in the art to be NFAT-responsive promoters.
- the one or more NFAT-binding sites can be derived from an IL-2, IL-4, and/or IL-8 promoters.
- the one or more NFAT-binding sites can be derived from an IL-2 promoter.
- the NFAT-responsive promoter can include 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 NFAT-binding sites. In illustrative embodiments, the NFAT-responsive promoter can include 4, 6, or 9 NFAT-binding sites. In some embodiments, the NFAT-binding sites of an NFAT- responsive promoter can include functional sequence variants which retain the ability to bind NFAT, to avoid exact repeats. In some embodiments, the NFAT-responsive promoter is responsive to NFATcl, NFATc2, NFATc3, NFATc4, and/or NFATc5. In some embodiments, the NFAT-responsive promoter includes one or more NFAT-binding sites of SEQ ID NO:352.
- the spacing between copies of the NFAT-binding sites can be between 3 and 60 nucleotides or between 6 and 20 nucleotides.
- the NFAT-responsive promoter comprises 6 NFAT-binding sites and the nucleotide sequence comprises or consists of SEQ ID NO: 353 or a functional portion or functional variant thereof.
- a transcriptional unit encoding a lymphoproliferative element includes a minimal constitutive promoter with upstream NFAT-binding sites to generate an inducible or activatable promoter with a low level of transcription even in the absence of an inducing signal.
- the low level of transcription of a lymphoproliferative element from such an inducible promoter can be less than 1/2, 1/4, 1/5 1/10, 1/25, 1/50, 1/100, 1/200, 2/250, 1/500, or 1/1,000 the level of transcription of a CAR from the constitutive promoter.
- the minimal constitutive promoter can include the minimal IL-2, the minimal CMV, or minimal MF1C promoters.
- the minimal promoter can be the minimal IL-2 promoter (SEQ ID NO:354) or a functional portion or functional variant thereof.
- the NFAT-responsive promoter includes six NFAT-binding sites upstream of the minimal IL-2 promoter and the nucleotide sequence includes or consists of SEQ ID NO: 355, or a functional portion or functional variant thereof.
- the inducible and constitutive promoters in the polynucleotides disclosed above with a first sequence in reverse orientation and a second sequence in forward orientation can interfere with each other in unpredictable ways, especially in the presence of a strong constitutive promoter such as the EF1- a, CMV, and CAG promoters.
- Promoter interference can result in an increase or decrease in transcription from one or both promoters. Promoter interference can also result in a decrease in the dynamic range of an inducible promoter.
- an insulator is located between the divergent transcriptional units. In some embodiments, an insulator is located between the inducible and constitutive promoters.
- the insulator can be chicken HS4 insulator, Kaiso insulator, SAR/MAR elements, chimeric chicken insulator-SAR elements, CTCF insulator, the gypsy insulator, or the b-globin insulator or fragments thereof known in the art.
- the insulator can be b-globin polyA spacer B (SEQ ID NO:356), b-globin polyA spacer A (SEQ ID NO:357), 250 cHS4 insulator vl (SEQ ID NO:358), 250 cHS4 insulator v2 (SEQ ID NO:359), 650 cHS4 insulator (SEQ ID NO:360), 400 cHS4 insulator (SEQ ID NO:361), 650 cHS4 insulator and b-globin polyA spacer B (SEQ ID NO:362), or b- globin polyA spacer B and 650 cHS4 insulator (SEQ ID NOG).
- the insulator can be in the forward orientation. In other embodiments, the insulator can be in the reverse orientation. A skilled artisan will understand how to incorporate an insulator between promoters to prevent or reduce promoter interference.
- the polynucleotide can include a number of adenosine nucleotides, known as a polyadenylation sequence, following the 3’ end of the sequence encoding a lymphoproliferative element in the reverse orientation.
- the polyadenylation sequence can be used with an insulator. In other embodiments, the polyadenylation sequence can be used in the absence of an insulator.
- the polyadenylation sequence can be derived from the b-globin polyadenylation sequence or the hGH polyadenylation sequence. In some embodiments, the polyadenylation sequence can be synthetic. In some embodiments, the polyadenylation sequence can include one or more of the sequences selected from hGH polyA (SEQ ID NO:316), SPA1 (SEQ ID NOG 17), or SPA2 (SEQ ID NOG 18). In some embodiments, the polynucleotide does not include exogenous splice sites. In illustrative embodiments, the polynucleotide does not include exogenous splice sites in the forward or reverse orientation.
- the polynucleotide can include one or more inhibitory RNA molecules, such as for example, a miRNA or shRNA, as disclosed elsewhere herein.
- the inhibitory RNA molecules can be encoded within introns, including for example, an EFl-a intron.
- the inhibitory RNA molecules can target any of the targets identified herein, including, but not limited to the Inhibitory RNA Molecules section herein.
- the inducible promoter can drive expression of a lymphoproliferative element, as disclosed elsewhere herein.
- the lymphoproliferative element is a non-secreted and constitutively active lymphoproliferative element.
- the delivery solution or the cell formulation includes synthetic RNA.
- the synthetic RNA includes inhibitory RNAs such as siRNAs directed to one or more targets.
- the targets for these inhibitory RNAs can be any of the targets for siRNAs or miRNAs disclosed elsewhere herein.
- the synthetic RNA includes mRNA encoding for one or more proteins or peptides.
- the mRNA encodes for one or more CARs.
- the CARs may be any CAR composition disclosed herein, including bispecific CARs that include an anti idiotype extracellular recognition domain (also referred to herein as an anti-id ERD) as disclosed herein.
- the mRNA can encode any anti-idiotype polypeptide disclosed herein.
- the mRNA encodes for the target antibody to an anti-idiotype polypeptide disclosed herein.
- Such embodiment can have an advantage of providing a target antibody that can be cytotoxic when delivered in soluble form, but less or not cytotoxic when taken up by cells after in vivo administration of an mRNA encoding the target antibody.
- cells that take up and express the target antibody can become artificial antigen presenting cells for embodiments where the anti-idiotype polypeptide has an ICD that is the ICD of an LE, or of a CAR (e.g., a bi-specific CAR).
- the mRNA encodes for one or more cytokines. In some embodiments, mRNA encodes for IL-2 or a functional variant thereof. In some embodiments, the mRNA encodes for IL-7 or a functional variant thereof. In some embodiments, the mRNA encodes for IL-15 or a functional variant thereof. In some embodiments, the mRNA encodes for IL-21 or a functional variant thereof. In some embodiments, the mRNA encodes one or more proteins or polypeptides that bind and activate a CAR. In some embodiments, the mRNA encodes for an antigen recognized by the ASTR of the CAR. In some embodiments, the mRNA encodes for HER2 or an extracellular domain of HER2.
- the mRNA encodes for EGFR or an extracellular domain of EGFR. In some embodiments, the mRNA encodes for Axl or an extracellular domain of Axl. In some embodiments, the mRNA encodes for CD19 or an extracellular domain of CD19. In some embodiments, the mRNA encodes for CD22 or an extracellular domain of CD22. In some embodiments, the mRNA encodes for an antibody recognized by the ASTR of the CAR. In some embodiments, the mRNA encoding for an antibody recognized by the ASTR of the CAR is an anti-idiotype antibody directed to the antibody or scFv of the ASTR.
- the mRNA encodes for an antibody that binds an epitope tag of the CAR and can cross-link two CARs as described elsewhere herein.
- the mRNA encodes for one or more T and/or NK cell co-stimulatory proteins.
- co-stimulatory proteins may comprise one or more ligands or antibodies to a co-stimulatory receptor on T and/or NK cells.
- the co-stimulatory receptor is CD28.
- the co-stimulatory receptor is 4-1BB.
- the mRNA encodes a protein or polypeptide that is soluble.
- the mRNA encodes a protein or polypeptide that is membrane-bound.
- the membrane-bound protein or polypeptide is operatively linked to a transmembrane domain.
- the synthetic RNA includes both inhibitory RNAs such as siRNAs directed to one or more targets and mRNA encoding for one or more proteins or peptides.
- a method for generating mRNA for use in the delivery solution or cell formulation may involve in vitro transcription of a template with specially designed primers, followed by PolyA addition, to produce a construct containing 3’ and 5’ untranslated sequence, a 5’ cap and/or IRES, the nucleic acid to be expressed, and a polyA tail, typically 50-200 bases in length.
- the synthetic RNA is a naturally occurring, endogenous RNA for the nucleic acid of interest.
- the RNA is not the naturally occurring, endogenous RNA for the nucleic acid of interest.
- the RNA is modified to change the stability and/or translation efficiency of the RNA.
- the 5’ UTR, 3’UTR, Kozak sequence, polyA tail is modified.
- the RNA includes a 5’ cap.
- the RNA is encapsulated in lipid-based carrier vehicles.
- One approach for assembling lipid nanocarriers includes directly mixing of a solution of lipids in ethanol with an aqueous solution of the nucleic acid to obtain lipid nanoparticles (LNPs).
- the LNPs comprise PEG-conjugated lipid. PEG conjugated lipids prevent the aggregation during particle formation and allow the controlled manufacturing of particles with defined diameters in the range between approximately 50 nm and 150 nm.
- the LNPs do not comprise PEG.
- the LNPs comprise poly (glycerol) (PGs), poly(oxazolines), sugar- based systems, and poly (peptides).
- the polypeptides include polysarcosine (pSAR).
- the LNPs comprise a dendritic cell targeting moiety.
- the dendritic cell targeting moiety comprises mannose.
- the RNA can be added to a cell formulation comprising, or co administered with, modified and/or genetically modified T cells and/or NK cells in cell formulations and methods provided herein.
- the RNA is added to the isolated blood of a subject and processed in parallel with the T cells and/or NK cells.
- the RNA can be formulated separately from the modified and/or genetically modified T cells and/or NK cells.
- the synthetic RNA may be delivered by any means known in the art for therapeutic delivery of RNA.
- the RNA is delivered intravenously.
- the RNA is delivered intraperitoneally.
- the RNA is delivered intramuscularly.
- the RNA is delivered intratumorally. In some embodiments, the RNA is delivered intradermally. In illustrative embodiments, the RNA is delivered subcutaneously. In some embodiments, the RNA is delivered at the same site as the site of administration of the modified and/or genetically modified T cells and/or NK cells. In some embodiments, the RNA is delivered at a site adjacent to the site of administration of the modified and/or genetically modified T cells and/or NK cells. In some embodiments, the RNA is administered once. In some embodiments, the RNA is administered, 2, 3, 4, 5, 6 or more times.
- a cell formulation comprising an aggregate(s) of T cells and/or NK cells, wherein the T cells and/or NK cells in illustrative embodiments are modified with a polynucleotide comprising one or more transcriptional units, wherein each of the transcriptional units is operatively linked to a promoter active in T cells and/or NK cells, and wherein the one or more transcriptional units encode a first polypeptide comprising a chimeric antigen receptor (CAR) in a solution, in illustrative embodiments a delivery solution; and further wherein the aggregate comprises at least 4, 5, 6, or 8 T cells and/or NK cells, wherein the cell aggregate is at least 15 mM in its smallest dimension, and/or wherein the cell aggregate is retained, or capable of being retained, by a coarse filter having a diameter of at least 15 ⁇ m , or a coarse filter having a diameter of between 15 ⁇ m and 60 ⁇ m .
- CAR chimeric antigen receptor
- cell aggregates have a diameter less than 40 pm.
- at least 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% of the cell aggregates in a cell formulation have a diameter less than 40 pm.
- at least 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% of the cell aggregates in a cell formulation have a diameter less than 40 pm, and the cell formulation is administered intravenously.
- a “binding polypeptide” includes one or more polypeptides, typically glycoproteins, that identify and bind the target host cell.
- a “fusogenic polypeptide” mediates fusion of the retroviral and target host cell membranes, thereby allowing a retroviral genome to enter the target host cell.
- the binding polypeptide(s) and the fusogenic polypeptide(s) are on the same envelope protein, e.g., a heterologous glycoprotein.
- the binding polypeptide(s) and the fusogenic polypeptide(s) are on two or more different heterologous glycoproteins.
- binding and fusogenic polypeptide functions can be provided by a pseudotyping element.
- the pseudotyping element can be one or more viral envelope proteins.
- the binding polypeptide function of a viral envelope protein can be altered, reduced, or eliminated (e.g., the amino acids corresponding to the binding polypeptide function can be mutated or deleted).
- the viral envelope protein with reduced or eliminated binding polypeptide function can be retargeted with a new binding polypeptide function or by mutating the original binding polypeptide function.
- the binding polypeptide function can be provided by any polypeptide that binds to a cell surface marker on the target cell.
- the binding polypeptide function can be provided by an activation element, as disclosed elsewhere herein.
- the pseudotyping of replication incompetent recombinant retroviral particles with heterologous envelope glycoproteins typically alters the tropism of a virus and facilitates the transduction of host cells.
- pseudotyping elements are provided as polypeptide(s)/protein(s), or as nucleic acid sequences encoding the polypeptide(s)/protein(s).
- a pseudotyping element and/or a fusogenic envelope protein herein is a full-length polypeptide(s), functional fragment(s), homolog(s), or functional variant(s) of a syncytium- inducing polypeptide.
- a fusogenic envelope protein herein is a full-length polypeptide(s), functional fragment(s), homolog(s), or functional variant(s) of Human immunodeficiency virus (HIV) gpl60, Murine leukemia virus (MLV) gp70, Gibbon ape leukemia virus (GALV) gp70, Feline leukemia virus (RD114) gp70, Amphotropic retrovirus (Ampho) gp70, 10A1 MLV (10A1) gp70, Ecotropic retrovirus (Eco) gp70, Baboon ape leukemia virus (BaEV) gp70, Measles virus (MV) H and F, Nipah virus (NiV) H and F, Rabies virus (RabV) G, Mokola virus (MOKV) G, Ebola Zaire virus (EboZ) G, Lymphocytic choriomeningitis virus (LCMV) GP1 and GP2,
- the fusion glycoprotein or functional variant thereof is a full-length polypeptide, functional fragment, homolog, or functional variant of the G protein of Vesicular Stomatitis Alagoas Virus (VSAV), Carajas Vesiculovirus (CJSV), Chandipura Vesiculovirus (CHPV), Cocal Vesiculovirus (COCV), Vesicular Stomatitis Indiana Virus (VSIV), Isfahan Vesiculovirus (ISFV), Maraba Vesiculovirus (MARAV), Vesicular Stomatitis New Jersey virus (VSNJV), Bas-Congo Virus (BASV).
- the fusion glycoprotein or functional variant thereof is the Cocal virus G protein.
- a pseudotyping element and/or a fusogenic envelope protein herein is a full-length polypeptide(s), functional fragment(s), homolog(s), or functional variant(s) of type G membrane glycoprotein of rabies virus, type G membrane glycoprotein of Mokola virus, type G membrane glycoprotein of vesicular stomatitis virus, type G membrane glycoprotein of Togaviruses, murine hepatitis virus JHM surface projection protein, porcine respiratory coronavirus spike glycoprotein, porcine respiratory coronavirus membrane glycoprotein, avian infectious bronchitis spike glycoprotein and its precursor, bovine enteric coronavirus spike protein, paramyxovirus SV5 F protein, Measles virus F protein, canine distemper virus F protein, Newcastle disease virus F protein, human parainfluenza virus 3 F protein, simian virus 41 F protein, Sendai virus F protein, human respiratory syncytial vims F protein, Measles vims
- a pseudotyping element and/or a fusogenic envelope protein that can be employed include, but are not limited to, a full-length polypeptide(s), functional fragment(s), homolog(s), or functional variant(s) of: MLV envelopes, 10A1 envelope, BAEV, FeLV-B, RD114, SSAV, Ebola, Sendai, FPV (Fowl plague virus), and influenza virus envelopes.
- RNA viruses e.g., RNA virus families of Picomaviridae, Calciviridae, Astroviridae, Togaviridae, Flaviviridae, Coronaviridae, Paramyxoviridae, Rhabdoviridae, Filoviridae, Orthomyxoviridae, Bunyaviridae, Arenaviridae, Reoviridae, Bimaviridae, Retroviridae) as well as from the DNA viruses (families of Flepadnaviridae, Circoviridae, Parvoviridae, Papovaviridae, Adenoviridae, Flerpesviridae, Poxyiridae, and Iridoviridae) may be utilized.
- RNA viruses e.g., RNA virus families of Picomaviridae, Calciviridae, Astroviridae, Togaviridae, Flaviviridae, Coronaviridae, Paramyxovirid
- Representative examples include, FeLV, VEE, HFVW, WDSV, SFV, Rabies, ALV, BIV, BLV, EBV, CAEV, SNV, ChTLV, STLV, MPMV, SMRV, RAV, FuSV, MH2, AEV, AMV, CT10, and EIAV.
- pseudotyping elements and/or fusogenic envelope proteins include, but are not limited to a full-length polypeptide(s), functional fragment(s), homolog(s), or functional variant(s) of fusogenic envelope proteins from any of the following sources: Influenza A such as F11N1, H1N2, H3N2 and H5N 1 (bird flu), Influenza B, Influenza C virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Hepatitis D virus, Hepatitis E virus, Rotavirus, any virus of the Norwalk virus group, enteric adenoviruses, parvovirus, Dengue fever virus, Monkey pox, Mononegavirales, Lyssavirus such as rabies virus, Lagos bat virus, Mokola virus, Duvenhage virus, European bat virus 1 & 2 and Australian bat virus, Ephemerovirus, Vesiculovirus, Vesicular Stomatitis Virus (VSV), Herpesviruses such as Her
- the pseudotyping element and/or the fusogenic envelope protein comprises the envelope protein from a different virus.
- the pseudotyping element is the feline endogenous virus (RD114) envelope protein, an oncoretroviral amphotropic envelope protein, an oncoretro viral ecotropic envelope protein, the vesicular stomatitis virus envelope protein (VSV-G) (SEQ ID NO: 336), the baboon retroviral envelope glycoprotein (BaEV) (SEQ ID NO: 337), the murine leukemia envelope protein (MuLV) (SEQ ID NO: 338), the influenza glycoprotein HA surface glycoprotein (HA), the influenza glycoprotein neurominidase (NA), the paramyxovirus Measles envelope protein H, the paramyxovirus Measles envelope protein F, the Tupaia paramyxovirus (TPMV) envelope protein H, the TPMV envelope protein F, glycoproteins G and F from the Henipavirus genus, the Nipa
- the pseudotyping element can be wild-type BaEV.
- BaEV contains an R peptide that has been shown to inhibit transduction.
- the BaEV can contain a deletion of the R peptide.
- the BaEV can contain a deletion of the inhibitory R peptide after the nucleotides encoding the amino acid sequence HA, referred to herein as BaEVAR (HA) (SEQ ID NO: 339).
- the BaEV can contain a deletion of the inhibitory R peptide after the nucleotides encoding the amino acid sequence HAM, referred to herein as BaEVAR (HAM) (SEQ ID NO: 340).
- the pseudotyping element and/or fusogenic polypeptide can be wild-type MuLV.
- the MuLV can contain one or more mutations to remove the furin- mediated cleavage site located between the transmembrane (TM) and surface (SU) subunits of the envelope glycoprotein.
- the MuLV contains the SUx mutation (MuLVSUx) (SEQ ID NO:372) which inhibits furin-mediated cleavage of MuLV envelope protein in packaging cells.
- the C-terminus of the cytoplasmic tail of the MuLV or MuLVSUx protein is truncated by 4 to 31 amino acids.
- the C-terminus of the cytoplasmic tail of the MuLV or MuLVSUx protein is truncated by 4, 8, 12, 16, 20, 24, 28, or 31 amino acids.
- the pseudotyping elements include a binding polypeptide and a fusogenic polypeptide derived from different proteins.
- the pseudotyping element can comprise an influenza protein hemagglutinin HA and/or a neuraminidase (NA).
- the HA is from influenza A virus subtype H1N1.
- the HA is from H1N1 PR8 1934 in which the monobasic trypsin-dependent cleavage site has been mutated to a more promiscuous multibasic sequence (SEQ ID NOG 11).
- the NA is from influenza A virus subtype H10N7.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2022229358A AU2022229358A1 (en) | 2021-03-01 | 2022-03-01 | Methods and compositions for the delivery of retroviral particles |
EP22715804.5A EP4301862A1 (en) | 2021-03-01 | 2022-03-01 | Methods and compositions for the delivery of retroviral particles |
CA3212366A CA3212366A1 (en) | 2021-03-01 | 2022-03-01 | Methods and compositions for the delivery of retroviral particles |
CN202280017784.1A CN117043346A (en) | 2021-03-01 | 2022-03-01 | Methods and compositions for delivery of retroviral particles |
JP2023553055A JP2024510933A (en) | 2021-03-01 | 2022-03-01 | Methods and compositions for delivery of retroviral particles |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163200329P | 2021-03-01 | 2021-03-01 | |
US63/200,329 | 2021-03-01 | ||
PCT/US2021/020922 WO2021178701A1 (en) | 2020-03-05 | 2021-03-04 | Methods and compositions for the delivery of modified lymphocyte aggregates |
USPCT/US2021/020922 | 2021-03-04 | ||
US202163197315P | 2021-06-04 | 2021-06-04 | |
US63/197,315 | 2021-06-04 | ||
PCT/US2021/048532 WO2022047417A1 (en) | 2020-08-31 | 2021-08-31 | Anti-idiotype compositions and methods of use thereof |
USPCT/US2021/048532 | 2021-08-31 | ||
US202163261099P | 2021-09-10 | 2021-09-10 | |
US63/261,099 | 2021-09-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022187289A1 true WO2022187289A1 (en) | 2022-09-09 |
Family
ID=81326006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/018404 WO2022187289A1 (en) | 2021-03-01 | 2022-03-01 | Methods and compositions for the delivery of retroviral particles |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022187289A1 (en) |
Citations (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993003769A1 (en) | 1991-08-20 | 1993-03-04 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES | Adenovirus mediated transfer of genes to the gastrointestinal tract |
WO1993009239A1 (en) | 1991-11-08 | 1993-05-13 | Research Corporation Technologies, Inc. | Adeno-associated virus-2 basal vectors |
WO1993019191A1 (en) | 1992-03-16 | 1993-09-30 | Centre National De La Recherche Scientifique | Defective recombinant adenoviruses expressing cytokines for use in antitumoral treatment |
WO1994012649A2 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Gene therapy for cystic fibrosis |
WO1994028938A1 (en) | 1993-06-07 | 1994-12-22 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy sponsorship |
WO1995000655A1 (en) | 1993-06-24 | 1995-01-05 | Mc Master University | Adenovirus vectors for gene therapy |
WO1995011984A2 (en) | 1993-10-25 | 1995-05-04 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
WO1996017951A2 (en) | 1994-12-09 | 1996-06-13 | Rpms Technology Limited | Identification of genes responsible for in vivo survival of microorganisms |
WO1996041865A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamcycin-based regulation of biological events |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
WO1999036553A2 (en) | 1998-01-15 | 1999-07-22 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
WO2001014387A1 (en) | 1999-08-24 | 2001-03-01 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
US6489458B2 (en) | 1997-03-11 | 2002-12-03 | Regents Of The University Of Minnesota | DNA-based transposon system for the introduction of nucleic acid into DNA of a cell |
US20040131637A1 (en) | 2001-03-09 | 2004-07-08 | Chatfield Steven Neville | Salmonella promoter for heterologous gene expression |
US6916846B2 (en) | 2000-05-12 | 2005-07-12 | Merck & Co. Inc. | Coumermycin analogs as chemical dimerizers of chimeric proteins |
US7387896B2 (en) | 2003-03-26 | 2008-06-17 | The Regents Of The University Of Michigan | MicroRNA vectors |
WO2013188864A2 (en) | 2012-06-15 | 2013-12-19 | Sinomab Bioscience Limited | Anti-cd22 anti-idiotypic antibodies and uses thereof |
US8709755B2 (en) | 2009-03-09 | 2014-04-29 | Bioatla, Llc | Mirac proteins |
US8802374B2 (en) | 2009-11-03 | 2014-08-12 | City Of Hope | Truncated epiderimal growth factor receptor (EGFRt) for transduced T cell selection |
WO2016033331A1 (en) | 2014-08-28 | 2016-03-03 | Bioatla, Llc | Conditionally active chimeric antigen receptors for modified t-cells |
WO2017165245A2 (en) | 2016-03-19 | 2017-09-28 | F1 Oncology, Inc. | Methods and compositions for transducing lymphocytes and regulated expansion thereof |
WO2017182585A1 (en) | 2016-04-21 | 2017-10-26 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
WO2018009923A1 (en) | 2016-07-08 | 2018-01-11 | F1 Oncology, Inc. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
WO2018161064A1 (en) | 2017-03-03 | 2018-09-07 | F1 Oncology, Inc. | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
WO2018226897A1 (en) | 2017-06-07 | 2018-12-13 | Intrexon Corporation | Expression of novel cell tags |
WO2019005546A1 (en) | 2017-06-28 | 2019-01-03 | Corning Research & Development Corporation | High fiber count pre-terminated optical distribution assembly |
WO2019055946A1 (en) | 2017-09-18 | 2019-03-21 | F1 Oncology, Inc. | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof |
WO2020047527A2 (en) * | 2018-09-02 | 2020-03-05 | F1 Bioventures, Llc | Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs |
WO2020180664A1 (en) | 2019-03-01 | 2020-09-10 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a pd-1 ectodomain |
WO2021178701A1 (en) * | 2020-03-05 | 2021-09-10 | Exuma Biotech Corp. | Methods and compositions for the delivery of modified lymphocyte aggregates |
WO2022047417A1 (en) * | 2020-08-31 | 2022-03-03 | Exuma Biotech Corp. | Anti-idiotype compositions and methods of use thereof |
-
2022
- 2022-03-01 WO PCT/US2022/018404 patent/WO2022187289A1/en active Application Filing
Patent Citations (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
WO1993003769A1 (en) | 1991-08-20 | 1993-03-04 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES | Adenovirus mediated transfer of genes to the gastrointestinal tract |
WO1993009239A1 (en) | 1991-11-08 | 1993-05-13 | Research Corporation Technologies, Inc. | Adeno-associated virus-2 basal vectors |
WO1993019191A1 (en) | 1992-03-16 | 1993-09-30 | Centre National De La Recherche Scientifique | Defective recombinant adenoviruses expressing cytokines for use in antitumoral treatment |
WO1994012649A2 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Gene therapy for cystic fibrosis |
WO1994028938A1 (en) | 1993-06-07 | 1994-12-22 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy sponsorship |
WO1995000655A1 (en) | 1993-06-24 | 1995-01-05 | Mc Master University | Adenovirus vectors for gene therapy |
WO1995011984A2 (en) | 1993-10-25 | 1995-05-04 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
WO1996017951A2 (en) | 1994-12-09 | 1996-06-13 | Rpms Technology Limited | Identification of genes responsible for in vivo survival of microorganisms |
WO1996041865A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamcycin-based regulation of biological events |
US6489458B2 (en) | 1997-03-11 | 2002-12-03 | Regents Of The University Of Minnesota | DNA-based transposon system for the introduction of nucleic acid into DNA of a cell |
WO1999036553A2 (en) | 1998-01-15 | 1999-07-22 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
WO2001014387A1 (en) | 1999-08-24 | 2001-03-01 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
US6916846B2 (en) | 2000-05-12 | 2005-07-12 | Merck & Co. Inc. | Coumermycin analogs as chemical dimerizers of chimeric proteins |
US20040131637A1 (en) | 2001-03-09 | 2004-07-08 | Chatfield Steven Neville | Salmonella promoter for heterologous gene expression |
US7387896B2 (en) | 2003-03-26 | 2008-06-17 | The Regents Of The University Of Michigan | MicroRNA vectors |
US8709755B2 (en) | 2009-03-09 | 2014-04-29 | Bioatla, Llc | Mirac proteins |
US8802374B2 (en) | 2009-11-03 | 2014-08-12 | City Of Hope | Truncated epiderimal growth factor receptor (EGFRt) for transduced T cell selection |
WO2013188864A2 (en) | 2012-06-15 | 2013-12-19 | Sinomab Bioscience Limited | Anti-cd22 anti-idiotypic antibodies and uses thereof |
WO2016033331A1 (en) | 2014-08-28 | 2016-03-03 | Bioatla, Llc | Conditionally active chimeric antigen receptors for modified t-cells |
WO2017165245A2 (en) | 2016-03-19 | 2017-09-28 | F1 Oncology, Inc. | Methods and compositions for transducing lymphocytes and regulated expansion thereof |
WO2017182585A1 (en) | 2016-04-21 | 2017-10-26 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
WO2018009923A1 (en) | 2016-07-08 | 2018-01-11 | F1 Oncology, Inc. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
WO2018161064A1 (en) | 2017-03-03 | 2018-09-07 | F1 Oncology, Inc. | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
WO2018226897A1 (en) | 2017-06-07 | 2018-12-13 | Intrexon Corporation | Expression of novel cell tags |
WO2019005546A1 (en) | 2017-06-28 | 2019-01-03 | Corning Research & Development Corporation | High fiber count pre-terminated optical distribution assembly |
WO2019055946A1 (en) | 2017-09-18 | 2019-03-21 | F1 Oncology, Inc. | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof |
WO2020047527A2 (en) * | 2018-09-02 | 2020-03-05 | F1 Bioventures, Llc | Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs |
WO2020180664A1 (en) | 2019-03-01 | 2020-09-10 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a pd-1 ectodomain |
WO2021178701A1 (en) * | 2020-03-05 | 2021-09-10 | Exuma Biotech Corp. | Methods and compositions for the delivery of modified lymphocyte aggregates |
WO2022047417A1 (en) * | 2020-08-31 | 2022-03-03 | Exuma Biotech Corp. | Anti-idiotype compositions and methods of use thereof |
Non-Patent Citations (124)
Title |
---|
"GenBank", Database accession no. AX798183 |
AGUILAR ET AL., J VIROL, vol. 81, no. 19, 2007, pages 10804 - 10814 |
ALEXANDER ET AL., EMBO J, vol. 15, no. 23, 2 December 1996 (1996-12-02), pages 6531 - 40 |
ALI ET AL., HUM GENE THER, vol. 9, 1998, pages 81 - 86 |
ALI ET AL., HUM MOL GENET, vol. 5, 1996, pages 591 - 594 |
AL-LAZIKAM ET AL., J. MOL. BIOL., vol. 273, no. 4, 1997 |
ALPUCHE-ARANDA ET AL., PNAS, vol. 89, no. 21, 1992, pages 10079 - 83 |
BENDER ET AL., PLOS PATHOG, vol. 12, no. 2, 2016, pages e1005445 |
BENIT ET AL., J VIROL, vol. 68, no. 8, August 1994 (1994-08-01), pages 5270 - 4 |
BENNETT ET AL., INVEST OPTHALMOL VIS SCI, vol. 38, 1997, pages 2857 - 2863 |
BHASKAR THYAGARAJAN ET AL.: "Site-Specific Genomic Integration in Mammalian Cells Mediated by Phage cpC31 Integrase", MOL CELL BIOL, vol. 21, no. 12, June 2001 (2001-06-01), pages 3926 - 3934 |
BIERING ET AL., J VIROL, vol. 86, no. 22, 2012, pages 11991 - 12002 |
BORRAS ET AL., GENE THER, vol. 6, 1999, pages 515 - 524 |
BRADEL-TRETHEWAY ET AL., J VIROL, vol. 93, no. 13, 2019, pages e00577 - 19 |
BURTON, MOLEC. IMMUNOL., vol. 22, 1985, pages 161 - 206 |
C. FERNANDEZ ET AL., J. INTERNAL. MEDICINE, vol. 284, 2018, pages 377 - 387 |
CAVALIERI ET AL., BLOOD, vol. 101, no. 2, 2003, pages 3416 - 1644 |
CHATFIELD ET AL., BIOTECHNOL, vol. 10, 1992, pages 888 - 892 |
CHOTHIA ET AL., J. MOL. BIOL., vol. 227, 1992, pages 799 - 817 |
CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877 - 883 |
CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917 |
CHUNG, K. ET AL., NUCLEIC ACIDS RESEARCH, vol. 34, no. 7, 2006, pages e53 |
COFFIN ET AL.: "Retroviruses", 1997, COLD SPRING HARBOR LABORATORY PRESS, pages: 758 - 763 |
CONSTANTINESCU ET AL., MOL CELL, vol. 7, no. 2, February 2001 (2001-02-01), pages 377 - 85 |
DEBOER ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 80, 1983, pages 21 - 25 |
DRACHMANKAUSHANSKY, PROC NATL ACAD SCI USA, vol. 94, no. 6, 18 March 1997 (1997-03-18), pages 2350 - 5 |
DRACHMANKAUSHANSKY, PROC NATL ACAD SCI USA., vol. 94, no. 6, 18 March 1997 (1997-03-18), pages 2350 - 5 |
DUNSTAN ET AL., INFECT. IMMUN., vol. 67, 1999, pages 5133 - 5141 |
ECKELHART ET AL., BLOOD, vol. 117, 2011, pages 1565 |
ELGUETA ET AL., IMMUNOL REV, vol. 229, no. 1, May 2009 (2009-05-01), pages 152 - 72 |
FARRAR ET AL., NATURE, vol. 383, 1996, pages 178 - 181 |
FERGUSON MAJKINOSHITA THART GW ET AL.: "Essentials of Glycobiology", 2009, COLD SPRING HARBOR LABORATORY PRESS, article "Glycosylphosphatidylinositol Anchors" |
FLANNERY ET AL., PNAS, vol. 94, 1997, pages 10319 - 6921 |
FLOTTE ET AL., PNAS, vol. 90, 1993, pages 10613 - 10617 |
FRANK ET AL., BLOOD ADV, vol. 4, no. 22, 2020, pages 5702 - 5715 |
FRANKBUCHOLZ, MOL THER METHODS CLIN DEV, vol. 12, 17 October 2018 (2018-10-17), pages 19 - 31 |
FRECHA ET AL., BLOOD, vol. 112, no. 13, 2008, pages 4843 - 4852 |
FUHRMANN-BENZAKEIN ET AL., PNAS, vol. 28, 2000, pages e99 |
FUKUNAGA ET AL., EMBO J, vol. 10, no. 10, October 1991 (1991-10-01), pages 2855 - 65 |
FUNKE ET AL., MOLECULAR THERAPY, vol. 16, no. 8, 2008, pages 1427 - 1436 |
GLASER ET AL., J. BIOL. CHEM., vol. 280, 2005, pages 41494 |
GRINDLEY ET AL., ANNUAL REVIEW OF BIOCHEMISTRY, 2006, pages 567 - 605 |
GUILLAUME ET AL., J VIROL, vol. 80, no. 15, 2006, pages 7546 - 7554 |
HARBORNE ET AL., MAL. MICRO., vol. 6, 1992, pages 2805 - 2813 |
HIGASHIMOTO ET AL., GENE THER, vol. 14, 2007, pages 1298 |
HILLEN, W.WISSMANN, A.: "Topics in Molecular and Structural Biology, Protein-Nucleic Acid Interaction", vol. 10, 1989, MACMILLAN, pages: 143 - 162 |
HITCHCOCK ET AL., BLOOD, vol. 112, no. 6, 15 September 2008 (2008-09-15), pages 2222 - 31 |
HUANG ET AL., MOL CELL, vol. 8, no. 6, December 2001 (2001-12-01), pages 1327 - 38 |
HUCK ET AL., NUCL. ACIDS RES., vol. 14, 1986, pages 1779 |
HUDECEK ET AL., RECENT RESULTS CANCER RES, vol. 209, 2016, pages 37 - 50 |
JABER A ET AL., BMC NEUROL, vol. 8, 10 October 2008 (2008-10-10), pages 38 |
JAE SEONG LEE ET AL., SCIENTIFIC REPORTS, vol. 5, 2015 |
JAMALI ET AL., MOL THER-METH CLIN D, vol. 13, 2019, pages 371 - 379 |
JAYAPRAKASH V ET AL., ADV HEALTHC MATER, 24 August 2020 (2020-08-24), pages e2001022 |
JI ET AL., J BIOL CHEM, vol. 277, no. 49, 6 December 2002 (2002-12-06), pages 47898 - 906 |
JOHNSON ET AL., NUCLEIC ACIDS RES, vol. 29, 2001, pages 205 - 206 |
JOHNSONWU, NUCLEIC ACIDS RES, vol. 28, no. 1, 1 January 2000 (2000-01-01), pages 214 - 218 |
JOHNSTON ET AL., J VIROL, vol. 91, no. 10, 2017, pages e02150 - 16 |
JOMARY ET AL., GENE THER, vol. 4, 1997, pages 683 - 690 |
JONES ET AL., HUMAN GENE THERAPY, vol. 20, 2009, pages 630 - 40 |
KAYKAS ET AL., EMBO J, vol. 20, 2001, pages 2641 |
KHETAWAT ET AL., VIROL J, vol. 7, 2010, pages 312 |
LAMINET ET AL., J BIOL CHEM, vol. 271, no. 1, 5 January 1996 (1996-01-05), pages 264 - 9 |
LEE, PLOS ONE, vol. 6, no. 8, 2011, pages e23396 |
LI ET AL., INVEST OPTHALMOL VIS SCI, vol. 113, 1994, pages 2543 - 2549 |
LIDAVIDSON, PNAS, vol. 92, 1995, pages 7700 - 7704 |
LOCKSLEY RM ET AL., CELL, vol. 104, no. 4, 23 February 2001 (2001-02-23), pages 487 - 501 |
LOPES ET AL., J IMMUNOTHER CANCER, vol. 8, no. 1, April 2020 (2020-04-01), pages e000673 |
LU ET AL., J BIOL CHEM, vol. 278, no. 46, 14 November 2003 (2003-11-14), pages 45414 - 8 |
M. C. NGO ET AL: "Ex vivo gene transfer for improved adoptive immunotherapy of cancer", HUMAN MOLECULAR GENETICS, vol. 20, no. R1, 17 March 2011 (2011-03-17), GB, pages R93 - R99, XP055400951, ISSN: 0964-6906, DOI: 10.1093/hmg/ddr102 * |
MANURI ET AL., HUM GENE THER, vol. 21, no. 4, April 2010 (2010-04-01), pages 427 - 37 |
MATZ ET AL., NATURE BIOTECHNOL, vol. 17, 1999, pages 969 - 973 |
MAY ET AL., FEBS LETT, vol. 394, no. 2, 30 September 1996 (1996-09-30), pages 221 - 6 |
MCKELVIE ET AL., VACCINE, vol. 22, 2004, pages 3243 - 3255 |
MELTON ET AL., NUCL. ACIDS RES., vol. 12, 1984, pages 7035 |
MENDELSON ET AL., VIROL, vol. 166, 1988, pages 154 - 165 |
MILLER, NATURE, vol. 357, 1992, pages 455 - 460 |
MOLLOVA ET AL., BMC SYSTEMS BIO, vol. S1, pages 30 |
MONJEZI ET AL., LEUKEMIA, vol. 31, no. 1, January 2017 (2017-01-01), pages 186 - 194 |
MORELLO ET AL., BLOOD, vol. 86, no. 8, July 1995 (1995-07-01), pages 557 - 71 |
MORGANBOYERINAS, BIOMEDICINES, vol. 4, no. 2, 20 April 2016 (2016-04-20), pages E9 |
MORRIS ET AL.: "The molecular details of cytokine signaling via the JAK/STAT pathway", PROTEIN SCIENCE, vol. 27, 2018, pages 1984 - 2009, XP055809868, DOI: 10.1002/pro.3519 |
MURAKAMI ET AL., PROC NATL ACAD SCI USA, vol. 88, no. 24, 15 December 1991 (1991-12-15), pages 11349 - 53 |
MURAKAMI ET AL., PROC NATL ACAD SCI USA., vol. 88, no. 24, 15 December 1991 (1991-12-15), pages 11349 - 53 |
O'NEALLEE, LYMPHOKINE CYTOKINE RES, vol. 12, no. 5, October 1993 (1993-10-01), pages 309 - 12 |
O'NEILL ET AL., GENE THER, vol. 8, no. 5, March 2001 (2001-03-01), pages 362 - 8 |
PAGER A, EXPERT OPIN DRUG DELIV, 9 August 2020 (2020-08-09), pages 1 - 14 |
PALOMARES ET AL., J VIROL, vol. 87, no. 8, 2013, pages 4794 - 4794 |
PANDARAVINDRAN: "Isolation of Human PBMCs", BIOPROTOC, vol. 3, no. 3, 2013 |
PECQUET ET AL., BLOOD, vol. 115, no. 5, 4 February 2010 (2010-02-04), pages 1037 - 48 |
PULKKINENMILLER, J. BACTERIAL., vol. 173, no. 1, 1991, pages 86 - 93 |
RETTER, NUCLEIC ACIDS RES, vol. 15, no. 20, 26 October 1987 (1987-10-26), pages 8125 - D674 |
ROLLING ET AL., HUM GENE THER, vol. 10, 1999, pages 641 - 648 |
RUELLA ET AL., NAT MED, vol. 24, no. 10, October 2018 (2018-10-01), pages 1499 - 1503 |
SAKAMOTO ET AL., H GENE THER, vol. 5, 1999, pages 1088 - 1097 |
SALMON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 7739 |
SAMULSKI ET AL., J. VIR., vol. 63, 1989, pages 3822 - 3828 |
SCHERAGA, REV. COMPUTATIONAL CHEM., 1992, pages 11173 - 142 |
SHANER ET AL., NAT. METHODS, vol. 2, 2005, pages 905 - 909 |
SHETRON-RAMA ET AL., INFECT, vol. 70, 2002, pages 1087 - 1096 |
SMITH ET AL., NAT NANOTECHNOL, vol. 12, no. 8, August 2017 (2017-08-01), pages 813 - 820 |
STAHL ET AL., SCIENCE, vol. 267, no. 5202, 3 March 1995 (1995-03-03), pages 1349 - 53 |
TAKAHASHI ET AL., J VIROL, vol. 73, 1999, pages 7812 - 7816 |
TAN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 162 |
TROPP: "Molecular Biology", 2012, JONES & BARTLETT PUBLISHERS |
TRUTER ET AL., INTENSIVE CARE MED, vol. 7, 1981, pages 115 - 119 |
TSUKAHARA ET AL., GENE THER, vol. 22, no. 2, February 2015 (2015-02-01), pages 209 - 215 |
VALDIVIAFALKOW, MAL. MICROBIAL., vol. 22, 1996, pages 367 |
VAN DER GEER ET AL., PROC NATL ACAD SCI USA, vol. 93, no. 3, 6 February 1996 (1996-02-06), pages 963 - 8 |
VARGHESE ET AL., FRONT ENDOCRINOL (LAUSANNE, vol. 8, 31 March 2017 (2017-03-31), pages 59 |
VERHOEYEN ET AL., METHODS MOL BIOL, vol. 506, 2009, pages 97 - 114 |
VERMONDEN, LANGMUIR, vol. 22, 2006, pages 10180 - 10184 |
VIRAL VECTOR CHARACTERIZATION: A LOOK AT ANALYTICAL TOOLS, 10 October 2018 (2018-10-10) |
WANG ET AL., J. IMMUNOTHER., vol. 35, no. 9, 2012, pages 689 - 701 |
WEIS ET AL., EUR J CELL BIOL, vol. 94, no. 7-9, 2015, pages 316 - 322 |
WITTING ET AL., GENE THER, vol. 20, no. 10, 2013, pages 997 - 1005 |
XU ET AL., P NATL ACAD SCI USA, vol. 105, no. 29, 2008, pages 9953 - 9958 |
XU ET AL., PLOS ONE, vol. 7, no. 11, 2012, pages e48742 |
YAN ET AL., J. BIOL. CHEM., vol. 287, 2012, pages 5891 |
YANG ET AL., PHARM RES, vol. 26, no. 6, 2009, pages 1432 - 1445 |
YAO X ET AL., CELL RES, vol. 27, no. 6, 19 May 2017 (2017-05-19), pages 801 - 814 |
YE ET AL., SCIENCE, vol. 283, 1999, pages 88 - 91 |
ZAPATA ET AL., PROTEIN ENG, vol. 8, no. 10, 1995, pages 1057 - 1062 |
ZHAO ET AL., CANCER RES, vol. 15, 2010, pages 9053 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3735460A1 (en) | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof | |
US20230111159A1 (en) | Methods and compositions for the delivery of modified lymphocyte aggregates | |
EP3589733A1 (en) | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof | |
US20220340927A1 (en) | Methods and compositions for the modification and delivery of lymphocytes | |
US11325948B2 (en) | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL | |
US20200255864A1 (en) | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof | |
US20210317408A1 (en) | Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs | |
WO2020047527A2 (en) | Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs | |
US20200397821A1 (en) | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof | |
WO2022047417A1 (en) | Anti-idiotype compositions and methods of use thereof | |
US20230044451A1 (en) | Methods and compositions for the delivery of modified lymphocytes and/or retroviral particles | |
US20230357436A1 (en) | Anti-idiotype compositions and methods of use thereof | |
EP4301862A1 (en) | Methods and compositions for the delivery of retroviral particles | |
WO2022187289A1 (en) | Methods and compositions for the delivery of retroviral particles | |
CN117043346A (en) | Methods and compositions for delivery of retroviral particles | |
EP4204004A1 (en) | Anti-idiotype compositions and methods of use thereof | |
US20230392139A1 (en) | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof | |
WO2023168305A1 (en) | Viral particles with membrane-bound hyaluronidase | |
JP2023513458A (en) | Chimeric antigen receptor for HER2 and methods of use thereof | |
AU2022267891A1 (en) | Viral vector production system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22715804 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022229358 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2023/010059 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280017784.1 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 3212366 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023553055 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2022229358 Country of ref document: AU Date of ref document: 20220301 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022715804 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022715804 Country of ref document: EP Effective date: 20231002 |